=== МЕТАДАННЫЕ ===
{
  "original_filename": "ehaf193.pdf",
  "converted_date": "2026-01-31T14:48:04.067761",
  "file_size_bytes": 7379042,
  "original_format": "pdf",
  "document_type": "Guidelines",
  "source_folder": "Guidelines",
  "full_path": "00_RAW_CARDIOLOGY/Guidelines/ehaf193.pdf"
}

=== СОДЕРЖАНИЕ ===

ESC GUIDELINES
European Heart Journal (2025) 46, 4462–4568

2025 ESC Guidelines for the management
of cardiovascular disease and pregnancy
Developed by the task force on the management of cardiovascular
disease and pregnancy of the European Society of Cardiology (ESC)
Endorsed by the European Society of Gynecology (ESG)
Authors/Task Force Members: Julie De Backer *†, (Chairperson) (Belgium),
Kristina H. Haugaa *†, (Chairperson) (Norway), Nina Eide Hasselberg ‡,
(Task Force Co-ordinator) (Norway), Michèle de Hosson ‡, (Task Force
Co-ordinator) (Belgium), Margarita Brida (Croatia), Silvia Castelletti (Italy),
Matthew Cauldwell (United Kingdom), Elisabetta Cerbai (Italy), Lia Crotti
(Italy), Natasja M.S. de Groot (Netherlands), Mette-Elise Estensen (Norway),
Eva S. Goossens (Belgium), Bernhard Haring (Germany), Donata Kurpas
(Poland), Carmel M. McEniery (United Kingdom), Sanne A.E. Peters
(Netherlands), Amina Rakisheva (Kazakhstan), Antonia Sambola (Spain),
Oliver Schlager (Austria), Florian S. Schoenhoff (Switzerland),
Tommaso Simoncini 1 (Italy), Françoise Steinbach (France), Isabella Sudano
(Switzerland), Lorna Swan (United Kingdom), Anne Marie Valente
(United States of America), and ESC Scientific Document Group
* Corresponding authors: Julie De Backer, Cardiology, Ghent University Hospital, Ghent, Belgium, and Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.
Tel: +3293323344, E-mail: julie.debacker@ugent.be. Kristina H. Haugaa, Department of Cardiology, Oslo University Hospital, Oslo, Norway, and Institute for Clinical Medicine,
University of Oslo, Oslo, Norway. Tel: +4723070000, E-mail: kristina.haugaa@medisin.uio.no.
† The two Chairpersons contributed equally to the document and are joint corresponding authors.
‡ The two Task Force Co-ordinators contributed equally to the document.
Author/Task Force Member affiliations are listed in author information.
1 Representing the European Society of Gynecology (ESG)
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association of Cardiovascular Nursing & Allied Professions (ACNAP), Association for Acute CardioVascular Care (ACVC), European Association of Cardiovascular Imaging
(EACVI), European Association of Preventive Cardiology (EAPC), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA).
Councils: Council on Cardiovascular Genomics, Council on Hypertension.
Working Groups: Adult Congenital Heart Disease, Aorta and Peripheral Vascular Diseases, Cardiovascular Pharmacotherapy, Cardiovascular Surgery, Myocardial and Pericardial Diseases,
Pulmonary Circulation and Right Ventricular Function, Thrombosis.
Patient Forum
Disclaimer The European Society of Cardiology (ESC) Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and
the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other
official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are
encouraged to take the ESC Guidelines fully into account when exercising their clinical judgement, as well as in the determination and the implementation of preventive, diagnostic or thera-
peutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions
in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt
health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to
manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the
applicable rules and regulations relating to drugs and medical devices prior to making any clinical decision and to check whether a more recent version of this document exists. The ESC warns
readers that the technical language may be misinterpreted and declines any responsibility in this respect.
Permissions The content of these ESC Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be
translated or reproduced in any form without written permission from the ESC. Permissions can be obtained upon submission of a written request to Oxford University Press, the publisher
of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
© The European Society of Cardiology 2025. All rights reserved.
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4463
Document Reviewers: Werner Budts, (CPG Review Co-ordinator) (Belgium), Karen Sliwa,
(CPG Review Co-ordinator) (South Africa), Marianna Adamo (Italy), Elena Arbelo (Spain), Eloisa Arbustini (Italy),
Giuseppe Boriani (Italy), Antonio Brucato (Italy), Sergio Buccheri (Sweden), Alessandra Bura Riviere (France),
Pavel Calda1 (Czech Republic), G.-Andrei Dan (Romania), Konstantinos Dimopoulos (United Kingdom),
Alexandra Frogoudaki (Greece), Estelle Gandjbakhch (France), Eva Gerdts (Norway), Sofie A Gevaert (Belgium),
Bruna Gigante (Sweden), Bettina Heidecker (Germany), Borja Ibanez (Spain), Stefan James (Sweden),
Mark Johnson (United Kingdom), Peter Jüni (United Kingdom), Jolanda Kluin (Netherlands), Lars Køber
(Denmark), Konstantinos C. Koskinas (Switzerland), Greg Lip (United Kingdom), Emma F. Magavern
(United Kingdom), John William McEvoy (Ireland), Borislava Mihaylova (United Kingdom), Richard Mindham
(United Kingdom), Inge Moelgaard (Denmark), Philip Moons (Belgium), Jens Cosedis Nielsen (Denmark),
Ntobeko A. B. Ntusi (South Africa), Agnes A. Pasquet (Belgium), Tatjana Potpara (Serbia), Eva Prescott
(Denmark), Bianca Rocca (Italy), Jolien Roos-Hesselink (Netherlands), Xavier Rosselló (Spain), Anna Sannino
(Germany), Felix Tanner (Switzerland), Ulf Landmesser (Germany), Ilonca Vaartjes (Netherlands),
Christiaan Vrints (Belgium), Katja Zeppenfeld (Netherlands), and Dayenne Zwaagman (Netherlands)
All experts involved in the development of these guidelines have submitted declarations of interest
which are reported in a supplementary document to the guidelines. See the European Heart Journal online or
 for supplementary documents as well as evidence tables.
------------------------------------------------------------------------------------------------------------------------------------------------------------
Keywords Guidelines • Pregnancy • Cardiovascular • Heart failure • Arrhythmias • Genetic counselling • Risk stratification •
Pregnancy heart team • Cardiomyopathies • Drugs in pregnancy • Aortic disease • Adult congenital heart disease •
Peripartum cardiomyopathy • Hypertensive disorders of pregnancy • Adverse pregnancy outcomes
Table of contents 4.3.5.2. Computed tomography and nuclear medicine
imaging........................................................................................................ 4484
1. Preamble.............................................................................................................. 4468 4.3.5.3. Cardiac catheterization........................................................ 4485
2. Introduction ....................................................................................................... 4469 4.3.6. Cardiovascular magnetic resonance ....................................... 4485
2.1. Why we need new Guidelines on cardiovascular disease and 4.4. Foetal assessment................................................................................... 4485
pregnancy ........................................................................................................... 4469 4.4.1. Risk of foetal/obstetric complications.................................... 4485
2.2. Why these Guidelines are important............................................ 4469 4.4.2. Screening for congenital heart disease in the foetus....... 4485
2.3. What is new ............................................................................................. 4469 4.4.3. Assessing foetal well-being ......................................................... 4485
2.4. What has changed ................................................................................. 4472 4.4.4. Foetal assessment of heritable primary arrhythmias....... 4486
3. General considerations.................................................................................. 4473 4.5. Timing and mode of delivery ............................................................ 4486
3.1. Epidemiology............................................................................................ 4473 4.5.1. Timing of delivery........................................................................... 4486
3.2. Physiology of pregnancy...................................................................... 4473 4.5.2. Induction of labour ........................................................................ 4486
4. The Pregnancy Heart Team........................................................................ 4475 4.5.3. Vaginal or caesarean delivery .................................................... 4486
4.1. Concept and requirements................................................................ 4475 4.5.4. Haemodynamic monitoring during delivery........................ 4486
4.2. Pre-pregnancy counselling and family planning ......................... 4475 4.5.5. Anaesthesia/analgesia .................................................................... 4486
4.2.1. Risk assessment ............................................................................... 4475 4.5.6. Delivery in women on anticoagulants ................................... 4487
4.2.1.1. Maternal risk assessment .................................................... 4475 4.5.6.1. Planned delivery...................................................................... 4487
4.2.2. Genetic counselling........................................................................ 4475 4.5.6.2. Urgent delivery on therapeutic anticoagulation ....... 4487
4.2.2.1. Pre-natal and pre-implantation diagnosis..................... 4475 4.5.6.2.1. Delivery on vitamin K antagonists.......................... 4487
4.2.3. Reproductive technology ............................................................ 4475 4.5.6.2.2. Delivery on heparin...................................................... 4487
4.2.4. Contraception.................................................................................. 4482 4.5.6.3. Restarting anticoagulation after delivery...................... 4487
4.2.5. Termination of pregnancy including psychological 4.5.7. Endocarditis prophylaxis for delivery..................................... 4487
support............................................................................................................ 4482 4.6. Post-partum monitoring and complications............................... 4489
4.3. Diagnostic methods in pregnancy................................................... 4484 4.6.1. Monitoring ......................................................................................... 4489
4.3.1. Electrocardiogram, including mobile rhythm devices...... 4484 4.6.2. Breastfeeding and lactation......................................................... 4489
4.3.2. Echocardiography ........................................................................... 4484 4.6.3. Complications .................................................................................. 4489
4.3.3. Cardiopulmonary exercise testing .......................................... 4484 4.6.3.1. Haemorrhage........................................................................... 4489
4.3.4. Biomarkers......................................................................................... 4484 4.6.3.2. Psychological reactions, post-partum depression.... 4489
4.3.5. Ionizing radiation exposure........................................................ 4484 5. Drugs during pregnancy and lactation.................................................... 4489
4.3.5.1. Chest radiography ................................................................. 4484 5.1. General principles .................................................................................. 4489
Downloaded
from

by
guest
on
22
January
2026

4464 E S C G u id e l in e s
5.1.1. Pharmacokinetics and pharmacodynamics in pregnancy 4489 8.2. Turner syndrome................................................................................... 4501
5.1.2. Pharmacogenetics........................................................................... 4489 8.3. Bicuspid aortic valve disease.............................................................. 4501
5.1.3. Newborn drug exposure in breast milk............................... 4489 8.4. Aortic aneurysms other than root or ascending aorta ......... 4502
5.2. Drug classes in pregnancy .................................................................. 4489 8.5. Aortic dissection..................................................................................... 4502
5.2.1. Anticoagulants.................................................................................. 4489 8.6. Management ............................................................................................. 4502
5.2.1.1. Vitamin K antagonists........................................................... 4490 8.7. Cardiac surgery during pregnancy .................................................. 4503
5.2.1.2. Low-molecular-weight heparins ...................................... 4491 9. Pregnancy in women with known congenital heart disease ......... 4504
5.2.1.2.1. Low-molecular-weight heparin dosing................. 4491 10. Pregnancy in women with pulmonary arterial hypertension..... 4508
5.2.1.2.2. Once-daily vs twice-daily administration............. 4491 10.1. Pre-existing pulmonary arterial hypertension......................... 4508
5.2.1.3. Unfractionated heparin ....................................................... 4491 10.1.1. Maternal and foetal risk............................................................. 4508
5.2.1.4. Fondaparinux ........................................................................... 4491 10.1.2. Counselling and contraception .............................................. 4508
5.2.1.5. Direct oral anticoagulants .................................................. 4491 10.1.3. Management during pregnancy .............................................. 4508
5.2.2. Antiplatelet treatment.................................................................. 4492 10.2. New diagnosis in pregnancy ........................................................... 4509
5.2.3. Diuretics and SGLT2 inhibitors................................................ 4492 10.3. Delivery in women with pulmonary arterial hypertension 4509
5.2.4. Pulmonary hypertension.............................................................. 4492 10.3.1. Peri- and post-partum monitoring ....................................... 4509
5.2.5. Anti-arrhythmic agents................................................................. 4492 11. Venous thromboembolism in pregnancy and post-partum........ 4509
5.2.6. Calcium channel blockers............................................................ 4492 11.1. Epidemiology and maternal risk .................................................... 4509
5.2.7. Renin–angiotensin–aldosterone system inhibitors........... 4493 11.2. Risk factors for pregnancy-related venous
5.2.8. Lipid-lowering agents .................................................................... 4493 thromboembolism.......................................................................................... 4509
5.2.9. Beta-adrenergic blocking agents............................................... 4493 11.3. Prevention of venous thromboembolism................................. 4510
5.2.10. Immunosuppressants.................................................................. 4493 11.3.1. Pregnant women with no prior indications for long-term
5.2.11. Neuroactive drugs ....................................................................... 4493 anticoagulation ............................................................................................. 4510
5.2.12. Obstetric drugs in patients with cardiovascular disease 4493 11.3.2. Pregnant women with prior indication for long-term
5.3. Internet databases.................................................................................. 4493 anticoagulation ............................................................................................. 4510
5.4. List of drugs .............................................................................................. 4493 11.4. Management of acute venous thromboembolism................. 4510
6. Pregnancy in women with cardiomyopathies and primary 11.4.1. Clinical presentation and diagnosis....................................... 4510
arrhythmia syndromes........................................................................................ 4495 11.4.1.1. Deep vein thrombosis....................................................... 4510
6.1. Cardiomyopathies.................................................................................. 4495 11.4.1.2. Pulmonary embolism ......................................................... 4511
6.1.1. Dilated cardiomyopathy and non-dilated left ventricular 11.4.2. Treatment of venous thromboembolism in pregnancy 4511
cardiomyopathy........................................................................................... 4495 11.5. Management of delivery and the post-partum period ........ 4513
6.1.2. Arrhythmogenic right ventricular cardiomyopathy ......... 4495 12. Pregnancy in women with acquired heart disease ......................... 4513
6.1.3. Hypertrophic cardiomyopathy ................................................. 4495 12.1. Acute chest pain in pregnancy....................................................... 4513
6.1.3.1. Treatment of hypertrophic cardiomyopathy in 12.2. Coronary artery disease................................................................... 4513
pregnancy .................................................................................................. 4495 12.2.1. Acute coronary syndrome....................................................... 4513
6.1.3.2. Left ventricular outflow tract obstruction.................. 4495 12.2.1.1. Coronary artery disease epidemiology and
6.1.4. Hypertrabeculation of the left ventricle ............................... 4496 aetiology..................................................................................................... 4513
6.1.5. Labour and delivery in cardiomyopathies ............................ 4496 12.2.1.2. Presentation and diagnosis .............................................. 4515
6.2. Primary arrhythmia syndromes........................................................ 4496 12.2.1.3. Pregnancy-associated spontaneous coronary artery
6.2.1. Long QT syndrome....................................................................... 4496 dissection................................................................................................... 4515
6.2.2. Brugada syndrome ......................................................................... 4497 12.2.2. Coronary artery interventions............................................... 4515
6.2.3. Catecholaminergic polymorphic ventricular 12.2.3. Chronic coronary syndromes in pregnancy..................... 4515
tachycardia ..................................................................................................... 4497 12.2.4. Management and delivery......................................................... 4515
6.2.4. Short QT syndrome...................................................................... 4497 12.3. Hypertensive disorders..................................................................... 4516
6.2.5. Labour and delivery in primary arrhythmia syndromes. 4497 12.3.1. Definition and classification of hypertension in
7. Peripartum cardiomyopathy ....................................................................... 4498 pregnancy ....................................................................................................... 4517
7.1. Epidemiology............................................................................................ 4498 12.3.1.1. Pre-eclampsia/eclampsia ................................................... 4517
7.2. Mechanisms............................................................................................... 4498 12.3.2. Diagnosis and risk assessment................................................ 4517
7.3. Diagnosis and clinical interventions................................................ 4498 12.3.2.1. Blood pressure measurement........................................ 4517
7.4. Outcomes.................................................................................................. 4500 12.3.2.2. Laboratory tests................................................................... 4517
8. Pregnancy in women with aortopathies................................................ 4500 12.3.3. Management of hypertension in pregnancy ..................... 4517
8.1. Women with heritable thoracic aortic disease......................... 4500 12.3.3.1. Non-pharmacological management............................. 4517
8.1.1. Marfan syndrome............................................................................ 4501 12.3.3.2. Pharmacological treatment ............................................. 4518
8.1.2. Loeys–Dietz syndrome ................................................................ 4501 12.3.3.2.1. Mild hypertension (BP 140/90 – 159/109
8.1.3. Vascular Ehlers–Danlos syndrome.......................................... 4501 mmHg)................................................................................................... 4518
8.1.4. Non-syndromic heritable thoracic aortic diseases........... 4501 12.3.3.2.2. Pre-eclampsia................................................................ 4518
8.1.5. Aortic disease with no identifiable (likely) pathogenic 12.3.3.2.3. Severe hypertension (BP ≥160/110 mmHg) .. 4521
variant .............................................................................................................. 4501 12.3.4. Hypertension and delivery....................................................... 4521
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4465
12.4. Arrhythmias ........................................................................................... 4522 16. ‘What to do’ and ‘what not to do’ messages from the
12.4.1. Supraventricular arrhythmias.................................................. 4522 Guidelines................................................................................................................. 4544
12.4.1.1. New-onset narrow QRS tachycardia ........................ 4522 17. Evidence tables ............................................................................................... 4544
12.4.1.2. Atrial fibrillation including anticoagulation................ 4523 18. Data availability statement......................................................................... 4544
12.4.1.3. Pre-existing supraventricular tachycardia.................. 4524 19. Author information...................................................................................... 4549
12.4.2. Ventricular arrhythmias............................................................. 4525 20. Appendix........................................................................................................... 4549
12.4.3. Cardioversion, ablation, and device implantation, and 21. References........................................................................................................ 4550
implantable cardioverter defibrillator management..................... 4525
12.4.3.1. Electrical cardioversion ..................................................... 4525
12.4.3.2. Catheter ablation................................................................. 4525 Tables of Recommendations
12.4.3.3. Device implantation............................................................ 4526
12.4.3.4. Implantable cardioverter defibrillator management 4527 Recommendation Table 1 — Recommendations for counselling,
12.4.4. Cardiac arrest................................................................................ 4529 pregnancy risk assessment, contraception, assisted reproductive
12.4.5. Bradycardia ..................................................................................... 4530 technology, and the involvement of a Pregnancy Heart Team (see
12.4.5.1. Sinus node dysfunction ..................................................... 4530 Evidence Table 1)............................................................................................ 4483
12.4.5.2. Atrioventricular block........................................................ 4530 Recommendation Table 2 — Recommendations for diagnostic
12.4.5.3. Management of sinus node dysfunction and methods in pregnancy (see Evidence Table 2)......................................... 4485
atrioventricular block ........................................................................... 4530 Recommendation Table 3 — Recommendations for timing and
mode of delivery (see Evidence Table 3) ................................................... 4487
12.5. Valvular heart disease ........................................................................ 4530
Recommendation Table 4 — Recommendation for direct oral
12.5.1. Stenotic native valve lesions .................................................... 4530
anticoagulants and pregnancy.......................................................................... 4492
12.5.1.1. Mitral valve stenosis............................................................ 4531
Recommendation Table 5 — Recommendations for
12.5.1.1.1. Management.................................................................. 4531
cardiomyopathies and pregnancy................................................................... 4496
12.5.1.1.2. Interventions................................................................. 4531
Recommendation Table 6 — Recommendations for primary
12.5.1.1.3. Delivery........................................................................... 4531
arrhythmia syndromes and pregnancy (see Evidence Tables 4–6) . 4497
12.5.1.1.4. Post-partum .................................................................. 4531
Recommendation Table 7 — Recommendations for peripartum
12.5.1.2. Valvular aortic stenosis ..................................................... 4531
cardiomyopathy (see Evidence Table 7)..................................................... 4500
12.5.1.2.1. Management.................................................................. 4531
Recommendation Table 8 — Recommendations for aortopathies,
12.5.2. Regurgitant native valve lesions.............................................. 4531
cardiac surgery, and pregnancy....................................................................... 4503
12.5.2.1. Mitral and aortic valve regurgitation ........................... 4531
Recommendation Table 9 — Recommendations for congenital
12.5.2.1.1. Management.................................................................. 4531
heart disease and pregnancy (see Evidence Table 8)............................ 4508
12.5.2.2. Arrhythmogenic mitral valve prolapse....................... 4531 Recommendation Table 10 — Recommendations for pulmonary
12.5.2.3. Tricuspid regurgitation...................................................... 4532 arterial hypertension and pregnancy............................................................ 4509
12.5.3. Prosthetic valves........................................................................... 4533 Recommendation Table 11 — Recommendations for venous
12.5.3.1. Bioprosthetic valves............................................................ 4533 thromboembolic diseases and pregnancy (see Evidence Tables 9 and
12.5.3.2. Mechanical valves................................................................. 4533 10) ............................................................................................................................... 4513
12.5.3.2.1. Anticoagulation during pregnancy ....................... 4534 Recommendation Table 12 — Recommendations for coronary
12.5.3.2.2. Mechanical valve thrombosis ................................. 4534 artery disease and pregnancy (see Evidence Table 11)........................ 4516
12.5.3.2.3. Anticoagulation during delivery in women with Recommendation Table 13 — Recommendations for hypertensive
mechanical heart valves.................................................................. 4534 disorders and pregnancy (see Evidence Tables 12–17) ....................... 4521
12.5.4. Endocarditis prophylaxis........................................................... 4536 Recommendation Table 14 — Recommendations for
12.6. Heart failure........................................................................................... 4536 supraventricular tachycardia and pregnancy ............................................. 4525
Recommendation Table 15 — Recommendations for ventricular
12.6.1. Chronic heart failure .................................................................. 4536
tachycardia, device implantation, catheter ablation, and pregnancy 4528
12.6.2. Acute heart failure (including cardiogenic shock).......... 4536
Recommendation Table 16 — Recommendations for cardiac arrest
12.7. Special populations.............................................................................. 4538
and pregnancy ........................................................................................................ 4530
12.7.1. Heart transplantation................................................................. 4538
Recommendation Table 17 — Recommendation for congenital
12.7.2. Cardio-oncology........................................................................... 4538
atrioventricular block and pregnancy........................................................... 4530
12.7.2.1 Gestational cancer ............................................................... 4538
Recommendation Table 18 — Recommendations for native valve
12.7.2.2 Pregnancy in cancer survivors......................................... 4539
disease and pregnancy ........................................................................................ 4533
13. Adverse pregnancy outcomes and long-term management....... 4539
Recommendation Table 19 — Recommendations for prosthetic
13.1. Adverse pregnancy outcomes........................................................ 4539
valves and pregnancy (see Evidence Table 18) ........................................ 4534
13.1.1. Post-partum hypertensive disorders ................................... 4539
Recommendation Table 20 — Recommendations for chronic and
13.1.2. Gestational diabetes mellitus .................................................. 4539
acute heart failure and pregnancy (see Evidence Table 19)............... 4536
13.1.3. Pre-term birth ............................................................................... 4539
Recommendation Table 21 — Recommendations for heart
13.1.4. Small for gestational age............................................................ 4539 transplantation and pregnancy ........................................................................ 4538
13.1.5. Pregnancy loss and placental abruption ............................. 4539 Recommendation Table 22 — Recommendations for
13.2. Breastfeeding ......................................................................................... 4539 cardio-oncology and pregnancy...................................................................... 4539
13.3. Women’s Heart Clinics .................................................................... 4540 Recommendation Table 23 — Recommendations for
14. Key messages .................................................................................................. 4542 long-term effects of adverse pregnancy outcomes (see Evidence
15. Gaps in evidence............................................................................................ 4543 Tables 20 and 21) ................................................................................................. 4542
Downloaded
from

by
guest
on
22
January
2026

4466 E S C G u id e l in e s
List of tables Figure 15 Management of atrial fibrillation and atrial flutter in
pregnancy ................................................................................................................. 4524
Table 1 Classes of recommendations.......................................................... 4468 Figure 16 Management of ventricular tachycardias in pregnancy .... 4526
Table 2 Levels of evidence................................................................................ 4469 Figure 17 Management of pacemaker and implantable cardioverter
Table 3 Updates of the 2025 Guidelines on cardiovascular disease defibrillator and pregnancy............................................................................... 4527
and pregnancy ........................................................................................................ 4470 Figure 18 Management of implantable cardioverter defibrillator
Table 4 New recommendations .................................................................... 4470 shocks in pregnancy............................................................................................. 4528
Table 5 Revised recommendations............................................................... 4472 Figure 19 Management of cardiac arrest in pregnancy......................... 4529
Table 6 Modified World Health Organization 2.0 classification of Figure 20 Valvular heart disease and pregnancy...................................... 4532
maternal cardiovascular risk............................................................................. 4477 Figure 21 Management of anticoagulants during the different stages
Table 7 Pre-implantation and pre-natal options and implications... 4481 of pregnancy in women with mechanical heart valves ......................... 4535
Table 8 Overview of benefits and risks of different methods of Figure 22 Management of acute heart failure and cardiogenic shock
contraception in women with cardiovascular disease .......................... 4482 in pregnancy and up to 6 months post-partum ...................................... 4537
Table 9 Predictors of neonatal events in pregnancies of women with Figure 23 Multidisciplinary approach of adverse pregnancy
cardiovascular disease ......................................................................................... 4486 outcomes.................................................................................................................. 4540
Table 10 List of anticoagulation regimens and disease entities in Figure 24 Algorithm for the management of new-onset post-partum
which they are indicated.................................................................................... 4490 hypertension ........................................................................................................... 4541
Table 11 Dosing regimens for the commonly used Figure 25 Algorithm for the management of adverse pregnancy
low-molecular-weight heparins....................................................................... 4491 outcomes.................................................................................................................. 4541
Table 12 Risks, monitoring, and management during pregnancy and
delivery in women with congenital heart disease................................... 4505 Abbreviations and acronyms
Table 13 Reasons for antepartum/post-partum
thromboprophylaxis ............................................................................................ 4510 ACE-(I) Angiotensin-converting enzyme(-inhibitor)
Table 14 Hypertensive disorders of pregnancy....................................... 4516 ACHD Adult congenital heart disease
Table 15 Risk factors for pre-eclampsia ..................................................... 4517 ACS Acute coronary syndrome
Table 16 ‘What to do’ and ‘what not to do’............................................ 4544 ADR Adverse drug reaction
AF Atrial fibrillation
List of figures AFL Atrial flutter
AHF Acute heart failure
Figure 1 Physiology of haemodynamic changes, and changes in AHT Arterial hypertension
electrocardiogram and echocardiography during and post ALARA As low as reasonably achievable
pregnancy ................................................................................................................. 4474 ALT Alanine transaminase
Figure 2 Central illustration. Role of Pregnancy Heart Team in AMVP Arrhythmic mitral valve prolapse
pregnancy pathway............................................................................................... 4476 APO Adverse pregnancy outcomes
Figure 3 Composition of the core and expanded case-based aPTT Activated partial thromboplastin time
Pregnancy Heart Team....................................................................................... 4480 ARB Angiotensin receptor blocker
Figure 4 Pre-conception counselling and genetic aspects ................... 4481 ARNI Angiotensin receptor/neprilysin inhibitor
Figure 5 Management of urgent delivery in women under ARVC Arrhythmogenic right ventricular
anticoagulants ......................................................................................................... 4488 cardiomyopathy
Figure 6 Choice of medication during pregnancy (left) and during ASA Acetylsalicylic acid
lactation and breastfeeding (right)................................................................. 4494 ASCVD Atherosclerotic cardiovascular disease
Figure 7 Risk factors and management of peripartum ASD Atrial septal defect
cardiomyopathy..................................................................................................... 4499 ASI Aortic size index
Figure 8 Thresholds for prophylactic surgical treatment prior to AST Aspartate aminotransferase
pregnancy of aortic root/ascending aneurysm (above the line) and AV Atrioventricular
recommended mode of delivery according to aortic diameter AV(N)RT Atrioventricular (nodal) re-entry tachycardia
(below the line)...................................................................................................... 4502 AVSD Atrioventricular septal defect
Figure 9 Algorithm for the diagnosis and treatment of deep vein BAV Bicuspid aortic valve
thrombosis during pregnancy.......................................................................... 4511 B-blocker Beta-blocker
Figure 10 Algorithm for the diagnosis and treatment of pulmonary b.i.d. Bis in die (twice a day)
embolism in pregnancy in stable (A) and unstable women (B) ........ 4512 BMI Body mass index
Figure 11 Management of chest pain during pregnancy and within 6 BNP B-type natriuretic peptide
months post-partum ........................................................................................... 4514 BP Blood pressure
Figure 12A Management of hypertension and pre-eclampsia in the b.p.m. Beats per minute
emergency ward.................................................................................................... 4518 BrS Brugada syndrome
Figure 12B Proteinuria assessment and diagnosis of pre-eclampsia 4519 CABG Coronary artery bypass graft
Figure 12C Monitoring and treatment of hypertension and pre- CAD Coronary artery disease
eclampsia................................................................................................................... 4520 CARPREG II Cardiac Disease in Pregnancy study II
Figure 13 Arrhythmogenesis in pregnant women.................................. 4522 CCB Calcium channel blocker
Figure 14 Management of narrow QRS tachycardia in pregnant CCS Chronic coronary syndromes
women....................................................................................................................... 4523 CI Confidence interval
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4467
CMP Cardiomyopathy MR Mitral valve regurgitation
CMR Cardiovascular magnetic resonance MRA Mineralocorticoid receptor antagonist
CO Cardiac output mU Milliunit
COR Class of recommendation mWHO modified World Health Organization
CPG Clinical Practice Guidelines NA Not applicable
CPR Cardiopulmonary resuscitation NDLVC Non-dilated left ventricular cardiomyopathy
CPVT Catecholaminergic polymorphic ventricular NP Natriuretic peptide (NT-proBNP and BNP)
tachycardia NSAID Non-steroidal anti-inflammatory drug
CT Computed tomography nsHTAD Non-syndromic heritable thoracic aortic disease
cTnI Cardiac troponin I NSTE ACS Non-ST-elevation acute coronary syndrome
cTnT Cardiac troponin T NT-proBNP N-terminal pro-brain natriuretic peptide
CTPA Computed tomography pulmonary angiography NYHA New York Heart Association
CTRCD Cancer-therapy-related cardiac dysfunction o.d. Omni die (once a day)
CVD Cardiovascular disease oGTT Oral glucose tolerance test
DAPT Dual antiplatelet therapy OR Odds ratio
DCM Dilated cardiomyopathy P/LP Pathogenic/likely pathogenic
DOAC Direct oral anticoagulant PAH Pulmonary arterial hypertension
DVT Deep vein thrombosis PAP Pulmonary arterial pressure
ECG Electrocardiogram PASP Pulmonary arterial systolic pressure
ECMO Extracorporeal membrane oxygenation PCI Percutaneous coronary intervention
EF Ejection fraction PE Pulmonary embolism
EORP EURObservational Research Programme PH Pulmonary hypertension
ERA Endothelin receptor antagonist PlGF Placental growth factor
ESC European Society of Cardiology p.o. Per os (by mouth)
ESH European Society of Hypertension PPCM Peripartum cardiomyopathy
FAT Focal atrial tachycardia PPH Post-partum haemorrhage
FDA Food and Drug Administration PREM Patient-reported experience measure
FFP Fresh frozen plasma PROM Patient-reported outcome measure
GDM Gestational diabetes mellitus PV Pulmonary valve
HCM Hypertrophic cardiomyopathy QRS Q, R, and S waves
HELLP Haemolysis, elevated liver enzymes, low platelet RBC Red blood cell
count RID Relative infant dose
HF Heart failure ROPAC Registry of Pregnancy and Cardiac Disease
HFrEF Heart failure with reduced ejection fraction ROSC Return of spontaneous circulation
HLA Human leucocyte antigen RV Right ventricle
HR Heart rate RVEF Right ventricular ejection fraction
HTAD Heritable thoracic aortic disease RVH Right ventricular hypertrophy
ICD Implantable cardioverter defibrillator RVOT(O) Right ventricular outflow tract (obstruction)
INR International normalized ratio RVOT-VT Right ventricular outflow tract ventricular
IU International unit tachycardia
IUGR Intrauterine growth restriction SBP Systolic blood pressure
IUD Intrauterine device SCAD Spontaneous coronary artery dissection
i.v. Intravenous SGA Small for gestational age
IVF In vitro fertilization SGLT2 Sodium–glucose co-transporter-2
LA Left atrium SPAP Systolic pulmonary artery pressure
LDL Low-density lipoprotein SpO Oxygen saturation
2
LDS Loeys–Dietz syndrome SQTS Short QT syndrome
LMWH Low-molecular-weight heparin STEMI ST-elevation myocardial infarction
LQT1/2/3 Long QT syndrome type 1, 2, or 3 SVT Supraventricular tachycardia
LQTS Long QT syndrome TAD Thoracic aortic disease
LV Left ventricle TAVI Transcatheter aortic valve implantation
LVAD Left ventricular assist device TGA Transposition of the great arteries
LVEDD Left ventricular end-diastolic diameter TOF Tetralogy of Fallot
LVEF Left ventricular ejection fraction TPVI Transcatheter pulmonary valve implementation
LVH Left ventricular hypertrophy TR Tricuspid regurgitation
LVOT(O) Left ventricular outflow tract (obstruction) TS Turner syndrome
MACE Major adverse cardiovascular events TTE Transthoracic echocardiogram
MFS Marfan syndrome UACR Urine albumin–creatinine ratio
MHV Mechanical heart valve UFH Unfractionated heparin
MINOCA Myocardial infarction with non-obstructive VA-ECMO Veno-arterial extracorporeal membrane
coronary arteries oxygenation
Downloaded
from

by
guest
on
22
January
2026

4468 E S C G u id e l in e s
VF Ventricular fibrillation can be found on the ESC website (
VHD Valvular heart disease Guidelines/Clinical-Practice-Guidelines/Guidelines-development/
VKA Vitamin K antagonist Writing-ESC-Guidelines).
VSD Ventricle septal defect This guideline updates and replaces the previous version from 2018.
VT Ventricular tachycardia This Task Force was selected by the ESC to include professionals
VTE Venous thromboembolism involved with the medical care of patients with this pathology and to in-
WCD Wearable cardioverter defibrillator clude patient representatives and methodologists. The selection proced-
WHO World Health Organization ure included an open call for authors and aimed to include members from
WPW Wolff–Parkinson–White across the whole of the ESC region and from relevant ESC Subspecialty
Communities. Consideration was given to diversity and inclusion.
Guidelines Task Forces perform a critical review and evaluation of
1. Preamble
the published literature on diagnostic and therapeutic approaches
including assessment of the risk–benefit ratio. Recommendations
Guidelines evaluate and summarize available evidence with the aim
are based on major randomized trials and relevant systematic re-
of assisting health professionals in proposing the best diagnostic or
views and meta-analyses, when available. Systematic literature
therapeutic approach for an individual patient with a given condition.
searches are conducted in cases of controversy or uncertainty to
European Society of Cardiology (ESC) Guidelines are intended for
ensure that all key studies were considered. For recommendations
use by health professionals but do not override their individual re-
sponsibility to make appropriate and accurate decisions in consider- related to diagnosis and prognosis, additional types of evidence
ation of each patient’s health condition and in consultation with the are included, such as diagnostic accuracy studies and studies focused
patient or the patient’s caregiver where appropriate and/or neces- on the development and validation of prognostic models. The
sary. It is also the health professional’s responsibility to verify the strength of each recommendation and the level of evidence support-
rules and regulations applicable in each country to drugs and devices ing it are weighed and scored according to predefined criteria as
at the time of prescription and to respect the ethical rules of their outlined in Tables 1 and 2. Patient-reported outcome measures
profession. (PROMs) and patient-reported experience measures (PREMs) are
ESC Guidelines represent the official position of the ESC on a given also evaluated when available as the basis for recommendations
topic. Guideline topics are selected for updating after annual expert re- and/or discussion in these guidelines.
view of new evidence conducted by the ESC Clinical Practice Evidence tables summarizing key information from relevant studies
Guidelines (CPG) Committee. European Society of Cardiology are generated to facilitate the formulation of recommendations, to en-
Policies and Procedures for formulating and issuing ESC Guidelines hance comprehension of recommendations after publication, and to
Table 1 Classes of recommendations
(cid:157)(cid:21)(cid:3)(cid:15)(cid:12)(cid:13)(cid:12)(cid:20)(cid:15) (cid:144)(cid:20)(cid:18)(cid:14)(cid:12)(cid:15)(cid:8)(cid:28)(cid:13)(cid:20)(cid:28)(cid:5)(cid:22)(cid:21)
(cid:29)(cid:24)(cid:23)(cid:22)(cid:22)(cid:28)(cid:11)(cid:28) (cid:31)(cid:10)(cid:12)(cid:14)(cid:21)(cid:15)(cid:17)(cid:21)(cid:28)(cid:23)(cid:15)(cid:14)(cid:9)(cid:20)(cid:18)(cid:28)(cid:8)(cid:21)(cid:15)(cid:21)(cid:18)(cid:23)(cid:24)(cid:28)(cid:23)(cid:8)(cid:18)(cid:21)(cid:21)(cid:16)(cid:21)(cid:15)(cid:13) (cid:11)(cid:22)(cid:28)(cid:18)(cid:21)(cid:17)(cid:20)(cid:16)(cid:16)(cid:21)(cid:15)(cid:14)(cid:21)(cid:14)(cid:28)(cid:20)(cid:18)(cid:28)(cid:12)(cid:22)(cid:28)(cid:12)(cid:15)(cid:14)(cid:12)(cid:17)(cid:23)(cid:13)(cid:21)(cid:14)
(cid:13)(cid:7)(cid:23)(cid:13)(cid:28)(cid:23)(cid:28)(cid:8)(cid:12)(cid:10)(cid:21)(cid:15)(cid:28)(cid:13)(cid:18)(cid:21)(cid:23)(cid:13)(cid:16)(cid:21)(cid:15)(cid:13)(cid:28)(cid:20)(cid:18)(cid:28)(cid:6)(cid:18)(cid:20)(cid:17)(cid:21)(cid:14)(cid:5)(cid:18)(cid:21)(cid:28)(cid:12)(cid:22)
(cid:4)(cid:21)(cid:15)(cid:21)(cid:3)(cid:17)(cid:12)(cid:23)(cid:24)(cid:2)(cid:28)(cid:5)(cid:22)(cid:21)(cid:19)(cid:5)(cid:24)(cid:2)(cid:28)(cid:21)(cid:1)(cid:21)(cid:17)(cid:13)(cid:12)(cid:10)(cid:21)(cid:127)(cid:28)
(cid:29)(cid:24)(cid:23)(cid:22)(cid:22)(cid:28)(cid:11)(cid:11)(cid:28) (cid:29)(cid:20)(cid:15)(cid:129)(cid:12)(cid:17)(cid:13)(cid:12)(cid:15)(cid:8)(cid:28)(cid:21)(cid:10)(cid:12)(cid:14)(cid:21)(cid:15)(cid:17)(cid:21)(cid:28)(cid:23)(cid:15)(cid:14)(cid:9)(cid:20)(cid:18)(cid:28)(cid:23)(cid:28)(cid:14)(cid:12)(cid:10)(cid:21)(cid:18)(cid:8)(cid:21)(cid:15)(cid:17)(cid:21)(cid:28)(cid:20)(cid:19)(cid:28)(cid:20)(cid:6)(cid:12)(cid:15)(cid:12)(cid:20)(cid:15)(cid:28)(cid:23)(cid:4)(cid:20)(cid:5)(cid:13)(cid:28)(cid:13)(cid:7)(cid:21)(cid:28)(cid:5)(cid:22)(cid:21)(cid:19)(cid:5)(cid:24)(cid:15)(cid:21)(cid:22)(cid:22)(cid:9)(cid:28)
(cid:21)(cid:141)(cid:17)(cid:23)(cid:17)(cid:143)(cid:28)(cid:20)(cid:19)(cid:28)(cid:13)(cid:7)(cid:21)(cid:28)(cid:8)(cid:12)(cid:10)(cid:21)(cid:15)(cid:28)(cid:13)(cid:18)(cid:21)(cid:23)(cid:13)(cid:16)(cid:21)(cid:15)(cid:13)(cid:28)(cid:20)(cid:18)(cid:28)(cid:6)(cid:18)(cid:20)(cid:17)(cid:21)(cid:14)(cid:5)(cid:18)(cid:21)(cid:127)(cid:28)
(cid:28)(cid:28)(cid:28)(cid:29)(cid:24)(cid:23)(cid:22)(cid:22)(cid:28)(cid:11)(cid:11)(cid:23) (cid:144)(cid:21)(cid:12)(cid:8)(cid:7)(cid:13)(cid:28)(cid:20)(cid:19)(cid:28)(cid:21)(cid:10)(cid:12)(cid:14)(cid:21)(cid:15)(cid:17)(cid:21)(cid:9)(cid:20)(cid:6)(cid:12)(cid:15)(cid:12)(cid:20)(cid:15)(cid:28)(cid:12)(cid:22)(cid:28)(cid:12)(cid:15) (cid:30)(cid:7)(cid:20)(cid:5)(cid:24)(cid:14)(cid:28)(cid:4)(cid:21)(cid:28)(cid:17)(cid:20)(cid:15)(cid:22)(cid:12)(cid:14)(cid:21)(cid:18)(cid:21)(cid:14) (cid:28)
(cid:19)(cid:23)(cid:10)(cid:20)(cid:5)(cid:18)(cid:28)(cid:20)(cid:19)(cid:28)(cid:5)(cid:22)(cid:21)(cid:19)(cid:5)(cid:24)(cid:15)(cid:21)(cid:22)(cid:22)(cid:9)(cid:21)(cid:141)(cid:17)(cid:23)(cid:17)(cid:143)(cid:127)(cid:28)
(cid:28)(cid:28) (cid:28)(cid:28)(cid:28)(cid:29)(cid:24)(cid:23)(cid:22)(cid:22)(cid:28)(cid:11)(cid:11)(cid:4) (cid:22)(cid:21)(cid:19)(cid:5)(cid:24)(cid:15)(cid:21)(cid:22)(cid:22)(cid:9)(cid:21)(cid:141)(cid:17)(cid:23)(cid:17)(cid:143)(cid:28)(cid:12)(cid:22)(cid:28)(cid:24)(cid:21)(cid:22)(cid:22)(cid:28) (cid:21)(cid:24)(cid:24) €(cid:23)(cid:143)(cid:28)(cid:4)(cid:21)(cid:28)(cid:17)(cid:20)(cid:15)(cid:22)(cid:12)(cid:14)(cid:21)(cid:18)(cid:21)(cid:14)
(cid:21)(cid:22)(cid:13)(cid:23)(cid:4)(cid:24)(cid:12)(cid:22)(cid:7)(cid:21)(cid:14)(cid:28)(cid:4)(cid:143)(cid:28)(cid:21)(cid:10)(cid:12)(cid:14)(cid:21)(cid:15)(cid:17)(cid:21)(cid:9)(cid:20)(cid:6)(cid:12)(cid:15)(cid:12)(cid:20)(cid:15)(cid:127)
(cid:29)(cid:24)(cid:23)(cid:22)(cid:22)(cid:28)(cid:11)(cid:11)(cid:11)(cid:28) (cid:31)(cid:10)(cid:12)(cid:14)(cid:21)(cid:15)(cid:17)(cid:21)(cid:28)(cid:20)(cid:18)(cid:28)(cid:8)(cid:21)(cid:15)(cid:21)(cid:18)(cid:23)(cid:24)(cid:28)(cid:23)(cid:8)(cid:18)(cid:21)(cid:21)(cid:16)(cid:21)(cid:15)(cid:13)(cid:28)(cid:13)(cid:7)(cid:23)(cid:13)(cid:28)(cid:13)(cid:7)(cid:21) (cid:11)(cid:22)(cid:28)(cid:15)(cid:20)(cid:13)(cid:28)(cid:18)(cid:21)(cid:17)(cid:20)(cid:16)(cid:16)(cid:21)(cid:15)(cid:14)(cid:21)(cid:14)
(cid:8)(cid:12)(cid:10)(cid:21)(cid:15)(cid:28)(cid:13)(cid:18)(cid:21)(cid:23)(cid:13)(cid:16)(cid:21)(cid:15)(cid:13)(cid:28)(cid:20)(cid:18)(cid:28)(cid:6)(cid:18)(cid:20)(cid:17)(cid:21)(cid:14)(cid:5)(cid:18)(cid:21)(cid:28)(cid:12)(cid:22)(cid:28)(cid:15)(cid:20)(cid:13)
(cid:5)(cid:22)(cid:21)(cid:19)(cid:5)(cid:24)(cid:9)(cid:21)(cid:1)(cid:21)(cid:17)(cid:13)(cid:12)(cid:10)(cid:21)(cid:2)(cid:28)(cid:23)(cid:15)(cid:14)(cid:28)(cid:12)(cid:15)(cid:28)(cid:22)(cid:20)(cid:16)(cid:21)(cid:28)(cid:17)(cid:23)(cid:22)(cid:21)(cid:22)
(cid:16)(cid:23)(cid:143)(cid:28)(cid:4)(cid:21)(cid:28)(cid:7)(cid:23)(cid:18)(cid:16)(cid:19)(cid:5)(cid:24)(cid:127)(cid:28)
(cid:22)(cid:15)(cid:20)(cid:12)(cid:13)(cid:23)(cid:14)(cid:15)(cid:21)(cid:16)(cid:16)(cid:20)(cid:17)(cid:21)(cid:18)(cid:28)(cid:19)(cid:20)(cid:28)(cid:22)(cid:21)(cid:22)(cid:22)(cid:23)(cid:24)(cid:29)
(cid:25)(cid:27)(cid:26)(cid:27)(cid:28)(cid:29)(cid:30)(cid:31)©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4469
Table 2 Levels of evidence
(cid:31)(cid:30)(cid:29)(cid:30)(cid:28)(cid:27)(cid:26)(cid:25) (cid:17)(cid:16)(cid:15)(cid:16)(cid:27)(cid:23)(cid:30)(cid:14)(cid:24)(cid:29)(cid:30)(cid:23)(cid:27)(cid:25)(cid:14)(cid:26)(cid:13)(cid:27)(cid:13)(cid:12)(cid:28)(cid:15)(cid:24)(cid:11)(cid:28)(cid:30)(cid:27)(cid:14)(cid:16)(cid:22)(cid:23)(cid:26)(cid:13)(cid:24)(cid:10)(cid:30)(cid:23)(cid:27)(cid:21)(cid:28)(cid:24)(cid:22)(cid:24)(cid:21)(cid:16)(cid:28)(cid:27)(cid:15)(cid:14)(cid:24)(cid:16)(cid:28)(cid:9)
(cid:30)(cid:29)(cid:24)(cid:23)(cid:30)(cid:22)(cid:21)(cid:30)(cid:27)(cid:20) (cid:26)(cid:14)(cid:27)(cid:13)(cid:30)(cid:15)(cid:16)(cid:8)(cid:16)(cid:22)(cid:16)(cid:28)(cid:7)(cid:9)(cid:30)(cid:9)(cid:6)
(cid:31)(cid:30)(cid:29)(cid:30)(cid:28)(cid:27)(cid:26)(cid:25) (cid:17)(cid:16)(cid:15)(cid:16)(cid:27)(cid:23)(cid:30)(cid:14)(cid:24)(cid:29)(cid:30)(cid:23)(cid:27)(cid:25)(cid:14)(cid:26)(cid:13)(cid:27)(cid:16)(cid:27)(cid:9)(cid:24)(cid:22)(cid:5)(cid:28)(cid:30)(cid:27)(cid:14)(cid:16)(cid:22)(cid:23)(cid:26)(cid:13)(cid:24)(cid:10)(cid:30)(cid:23)(cid:27)(cid:21)(cid:28)(cid:24)(cid:22)(cid:24)(cid:21)(cid:16)(cid:28)(cid:27)(cid:15)(cid:14)(cid:24)(cid:16)(cid:28)
(cid:30)(cid:29)(cid:24)(cid:23)(cid:30)(cid:22)(cid:21)(cid:30)(cid:27)(cid:19) (cid:26)(cid:14)(cid:27)(cid:28)(cid:16)(cid:14)(cid:5)(cid:30)(cid:27)(cid:22)(cid:26)(cid:22)(cid:8)(cid:14)(cid:16)(cid:22)(cid:23)(cid:26)(cid:13)(cid:24)(cid:10)(cid:30)(cid:23)(cid:27)(cid:9)(cid:15)(cid:12)(cid:23)(cid:24)(cid:30)(cid:9)(cid:6)
(cid:31)(cid:30)(cid:29)(cid:30)(cid:28)(cid:27)(cid:26)(cid:25) (cid:18)(cid:26)(cid:22)(cid:9)(cid:30)(cid:22)(cid:9)(cid:12)(cid:9)(cid:27)(cid:26)(cid:25)(cid:27)(cid:26)(cid:11)(cid:24)(cid:22)(cid:24)(cid:26)(cid:22)(cid:27)(cid:26)(cid:25)(cid:27)(cid:15)(cid:4)(cid:30)(cid:27)(cid:30)(cid:3)(cid:11)(cid:30)(cid:14)(cid:15)(cid:9)(cid:27)(cid:16)(cid:22)(cid:23)(cid:2)(cid:26)(cid:14)(cid:27)(cid:9)(cid:13)(cid:16)(cid:28)(cid:28)(cid:27)(cid:9)(cid:15)(cid:12)(cid:23)(cid:24)(cid:30)(cid:9)(cid:1)
(cid:30)(cid:29)(cid:24)(cid:23)(cid:30)(cid:22)(cid:21)(cid:30)(cid:27)(cid:18) (cid:14)(cid:30)(cid:15)(cid:14)(cid:26)(cid:9)(cid:11)(cid:30)(cid:21)(cid:15)(cid:24)(cid:29)(cid:30)(cid:27)(cid:9)(cid:15)(cid:12)(cid:23)(cid:24)(cid:30)(cid:9)(cid:1)(cid:27)(cid:14)(cid:30)(cid:5)(cid:24)(cid:9)(cid:15)(cid:14)(cid:24)(cid:30)(cid:9)(cid:6)
reinforce transparency in the guidelines’ development process. The ta- 2. Introduction
bles are published in their own section of ESC Guidelines and reference
specific recommendation tables. 2.1. Why we need new Guidelines on
After an iterative process of deliberations, a first Task Force vote on all cardiovascular disease and pregnancy
recommendations is conducted prior to the initiation of rounds of re-
Since the previous version of these Guidelines was published in 2018,
view. A second Task Force vote on all recommendations is conducted
new evidence has emerged, and clinical focus has changed in various as-
after the final round of review and revision. For each vote, the Task
pects, requiring an updated discussion. These include the importance of
Force follows ESC voting procedures and all recommendations require
the Pregnancy Heart Team, the modalities for pre-pregnancy counsel-
at least 75% agreement among voting members to be approved.
ling and risk stratification, and drugs during pregnancy, lactation and/or
Voting restrictions may be applied based on declarations of interests.
breastfeeding, and post-partum stages. In Table 3, the most relevant up-
The writing and reviewing panels provide declaration of interest
dates are listed with their respective rationale.
forms for all relationships that might be perceived as real or potential
sources of conflicts of interest. Their declarations of interest are re-
viewed according to the ESC declaration of interest rules, which can 2.2. Why these Guidelines are important
be found on the ESC website ( and are
Cardiovascular disease (CVD) is a major cause of maternal mortality
compiled in a report published in a supplementary document with the
and morbidity. With these new Guidelines we wish to provide updated
guidelines. Funding for the development of ESC Guidelines is derived en-
evidence-based guidance for patients and caregivers. Reducing maternal
tirely from the ESC with no involvement of the healthcare industry.
mortality and morbidity is a key priority of the World Health
The CPG Committee supervises and coordinates the preparation of Organization (WHO).
new guidelines and approves their publication. In addition to review by In managing maternal and foetal health, it is essential to balance the
the CPG Committee, ESC Guidelines undergo multiple rounds of
risks and benefits of maternal and foetal therapeutic needs. Due to
double-blind peer review on a dedicated online review platform. The re-
the scarcity of prospective or randomized studies within this field,
view is conducted by topic experts, including members from ESC
which often cannot be performed for ethical reasons, most recommen-
National Cardiac Societies and from relevant ESC Subspecialty
dations in these Guidelines are based on evidence level
Communities. Guideline Task Forces consider all review comments
C. Consequently, there is an ongoing need for more registries, such
and are required to respond to all those classified as major. After appro-
as the Registry of Pregnancy and Cardiac Disease (ROPAC) and the
priate revisions, the Task Force and the CPG Committee members ap-
European Surveillance of Congenital Anomalies network, and pro-
prove the final document for publication in the European Heart Journal.
spective studies to enhance our understanding in this area.
Unless otherwise stated, ESC Guidelines content refers to sex,
understood as the biological condition of being male or female, defined
2.3. What is new
by genes, hormones, and sexual organs. Off-label use of medication may
be presented in this guideline if a sufficient level of evidence shows that As mentioned in Section 2.1, this new version of the guidelines not only
it can be considered medically appropriate for a given condition. includes an update to several recommendations (Table 4) but also in-
However, decisions on off-label use must be made by the responsible troduces a structural revision. See Supplementary data online
health professional giving special consideration to ethical rules concern- (Table S1) for a detailed overview of the new recommendations.
ing healthcare, the specific situation of the patient, patient consent, and Below we discuss the key updates per section, highlighting a selection
country-specific health regulations. of new and revised recommendations along with their rationale.
(cid:144)(cid:141)(cid:143)(cid:141)(cid:27)(cid:18)(cid:129)(cid:127)©
Downloaded
from

by
guest
on
22
January
2026

4470 E S C G u id e l in e s
Table 3 Updates of the 2025 Guidelines on cardiovascular disease and pregnancy
Topic New information Rationale
Pregnancy Heart Teama Broader acceptance, dedicated section Ensure comprehensive care throughout reproductive
stagesb
Risk stratificationa,c mWHO 2.0 classification, refined and expanded More data have emerged, necessitating more nuanced risk
clinical categories assessment for patient counselling1,2
Clinical data and research ROPAC3–12 and PPCM13–17 registries New or updated clinical management
Cardiomyopathies
Primary arrhythmia syndromes
Clinical scenarios Algorithms for management of clinical situations in Provide practical information for the clinical cardiologist
pregnant women
Genetic testing and counselling Advancements in testing and pre-implantation Incorporation of latest management of genetic testing and
procedures counselling
Revision of contraindications (COR III) for Emphasis on the critical role of comprehensive Recognition of a woman’s autonomy in making
pregnancy in women classified as mWHO counselling by the Pregnancy Heart Team (COR I) reproductive choices
class IV Promoting a detailed and transparent dialogue about the
heightened risks and encouraging shared decision-making
Adverse pregnancy outcomes (APO) Increased focus on long-term outcomes Evidence supports the need for thorough discussion and
management of APOs18
COR, class of recommendation; mWHO, modified World Health Organization; PPCM, peripartum cardiomyopathy; ROPAC, Registry of Pregnancy and Cardiac Disease.
aSee Section 4.
bSee Figure 2.
cSee Table 6.
Table 4 New recommendations
Recommendations Classa Levelb
Section 4. The Pregnancy Heart Team
Although the concept of the Pregnancy Heart Team was previously part of the general principles, it has now been given its own dedicated section, which covers all
aspects from pre-conception through to the postpartum period.
A discussion by the Pregnancy Heart Team about the high risk of maternal mortality or morbidity and the related high foetal risk is
recommended for women with mWHO 2.0 class IV conditions, including a shared decision-making process for pregnancy termination, I C
involving psychological support.
It is recommended that women with CVD of mWHO 2.0 class II–III and above are evaluated and managed by a Pregnancy Heart Team from
I C
pre-pregnancy onwards through pregnancy and post-partum.
Measurement of BNP and NT-proBNP levels should be considered prior to pregnancy in women with HF of any aetiology, including
previous PPCM, cardiomyopathy, ACHD, and PAH, and be monitored during pregnancy according to the underlying disorder and in case of IIa B
new-onset or worsening symptoms.
Section 5. Drugs during pregnancy and lactation
Given the importance of medication use throughout this document, this section has been brought forward and revised. The former comprehensive medication
table has been moved to the Supplementary data online, and we provide a summary figure (Figure 6) listing the (contra)indicated medications.
Section 6. Pregnancy in women with cardiomyopathies and primary arrhythmia syndromes
This section has been expanded since 2018 for advice in specific cardiomyopathies and primary arrhythmias.
Vaginal delivery is recommended in most women with CMPs, unless there are obstetric indications for caesarean section, severe HF
(EF <30% and/or NYHA class III/IV), uncontrolled arrhythmias, or severe outflow obstruction (≥50 mmHg) in women with HCM, or in I C
women presenting in labour on VKAs.
In women with DCM and worsening of EF during pregnancy, counselling on the risk of recurrence during a subsequent pregnancy is
I C
recommended in all cases, even after recovery of LV function.
It is recommended that women with HCM with symptomatic LV dysfunction (EF <50%) and or severe LVOTO (≥50 mmHg) wishing to
I C
become pregnant are counselled by the Pregnancy Heart Team regarding the high risk of pregnancy-related adverse events.
Myosin inhibitors are not recommended in women during pregnancy due to lack of safety data. III C
Continued
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4471
Beta-blockers, with pre-pregnancy dose and with nadolol and propranolol as drugs of choice, are recommended during pregnancy in
I B
women with LQTS.
It is recommended to continue beta-blocker therapy during lactation in women with LQTS to reduce arrhythmic risk. I B
Pre-pregnancy dose beta-blockers of nadolol or propranolol is recommended in patients with LQT2, particularly in the post-partum period,
I B
which represents a high-risk period for life-threatening arrhythmias.
Beta-blockers, with pre-pregnancy dose and with nadolol and propranolol as drugs of choice, are recommended during pregnancy and
I C
lactation in women with CPVT.
Flecainide, in addition to beta-blockers, is recommended in women with CPVT who experience cardiac events, such as syncope, VT, or
I C
cardiac arrest during pregnancy.
Section 7. Peripartum cardiomyopathy
We have provided a separate section on PPCM in these guidelines.
Genetic counselling and testing should be considered in women with PPCM. IIa C
When a reversible course of HF is assumed, treatment in accordance with HF guidelines should be considered for at least 12 months after
IIa C
complete LV recovery (normalization of LV volumes and EF).
Section 8. Pregnancy in women with aortopathies
Since 2018, significant evidence has emerged in the context of heritable thoracic aortic disease (HTAD), supporting a more gene- and variant-based approach,
which has been incorporated in this version of the guidelines.
It is recommended that women with a history of aortic dissection or -surgery have pre-pregnancy counselling about the high risk by an
extended Pregnancy Heart Team considering the presence and type of genetic variant, aortic morphology, growth rate, and aetiology of I C
aortic dissection.
Section 9. Pregnancy in women with known congenital heart disease
This section has undergone a major update based on recent reports, which have been summarized in a clear and concise table.
It is recommended that all women with Fontan circulation who wish to become pregnant receive counselling from the Pregnancy Heart
I C
Team regarding the high risk of pregnancy-related adverse events.
Section 10. Pregnancy in women with pulmonary arterial hypertension
This subject is now covered in a separate section in these guidelines, in line with growing insights into management.
It is recommended that women of childbearing potential with PAH wishing to become pregnant are counselled by a multidisciplinary team regarding
I C
the very high risk of pregnancy-related adverse events, encouraging a shared decision-making process about whether to become pregnant.
Section 11. Venous thromboembolism in pregnancy and post-partum
Guidance on the involvement of an expert team and more prompt initiation of treatment are now provided in dedicated flowcharts and recommendations.
In pregnant women or women in the post-partum period with suspicion of venous thromboembolism (VTE) [deep vein thrombosis (DVT)
I B
and/or PE], an immediate formal diagnostic assessment with validated methods is recommended and should not be postponed.
Section 12. Pregnancy in women with acquired heart disease
Recommendations for emergency situations are provided for acquired heart diseases in addition to the new sections on cardio-oncology and heart transplantation.
Recommendations for coronary artery disease and pregnancy
In pregnant women with chest pain, it is recommended to exclude life-threatening cardiovascular conditions, including PE, ACS (including
I C
SCAD), and acute aortic syndrome.
The duration of DAPT (aspirin and clopidogrel) in pregnant women undergoing coronary stent implantation is recommended to be the
I C
same as in non-pregnant women, with an individual approach considering ischaemic risk and delivery-related bleeding risks.
Continuation of statins may be considered during pregnancy in women with established ASCVD. IIb C
Recommendations for hypertensive disorders and pregnancy
It is recommended to aim for systolic BP <140 mmHg and diastolic BP <90 mmHg in pregnant women. I B
In severe hypertension, drug treatment with i.v. labetalol, urapidil, nicardipine, or oral short acting nifedipine or methyldopa is
I C
recommended for acute reduction in blood pressure. Intravenous hydralazine is a second-line option.
Recommendations for supraventricular tachycardia and pregnancy
Therapeutic anticoagulation with LMWH is recommended for pregnant women with persistent or permanent AF at elevated
I C
thromboembolic risk.
Flecainide, in addition to beta-blockers, should be considered for long-term AF rhythm control in pregnancy. IIa C
Recommendation for ventricular tachycardia, device implantation and catheter ablation and pregnancy
When performing catheter ablation during pregnancy, the use of non-fluoroscopic mapping and navigation systems should be considered. IIa C
Continued
Downloaded
from

by
guest
on
22
January
2026

4472 E S C G u id e l in e s
Recommendations for cardiac arrest and pregnancy
Continuous manual left uterine displacement during CPR in pregnant women (≥20 weeks) with cardiac arrest is recommended to relieve
I C
aortocaval compression.
It is recommended to establish i.v. access above the diaphragm to ensure that the i.v. therapy is not obstructed by the gravid uterus. I C
It is recommended that no drugs are withheld in pregnant women with cardiac arrest due to concerns of teratogenicity. I C
Recommendation for congenital atrioventricular block and pregnancy
In pregnant women with asymptomatic congenital AV block, normal cardiac anatomy and function, a narrow QRS complex, and ventricular
III C
rate (≥50 b.p.m.) a prophylactic temporary pacemaker during delivery is not recommended.
Recommendation for native valve disease and pregnancy
Valve surgery during pregnancy should only be considered when there is a maternal mortality risk and other treatment options have failed. IIa C
Recommendation for prosthetic valves disease and pregnancy
It is recommended that a care plan documenting the agreed anticoagulant strategy (including the decision to continue VKAs or converting to
therapeutic-dose LMWH in the first trimester) is in place for women of childbearing age with a MHV prior to pregnancy or as soon as I C
pregnancy is recognized.
Recommendations for chronic and acute heart failure and pregnancy
Inotropes and/or vasopressors are recommended in pregnant women with cardiogenic shock with levosimendan, dobutamine, and
I C
milrinone as recommended agents.
ACE-Is, ARBs, ARNIs, MRAs, ivabradine, and SGLT2 inhibitors are not recommended during pregnancy due to adverse foetal effects. III C
Recommendations for heart transplantation and pregnancy
It is recommended to postpone pregnancy until at least 1 year after heart transplantation, taking individual risk factors into account. I C
In women with a heart transplant, it is recommended that immunosuppression serum drug levels are monitored during pregnancy every 4 weeks
I C
until the 32nd week, then every 2 weeks until the 36th week, then weekly until delivery and for 6–12 months after delivery to guide dosing.
Recommendation for cardio-oncology and pregnancy
It is recommended that pregnant women with cancer who require cardiotoxic cancer therapy are jointly managed by the Pregnancy Heart
I C
Team and the cardio-oncology team.
Section 13. Long-term effects of adverse pregnancy outcomes
This is a completely new section in the guidelines, reflecting the growing recognition of the importance of APOs.
It is recommended to undertake a cardiovascular risk assessment in women with APOs, to recognize and document APOs when CVD risk is
I B
evaluated in women, and to provide counselling on the importance of healthy lifestyle choices that optimize cardiovascular health.
ACE-I, angiotensin-converting enzyme inhibitor; ACHD, adult congenital heart disease; ACS, acute coronary syndrome; AF, atrial fibrillation; APO, adverse pregnancy outcomes; ARB,
angiotensin receptor blocker; ARNI, angiotensin receptor/neprilysin inhibitor; ASCVD, atherosclerotic cardiovascular disease; AV, atrioventricular; BNP, brain natriuretic peptide; BP,
blood pressure; CMP; cardiomyopathy; CPR, cardiopulmonary resuscitation; CPVT, catecholaminergic polymorphic ventricular tachycardia; CVD, cardiovascular disease; DAPT, dual
antiplatelet therapy; DCM, dilated cardiomyopathy; DVT, deep vein thrombosis; EF, ejection fraction; HCM, hypertrophic cardiomyopathy; HF, heart failure; HTAD, heritable thoracic
aortic disease; i.v., intravenous; LMWH, low-molecular-weight heparin; LQT2, long QT syndrome type 2; LQTS, long QT syndrome; LV, left ventricle; LVOTO, left ventricular outflow
tract obstruction; MHV, mechanical heart valve; MRA, mineralocorticoid receptor antagonist; mWHO, modified World Health Organization; NT-proBNP, N-terminal pro-brain
natriuretic peptide; NYHA, New York Heart Association; PAH, pulmonary arterial hypertension; PE, pulmonary embolism; PPCM, peripartum cardiomyopathy; SCAD, spontaneous
coronary artery dissection; SGLT2, sodium–glucose co-transporter-2; VKA, vitamin K antagonist; VT, ventricular tachycardia; VTE, venous thromboembolism.
aClass of recommendation.
bLevel of evidence.
2.4. What has changed of cardiovascular diseases during pregnancy. See Supplementary
data online (Table S2) for a detailed overview of all modified
Table 5 lists the recommendations with a revised Class of
recommendations.
Recommendation since the 2018 Guidelines for the management
Table 5 Revised recommendations
Recommendations in 2018 Classa Levelb Recommendations in 2025 Classa Levelb
Section 4. The Pregnancy Heart Team
Prophylactic antibiotic therapy to prevent endocarditis Systemic antibiotic prophylaxis may be considered for
III C IIb C
during delivery is not recommended. delivery in women at high risk.
Section 6. Recommendations for cardiomyopathies and pregnancy
In patients with HCM, it is recommended that Continuation of beta-blockers should be considered
beta-blockers are continued in women who used them I C during pregnancy in women with CMPs, with close IIa C
before pregnancy. follow-up of foetal growth.
Continued
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4473
Section 8. Recommendations for aortopathies, cardiac surgery, and pregnancy
Pregnancy is not recommended in patients with It is recommended that women with vascular Ehlers–
vascular Ehlers–Danlos syndrome. Danlos syndrome wishing to become pregnant are
counselled regarding the very high risk of
III C I C
pregnancy-related adverse events by a multidisciplinary
team, considering family history, genetic variant, and
previous vascular events.
Beta-blocker therapy throughout pregnancy should be Beta-blocker therapy throughout pregnancy and in the
considered in women with Marfan syndrome and other IIa C post-partum period is recommended in women with I C
heritable thoracic aortic diseases. MFS and other HTADs.
Section 9. Recommendations for congenital heart disease and pregnancy
Patients with a systemic right ventricle (Mustard/ It is recommended that women with a systemic RV
Senning or congenitally corrected TGA), in NYHA class (Mustard/Senning or congenitally corrected TGA), in
III/IV, systemic ventricular dysfunction (EF <40%), or NYHA class III/IV, systemic ventricular dysfunction
IIa C I C
severe TR should be advised against pregnancy. (EF <40%), or severe TR wishing to become pregnant
are counselled by the Pregnancy Heart Team regarding
the high risk of pregnancy-related adverse events.
Section 12. Recommendations for acquired heart disease and pregnancy
An invasive management strategy should be considered It is recommended to manage pregnant women with
for NSTE ACS with high-risk criteria. IIa C ACS in the same way as non-pregnant women, including I C
diagnostic investigations and interventions.
Catheter ablation with electro-anatomical systems Catheter ablation may be considered in pregnant
should be considered in experienced centres in cases of IIa C women with recurrent, long symptomatic SVT or with IIb C
drug-refractory and poorly tolerated SVT. contraindications to pharmacological therapies.
Balloon aortic valvuloplasty should be considered In very selected symptomatic pregnant women with
during pregnancy in patients with severe aortic stenosis severe aortic stenosis not responding to medical
IIa C IIb C
and severe symptoms. therapy, non-surgical options such as balloon
valvuloplasty or TAVI may be considered.
A bioprosthesis should be considered in young women A bioprosthetic valve is recommended (over a
contemplating pregnancy. IIa C mechanical valve) in young women contemplating I B
pregnancy requiring a valve prosthesis.
During the second and third trimesters, LMWH with During the second and third trimesters until the 36th
anti-factor Xa level monitoring and dose adjustment week, continuing VKAs should be considered in women
(see separate recommendations) may be considered in IIb C with prosthetic heart valves at higher risk of thrombosis. IIa C
women who need a high dose of VKA after patient
information and consent.
ACS, acute coronary syndrome; CMP, cardiomyopathy; EF, ejection fraction; HCM, hypertrophic cardiomyopathy; HTAD, heritable thoracic aortic disease; LMWH, low-molecular-weight
heparin; MFS, Marfan syndrome; NSTE ACS, non-ST-elevation myocardial infarction; NYHA, New York Heart Association; RV, right ventricle; SVT, supraventricular tachycardia; TAVI,
transcatheter aortic valve implantation; TGA, transposition of the great arteries; TR, tricuspid regurgitation; VKA, vitamin K antagonist.
aClass of recommendation.
bLevel of evidence.
3. General considerations caused by CVD are preventable.33 Women with CVD during pregnancy
face higher risk of cardiac events later in life, making secondary prevention
3.1. Epidemiology crucial.25 Adverse neonatal outcomes occur in ∼25% of these pregnancies
in women with CVD34,35 with high rates of obstetric complications (17%)
Within high-income countries the number of pregnancies and deliveries in
and maternal mortality/morbidity (11%).34,35 Of note, recent research in-
women with acquired, congenital, or inherited CVD is growing significant-
ly.19–21 This trend originates from several factors: higher maternal age at dicates that pre-existing CVD in the mother is associated with an in-
creased risk of CVD in her children, and this association is unlikely to be
first pregnancy, a growing number of women with congenital heart disease
explained by unmeasured familial or genetic factors.36
reaching childbearing age, and a rising prevalence of cardiovascular co-
morbidities.19–21 Globally, up to 4% of pregnancies are complicated by
CVD, rising to 10% when including hypertensive disorders.22–25 3.2. Physiology of pregnancy
Maternal CVD is now the leading cause of non-obstetric mortality in preg- Pregnancy induces physiological changes in the cardiovascular system to
nant women24,26, accounting for 33% of pregnancy-related deaths world- meet the increased metabolic needs of the mother and foetus (Figure 1).
wide.25,27,28 In women with pre-existing CVD, up to 16% of pregnancies These changes occur from the early stages of pregnancy onward. Starting
are complicated by CVD.29–32 Notably, 68% of pregnancy-related deaths at 6 weeks of gestation, stroke volume and cardiac output (CO) increase
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

4474 E S C G u id e l in e s
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:24)(cid:30)(cid:28)(cid:23)(cid:22)(cid:21)(cid:22)(cid:20)(cid:30)(cid:24)(cid:19)(cid:29)(cid:18)
(cid:22)(cid:23)(cid:21)(cid:25)(cid:20)(cid:23)(cid:26)(cid:19)
(cid:18)(cid:17)(cid:16)(cid:15)(cid:14)(cid:13)(cid:12)(cid:23)(cid:17)(cid:11)(cid:26)(cid:10)(cid:24)
(cid:29)(cid:28)(cid:27) (cid:143)(cid:13)(cid:6) (cid:144)(cid:26)(cid:6)(cid:17) (cid:4)(cid:10)(cid:28)(cid:27)(cid:8)
(cid:9)(cid:26)(cid:23)(cid:8)(cid:9)(cid:26)(cid:23)(cid:12)(cid:13)(cid:14)(cid:13)(cid:16)(cid:19)
(cid:27)(cid:26)(cid:25)(cid:24)(cid:23)(cid:28)(cid:27)(cid:23)(cid:26) (cid:17)(cid:27)(cid:26)(cid:25)(cid:24)(cid:23)(cid:28)(cid:27)(cid:23)(cid:26) (cid:27)(cid:26)(cid:25)(cid:24)(cid:23)(cid:28)(cid:27)(cid:23)(cid:26) (cid:9)(cid:14)(cid:26)(cid:27)(cid:5)(cid:24)
(cid:7)(cid:14)(cid:26)(cid:6)(cid:25)(cid:14)(cid:16)(cid:17)(cid:10)(cid:5)(cid:27)(cid:9)(cid:5)(cid:27)
(cid:31)(cid:30)
(cid:4)(cid:21)(cid:14)(cid:28)(cid:24)(cid:14)(cid:17)(cid:20)(cid:10)(cid:21)(cid:5)(cid:24)(cid:23)
(cid:3)(cid:23)(cid:14)(cid:26)(cid:27)(cid:17)(cid:26)(cid:14)(cid:27)(cid:23)
(cid:143)(cid:30)
(cid:30)
(cid:4)(cid:23)(cid:26)(cid:25)(cid:9)(cid:15)(cid:23)(cid:26)(cid:14)(cid:21)(cid:17)(cid:20)(cid:14)(cid:28)(cid:16)(cid:5)(cid:21)(cid:14)(cid:26)(cid:17)(cid:26)(cid:23)(cid:28)(cid:25)(cid:28)(cid:27)(cid:14)(cid:13)(cid:16)(cid:23) (cid:1)(cid:17)(cid:127)(cid:23)(cid:23)(cid:129)(cid:28)(cid:17)(cid:9)(cid:10)(cid:28)(cid:27)(cid:8)(cid:9)(cid:14)(cid:26)(cid:27)(cid:5)(cid:24)(cid:141)
(cid:22)(cid:25)(cid:14)(cid:28)(cid:27)(cid:10)(cid:21)(cid:25)(cid:16)(cid:17)(cid:14)(cid:13)(cid:6)(cid:17)(cid:28)(cid:19)(cid:28)(cid:27)(cid:10)(cid:21)(cid:25)(cid:16)(cid:17)(cid:2)(cid:4) (cid:16)(cid:14)(cid:26)(cid:6)(cid:25)(cid:14)(cid:16)(cid:17)(cid:10)(cid:5)(cid:27)(cid:9)(cid:5)(cid:27)(cid:17)(cid:14)(cid:27)
(cid:9)(cid:26)(cid:23)(cid:8)(cid:9)(cid:26)(cid:23)(cid:12)(cid:13)(cid:14)(cid:13)(cid:16)(cid:19)(cid:17)(cid:20)(cid:14)(cid:21)(cid:5)(cid:23)(cid:28)(cid:17)
(cid:8)(cid:143)(cid:30)
(cid:17)(cid:16)(cid:15)(cid:21)(cid:22)(cid:20)(cid:30)(cid:24)(cid:19)(cid:29)(cid:18) (cid:17)(cid:22)(cid:20)(cid:27)(cid:22)(cid:30)(cid:14)(cid:26)(cid:23)(cid:27)(cid:19)(cid:14)(cid:30)(cid:13)(cid:20)(cid:23)(cid:22)(cid:21)(cid:22)(cid:20)(cid:30)(cid:24)(cid:19)(cid:29)(cid:18)
(cid:10)(cid:24)(cid:22)(cid:20)(cid:30)(cid:24)(cid:19)(cid:29)(cid:26)
‚(cid:10)(cid:26)(cid:27)(cid:25)(cid:16)(cid:17)(cid:26)(cid:10)(cid:10)(cid:27)(cid:17)(cid:6)(cid:25)(cid:14)(cid:24)(cid:23)(cid:27)(cid:23)(cid:26)
€„(cid:157)‰
(cid:4)…(cid:17)(cid:25)(cid:13)(cid:27)(cid:23)(cid:26)(cid:20)(cid:14)(cid:21)
…„(cid:157)‰
(cid:28)(cid:15)(cid:10)(cid:26)(cid:27)(cid:23)(cid:13)(cid:23)(cid:6)(cid:17)
‡(cid:4)‚(cid:4) €‚(cid:17)(cid:28)(cid:25)ƒ(cid:23)(cid:17)(cid:14)(cid:13)(cid:6)
(cid:20)(cid:10)(cid:21)(cid:5)(cid:24)(cid:23)
(cid:12)(cid:28)(cid:30)(cid:11)(cid:11)(cid:21)(cid:22)(cid:20)(cid:30)(cid:24)(cid:19)(cid:29)(cid:18)
€„(cid:157)(cid:22)(cid:22)
(cid:4)(cid:26)(cid:10)(cid:24)(cid:25)(cid:13)(cid:23)(cid:13)(cid:27)(cid:17) ‡(cid:24)(cid:14)(cid:21)(cid:21)(cid:17)(cid:9)(cid:23)(cid:26)(cid:25)(cid:16)(cid:14)(cid:26)(cid:6)(cid:25)(cid:14)(cid:21)(cid:17)
Š(cid:17)(cid:127)(cid:14)(cid:20)(cid:23) ‰(cid:21)(cid:14)(cid:27)(cid:27)(cid:23)(cid:13)(cid:23)(cid:6)‹(cid:25)(cid:13)(cid:20)(cid:23)(cid:26)(cid:27)(cid:23)(cid:6) (cid:23)ˆ(cid:5)(cid:28)(cid:25)(cid:10)(cid:13)(cid:17)
Œ(cid:17)(cid:127)(cid:14)(cid:20)(cid:23) €„(cid:17)(cid:24)(cid:14)(cid:28)(cid:28)
…„(cid:17)†(cid:14)(cid:28)(cid:14)(cid:21)(cid:17)(cid:14)(cid:13)(cid:6)
(cid:10)(cid:26)(cid:24)(cid:14)(cid:21)(cid:17)(cid:157)(cid:7)
(cid:24)(cid:25)(cid:6)(cid:17)(cid:6)(cid:25)(cid:14)(cid:24)(cid:23)(cid:27)(cid:23)(cid:26)(cid:28)
(cid:4)(cid:26)(cid:23)(cid:12)(cid:13)(cid:14)(cid:13)(cid:16)(cid:19)(cid:17)(cid:157)(cid:7)
Figure 1 Physiology of haemodynamic changes, and changes in electrocardiogram and echocardiography during and post pregnancy. BP, blood pressure;
ECG, electrocardiogram; LA, left atrium; LV, left ventricle; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; RV, right
ventricle; RVEF, right ventricular ejection fraction; SPAP, systolic pulmonary artery pressure.
by 30%–50%, and heart rate increases by 10–20 beats per minute. atrial and ventricular tachyarrhythmias. Atrial arrhythmias may develop
Peripheral vascular resistance decreases by 20%–50%.37 in response to cardiac stretch and hormonal changes in pregnancy and
Left and right atrial and ventricular diameters and volumes increase may not be well tolerated in women with CVD. The haemodynamic
while ventricular function is preserved.38 Blood pressure and CO in- and hormonal changes during pregnancy are risk factors for aortic dis-
crease during labour.39 After delivery, the uterus contracts, and CO section in women with aortopathy.40 Pregnancy is a hypercoagulable
drops rapidly to ∼15%–25% above normal. A gradual decrease of state associated with an increased risk of thromboembolism.41
CO follows over the next 3–4 weeks and reaches pre-pregnancy levels Increased activity of gastrointestinal–hepatic metabolism, liver enzyme
at ∼6 weeks post-partum. systems, glomerular filtration rate and plasma volume, changes in pro-
In women with heart disease, left and right ventricular adaptation to tein binding, and decreased serum albumin levels all contribute to
pregnancy can be suboptimal and can lead to heart failure (HF) and changes in the pharmacokinetics of many drugs.42
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4475
4. The Pregnancy Heart Team Maternal preferences should be thoroughly explored as part of the
shared decision-making process.
4.1. Concept and requirements
The central role of the Pregnancy Heart Team is illustrated in 4.2.1.1. Maternal risk assessment
Figure 2. The concept of the Pregnancy Heart Team was first intro- Depending on the diagnosis, a cardiovascular assessment may include im-
duced in the 2018 ESC Guidelines for the management of cardiovas- aging, biomarker-level assessment, and functional testing. Cardiopulmonary
cular diseases during pregnancy.43 It has become an established exercise testing can be useful for pre-pregnancy risk stratification.59,60
component in the care of women with CVD or those who develop Assessment may include re-evaluation after discontinuation of teratogenic
cardiovascular problems during pregnancy.44–49 This care provision medications and whether pre-pregnancy intervention is required.
commences prior to pregnancy and persists through the post- Various scoring systems are available to assess maternal risk and foetal
partum period. Research has shown that management by a risk. These do not fully explore the interaction with non-cardiac risk factors,
Pregnancy Heart Team is associated with favourable maternal, foetal, only focus on maternal cardiac events, and have mainly been validated in
and healthcare services outcomes, including lowered maternal mor- higher-income countries. Further adaptation and validation in other coun-
tality and readmission rates and subsequently improved patient tries may be required.51 Despite these limitations, disease-specific risks can
safety.50 Institutional Pregnancy Heart Teams should be established be effectively assessed using the mWHO classification, validated as the
in referral hospitals, taking into account the geographical regions, best-available risk assessment model.1,61 However, the mWHO classifica-
disciplines represented, and numbers of births, as well as sociocul- tion is oriented towards adult congenital heart disease (ACHD) and iden-
tural aspects.44,45,47–49 Maintaining a balance between the need for tifying those at the highest risk. Therefore, the mWHO 2.0 classification has
follow-up by such teams and the workload on these teams is crucial, now been expanded with other CVDs and refined by integrating the
emphasizing the importance of carefully selecting women who should Cardiac Disease in Pregnancy study (CARPREG) II (Table 6).52 Specific ex-
be directed to a Pregnancy Heart Team. Patient selection is best ac- pertise and collaborative management by a Pregnancy Heart Team is man-
complished by a risk assessment using the modified World Health datory for all women with a condition of mWHO 2.0 class II–III or above.
Organization (mWHO) 2.0 classification (Table 6). The Pregnancy
Heart Team should encompass a core team that can be expanded 4.2.2. Genetic counselling
with other experts (see Figure 3), tailored to women’s physical and
Several CVDs have a genetic basis, including heritable cardiac conditions
mental health or emerging complications.53
such as some aortopathies, channelopathies, cardiomyopathies, congenital
The primary responsibilities of the Pregnancy Heart Team encompass
heart disease, and subsets of pulmonary arterial hypertension (PAH) and
risk assessment, collaborative care plan development, continuous
thromboembolic disease. Most show autosomal dominant inheritance
progress monitoring, coordination, patient education, and psycho-
with a 50% transmission risk. Knowledge of an underlying pathogenic/likely
logical counselling. A staged approach is recommended, from
pathogenic (P/LP) variant (adjusted terminology for mutation) is of increas-
pre-conception and pregnancy through to labour, delivery, and
ing importance to better assess pregnancy-related outcomes and to adjust
post-partum care. Promoting shared decision-making is essential management (Figure 4).62,63 Therefore, it is recommended that genetic
at all stages. Not every hospital needs to establish a dedicated
testing for CVD is performed pre-pregnancy in a specialized cardiogenetic
Pregnancy Heart Team, but each hospital should establish commu-
centre or a network model with access to a multidisciplinary team, involv-
nication and collaboration with nearby expert teams, optimizing
ing appropriately trained professionals with expertise in genetic testing
emergency and elective referral pathways within a shared-approach
methodology, sequence variant interpretation, clinical application of genet-
care model.
ic testing, and pre- and post-testing genetic counselling about the transmis-
sion risk and the variable expression of an inherited genetic condition.64,65
4.2. Pre-pregnancy counselling and family
planning 4.2.2.1. Pre-natal and pre-implantation diagnosis
Women should receive pre-pregnancy counselling and education about A timely discussion about pre-implantation (or pre-gestational) genetic
the maternal, foetal, and transmission risk(s).54 In adolescents diagnosed testing and pre-natal testing should be offered to every woman and/or
with congenital or inherited heart disease, tailored discussions about re- couple when there is a known parental monogenic or chromosomal ab-
productive health should start early, ideally from menarche. Girls and wo- normality. Pre-implantation genetic testing requires in vitro fertilization
men with congenital heart disease may not demonstrate appropriate (IVF). The modalities of pre-natal and pre-implantation testing, including
understanding of safe contraception and pregnancy risk. High rates of un- precautions, are summarized in Table 7. The decision whether to pur-
intended pregnancies (up to 45%) have been reported in adolescents sue pre-implantation or pre-natal genetic testing should include consid-
with congenital heart disease.55 Transition programmes showed im- eration of a spectrum of aspects related to the disease, including
proved disease-related knowledge levels in adolescents with congenital cultural, religious, and legal issues, but also accessibility of required tech-
heart disease.56–58 niques and expertise.67 Counselling should be provided at an experi-
enced centre with an expert multidisciplinary team. An individualized
4.2.1. Risk assessment approach is required to ensure autonomous choice and informed
decision-making within the local ethical and legal framework. Several
A personalized pregnancy-related risk assessment is needed in all wo-
of these options take time and require early referral.
men with CVD and should encompass the specific cardiovascular diag-
nosis, functional status, and medication regimen, as well as non-cardiac
risk factors such as maternal age, smoking history, comorbidities, body 4.2.3. Reproductive technology
mass index (BMI), obstetric history, logistical care aspects, maternal Infertility rates in most women with CVD are similar to
ethnicity, and socioeconomic status. It is also crucial to integrate foetal those in the general population, but managing infertility and
and obstetric outcomes with specific cardiovascular considerations. medically assisted reproductive treatment is more complex.68
Downloaded
from

by
guest
on
22
January
2026

4476 E S C G u id e l in e s
(cid:31)(cid:30)(cid:29)(cid:21)(cid:25)(cid:20)(cid:25)(cid:27)(cid:19)(cid:18)(cid:17)(cid:29)(cid:20)(cid:30)(cid:23)(cid:18)(cid:16)(cid:29)(cid:20)(cid:15)(cid:18)
„…(cid:17)(cid:30)(cid:29)(cid:11)(cid:30)(cid:11)(cid:18)€(cid:14)(cid:17)(cid:16)(cid:18)(cid:26)(cid:24)(cid:30)(cid:12)(cid:14)†(cid:12)(cid:18)(cid:22)(cid:27)(cid:23)(cid:17)(cid:14)(cid:11)(cid:14)(cid:26)(cid:12)(cid:14)(cid:24)(cid:23)(cid:14)(cid:29)(cid:21)(cid:20)(cid:19)(cid:18)(cid:17)(cid:30)(cid:21)(cid:22)(cid:26)(cid:18)(cid:14)(cid:9)(cid:18)(cid:14)(cid:29)(cid:11)(cid:14)(cid:12)(cid:21)(cid:17)(cid:30)(cid:11)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:27)(cid:29)(cid:24)(cid:23)(cid:22)(cid:26)(cid:25)
(cid:2)(cid:14)(cid:26)(cid:1)(cid:18)(cid:21)(cid:26)(cid:26)(cid:30)(cid:26)(cid:26)(cid:22)(cid:30)(cid:29)(cid:17)(cid:18)(cid:22)(cid:127)(cid:10)(cid:129)(cid:18)(cid:141)(cid:143)(cid:144)
(cid:157)(cid:30)(cid:29)(cid:30)(cid:17)(cid:14)(cid:12)(cid:18)(cid:12)(cid:28)(cid:27)(cid:29)(cid:26)(cid:30)(cid:23)(cid:23)(cid:14)(cid:29)(cid:6)
(cid:14)(cid:9)(cid:30)(cid:26)(cid:17)(cid:19)(cid:23)(cid:30)(cid:18)(cid:12)(cid:28)(cid:27)(cid:29)(cid:26)(cid:30)(cid:23)(cid:23)(cid:14)(cid:29)(cid:6)
(cid:2)(cid:30)(cid:24)(cid:20)(cid:28)(cid:11)(cid:27)(cid:12)(cid:17)(cid:14)(cid:8)(cid:30)(cid:18)(cid:17)(cid:30)(cid:12)(cid:16)(cid:29)(cid:28)(cid:23)(cid:28)(cid:6)(cid:19)
(cid:20)(cid:27)(cid:6)(cid:18)(cid:20)(cid:30)(cid:8)(cid:14)(cid:30)€
(cid:7)(cid:23)(cid:14)(cid:29)(cid:14)(cid:12)(cid:21)(cid:23)(cid:18)(cid:28)(cid:24)(cid:17)(cid:14)(cid:22)(cid:14)‚(cid:21)(cid:17)(cid:14)(cid:28)(cid:29)
(cid:7)(cid:28)(cid:29)(cid:17)(cid:20)(cid:21)(cid:12)(cid:30)(cid:24)(cid:17)(cid:14)(cid:28)(cid:29)
(cid:31)(cid:30)(cid:29)(cid:21)(cid:25)(cid:20)(cid:25)(cid:27)(cid:19)
(cid:14)(cid:26)(cid:30)(cid:21)(cid:26)(cid:30)ƒ(cid:26)(cid:24)(cid:30)(cid:12)(cid:14)†(cid:12)
(cid:2)(cid:30)(cid:6)(cid:27)(cid:23)(cid:21)(cid:20)(cid:18)(cid:9)(cid:28)(cid:23)(cid:23)(cid:28)€ƒ(cid:27)(cid:24)(cid:18)(cid:21)(cid:29)(cid:11)(cid:18)(cid:20)(cid:14)(cid:26)(cid:1)(cid:18)(cid:21)(cid:26)(cid:26)(cid:30)(cid:26)(cid:26)(cid:22)(cid:30)(cid:29)(cid:17)
(cid:2)(cid:30)(cid:6)(cid:27)(cid:23)(cid:21)(cid:20)(cid:18)(cid:9)(cid:28)(cid:30)(cid:17)(cid:21)(cid:23)(cid:18)(cid:21)(cid:26)(cid:26)(cid:30)(cid:26)(cid:26)(cid:22)(cid:30)(cid:29)(cid:17)
(cid:28)(cid:12)(cid:27)(cid:22)(cid:30)(cid:29)(cid:17)(cid:30)(cid:11)(cid:18)(cid:11)(cid:30)(cid:23)(cid:14)(cid:8)(cid:30)(cid:20)(cid:19)(cid:18)(cid:24)(cid:23)(cid:21)(cid:29)
(cid:14)(cid:29)(cid:13)(cid:22)(cid:12)(cid:29)(cid:30)(cid:19)(cid:18)(cid:11)(cid:24)(cid:13)(cid:20)(cid:25)(cid:10)
‡(cid:14)(cid:22)(cid:14)(cid:29)(cid:6)(cid:18)(cid:21)(cid:29)(cid:11)(cid:18)(cid:22)(cid:28)(cid:11)(cid:30)(cid:18)(cid:28)(cid:9)(cid:18)(cid:11)(cid:30)(cid:23)(cid:14)(cid:8)(cid:30)(cid:20)(cid:19)
ˆ(cid:28)(cid:30)(cid:17)(cid:21)(cid:23)(cid:18)(cid:21)(cid:29)(cid:11)(cid:18)(cid:22)(cid:21)(cid:17)(cid:30)(cid:20)(cid:29)(cid:21)(cid:23)(cid:18)(cid:22)(cid:28)(cid:29)(cid:14)(cid:17)(cid:28)(cid:20)(cid:14)(cid:29)(cid:6)
(cid:13)(cid:29)(cid:21)(cid:30)(cid:26)(cid:17)(cid:16)(cid:30)(cid:26)(cid:14)(cid:21)(cid:18)(cid:21)(cid:29)(cid:11)(cid:18)(cid:24)(cid:21)(cid:14)(cid:29)(cid:18)(cid:20)(cid:30)(cid:23)(cid:14)(cid:30)(cid:9)(cid:18)(cid:22)(cid:30)(cid:17)(cid:16)(cid:28)(cid:11)(cid:26)
(cid:7)(cid:28)(cid:29)(cid:6)(cid:30)(cid:29)(cid:14)(cid:17)(cid:21)(cid:23)(cid:18) (cid:3)(cid:26)(cid:12)(cid:16)(cid:21)(cid:30)(cid:22)(cid:14)(cid:12)(cid:18) (cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:24)(cid:27)(cid:23)(cid:22)(cid:28)(cid:29)(cid:21)(cid:20)(cid:19)(cid:18)(cid:18) (cid:20)(cid:27)(cid:6)(cid:18)(cid:22)(cid:21)(cid:29)(cid:21)(cid:6)(cid:30)(cid:22)(cid:30)(cid:29)(cid:17)(cid:18)(cid:21)(cid:29)(cid:11)(cid:18)(cid:15)(cid:23)(cid:30)(cid:30)(cid:11)(cid:14)(cid:29)(cid:6)(cid:18)(cid:12)(cid:28)(cid:29)(cid:17)(cid:20)(cid:28)(cid:23)
(cid:16)(cid:30)(cid:21)(cid:20)(cid:17)(cid:18)(cid:11)(cid:14)(cid:26)(cid:30)(cid:21)(cid:26)(cid:30) (cid:16)(cid:30)(cid:21)(cid:20)(cid:17)(cid:18)(cid:11)(cid:14)(cid:26)(cid:30)(cid:21)(cid:26)(cid:30) (cid:17)(cid:16)(cid:20)(cid:28)(cid:22)(cid:15)(cid:28)(cid:30)(cid:22)(cid:15)(cid:28)(cid:23)(cid:14)(cid:26)(cid:22) (cid:30)(cid:8)(cid:14)(cid:12)(cid:30)(cid:18)(cid:22)(cid:21)(cid:29)(cid:21)(cid:6)(cid:30)(cid:22)(cid:30)(cid:29)(cid:17)
(cid:31)(cid:26)(cid:9)(cid:23)(cid:28)(cid:24)(cid:20)(cid:30)(cid:23)(cid:8)(cid:15)
(cid:5)(cid:30)(cid:20)(cid:14)(cid:24)(cid:21)(cid:20)(cid:17)(cid:27)(cid:22) (cid:7)(cid:21)(cid:20)(cid:11)(cid:14)(cid:21)(cid:12)(cid:18) (cid:5)(cid:27)(cid:23)(cid:22)(cid:28)(cid:29)(cid:21)(cid:20)(cid:19)
(cid:7)(cid:4)(cid:5) (cid:12)(cid:16)(cid:21)(cid:29)(cid:29)(cid:30)(cid:23)(cid:28)(cid:24)(cid:21)(cid:17)(cid:16)(cid:14)(cid:30)(cid:26) (cid:16)(cid:19)(cid:24)(cid:30)(cid:20)(cid:17)(cid:30)(cid:29)(cid:26)(cid:14)(cid:28)(cid:29)
‰(cid:20)(cid:30)(cid:21)(cid:26)(cid:17)(cid:9)(cid:30)(cid:30)(cid:11)(cid:14)(cid:29)(cid:6)(cid:18)(cid:21)(cid:29)(cid:11)(cid:18)(cid:23)(cid:21)(cid:12)(cid:17)(cid:21)(cid:17)(cid:14)(cid:28)(cid:29)
(cid:7)(cid:28)(cid:29)(cid:17)(cid:20)(cid:21)(cid:12)(cid:30)(cid:24)(cid:17)(cid:14)(cid:28)(cid:29)
(cid:4)(cid:21)(cid:17)(cid:30)(cid:20)(cid:29)(cid:21)(cid:23)(cid:18)(cid:12)(cid:21)(cid:20)(cid:11)(cid:14)(cid:21)(cid:12)(cid:18)(cid:9)(cid:28)(cid:23)(cid:23)(cid:28)€ƒ(cid:27)(cid:24)
(cid:13)(cid:28)(cid:20)(cid:17)(cid:14)(cid:12)(cid:18)(cid:11)(cid:14)(cid:26)(cid:30)(cid:21)(cid:26)(cid:30) (cid:13)(cid:20)(cid:20)(cid:16)(cid:19)(cid:17)(cid:16)(cid:22)(cid:14)(cid:21) (cid:10)(cid:30)(cid:21)(cid:20)(cid:17)(cid:18)(cid:9)(cid:21)(cid:14)(cid:23)(cid:27)(cid:20)(cid:30)
(cid:7)(cid:26)(cid:25)(cid:21)(cid:18)(cid:23)(cid:29)(cid:30)(cid:15)
(cid:3)(cid:11)(cid:30)(cid:29)(cid:17)(cid:14)(cid:9)(cid:19)(cid:18)(cid:21)(cid:11)(cid:8)(cid:30)(cid:20)(cid:26)(cid:30)(cid:18)(cid:24)(cid:20)(cid:30)(cid:6)(cid:29)(cid:21)(cid:29)(cid:12)(cid:19)(cid:18)(cid:28)(cid:27)(cid:17)(cid:12)(cid:28)(cid:22)(cid:30)
(cid:127)(cid:28)(cid:22)(cid:30)(cid:29)Š(cid:26)(cid:18)(cid:10)(cid:30)(cid:21)(cid:20)(cid:17)(cid:18)(cid:7)(cid:23)(cid:14)(cid:29)(cid:14)(cid:12)
(cid:7)(cid:21)(cid:20)(cid:11)(cid:14)(cid:28)(cid:8)(cid:21)(cid:26)(cid:12)(cid:27)(cid:23)(cid:21)(cid:20)(cid:18)(cid:20)(cid:14)(cid:26)(cid:1)(cid:18)(cid:9)(cid:21)(cid:12)(cid:17)(cid:28)(cid:20)(cid:18)(cid:26)(cid:12)(cid:20)(cid:30)(cid:30)(cid:29)(cid:14)(cid:29)(cid:6)
(cid:31)(cid:21)(cid:23)(cid:8)(cid:27)(cid:23)(cid:21)(cid:20) (cid:7)(cid:21)(cid:20)(cid:11)(cid:14)(cid:28)(cid:22)(cid:19)(cid:28)(cid:24)(cid:21)(cid:17)(cid:16)(cid:14)(cid:30)(cid:26) (cid:10)(cid:19)(cid:24)(cid:30)(cid:20)(cid:17)(cid:30)(cid:29)(cid:26)(cid:14)(cid:8)(cid:30)
(cid:16)(cid:30)(cid:21)(cid:20)(cid:17)(cid:18)(cid:11)(cid:14)(cid:26)(cid:30)(cid:21)(cid:26)(cid:30) (cid:11)(cid:14)(cid:26)(cid:28)(cid:20)(cid:11)(cid:30)(cid:20)(cid:26)
Figure 2 Central illustration. Role of Pregnancy Heart Team in pregnancy pathway. CMP, cardiomyopathy; mWHO, modified World Health Organization.
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4477
Table 6 Modified World Health Organization 2.0 classification of maternal cardiovascular risk
mWHO 2.0 I mWHO 2.0 II mWHO 2.0 II–III mWHO 2.0 III mWHO 2.0 IV
Diagnosis Ventricular (dys)function + pulmonary hypertension
Mild left ventricular Moderate left Severe left ventricular
impairment: EF >45%. ventricular impairment: impairment: EF <30%
Significantly impaired EF 30%–45%. or NYHA class III/IV.
RV (subpulmonary) Previous PPCM with Previous PPCM with
function. not more than mild more than mild left
residual left ventricular ventricular
impairment. impairment.
PAH.
Arrhythmias
Atrial or ventricular Most Low-risk LQTS: no Sustained ventricular
ectopic beats, isolated. supraventricular previous events + on tachycardia from any
arrhythmias. full dose beta-blocker aetiology.
Bradycardia therapy. LQT2 (post-partum).
requiring Low-risk CPVT: well Symptomatic CPVT
pacemaker. controlled by medical and LQTS not
therapy. adequately controlled
BrS with no previous by therapy.
events. BrS with previous
events.
Cardiomyopathy
HCM: genotype-positive Low-risk ARVC: ARVC with moderate/ DCM/NDLVC with
+ phenotype-negative. genotype-positive + no severe disease. severe left ventricular
or mild phenotype. HCM with arrhythmic impairment: EF <30%
HCM without and/or moderate or NYHA class III/IV.
complications. haemodynamic HCM with
DCM/NDLVC with complications. symptomatic severe
normal or mild left DCM/NDLVC with outflow tract
ventricular moderate left obstruction:
impairment: EF >45%. ventricular impairment: ≥50 mmHg.
EF 30%–45%. HCM with severely
symptomatic LV
dysfunction (EF <50%).
Congenital heart disease
Successfully repaired Unoperated Repaired Unrepaired cyanotic Systemic RV with
simple lesions without uncomplicated atrioventricular septal heart disease (not moderate or severely
significant residual atrial or ventricular defect without Eisenmenger). decreased ventricular
(haemodynamic) septal defect. significant residual Systemic RV with good function.
complications (atrial or Repaired tetralogy lesions. or mildly decreased Fontan with any
ventricular septal defect, of Fallot without Uncomplicated ventricular function. complication.
patent ductus arteriosus, significant residual Ebstein anomaly: mild Uncomplicated Fontan Eisenmenger
anomalous pulmonary haemodynamic/ to moderate TR, no circulation: good syndrome.
venous drainage). arrhythmic lesions. tricuspid stenosis, no ventricular function, no
Transposition of accessory pathway. significant valve disease
the great arteries or arrhythmias, good
with arterial switch exercise tolerance, and
without significant normal arterial
residual lesions. saturations.
Ebstein anomaly with
any complication.
Continued
Downloaded
from

by
guest
on
22
January
2026

4478 E S C G u id e l in e s
mWHO 2.0 I mWHO 2.0 II mWHO 2.0 II–III mWHO 2.0 III mWHO 2.0 IV
Valvular heart disease
Small or mild Native, homograft or Uncomplicated Severe mitral stenosis.
• pulmonary stenosis tissue valve disease not mechanical valve with Severe symptomatic
• mitral valve prolapse considered mWHO stable well controlled aortic stenosis.
without significant 2.0 I or IV: mild mitral INRs.
regurgitation. stenosis, moderate Moderate mitral stenosis.
aortic stenosis. Severe asymptomatic
Moderate valvular aortic stenosis.
regurgitation. Severe left-sided valvular
regurgitation.
Aortopathy
Non-HTAD mild aortic Turner syndrome Marfan or other Moderate aortic Severe aortic
dilatation (<40 mm). without HTAD syndrome dilatation: 40–45 mm in dilatation: >45 mm in
cardiovascular without aortic Marfan syndrome or Marfan syndrome or
features (BAV, dilatation. other HTAD; other HTAD,
coarctation, AHT, Aorta <45 mm in BAV 45–50 mm in BAV, >50 mm in BAV,
aortic dilatation). pathology. Turner syndrome ASI ASI >25 mm/m2 in
Repaired coarctation. 20–25 mm/m2, other Turner syndrome,
aortic dilatation other aortic dilatation
<50 mm. >50 mm.
Marfan with previous Vascular Ehlers–
aortic root replacement. Danlos syndrome.
Previous aortic Severe (re)coarctation.
dissection with stable Previous aortic
diameter. dissection with
increasing diameter.
Acquired + coronary heart disease + other
Prior SCAD.
Prior ischaemic cardiac
event (STEMI/NSTE
ACS).
Prior adverse pregnancy
outcome requiring
hospitalization.
Prior adverse
cardiovascular effects of
cancer treatment.
Risk No detectable increased Small increased risk Intermediate increased Significantly increased Extremely high risk of
risk of maternal mortality of maternal risk of maternal risk of maternal maternal mortality or
and no/mild increased risk mortality or mortality or moderate mortality or severe severe morbidity.
in morbidity. moderate increase to severe increase in morbidity.
in morbidity. morbidity.
Average Van Hagen 9.9% 7.7% 17.7% 28.9% 50.3%
maternal et al.
cardiac (2016)51
event Silversides 3.1% 21.7% 12.8% 21.1% 35.6%
ratesa et al.
(2018)52
Individualize each maternal risk with the modifiers belowb (derived from CARPREG II)52
CARPREG II score: 1 point CARPREG II score: 2 points CARPREG II score: 3 points
• No prior cardiac intervention indicated • Ventricular dysfunction • Prior cardiac event or arrhythmias
• Late pregnancy assessment • High-risk left-sided valve disease or outflow • Baseline NYHA III/IV or cyanosis
tract obstruction • Mechanical valve
• Pulmonary hypertension
• Coronary artery disease
• High-risk aortopathy
Continued
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4479
mWHO 2.0 I mWHO 2.0 II mWHO 2.0 II–III mWHO 2.0 III mWHO 2.0 IV
Involvement of the No No Yes Yes Yes
Pregnancy Heart
Team
Counselling Yes (by regular healthcare Yes (by regular Yes: expert counselling Yes: expert counselling Yes: expert
professional) healthcare by Pregnancy Heart by Pregnancy Heart counselling by
professional) Team is required Team is required Pregnancy Heart
Team is required, with
clear and thorough
discussion of very high
pregnancy risk and
shared
decision-making
process for
termination if
pregnancy occurs
Obstetric and cardiac Local hospital Local hospital Shared care with local Care led by Pregnancy Care led by Pregnancy
care during hospital + Pregnancy Heart Team Heart Team
pregnancy Heart Team
Location of delivery Local hospital Local hospital Shared care with local Expert centre, care led Expert centre, care led
hospital + Pregnancy by Pregnancy Heart by Pregnancy Heart
Heart Team. Location Team Team
depends on CV status
and evolution of
pregnancy
AHT, arterial hypertension; ARVC, arrhythmogenic right ventricular cardiomyopathy; ASI, aortic size index; BAV, bicuspid aortic valve; BrS, Brugada syndrome; CARPREG II, Cardiac Disease
in Pregnancy study II; CPVT, catecholaminergic polymorphic ventricular tachycardia; CV, cardiovascular; DCM, dilated cardiomyopathy; EF, ejection fraction; HCM, hypertrophic
cardiomyopathy; HTAD, heritable thoracic aortic diseases; INR, international normalized ratio; LQTS, long QT syndrome; LQT2, long QT syndrome type 2; LV, left ventricle; mWHO,
modified World Health Organization; NDLVC, non-dilated left ventricular cardiomyopathy; NSTE ACS, non-ST-elevation acute coronary syndrome; NYHA, New York Heart
Association; PAH, pulmonary arterial hypertension; PPCM, peripartum cardiomyopathy; RV, right ventricle; SCAD, spontaneous coronary artery dissection; STEMI, ST-elevation
myocardial infarction; TR, tricuspid regurgitation.
aDefinition of cardiac events: cardiac arrest, cardiac death, arrhythmia requiring treatment, left/right heart failure, thromboembolic event, aortic dissection, acute coronary syndrome, or
hospitalization for cardiac reason. Endocarditis only in van Hagen et al.51
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:29)(cid:26)(cid:25)(cid:24)(cid:23)(cid:22)(cid:21)(cid:23)(cid:20)(cid:19)(cid:18)(cid:29)(cid:30)(cid:17)(cid:29)
(cid:16)(cid:20)(cid:15)(cid:29)(cid:30)(cid:26)(cid:20)(cid:14)(cid:23)(cid:25)(cid:20)(cid:30)(cid:19)(cid:13)(cid:20)(cid:25)(cid:23)(cid:29)(cid:18)(cid:29)(cid:26)(cid:15)(cid:17) (cid:31)(cid:30)(cid:29)(cid:28)(cid:29)(cid:27)(cid:26)(cid:25)(cid:24)(cid:24) (cid:31)(cid:30)(cid:29)(cid:28)(cid:29)(cid:27)(cid:26)(cid:25)(cid:24)(cid:24) (cid:31)(cid:30)(cid:29)(cid:28)(cid:29)(cid:27)(cid:26)(cid:25)(cid:24)(cid:24)
(cid:143)(cid:5)(cid:4) (cid:144)(cid:25)(cid:22)(cid:30)(cid:29)(cid:23)(cid:157)(cid:23)(cid:5) (cid:144)(cid:25)(cid:22)(cid:30)(cid:29)(cid:23)(cid:157)(cid:23)(cid:3) (cid:144)(cid:25)(cid:22)(cid:30)(cid:29)(cid:23) (cid:3)
(cid:141)(cid:5)(cid:4)
(cid:129)(cid:5)(cid:4)
(cid:127)(cid:5)(cid:4)
(cid:1)(cid:5)(cid:4)
(cid:2)(cid:5)(cid:4)
(cid:3)(cid:5)(cid:4)
(cid:5)(cid:4)
(cid:16)(cid:12)(cid:11)(cid:10) (cid:16)(cid:12)(cid:11)(cid:10) (cid:16)(cid:12)(cid:11)(cid:10) (cid:16)(cid:12)(cid:11)(cid:10) (cid:16)(cid:12)(cid:11)(cid:10)
(cid:9)(cid:14)(cid:20)(cid:17)(cid:17)(cid:23)(cid:8) (cid:9)(cid:14)(cid:20)(cid:17)(cid:17)(cid:23)(cid:8)(cid:8) (cid:9)(cid:14)(cid:20)(cid:17)(cid:17)(cid:23)(cid:8)(cid:8)(cid:7)(cid:8)(cid:8)(cid:8) (cid:9)(cid:14)(cid:20)(cid:17)(cid:17)(cid:23)(cid:8)(cid:8)(cid:8) (cid:9)(cid:14)(cid:20)(cid:17)(cid:17)(cid:23)(cid:8)(cid:6)
bEstimation of maternal adverse cardiac event rate with integration of CARPREG II score. Reprinted from Silversides et al.52 with permission from Elsevier.
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

4480 E S C G u id e l in e s
(cid:17) (cid:28) (cid:6) (cid:23)
(cid:29)(cid:22)(cid:28)
(cid:26)(cid:8)(cid:29)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:27)(cid:24)(cid:23)(cid:24)(cid:22)(cid:27)(cid:21)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:30)(cid:27)(cid:26)(cid:25)(cid:28)(cid:24)(cid:23)(cid:22)(cid:21)(cid:28)
(cid:144)(cid:22)(cid:19)(cid:25)(cid:17)(cid:19)(cid:22)(cid:21)(cid:24)(cid:16)(cid:26)(cid:27)(cid:28)(cid:22)(cid:27)(cid:28)
(cid:27)(cid:20)(cid:28)(cid:23)(cid:26)(cid:22)(cid:19)(cid:26)(cid:27)(cid:29)
(cid:4)(cid:22)(cid:21)(cid:16)(cid:26)(cid:12)(cid:8)(cid:7)(cid:12)(cid:20)(cid:22)(cid:29)(cid:3)(cid:7)(cid:24)
(cid:24)
(cid:28)(cid:27)(cid:26)(cid:25)(cid:27)(cid:24)(cid:23) (cid:18) (cid:23)(cid:22)(cid:23) (cid:21)(cid:17) (cid:28)(cid:29) (cid:24)(cid:28) (cid:27)(cid:20)(cid:24)(cid:23) (cid:28)(cid:22) (cid:23)(cid:21) (cid:26)(cid:16) (cid:22)(cid:26) (cid:19)(cid:22) (cid:26)(cid:27)(cid:23)
(cid:29)
(cid:157) (cid:9)(cid:28)(cid:22) (cid:17)(cid:21) (cid:19)(cid:8)(cid:29)(cid:24)(cid:13) (cid:12)(cid:22)(cid:26) (cid:30)(cid:19)(cid:17) (cid:22)(cid:21) (cid:21)(cid:28) (cid:7)(cid:24)
(cid:24)(cid:3)(cid:7)(cid:20)(cid:28)(cid:21)(cid:29)(cid:28)(cid:30)(cid:27)(cid:26)(cid:12)(cid:30)
(cid:7)
(cid:26)
(cid:8) (cid:13)(cid:27)
(cid:29) (cid:4)(cid:12)(cid:21)(cid:12)(cid:30)(cid:22)(cid:21)(cid:7)(cid:24)(cid:22)(cid:21)(cid:29)(cid:28)(cid:21)(cid:7)(cid:24)(cid:16)(cid:26)(cid:27)(cid:28)(cid:22)(cid:27)(cid:28) (cid:15)
(cid:30) (cid:4)
(cid:26)
(cid:25)(cid:22)(cid:24) (cid:5)(cid:22)(cid:16)(cid:26)(cid:12)(cid:19)(cid:12)(cid:10)(cid:26)(cid:27)(cid:29) (cid:4)(cid:22)(cid:21)(cid:16)(cid:26)(cid:12)(cid:25)(cid:22)(cid:27)(cid:23)(cid:17)(cid:19)(cid:22)(cid:21)(cid:24)(cid:27)(cid:17)(cid:21)(cid:10)(cid:28)(cid:21)(cid:7) (cid:24) (cid:28)
(cid:26) (cid:6)
(cid:28) (cid:17)(cid:21)(cid:26)(cid:29)(cid:24)(cid:23)(cid:16)(cid:29)(cid:15) (cid:129)(cid:19)(cid:28)(cid:23)(cid:29)(cid:21)(cid:12)(cid:20)(cid:3)(cid:7)(cid:27)(cid:26)(cid:12)(cid:19)(cid:12)(cid:10)(cid:7) (cid:25)
(cid:29)(cid:13)(cid:27)
(cid:143)(cid:28)(cid:30)(cid:28)(cid:29)(cid:26)(cid:23)(cid:26)(cid:27)(cid:29) (cid:24)(cid:27)(cid:15)(cid:25)(cid:15)(cid:14)(cid:27)(cid:24)(cid:23)
(cid:7)(cid:26)(cid:8)(cid:13)(cid:27)(cid:15)(cid:25)(cid:15)(cid:14)(cid:27)(cid:24)(cid:23)
(cid:9)(cid:22)(cid:28)(cid:16)(cid:26)(cid:22)(cid:29)(cid:21)(cid:26)(cid:23)(cid:24)(cid:23)(cid:22)(cid:21)(cid:16)(cid:26)(cid:12)(cid:19)(cid:12)(cid:10)(cid:7)
(cid:26)
(cid:8) (cid:22)(cid:5)
(cid:5)
(cid:29)
(cid:8)(cid:22) (cid:9)(cid:17)(cid:19)(cid:8)(cid:12)(cid:30)(cid:12)(cid:19)(cid:12)(cid:10)(cid:26)(cid:27)(cid:29) (cid:18)(cid:16)(cid:17)(cid:19)(cid:29)(cid:24)(cid:23)(cid:12)(cid:30)(cid:10)(cid:28)(cid:30)(cid:26)(cid:29)(cid:22)(cid:19) (cid:13)
(cid:29) (cid:3)(cid:28)(cid:22)(cid:21)(cid:29)(cid:24)(cid:16)(cid:26)(cid:27)(cid:28)(cid:22)(cid:27)(cid:28) (cid:27) (cid:28)
(cid:16) (cid:27)
(cid:23) (cid:21)
(cid:10) (cid:9)(cid:21)(cid:26)(cid:8)(cid:22)(cid:21)(cid:7)(cid:24)(cid:23)(cid:22)(cid:21)(cid:28)(cid:24) (cid:29)
(cid:20)(cid:3)(cid:7)(cid:27)(cid:26)(cid:23)(cid:26)(cid:22)(cid:30)
(cid:20)(cid:19)(cid:18)(cid:24)
(cid:9)(cid:17)(cid:19)(cid:8)(cid:12)(cid:30)(cid:22)(cid:21)(cid:7)(cid:24)(cid:28)(cid:8)(cid:6)(cid:12)(cid:19)(cid:26)(cid:27)(cid:8)
(cid:21)(cid:28)(cid:27)(cid:20)(cid:12)(cid:30)(cid:27)(cid:28)(cid:24)(cid:29)(cid:28)(cid:22)(cid:8)
(cid:20)(cid:27)(cid:13)(cid:12)(cid:27)(cid:11)(cid:29) (cid:7)(cid:25)(cid:27)(cid:21)(cid:27)(cid:28)(cid:26)(cid:25)(cid:24)(cid:21)(cid:6)(cid:8)(cid:24)(cid:29)(cid:22)
(cid:4)(cid:19)(cid:26)(cid:30)(cid:26)(cid:23)(cid:22)(cid:19)
(cid:10)(cid:9)(cid:24)(cid:23)(cid:29)(cid:23)(cid:8)(cid:27)(cid:28)(cid:27)(cid:26)(cid:21) (cid:24)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:27)(cid:24)(cid:23) (cid:18)(cid:12)(cid:21)(cid:29)(cid:22)(cid:24)(cid:29)(cid:28)(cid:22)(cid:8)
(cid:20)(cid:3)(cid:22)(cid:21)(cid:8)(cid:22)(cid:23)(cid:12)(cid:19)(cid:12)(cid:10)(cid:26)(cid:27)(cid:29)
(cid:2)(cid:12)(cid:23)(cid:26)(cid:22)(cid:19)(cid:24)(cid:1)(cid:12)(cid:21)(cid:127)(cid:28)(cid:21)
(cid:17)
(cid:25)(cid:25)(cid:27)
(cid:9)(cid:27)(cid:7)(cid:23)(cid:3)(cid:12)(cid:19)(cid:12)(cid:10)(cid:26)(cid:27)(cid:29)
(cid:29)
(cid:13)(cid:22)
(cid:14)(cid:22)(cid:29)(cid:28)(cid:21)(cid:30)(cid:22)(cid:19)(cid:24)(cid:13)(cid:12)(cid:28)(cid:29)(cid:22)(cid:19)(cid:24)(cid:27)(cid:20)(cid:28)(cid:23)(cid:26)(cid:22)(cid:19)(cid:26)(cid:27)(cid:29)
(cid:30)
(cid:8)
(cid:15)
(cid:11)
(cid:29)
(cid:24) (cid:11)(cid:28)(cid:12)(cid:30)(cid:22)(cid:29)(cid:12)(cid:19)(cid:12)(cid:10)(cid:26)(cid:27)(cid:29)
(cid:24)(cid:27)
(cid:15)
(cid:21)
(cid:26)(cid:25)
(cid:24)
(cid:3)(cid:29)(cid:15)(cid:21)(cid:26)(cid:23)(cid:15)(cid:25)(cid:15)(cid:14)(cid:2)(cid:1)(cid:15)(cid:9)(cid:24)(cid:23)(cid:29)(cid:23)(cid:8)(cid:27) (cid:28) (cid:24)
(cid:4)(cid:12)(cid:21)(cid:28)(cid:24)(cid:29)(cid:28)(cid:22)(cid:8)
(cid:129)(cid:141)(cid:29)(cid:28)(cid:30)(cid:16)(cid:28)(cid:16)(cid:24)(cid:23)(cid:22)(cid:27)(cid:28)(cid:15)(cid:6)(cid:22)(cid:27)(cid:28)(cid:16)(cid:24)(cid:29)(cid:28)(cid:22)(cid:8)
Figure 3 Composition of the core and expanded case-based Pregnancy Heart Team. MDT, multidisciplinary team.
Nevertheless, women with CVD requesting reproductive treatment risk of ovarian hyperstimulation syndrome can be reduced by careful cy-
should not be turned down based on assumed cardiovascular risk un- cle monitoring, using a low-dose follicle-stimulating hormone in combin-
til their case has been discussed in a multidisciplinary setting involving ation with a gonadotropin-releasing hormone antagonist. Transferring
the Pregnancy Heart Team. a single embryo is strongly advised in women with CVD, as carrying
Assisted reproduction has added risks above those of pregnancy multiple gestations is associated with greater cardiovascular changes
alone; superovulation is pro-thrombotic and can be complicated by ovar- and more maternal and foetal complications.70,71
ian hyperstimulation syndrome, with marked fluid shifts and a high In women with mWHO 2.0 class III conditions or those who are an-
thrombosis risk. All women with CVD who are embarking on fertility ticoagulated (Table 6), the risk of complications from superovulation is
treatment should have an individual risk assessment for venous thrombo- very high. It is therefore recommended that these women have a full
embolism (VTE) given the risk associated with these techniques.69 The pre-pregnancy assessment by a Pregnancy Heart Team prior to the
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4481
(cid:31)(cid:30)(cid:29)(cid:30)(cid:28)(cid:27)(cid:26)(cid:25)(cid:24)(cid:26)(cid:29)(cid:23)
(cid:15)(cid:24)(cid:30)(cid:14)(cid:13)(cid:19)(cid:18)(cid:12) (cid:24)(cid:22)(cid:21)(cid:26)(cid:20)(cid:23)(cid:19)(cid:18)(cid:29)
(cid:17)(cid:30)(cid:29)(cid:30)(cid:23)(cid:24)(cid:20)(cid:19)(cid:23)(cid:30)(cid:11)(cid:23)(cid:24)(cid:29)(cid:17) (cid:21)(cid:25)(cid:30)(cid:17)(cid:29)(cid:26)(cid:29)(cid:20)(cid:16)
(cid:22)(cid:26)(cid:29)(cid:26)(cid:17)(cid:30)(cid:22)(cid:30)(cid:29)(cid:23)
(cid:10)(cid:18)(cid:25)(cid:23)(cid:24)(cid:20)(cid:19)(cid:13)(cid:24)(cid:11)(cid:30)(cid:26)(cid:11)(cid:30)
(cid:18)(cid:17)(cid:16)(cid:15)(cid:14)(cid:15)(cid:13)(cid:12)(cid:16) (cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)
(cid:8)(cid:7)(cid:26)(cid:7)(cid:15)(cid:25)(cid:22)(cid:29)ƒ(cid:22)(cid:27)(cid:4)
„(cid:22) … (cid:20)(cid:22)(cid:29)(cid:15)(cid:8)†(cid:20)(cid:23)(cid:29) ‡(cid:3)(cid:22)(cid:27)(cid:20)(cid:28) (cid:4)
(cid:129)(cid:28)(cid:23)€ ‡(cid:3)(cid:21)(cid:23)(cid:30)ˆ
(cid:9)(cid:26)(cid:25)(cid:13)(cid:24)(cid:26)(cid:20)
(cid:20)(cid:8)(cid:26)(cid:29)(cid:29)(cid:30)(cid:14)(cid:18)(cid:21)(cid:26)(cid:23)(cid:8)(cid:24)(cid:30)(cid:11)
(cid:18)(cid:17)(cid:16)(cid:15)(cid:14)(cid:15)(cid:13)(cid:12)(cid:16) (cid:25)(cid:28)(cid:24)(cid:23)(cid:29)(cid:22)(cid:30)(cid:23)
(cid:8)(cid:7)(cid:26)(cid:7)(cid:15)(cid:129)(cid:141)(cid:143)(cid:31)(cid:4)(cid:15)(cid:5)(cid:144)(cid:127)(cid:143)(cid:4)
(cid:157)(cid:29) (cid:26)(cid:22)(cid:24)(cid:22)(cid:15) €(cid:27)(cid:24)(cid:29)(cid:28)‚(cid:23)
(cid:9)(cid:26)(cid:25)(cid:13)(cid:24)(cid:18)(cid:22)(cid:16)(cid:18)(cid:21)(cid:26)(cid:23)(cid:8)(cid:24)(cid:30)(cid:11)
(cid:11)(cid:12)(cid:16)(cid:15)(cid:14)(cid:15)(cid:10)(cid:12)(cid:16) (cid:25)(cid:21)(cid:20)(cid:24)
(cid:8)(cid:7)(cid:26)(cid:7)(cid:15)(cid:6)(cid:5)(cid:25)(cid:4)(cid:15)(cid:3)(cid:5)(cid:25)(cid:4)(cid:15)(cid:2)(cid:1)(cid:127)(cid:5)
(cid:9)(cid:18)(cid:29)(cid:17)(cid:30)(cid:29)(cid:24)(cid:23)(cid:26)(cid:14)(cid:19)(cid:8)(cid:30)(cid:26)(cid:25)(cid:23)
(cid:13)(cid:24)(cid:11)(cid:30)(cid:26)(cid:11)(cid:30)(cid:19)(cid:26)(cid:29)(cid:13)(cid:19)(cid:7)(cid:10)(cid:6)
(cid:9)(cid:16)(cid:15)(cid:14)(cid:15)(cid:18)(cid:17)(cid:16) (cid:19)(cid:28)
(cid:8)(cid:7)(cid:26)(cid:7)(cid:15)(cid:31)(cid:31)(cid:30)(cid:29)(cid:29)(cid:15) €(cid:27)(cid:24)(cid:29)(cid:28)‚(cid:23)
Figure 4 Pre-conception counselling and genetic aspects. ARVC, arrhythmogenic right ventricular cardiomyopathy; CPVT, catecholaminergic polymorphic
ventricular tachycardia; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; LQTS, long QT syndrome; PAH, pulmonary arterial
hypertension.
Table 7 Pre-implantation and pre-natal options and implications
Pre-implantation genetic IVF procedure followed by biopsy and genetic testing of a single cell of the embryo. Embryo transfer with success rate of
diagnosis 25%–30% (dependent on mother’s age and fertility).
Risks to mother and offspring of IVF, such as multiple birth, premature labour and low birth weight, as well as side effects of
hormonal treatment.
Availability, expense and methods differ across countries.
Chorionic villus sampling Transcervical or transabdominal sampling of the chorionic villi at the end of the first trimester.
Procedure-related foetal loss rate ∼0.2%.66
Amniocentesis Direct sampling of amniotic fluid after 15 weeks of gestation.
Procedure-related foetal loss rate ∼0.1%.66
Adopted from the 2023 ESC Guidelines for the management of cardiomyopathies.60
IVF, in vitro fertilization.
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

4482 E S C G u id e l in e s
procedure, including an evaluation of the risk of hormonal treatment. 4.2.5. Termination of pregnancy including
The option of natural cycle IVF should be considered. Hysteroscopy psychological support
and laparoscopy can be life-threatening procedures in women with spe- It is strongly recommended to consider and discuss termination of
cific cardiac conditions, such as a Fontan circulation, and should only be pregnancy with women whose risk is classified as mWHO 2.0 class
undertaken in an experienced centre with appropriate support. IV due to the exceptionally elevated risk of maternal and foetal mor-
Fertility treatment should be avoided in women with mWHO 2.0 tality or severe morbidity.83 Efforts should be made to minimize de-
class IV conditions. lays for women seeking pregnancy termination because the risk of
procedure-related complications increases as gestational age ad-
4.2.4. Contraception vances. Surgical methods are often preferred, but pharmacological
To ensure informed decision-making about pregnancy, accurate methods remain an option until the ninth week of pregnancy.83
counselling about contraception should be provided to all girls Given the emotional and psychological impact of pregnancy termin-
and women of childbearing age with CVD, starting from menarche, ation, it is crucial to provide professional psychosocial support, which
to prevent unplanned pregnancies. An overview of the benefits and plays a significant role in reducing adverse mental health outcomes.89
risks of different types of contraception in women with CVD is pro- At the same time a discussion should be held regarding appropriate
vided in Table 8. contraception.
Table 8 Overview of benefits and risks of different methods of contraception in women with cardiovascular disease
Method Benefits Cardiovascular Cautious use and contraindications Contraceptive
risks efficacy
Hormonal oral contraceptives
Progestin-only oral Minimal/no impact Mild fluid retention LQTS not on beta-blockers74,75 ++ (general)
contraceptives on coagulation +++ (for
factors drospirenone)73
Safe CV risk
profile72,73
Combined oral Regular VTE, hypertension Known dyslipidaemia78 +++
contraceptives76,77 menstruation with and altered lipid Pre-existing hypertension79
reduced blood loss profilea Obesity80
Cyanosis
MHV
Fontan circulation
Risk factors for ACS81
Long-acting reversible contraceptives
Levonorgestrel-releasing ↓ Menstrual bleeding None specified Vasovagal responses on insertion and Safest and most
IUD and iron loss removal (done by gynaecologist) → caution effective option
and monitoring with availability of +++
anaesthesiologist recommended in PAH and
Fontan circulation82
Smaller levonorgestrel IUD ↓ Menstrual bleeding None specified — +++
and iron loss
Easier to insert
↓ Risk of vasovagal
responses
Copper IUD ↓ Cost — ↑ Intensity of menstrual bleeding +++
Etonogestrel-releasing No pelvic infection None specified Surgical subcutaneous insertion (in the +++
subcutaneous implants risk forearm with local anaesthesia—outpatient
procedure)
Depot Lighter menses Increased VTE risk, Irregular bleeding ++
medroxyprogesterone weight gain
acetate injection83
Barrier methods
— ↓ Pelvic infection risk84 — None specified +
Continued
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4483
Permanent sterilization
Tubal ligation Permanent Anaesthetic and Non-reversible +++
Vasectomy procedural risks
Emergency contraception
Oral contraceptive pills to delay ovulation
Ulipristal acetate ↑ Effectiveness than No ↑ thrombosis None specified +++ (only if taken
levonorgestrel risk85–87 before ovulation)
Levonorgestrel — No ↑ thrombosis risk None specified ++ (only if taken before
single dose of 1.5 mg <72 h after ovulation)
unprotected intercourse
Contraceptive device
Copper IUD — — None specified +++ (in addition to
<120 h after unprotected intercourse ongoing
contraception)85–88
ACS, acute coronary syndrome; CV, cardiovascular; IUD, intrauterine device; LQTS, long QT syndrome; mg, milligram; MHV: mechanical heart valve; PAH, pulmonary arterial hypertension;
VTE, venous thromboembolism.
↑ increase ↓ decrease.
aHigher in combined oral contraceptive pills containing ethyniloestradiol compared to natural oestradiol or oestetrol.
Recommendation Table 1 — Recommendations for counselling, pregnancy risk assessment, contraception, assisted re-
productive technology, and the involvement of a Pregnancy Heart Team (see Evidence Table 1)
Recommendations Classa Levelb
Maternal risk assessment
It is recommended to perform a risk assessment in all women with CVD of childbearing age using the mWHO 2.0 classificationc.44,45,47–49,54 I C
A discussion by the Pregnancy Heart Team about the high risk of maternal mortality or morbidity and the related high foetal risk is
recommended for women with mWHO 2.0c class IV conditions, including a shared decision-making process for pregnancy termination, I C
involving psychological support.65
It is recommended that women with CVD of mWHO 2.0c class II–III and above are evaluated and managed by a Pregnancy Heart Team
I C
from pre-pregnancy onwards through pregnancy and post-partum.44,45,47–49,54
Methods of contraception
It is recommended that women with CVD of mWHO 2.0c class II and above, or those at risk of developing CVD, receive individualized
I C
advice to determine the most suitable contraception method, including emergency contraception.90,91
Progestin-only treatment, contraceptive implants, and/or levonorgestrel IUDs should be considered when there is any risk of
IIa B
thromboembolic events.73,92–94
Genetic counselling
Assessment by a clinical geneticist prior to pregnancy is recommended in women fulfilling diagnostic criteria for inherited cardiovascular
I C
disease to guide risk stratification and pre-natal genetic testing.63,95
Pre-conception genetic counselling is recommended in couples with heritable CVD, whether genetic testing is being considered or not. It is
recommended that this counselling is provided by an appropriately trained healthcare professional within a multidisciplinary team that offers I C
psychological support and education to encourage decision-making.63,95
Reproductive technology
It is recommended that single embryo transfer is performed in women with CVD.70,71 I C
Pregnancy termination
It is recommended to offer women with CVD access to termination of pregnancy that is tailored to their cardiac condition to minimize the
I C
risks of the procedure.83
CVD, cardiovascular disease; IUD, intrauterine device; mWHO, modified WHO.
aClass of recommendation.
bLevel of evidence.
cThe mWHO 2.0 classification is the updated mWHO classification from the 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy43 and described in Table 6.
5202CSE©
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

4484 E S C G u id e l in e s
4.3. Diagnostic methods in pregnancy minimum and serial NP measurements on an individualized basis should
be considered to diagnose cardiac complications during pregnancy and
The pros and cons of the primary cardiovascular diagnostic methods
post-partum.113–118
for diagnosing cardiovascular disease in pregnancy are described here.
Although cardiac troponin I (cTnI) and cardiac troponin T (cTnT) are
Pre-pregnancy evaluation is covered in the risk assessment section
essential in diagnosing myocardial ischaemia, standardized values in preg-
(Section 4.2.1).
nancy and post-partum have not been established.112,119 Therefore, rou-
tine use of troponins alone during pregnancy is not recommended.
4.3.1. Electrocardiogram, including mobile rhythm
D-dimer testing has relevance in the diagnosis of VTE (see Section
devices
11), taking into account the physiological increase during pregnancy,
Pregnant women may present changes in their surface electrocardio-
particularly in the third trimester.
gram (ECG), including increased heart rate, minor leftward QRS axis
shift (15–20 degrees), slightly decreased (20 ms) PR interval, prominent
4.3.5. Ionizing radiation exposure
Q waves in II, III, and aVF, and flat or inverted T-waves in III, aVF, V1, V2,
and V3 (Figure 1).96–98 Risks of ionizing radiation exposure are highest during organogenesis
A 12-lead ECG is part of the standard evaluation of pregnant women and decrease with time.120,121 Exposing the foetus to radiation doses
presenting with new-onset cardiac signs or symptoms or suspected ar- >150–200 mGy may result in intrauterine growth restriction (IUGR),
rhythmia. In pregnant women presenting with syncope or palpitations, congenital malformations (in particular of the central nervous system),
long-term Holter monitoring or implantable loop recorders should be and malignancies. If possible, procedures should be delayed at least until
considered as additional diagnostic tools. As pregnant women are more the completion of major organogenesis (>12 weeks of gestation).
prone to arrhythmias, the threshold to perform long-term ambulatory However, the safety of the woman is important and should guide the
rhythm monitoring should be low. clinical decision. All radiation doses to the foetus must be kept ‘as
low as reasonably achievable’ (ALARA) (preferably <50 mGy) and
4.3.2. Echocardiography should be clearly documented. Manoeuvres to minimize radiation are:
(i) use echo guidance when possible; (ii) place the source as far and
Transthoracic echocardiography (TTE) is the first-line imaging method
the receiver as close as possible to the patient; (iii) use only low-dose
used in pregnancy.99,100 Physiological changes in cardiac geometry and
fluoroscopy (7.5 frames per second or lower); (iv) favour posterior-
functioning are expected during pregnancy (Figure 1).99,101–103 These
anterior projections; (v) avoid direct radiation of the abdominal region
are greatest early in the third trimester and resolve early post-partum.
(abdominal shielding is of limited benefit due to internal scatter from
Agitated saline contrast should not be used during pregnancy, given
thoracic tissues rather than direct foetal irradiation); (vi) collimate as
the risk of placental infarction due to microbubble embolism, resulting
tightly as possible to the area of interest; (vii) minimize fluoroscopy
in foetal distress.99,104 Relevant foetal exposure to intravenous (i.v.)
time; and (viii) ensure the procedure is performed by an experienced
echocardiographic contrast agents is not expected due to their very
cardiologist.122–126 Iodinated contrast can cross the placenta, but has
short half-life.105 Nevertheless, these agents should only be used select-
not been reported to have teratogenic effects.127 The potential risk
ively because studies during pregnancy or lactation are lacking.99
of congenital hypothyroidism is unclear but no abnormalities of foetal
Transoesophageal echocardiography is relatively safe, but the potential
thyroid function after application have been reported.122,128,129
risks and benefits must be weighed individually, including the risk of em-
esis/aspiration and sudden increase in intra-abdominal pressure.
Speckle-tracking echocardiography is a useful method to detect subclin- 4.3.5.1. Chest radiography
ical myocardial abnormalities in pregnancy.106,107 The chest radiograph is a practical and readily available diagnostic tool
for evaluating cardiopulmonary diseases. The foetal dose from chest
4.3.3. Cardiopulmonary exercise testing radiography is <0.01 mGy. Nevertheless, it should only be performed
If there is suspicion of new-onset CVD during pregnancy, submaximal in symptomatic women if other methods fail to clarify the cause of
exercise testing (at 80% of predicted maximal heart rate) can be useful the symptoms.
to assess cardiovascular response to exercise. There is no evidence that Lung ultrasound is a valuable tool for diagnosing pleural effusion, pul-
exercise testing increases the risk of spontaneous miscarriage.108,109 monary oedema, pneumothorax, and pneumonia. However, there is
Stress echocardiography using bicycle ergometry may improve diagnos- currently a lack of data about the regular ultrasound pattern during
tic specificity. The use of pharmacologic stress agents (e.g. dobutamine) pregnancy,130,131 and lung ultrasound is therefore not recommended
should be avoided.99,110 There is no evidence supporting a preference as an alternative to chest radiography.
for treadmill over bicycle exercise testing during pregnancy. The choice Protection of the foetus is governed by radiological standards. Both
should be based on women’s individual risk factors, contraindications, the technician and the radiologist should act accordingly.
pregnancy stage, and local availability of testing and expertise.
4.3.5.2. Computed tomography and nuclear medicine
4.3.4. Biomarkers imaging
Throughout pregnancy and the early post-partum stages, natriuretic The radiation dose to the foetus from a chest computed tomography
peptide [NP: B-type natriuretic peptide (BNP) and N-terminal pro- (CT) or pulmonary CT angiography is estimated at 0.02 mGy.121
brain natriuretic peptide (NT-proBNP)] values within the normal range Technetium-99m, used for ventilation–perfusion lung scanning for de-
have a strong negative predictive value for heart failure whereas the tection of pulmonary embolism, results in an embryonic or foetal ex-
positive predictive value tends to be lower.111,112 In women with pre- posure of <5 mGy, which is considered a safe dose in pregnancy.
existing cardiomyopathy, ACHD, or valvular heart disease, baseline as a Computed tomography or nuclear medicine techniques are generally
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4485
not recommended during pregnancy. However, if such techniques are 4.4. Foetal assessment
necessary because other diagnostic tools are insufficient or not readily
4.4.1. Risk of foetal/obstetric complications
available for the diagnosis in question, they should not be withheld from
The typical increase in CO during pregnancy may not occur optimal-
a pregnant patient.100,132
ly in some women with CVD, potentially affecting uteroplacental
blood flow. These and other cardiovascular risk factors contribute
4.3.5.3. Cardiac catheterization to an increased risk of obstetric and foetal complications, including
Cardiac catheterization is seldom needed during pregnancy but may be foetal loss, stillbirth, pre-term birth, pre-eclampsia, and IUGR.140
necessary for specific diagnostic and interventional purposes. Foetal Furthermore, the severity of obstetric and foetal outcomes varies
compromise decreases with gestational age. The highest risk is <20 depending on the maternal risk as defined in the mWHO 2.0 classi-
weeks gestation and is proportional to the radiation dose, with no re- fication. Adverse outcomes are more frequent in women with a
ports of foetal anomalies or loss when exposure is <50 mGy.133,134 higher mWHO 2.0 classification, emphasizing the importance of
Most coronary procedures can be performed within these dose limits risk stratification, comprehensive counselling, and multidisciplinary
and radiation exposure to the foetus itself is estimated to be lower than management, including neonatology expertise.2,134,140 Notably, pul-
20%. The radial approach by an experienced operator is preferable and monary hypertension (PH) represents one of the highest risks for
every effort to reduce radiation exposure should be made. obstetric and foetal complications.141 The main predictors of neo-
natal complications are indicated in Table 9.
4.3.6. Cardiovascular magnetic resonance
Cardiovascular magnetic resonance (CMR) is advised if other non-invasive 4.4.2. Screening for congenital heart disease in the
diagnostic measures are insufficient to provide a clinical diagnosis and is foetus
preferable to radiation-based imaging modalities.99,100,135 It seems prudent Foetal echocardiography should routinely be offered at 18–22 weeks
to avoid a scanner strength higher than 1.5 tesla due to the greater energy when parents have congenital heart disease. This will detect up to
deposition in tissue. Evidence regarding gadolinium-based contrast in preg- 80% of significant congenital cardiac defects.142–144
nancy is controversial and its use should be avoided unless absolutely ne-
cessary.135–137 Excretion of gadolinium-based agents into breast milk is
limited (<0.04% of an i.v. dose within the first 24 h, with 1%–2% absorp- 4.4.3. Assessing foetal well-being
tion).138 Lactating women receiving intravascular gadolinium should dis- Detailed anatomical foetal assessment is required in women using cardiac
continue lactation for 24 h.133,138,139 medication with teratogenic effects (see Section 5 for more details).145
Recommendation Table 2 — Recommendations for diagnostic methods in pregnancy (see Evidence Table 2)
Recommendations Classa Levelb
Echocardiography
Transthoracic echocardiography is recommended as first-line imaging tool in any pregnant woman with unexplained or new cardiovascular
I C
signs or symptoms.99
Biomarkers
Measurement of BNP and NT-proBNP levels should be considered prior to pregnancy in women with HF of any aetiology, including
previous PPCM, cardiomyopathy, ACHD, and PAH, and be monitored during pregnancy according to the underlying disorder and in case of IIa B
new-onset or worsening symptoms.114
Ionizing radiation
It is recommended to limit exposure to all medical ionizing radiation doses to ALARA levels.121 I C
It is recommended to keep the radiation dose to the foetus as low as possible (preferably <50 mGy), particularly if the foetus is in the field of
I C
view.120,121
A CT scan should be considered for PE when clinical benefits outweigh the risks to the mother and foetus.100,121,132 IIa C
A chest radiograph may be considered as a first-line imaging tool if other methods are not successful in clarifying the cause of dyspnoea. IIb C
Coronary angiography with minimal radiation may be considered during pregnancy if potential benefits outweigh the risks. IIb C
Cardiovascular magnetic resonance
Discontinuation of lactation for 24 h should be considered in women in whom i.v. gadolinium is required.133,139 IIa C
CMR imaging without gadolinium contrast should be considered for a definitive, clinically relevant diagnosis during pregnancy, if other
IIa C
non-invasive diagnostic measures are not sufficient.135,136
ACHD, adult congenital heart disease; ALARA, as low as reasonably achievable; BNP, B-type natriuretic peptide; CMR, cardiovascular magnetic resonance; CT, computed tomography; HF,
heart failure; i.v., intravenous; NT-proBNP, N-terminal pro-brain natriuretic peptide; PAH, pulmonary arterial hypertension; PE, pulmonary embolism; PPCM, peripartum cardiomyopathy.
aClass of recommendation.
bLevel of evidence.
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

4486 E S C G u id e l in e s
Table 9 Predictors of neonatal events in pregnan- early birth, induction of labour before 39 weeks should be reserved
cies of women with cardiovascular disease for obstetrical indications.154
Predictors of neonatal events 4.5.2. Induction of labour
NYHA class III/IV or cyanosis during baseline pre-natal visit Mechanical methods, prostaglandin E1 analogue (misoprostol),
Maternal left heart obstruction slow-release formulation of 10 mg prostaglandin E2 (dinoprostone),
oxytocin, and artificial rupture of membranes are all considered safe
Low maternal oxygen saturation (<90%)
to induce labour.4,155,156 High-dose (600 µg) misoprostol does not af-
Multiple gestations
fect cardiac parameters in women without heart disease, although
Use of anticoagulants
there remains a theoretical risk of coronary vasospasm and arrhyth-
Cardiac medication before pregnancy mias.155 Dinoprostone may cause profound hypotension, but only
Mechanical valve prosthesis when injected blindly into the myometrium, and this route of adminis-
Maternal cardiac event during pregnancy tration should be avoided.157 The use of an additional 2 IU of oxytocin
Maternal decline in CO during pregnancy for the management of the third stage in women with CVD has no car-
diac consequences and is associated with significantly lower blood
Derived from the 2018 ESC Guidelines for the management of cardiovascular loss.158 In women at high risk (mWHO 2.0 classes III–IV), oxytocin is
diseases during pregnancy.43
generally considered as a first-line uterotonic, misoprostol and carbo-
CO, cardiac output; NYHA, New York Heart Association.
prost are second line (see Supplementary data online, Table S3).159
Mechanical methods such as a cervical ripening balloon might be pref-
In women with beta-blocker exposure, higher small for gestational age erable in women where a drop in systemic vascular resistance would be
(SGA) rates and, more rarely, bradycardia have been reported, indicat- detrimental.160 If membranes are ruptured, augmentation of labour
ing the need for appropriate foetal monitoring.12,146 Foetal ductus ven- should be immediate to reduce the risk of infection and should be under-
osus Doppler velocity is a useful adjunct to evaluate foetal well-being and taken with oxytocin to minimize the number of vaginal examinations.4
determine the time to delivery in cases of increased risk of IUGR.147
4.5.3. Vaginal or caesarean delivery
4.4.4. Foetal assessment of heritable primary
Vaginal delivery is associated with less blood loss and lower risk of in-
arrhythmias fections and venous thromboembolism and should be advised for
In families with primary arrhythmia, the foetus may present with arrhyth- most women.161 Planned caesarean section does not confer any advan-
mias. Therefore, the foetal heart rate should be assessed at baseline tage over planned vaginal delivery in terms of maternal outcomes and
and during each pre-natal visit and compared against gestation-specific may be associated with adverse foetal outcomes.162,163
norms. In pregnancies complicated by suspected primary arrhythmia- Caesarean section is the preferred mode of delivery for obstetric in-
related foetal arrhythmias, complete foetal echocardiography, typically dications and for women presenting in labour who use or have used
performed at 20–22 weeks, is recommended to evaluate heart anatomy, vitamin K antagonist (VKA) within the past 2 weeks, with high-risk aor-
ventricular function, and the arrhythmia mechanism.148 Foetal magneto- topathy (mWHO 2.0 class III), with hypertrophic cardiomyopathy
cardiography, if available, offers valuable insights into arrhythmia type and (HCM) and severe left ventricle outflow tract obstruction, or in acute
severity and monitors anti-arrhythmic drug therapy, as it captures all car- intractable HF.43
diac time intervals (P, QRS, T-wave) between 17 and 24 weeks of gesta-
tion. It is currently the only method to detect repolarization 4.5.4. Haemodynamic monitoring during delivery
abnormalities, such as QT interval prolongation.149
Pulse oximetry, blood pressure monitoring, and continuous ECG mon-
itoring may help detect early signs of decompensation, arrhythmias, and
4.5. Timing and mode of delivery
ischaemia in women with significant CVD and identify those in whom
An individualized delivery plan should be made that covers the needs delivery should be expedited.164 Arterial lines should be reserved for
for induction of labour, labour management, delivery, and post-partum those women who have haemodynamic instability or are at risk of it.
surveillance, in shared decision-making with the pregnant women. This A right-heart catheter is of uncertain benefit, is associated with compli-
delivery plan should be widely accessible to the patient, her partner, and cations, and should be avoided in most cases. Minimally invasive CO
relevant health professionals, and should be placed in the patient’s monitoring is preferable, where possible.110
(electronic) health record.
4.5.5. Anaesthesia/analgesia
4.5.1. Timing of delivery Analgesia is crucial for labour in pregnant women with CVD to reduce
Pregnant women with CVD are more likely to have comorbidities and physical stress. Neuraxial methods are very effective analgesic blocks.
experience adverse events during delivery than those without CVD, The onset of conventional epidural analgesia is relatively slow (±15 min)
and require additional monitoring and care.150 Any maternal benefit and allows for careful titration of a local anaesthetic–opioid mix.165
of early term delivery (from 37 weeks 0 days to 38 weeks 6 days of ges- Spinal analgesia is suitable for women with high-risk CVD, where a faster
tation) should be weighed against the increased likelihood of adverse onset of sympathetic block is desirable.166 Combined spinal–epidural
foetal outcomes.151 Induction of labour between 39 and 40 weeks re- analgesia typically has a faster onset time (±5 min). However, adverse
duces the risk of emergency caesarean section by 12% and the risk of effects such as hypotension and foetal heart rate abnormalities occur
stillbirth by 50% in women without CVD. The benefit is likely to be more quickly and are more pronounced. Different techniques for admin-
greater for women with CVD who have higher rates of obstetric com- istering low-concentration, high-volume local anaesthetic–opioid regi-
plications.152,153 In the absence of maternal or foetal indications for mens allow maintenance of epidural analgesia through the epidural
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4487
catheter. Whenever an epidural catheter is in situ in a high-risk woman, vitamin K should be given.171,172 If 4F-PCC is not available, fresh frozen
higher doses can be administered for conversion to caesarean section, plasma (FFP) is an alternative, but it takes longer to reverse an elevated
avoiding airway and other complications of general anaesthesia. In women INR and requires a larger fluid challenge.171,173. The involvement of an
at risk of dural ectasia, including Marfan syndrome, extra caution and man- expert haematologist in these scenarios is essential, in addition to the
agement in an expert centre is essential. Furthermore, a pre-delivery con- Pregnancy Heart Team. The foetus may remain anticoagulated for 8–
sultation with the anaesthesia team is needed.167 When neuraxial analgesia 10 days after discontinuation of maternal VKAs, and may need to be gi-
is contraindicated due to conditions such as systemic anticoagulation or ven FFP and higher doses of vitamin K.170
spinal deformities, opioids (i.v. remifentanil) are an alternative despite
the risk of hypoventilation and apnoea.168,169 Single-shot spinal analgesia 4.5.6.2.2. Delivery on heparin. If delivery occurs after recent adminis-
is common in caesarean delivery for its simplicity and effectiveness.167 tration of heparin (e.g. within 4–6 h of UFH, with non-normalized aPTT,
or within 12 h of therapeutic LMWH) protamine sulfate should be given.
Neutralization of LMWH varies between products and may be less ef-
4.5.6. Delivery in women on anticoagulants
fective.174 Protamine dosage depends on timing after the last dose of 4.5.6.1. Planned delivery
LMWH (1 mg/1 mg enoxaparin <8 h; 0.5 mg/1 mg enoxaparin >8 h).
In women with mechanical heart valves (MHVs) taking VKAs, suspen- For UFH, 1 mg of protamine per 100 units of heparin is needed.175
sion of VKAs and bridging with heparin [either therapeutic-dose
In addition to the level of anticoagulation, the decision to reverse an-
low-molecular-weight heparin (LMWH) or i.v. unfractionated heparin
ticoagulation should also be related to the bleeding risk, which is higher
(UFH)] is recommended at least 2 weeks before planned delivery
with conditions such as placental abruption, placenta previa, and mul-
(see also Section 5 and Section 12). This is because of the slow metab- tiple previous caesarean sections.
olism of VKA in the foetus. If therapeutic-dose LMWH is used, one
strategy is to switch to i.v. therapeutic UFH at least 36 h before planned
4.5.6.3. Restarting anticoagulation after delivery
delivery.170 In these settings the target activated partial thromboplastin
The decision to restart anticoagulation post-delivery is challenging and
time (aPTT) is ≥2 times control values. UFH can then be stopped 4–6 h
must balance risk of bleeding and risk of thrombosis. Anaesthetic, cardiac,
before surgery (in case of caesarean section) or before insertion of re-
haematology, and obstetric teams may have different priorities, but all
gional anaesthesia or anticipated vaginal delivery. For women who are
need to be actively involved in decision-making, which should also involve
on therapeutic-dose LMWH for non-MHV indications, dosing can be
the patient. Late obstetric bleeding (>24 h) is common,176 as was also
omitted for 24 h prior to caesarean section or anticipated vaginal deliv-
confirmed in recent data from the ROPAC III trial177 (bleeding on
ery with no need for bridging. In women with MHVs who are on
mean post-partum day 3.6), suggesting that these events occur at a
LMWH and aspirin in combination, consideration should be given to
stopping aspirin 4 days before delivery.170 time when heparin is being used at the same time as the VKA is being re-
introduced. Restarting UFH (aPTT levels ≥2 times the control) or low/
intermediate doses of LMWH are all valid options.170 Techniques to re-
4.5.6.2. Urgent delivery on therapeutic anticoagulation
duce bleeding risk include active management of the third stage of labour
Managing women who are anticoagulated during delivery is complex with oxytocin. Recently, the effect of adding 2 IU oxytocin over 10 min to
and needs an individualized approach. Figure 5 gives an overview, but a standard treatment of low-dose infusion for 4 h [10 IU of oxytocin in
again each scenario may need a more tailored solution. 500 mL of normal saline given i.v. at 36 mL/h for 4 h (12 mU/min)] was
analysed. The addition of 2 IU of oxytocin was not associated with any
4.5.6.2.1. Delivery on vitamin K antagonists. If women require ur- greater derangement in cardiovascular measures, but with a significantly
lower volume of blood loss.158 VKA should only be started 7–14 days gent delivery and have been taking VKAs within the last 2 weeks,
or later post-partum to reduce the risk of late bleeding.170 then delivery by caesarean section is recommended to reduce the
risk of foetal intracranial bleeding. When urgent delivery is required,
preventing bleeding complications with administration of i.v. four-factor 4.5.7. Endocarditis prophylaxis for delivery
prothrombin complex concentrate (4F-PCC), depending on the inter- Systemic antibiotics according to the 2023 ESC Guidelines for the man-
national normalized ratio (INR) (25 U/kg for a therapeutic INR range of agement of endocarditis may be considered for delivery in women at
2–4) is the preferred method for rapid INR normalization. If necessary, high risk of endocarditis.178
Recommendation Table 3 — Recommendations for timing and mode of delivery (see Evidence Table 3)
Recommendations Classa Levelb
Timing and mode of delivery
Vaginal delivery is recommended in most women with CVD.161–163 I B
Systemic antibiotic prophylaxis may be considered for delivery in women at high riskc.178 IIb C
Routine induction of labour prior to 39 weeks is not recommended in women with stable CVD.44,154 III C
Delivery in women on anticoagulants
It is recommended that the timing of delivery is planned to ensure safe and effective peripartum anticoagulation. I C
It is recommended to discontinue VKAs and start therapeutic-dose LMWH or adjusted-dose i.v. UFH at the 36th week of gestation or 2
I C
weeks before the planned delivery.179
In women at low riskd on therapeutic-dose LMWH, neuraxial anaesthesia and vaginal delivery (or caesarean section for obstetric
I C
indications) is recommended 24 h after the last dose of LMWH.180
Continued
Downloaded
from

by
guest
on
22
January
2026

4488 E S C G u id e l in e s
In women at high riskd, it is recommended to convert LMWH to i.v. UFH at least 36 h prior to delivery and stop the UFH infusion 4–6 h
I C
prior to anticipated delivery. The aPTT should be normal before regional anaesthesia.180
If delivery starts while the mother is on VKAs or <2 weeks after discontinuation of VKAs, caesarean section is recommended for foetal
I C
protection.
Post-delivery, it is recommended that the decision to restart LMWH or UFH is made after discussion with the Pregnancy Heart Team and
I C
the woman who gave birth.170
It is recommended to postpone the switch from heparin back to oral anticoagulants until 7–14 days post-partum when the wound area has
I C
healed, in consultation with the Pregnancy Heart Team.177
In women on therapeutic-dose LMWH, planned delivery should be considered at around 39 weeks to avoid the risk of spontaneous labour
IIa C
while fully anticoagulated.
In women who are on antenatal anticoagulation, active management of the third stage of labour with oxytocin should be considered.158 IIa C
aPTT, activated partial thromboplastin time; CVD, cardiovascular disease; i.v., intravenous; LMWH, low-molecular-weight heparin; UFH, unfractionated heparin; VKA, vitamin K antagonist.
aClass of recommendation.
bLevel of evidence.
cPatients with prosthetic cardiac valves or a history of infective endocarditis, or cardiac transplant patients with residual valve defects.
dSee Table 10.
Woman on therapeutic anticoagulants arriving in established labour
VKA
Stop VKA and check INR LMWH i.v. UFH
Prepare RBC Stop LMWH Stop UFH
Give 4F-PCC
(FFP if 4F-PCC not available)
Consider vitamin K
Delivery in next
Delivery in next
4–6 h and aPTT
24 h
not normalized
Consider caesarean
Consider protamine
section with general
sulfate
anaesthesia
Proceed with neuraxial anaesthesia
and vaginal delivery unless obstetric
indication for caesarean section
(Class I)
Caesarean section with
Actively manage the third stage with
general anaesthesia for oxytocin to reduce risk of PPH
foetal protection
(Class IIa)
(Class I)
Post-delivery
After delivery, postpone the switch from heparin back to oral anticoagulants
until 7–14 days post-partum when the wound area has healed, in consultation
with the Pregnancy Heart Team
(Class I)
If neuraxial anaesthesia catheter insertion was traumatic
do not start therapeutic dose anticoagulation for at least 24 h after removal
Figure 5 Management of urgent dFiegluivree r5y M iann wagoemmeennt oufn udrgeern atn dteilcivoeargy uinla wnotms. eanP uTnTde, ra acntitvicaotaegdu lpanatrstial thromboplastin time; FFP, fresh frozen plasma; INR, inter-
national normalized ratio; i.v., intravenous; LMWH, low-molecular-weight heparin; 4F-PCC, four-factor prothrombin complex concentrate; N, no; PPH,
post-partum haemorrhage; RBC, red blood cell; UFH, unfractionated heparin; VKA, vitamin K antagonist; Y, yes.
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4489
4.6. Post-partum monitoring and with underlying health conditions such as CVD, where ∼1 in
complications 3 mothers have reported symptoms of depression in the post-
partum period.188 Those with PPCM are particularly vulnerable to
4.6.1. Monitoring depression.189–191 These findings emphasize the critical need for
The post-partum period is associated with significant haemodynamic early detection, regular mental health screening and the necessity
changes and fluid shifts. Hence, women are at risk of adverse outcomes, of holistic care models with psychological support and tailored
such as hypertension, HF, or stroke.181,182 Post-partum management interventions.191,192
must be individualized and depends on the woman’s underlying CVD,
risk or presence of arrhythmias and HF symptoms, and the course dur-
5. Drugs during pregnancy and
ing pregnancy and delivery. For women at the highest HF risk or with
HF symptoms during pregnancy or delivery, admission to an intensive lactation
(cardiac) care unit during the first 24–48 h for haemodynamic monitor-
ing should be considered.183 Early ambulation is important to reduce 5.1. General principles
the thromboembolism risk.
5.1.1. Pharmacokinetics and pharmacodynamics in
In women with hypertensive disorders of pregnancy, blood pressure
pregnancy
should be monitored in hospital (or with an equivalent level of out-
Physiological adaptation of maternal organ systems to pregnancy
patient surveillance) for 72 h after birth and checked again 7–10 days
affects the pharmacokinetics and pharmacodynamics of potentially
post-partum. Optimizing blood pressure levels from the immediate
all medical treatments, including cardiovascular drugs (see Section
post-partum period until the first post-natal months could help prevent
3.2).146,193,194
the development of hypertension and improve long-term cardiovascu-
lar health.184
5.1.2. Pharmacogenetics
4.6.2. Breastfeeding and lactation An overlap between individual genotypes associated with drug effects
Throughout these Guidelines, the term ‘lactation’ (including not only and pregnancy-induced modifications (e.g. liver enzymes) may unmask
breastfeeding but also other methods such as pumping) is used as the adverse effects or require careful titration, in particular for drugs that
default term in most sections, especially where it encompasses a broad- lead to severe adverse drug reactions (ADRs). As an example, war-
er scope, such as in medication-related contexts. We use ‘breastfeed- farin can cause severe ADR at the maternal (bleeding, thrombosis)
ing’ specifically in sections where the focus is on the act of nursing or and/or foetal level (embryotoxicity, teratogenesis).195 The most not-
direct feeding at the breast, particularly when discussing its physiological able cases refer to the polymorphisms of CYP2D6, associated with dif-
and long-term health outcomes. ferent phenotypes (extensive, ultrarapid, or poor metabolizers),
Breastfeeding is a global priority because interruption of lactation is leading to diverse pharmacokinetics/pharmacodynamics of drugs
associated with adverse health outcomes for the woman and her child, used in pregnancy such as beta-blockers (e.g. labetalol, metoprolol),
including higher maternal risks of breast cancer, ovarian cancer, dia- antidepressants (e.g. fluoxetine, paroxetine), and analgesic drugs
betes, and hypertension, and greater infant risks of infectious and meta- (e.g. tramadol, codeine).194 Poor and ultrarapid metabolizers may ex-
bolic disease.185,186 perience extreme variations in drug plasma level and bioavailability,
Inhibition of lactation can be obtained with standard doses of cabergo- and hence in their effects.195
line in general, or bromocriptine in peripartum cardiomyopathy (PPCM).
Several drugs are contraindicated during lactation (see Figure 6 in 5.1.3. Newborn drug exposure in breast milk
Section 5 and Supplementary data online, Table S4). The exposure of the newborn to maternal drugs via breast milk is ex-
pressed as a percentage value, calculated as the dose taken by the in-
4.6.3. Complications fant compared either to the therapeutic dose of the same drug (often
4.6.3.1. Haemorrhage unknown for newborns) or the maternal weight-adjusted dose.196
Post-partum haemorrhage (PPH) is more frequently reported in wo- The ‘relative infant dose’ (RID) depends on the relative amount of
men with CVD.187 To reduce the risk of PPH, an active third stage of drug secreted in the milk (milk-to-plasma concentration ratio) and
labour with early cord clamping and administration of oxytocin to de- the quantity of milk intake (the standard is 150 mL/kg/day) on a
liver the placenta should be pursued. Maternal anaemia is a known risk body weight basis.196 The dose per kg of the infant is compared to
factor for PPH, so anaemia should be managed aggressively in the ante- the maternal dose per kg over the same period. A RID lower than
natal period. 5%–10% is generally considered safe (see Figure 6; Supplementary
At the time of delivery, a slow i.v. infusion of 2 IU oxytocin over 10 data online; Table S4; and LactMed database).197
min immediately after birth, followed by 12 mU/min for 4 h, reduces
the PPH risk and has a minimal impact on cardiovascular parameters.158 5.2. Drug classes in pregnancy
In cases of PPH that are refractory to medical treatment, additional de- 5.2.1. Anticoagulants
vices may be used, such as the Bakri intrauterine balloon, uterine com-
The use of anticoagulants during pregnancy represents a complex
pression sutures, or further haemostatic measures including uterine
balance of risks and benefits, influenced by specific indications,
artery embolization or hysterectomy.
and hampered by low-quality evidence. Indications for anticoagula-
tion in pregnancy are diverse and covered in different sections in
4.6.3.2. Psychological reactions, post-partum depression these Guidelines. In this section, we cover drug-specific aspects
Although the general risk of post-partum depression among new and dosing regimens that explicitly pertain to the setting of
mothers in the general population is ∼10%–20%, this risk increases pregnancy.
Downloaded
from

by
guest
on
22
January
2026

4490 E S C G u id e l in e s
Table 10 List of anticoagulation regimens and disease entities in which they are indicated
Indication Type of Dosing Timing
anticoagulant
Low thrombosis risk
VTE prevention/no indication for oral LMWH Prophylactic dose o.d.
anticoagulationa
Uncomplicated Fontan circulationb LMWH Prophylactic dose o.d.
Intermediate thrombosis risk
VTE (DVT/PE) during pregnancya LMWH Therapeutic dose o.d. or
b.i.d.
Persistent/permanent AF at elevated LMWH Therapeutic dose o.d. or
thromboembolic riskc b.i.d.
Decreased ventricular function (EF <35%) and/ or LMWH Therapeutic dose o.d. or
intracardiac thrombusd b.i.d.
High thrombosis risk
Mechanical heart valvese
1. First trimester
Low VKA dose to achieve required INRf First trimester: VKA or INR: weekly to every 2 weeks
LMWH LMWH: dose adjusted to peak anti-factor Xa level b.i.d.
High VKA dose to achieve required INR Switch to LMWH Dose adjusted to peak anti-factor Xa level (weekly until b.i.d.
threshold, every 2–4 weeks thereafter)
2. From week 13: shared decision
(a) Continue/switch to VKA with weekly to every 2 weeks INR
(b) Continue LMWH with dose adjustment as above
Delivery: refer to Section 4.5.6.2. (for urgent delivery) and Section 4.5.6.1 (for planned delivery)
AF, atrial fibrillation; b.i.d., is in die (twice a day); DVT, deep vein thrombosis; EF, ejection fraction; INR, international normalized ratio; LMWH, low-molecular-weight heparin; o.d., omni die
(once a day); PE, pulmonary embolism; VKA, vitamin K antagonist; VTE, venous thromboembolism.
aRefer to Section 11 Venous thromboembolism.
bRefer to Section 9 Pregnancy in women with congenital heart disease.
cRefer to section 12.4.1.2. Atrial fibrillation including anticoagulation.
dRefer to section 12.6 Heart failure.
eRefer to Section 12.5.3.2 Mechanical heart valves.
f≤5 mg of warfarin; ≤2 mg/day acenocoumarol, ≤3 mg/day phenprocoumon.43
Low-molecular-weight heparin treatment regimen glossary 5.2.1.1. Vitamin K antagonists
To ensure consistency throughout these Guidelines, we apply the fol- Vitamin K antagonists cross the placenta and are associated with em-
lowing wording about LMWH treatment—any deviations from these bryopathy and foetopathy risk, even at low doses. They will therefore
standards are clearly indicated in the specific sections: be switched to LMWHs in most pregnant women, with the only excep-
tion being women with atrial fibrillation (AF) in the context of moder-
• Prophylactic-dose LMWH refers to low fixed doses with adjustment ate to severe mitral valve stenosis or MHVs, given the lower thrombosis
for extremes of body weight.198 risk with VKAs compared to LMWH in the latter (see Section 12).179,200
• Therapeutic-dose LMWH refers to high doses typically reserved for Women receiving chronic VKAs who are contemplating pregnancy
treatment of VTE (Section 11) and thrombosis prevention in need counselling regarding avoidance of the potential teratogenic ef-
MHVs (Section 12). fects. When switching (usually to LMWH) is desired, this should take
place as soon after conception as possible.
An individualized shared decision-making approach with careful con- Vitamin K antagonist embryopathy is thought to be related to inter-
sideration of maternal thrombosis risk vs foetopathy is needed, and ference with embryonic ossification.201,202 Adverse impact is highest in
strategies will vary from prophylactic dosing of LMWH to correctly the first trimester (0.6%–12% of embryopathy) and much lower but
dosed VKAs. Regional differences, also related to lower availability of persisting in later stages of pregnancy (0.7%–2% risk of foetopathy,
anti-factor Xa level monitoring in low- and middle-income countries e.g. central nervous anomalies, intracranial haemorrhage).200,203,204
as indicated by the ROPAC III study, also need to be taken into account. The risk of embryopathy in the first trimester depends on the VKA
Interestingly, this study shows that despite higher monitoring and bet- dose. The risk was 0.45%–0.9% in pregnancies with low-dose warfarin
ter resource availability, the risk of thrombosis was higher in high- according to two systematic reviews.199,205 In this setting, low-dose re-
income countries, specifically due to higher use of treatment regimens fers to the dose necessary to maintain the appropriate INR (according
with therapeutic LMWH.177 Haemorrhagic complications in the to current guidelines this equals doses of ≤5 mg of warfarin, ≤2 mg/day
mother can occur with all regimens.199 Table 10 lists the regimens acenocoumarol, ≤3 mg/day phenprocoumon).43 This approach may be
and disease entities in which anticoagulants are indicated. seen as a reasonable balance between the risks to the mother with
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4491
Table 11 Dosing regimens for the commonly used low-molecular-weight heparins
Enoxaparin Dalteparin Tinzaparin Target
Prophylactic LMWH 4000 IU o.d. 5000 IU o.d. 4500 IU o.d. NA
Body weight
50–100 kg
Therapeutic LMWH 150 IU/kg o.d. 200 IU/kg o.d. 175 IU/kg o.d. NA
(non-MHV)
Therapeutic LMWH 125 IU/kg b.i.d. (starting dose) 125 IU/kg (starting dose) b.i.d. 250 IU /kg (starting dose) 0.8–1.2 U/mL anti-factor Xa
MHV then 100 IU/kg b.i.d. then 100 IU/kg b.i.d. then 175 IU/kg o.d. (4–6 h post administration)
b.i.d., bis in die (twice a day); IU, international units; LMWH, low-molecular-weight heparin; MHV, mechanical heart valve; NA, not applicable; o.d., omni die (once a day).
MHV and the foetus.170,200,204,206,207 Due to incomplete development 5.2.1.2.2. Once-daily vs twice-daily administration. In pregnant wo-
of liver metabolism, the INR takes longer to normalize in the foetus and men with confirmed acute VTE, no clear benefit of a twice-daily
neonate than in the mother, which is why VKA should be discontinued LMWH administration vs a once-daily administration has been demon-
2 weeks before delivery (see Section 4). strated.217,218 Thus, either using a once- or twice-daily regimen, each
If the indication of anticoagulation is non-MHV, such as one resulting in a therapeutic dose, is reasonable.
pregnancy-related VTE, VKAs are not recommended. In case of pre- Twice-daily administration at slightly higher doses is the usual thera-
existing VKA or direct oral anticoagulant (DOAC) therapy due to pre- peutic dosing regimen for pregnant women with MHVs.177 There is in-
vious VTE, VKAs and DOACs should be replaced by LMWH when sufficient evidence for the use of LMWH injections more frequently
pregnancy is planned or at recognition of pregnancy.208 than twice daily.
Vitamin K antagonists are safe during lactation209 and are recom-
mended in all women with MHVs given their superior anticoagulant
5.2.1.3. Unfractionated heparin
properties in avoiding valve thrombosis.179,200
Intravenous UFH, although not crossing the placenta, is associated with
higher risks of thrombocytopenia and osteoporosis compared with
5.2.1.2. Low-molecular-weight heparins
LMWH. The risk of valve thrombosis during pregnancy with subcutane-
Embryopathy or foetopathy has not been reported with LMWHs, even ous UFH is unacceptably high and its use is not recommended.219
in therapeutic doses, but thromboembolic complications in women In women with MHVs in whom VKAs cannot be continued, intraven-
with MHVs are higher than with VKAs (8.7%, 5.8%, and 2.7% for ous UFH is only indicated when anti-factor Xa monitoring is not pos-
LMWH, UFH, and VKA, respectively).179,200 LMWHs appear less likely sible during the first trimester and at the time of delivery (see Section
to induce heparin-induced thrombocytopenia compared with UFH, al- 4.5.6). However, intravenous heparin dosing is challenging, requiring
though this has not been studied in pregnancy.210 hospitalization and multiple daily blood tests to achieve an aPTT ≥2
Data on optimal dosing and frequency of administration in pregnancy times control values.
are scarce and mostly limited to the setting of VTE and MHV.
5.2.1.4. Fondaparinux
5.2.1.2.1. Low-molecular-weight heparin dosing. In women with
In women requiring prophylaxis of VTE, good outcomes with subcuta-
MHVs, slightly higher starting doses are suggested to ensure minimal
neous fondaparinux were reported in an observational study of 65
delay in reaching the target range (See Table 11).176
pregnancies and a retrospective analysis in 84 women with one or
For prophylactic-dose LMWH, a fixed low-dose LMWH regimen can more previous pregnancies.220,221 Its use can be considered if there is
be used in most cases.207 In women with acute VTE requiring thera- an allergy or adverse response to LMWH (prophylactic dose: 2.5 mg
peutic LMWH dose, routine anti-factor Xa monitoring has not been
daily; therapeutic dose: up to 10 mg daily)221–223 (see Section 11).
shown to affect clinical outcomes despite fluctuations of anti-factor
Xa levels during pregnancy, and should only be considered in women
with renal insufficiency or obesity, where adjustment for body weight 5.2.1.5. Direct oral anticoagulants
may result in overdosing.211–213 Underweight patients show a low Direct oral anticoagulants have shown better bleeding profiles than a
prevalence of antepartum or post-partum VTE214 and do not require LMWH or VKA regimen across diverse indications in non-pregnant po-
specific recommendations compared to patients with normal pulations. Outcome data on their use in pregnancy are scarce and in-
weight.215 consistently captured in pharmacovigilance databases, indicating a
Monitoring of anti-factor Xa levels is essential in women with MHVs need for a more robust system of reporting.224,225 The foetal effects
on therapeutic-dose LMWH: at least weekly until target level is of DOACs are controversial.226,227 Animal and in vitro studies showed
achieved or when there is a below target level at any stage, and regular that dabigatran, rivaroxaban, and apixaban crossed the placenta.228–230
monitoring thereafter (e.g. every 2–4 weeks depending on stability) Prescription information based on these data reported variable adverse
(see Section 12.5.3.2). Recommended peak anti-factor Xa levels should effects in pregnant rodents and rabbits: post-implantation loss, mater-
be individualized based on type and location of the valve (between 1.0 nal bleeding, or malformation at >4 times the recommended maternal
and 1.2 U/mL) and additional trough level measurement may be indi- doses (see Supplementary data online, Table S4). Counselling women
cated in selected cases with increased thrombosis risk (see Section on DOACs who are planning a pregnancy is advised, considering the
12.5.3.2).216 complexity of pre- and post-conceptional switches to alternative
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

4492 E S C G u id e l in e s
regimens (LMWH, VKA) and the risk of VTE recurrence.227 DOACs Care must be taken to monitor for reduction in plasma volume or
may have an edge over VKAs, such as rapid reversal in case of prema- CO, and decrease in placental perfusion.
ture delivery and a short antepartum interruption period, due to their Pre-clinical data on SGLT2 inhibitors showed that they cross the pla-
reversible inhibition of procoagulant factors. The oral route is an advan- centa243 and exposure to these drugs may cause foetal damage in ro-
tage over LMWHs. However, evidence of safety is lacking for specific dents, especially during the second and third trimesters.244 SGLT2
DOAC antidotes (andexanet alfa, idarucizumab) in pregnant women inhibitors should be stopped before pregnancy and during lactation.
and can only be inferred from pre-clinical studies. After uncertain initial
reports on foetotoxicity,224 a recent retrospective cohort study (main- 5.2.4. Pulmonary hypertension
ly in women exposed to rivaroxaban) does not support a high risk of
Parenteral prostaglandin analogues (i.v. epoprostenol, treprostinil) can
embryotoxicity.231 It should be highlighted that despite promising stud-
be used in pregnant women with significant right ventricle (RV) dysfunc-
ies, clinical evidence on the benefits and risks of DOACs for the mother
tion, while recognizing that these agents may interfere with platelet ag-
and foetus is scarce and needed, and their foetal safety over VKAs dur- gregation and may promote bleeding.245 Oral phosphodiesterase 5
ing the second and third trimesters has not been established. DOACs inhibitors (e.g. sildenafil, tadalafil) can also be used, while recognizing
are not recommended in pregnancy and they should only be used in the the potential side effects of pre-term delivery and SGA babies.246
absence of any other option in consultation with the Pregnancy Heart
Combination therapy with sildenafil and inhaled iloprost has also
Team and the haematology team. Based on current data there is no ab- been reported.247 Calcium channel blockers should be continued dur-
solute indication to interrupt pregnancy in the case of accidental ing pregnancy for women with vasodilator-responsive PAH and normal
exposure.227,232
RV function. Endothelin receptor antagonists (ERAs, e.g. bosentan, am-
During lactation, alternative drugs should be preferred to DOACs
brisentan, macitentan) should not be used in pregnancy due to their
due to the paucity of data. However, there are relevant differences be-
teratogenic potential. There are few data on the safety of agents
tween the agents. In studies on lactating women treated with apixaban,
such as bosentan and sildenafil in the post-partum period for lactating
the concentration in milk was significantly higher than that of rivaroxa- mothers; however, successful cases have been reported.248,249
ban: the milk-to-plasma ratio was >12%,233 and the weight-adjusted in-
fant doses 14%–20%.234 Dabigatran etexilate mesylate, the orally
5.2.5. Anti-arrhythmic agents
available prodrug, is poorly excreted to the milk after biotransforma-
For women without structural heart disease, anti-arrhythmic drugs (such
tion to dabigatran, and its oral absorption by the neonatal gastrointes-
as flecainide, sotalol, and ibutilide) can be used for the prevention or ter-
tinal tract is likely negligible. In two breastfed neonates of women
mination of AF and atrial flutter (AFL).250,251 Beta-blockers are consid-
receiving dabigatran, the maximum drug concentrations in the neo-
ered safe, especially lipophilic compounds (labetalol, metoprolol, and
nates’ plasma were 100 000 times below the levels that would have a
significant effect on coagulation indices.235 In lactating women treated propranolol). In pregnant women with AF and concomitant congestive
HF, digoxin may be an alternative option for rate control. Amiodarone
with 15–20 mg/day rivaroxaban, the breastfed infant would receive a
can cause foetal abnormalities, bradycardia, and thyroid dysfunction,
low dose, corresponding to 1.3%–5% of the maternal weight-adjusted
dosage.233,236–238 Therefore, dabigatran and rivaroxaban may be taken and its routine use is contraindicated during pregnancy, but may be
used as single dose in emergencies like ventricular tachycardia (VT)
cautiously during lactation. Signs of bleeding should be monitored in
storm. There are no restrictions on amiodarone use in cardiac arrest.252
neonates of lactating mothers taking dabigatran.
Recommendation Table 4 — Recommendation for dir- 5.2.6. Calcium channel blockers
ect oral anticoagulants and pregnancy The safety and efficacy of nifedipine [the originator of dihydropyridine
calcium channel blockers (CCBs)] as an antihypertensive in pregnancy
Recommendation Classa Levelb has largely been proved in comparison with other antihypertensive
treatments (see Section 12.3). A meta-analysis of 22 randomized con-
DOACs are not recommended during pregnancy. III C
trol trials with 2595 participants found that nifedipine was significantly
DOAC, direct oral anticoagulants. more effective at reducing patients’ high blood pressure compared
aClass of recommendation.
with other antihypertensive drugs (labetalol, hydralazine, methyldopa)
bLevel of evidence.
in hypertensive patients.253 Foetal, neonatal, and maternal safety
outcomes were not statistically different between nifedipine and com-
5.2.2. Antiplatelet treatment parators, except for maternal headache and flushing.253 A randomized
No teratogenic effect is reported for aspirin doses up to 300 mg daily. controlled trial compared oral regimens with nifedipine, labetalol,
Clopidogrel is considered safe if dual antiplatelet therapy (DAPT) is or methyldopa in women requiring antihypertensive therapy due to
needed for the shortest possible duration.239,240 Ticagrelor is contrain- severe hypertension. It found that the primary outcome of blood pres-
dicated due to embryotoxicity. Prasugrel may be considered during sure control within 6 h with no adverse outcome was more common
pregnancy in special populations including poor metabolizers in with nifedipine or labetalol than with methyldopa254. Amlodipine
whom the prodrug clopidogrel has limited effect.241,242 The use of showed safety and efficacy similar to nifedipine.255 Studies on the non-
glycoprotein IIb/IIIa inhibitors (eptifibatide and tirofiban) should only dihydropyridine CCB diltiazem are inadequate and significant potential
be used in pregnancy if strictly necessary.240 teratogenic effects have been demonstrated in rodents and rabbits.
The drug passes in milk, reaching relevant infant concentrations.
Therefore, diltiazem is not recommended in pregnancy and lactation.
5.2.3. Diuretics and SGLT2 inhibitors Oral verapamil is considered safe; no teratogenicity has been observed.
Diuretics may be used in pregnancy to treat systemic hypertension es- The drug is excreted at low levels in milk, <1% of the mother’s weight-
pecially in emergencies or HF-related volume overload conditions. adjusted dosage.
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4493
5.2.7. Renin–angiotensin–aldosterone system reduced IUGR. Nadolol and pindolol are also safe in the case of ar-
inhibitors rhythmic events in cardiomyopathies and channelopathies (see
Angiotensin-converting enzyme inhibitors (ACE-Is), angiotensin re- Section 6).269–271 Of note, the metabolism of metoprolol (and perhaps
ceptor blockers (ARBs), angiotensin receptor/neprilysin inhibitors other oral lipophilic beta-blockers) was significantly higher in mid and
(ARNIs), and renin inhibitors can cause foetal malformations, late pregnancy than post-partum, likely due to enzymatic induction
IUGR and death, and are contraindicated in pregnancy. Caution during pregnancy.272 Changes in dosage (dose and frequency) are like-
should be recommended to childbearing women, especially in the ly required if inadequate clinical responses are encountered.272
absence of effective contraception. Captopril, enalapril, and benaze- Atenolol causes severe growth restriction, bradycardia, and hypogly-
pril are safe during lactation,146 whereas ARBs are not recom- caemia and is not recommended.250,268,272,273
mended. Candesartan may be an exception.256 Aldosterone Propranolol, metoprolol (combined with hydralazine), and labetalol
antagonists, canrenone, and spironolactone can have anti- had the lowest and sotalol the highest risk of neonatal bradycardia dur-
androgenetic effects and are contraindicated in pregnancy. ing lactation.274 For the lipophilic beta-blockers, milk level was <1% of
Spironolactone is considered safe during lactation because of exten- the maternal weight-adjusted dose, thus reducing the risks associated
sive metabolism to canrenone, thus the infant would receive less with neonatal exposure during lactation.272
than 1% of the mother’s daily dosage of canrenone.257 Case reports
of eplerenone in pregnant women with resistant hypertension iden-
5.2.10. Immunosuppressants
tified no adverse effects.258–261
The balance between maternal and foetal safety is challenging for im-
munosuppressant therapy, especially for women with heart trans-
5.2.8. Lipid-lowering agents
plantation. Medication can pass to the milk and expose neonates
Diagnosis of maternal hypercholesterolaemia at the first trimester or and infants to adverse drug effects. Changes in maternal physiology
familial hypercholesterolaemia have adverse consequences for both impact the pharmacokinetics of immunosuppressant drugs (see
foetus and mother.262 Low-density lipoprotein (LDL) levels increase Section 3.2).275 Calcineurin inhibitors (e.g. cyclosporine, tacrolimus),
by ∼30%–50%, high-density lipoprotein cholesterol by 20%–40%, mammalian target of rapamycin inhibitors (e.g. everolimus, sirolimus),
and triglycerides by 50%–100% during pregnancy262, so referring and azathioprine are the drugs of choice during pregnancy and lacta-
to reference range as for routine testing is of limited clinical use. tion, which should not be discouraged. Mycophenolate derivatives in-
Previously, lipid-lowering treatment was usually discontinued during crease the risk of miscarriage and foetal malformations especially
pregnancy because of limited safety data.43 Having been contraindi- during the first trimester and should be discontinued at least 6 weeks
cated in pregnancy since 1987, statins now remain contraindicated before conception.276,277
only during lactation. In July 2021 the United States Food and
Drug Administration (FDA)263 stated that the evidence was insuffi-
cient to conclude that a risk of miscarriage is increased with statins 5.2.11. Neuroactive drugs
and requested removal of the contraindication.264 Continuing Selective serotonin reuptake inhibitors, including sertraline, can be ta-
with statins may therefore be considered during pregnancy in wo- ken safely during pregnancy and lactation.278 Zuranolone, a synthetic
men with familial hypercholesterolaemia or established atheroscler- form of the neurosteroid allopregnanolone, has recently been ap-
otic cardiovascular disease (ASCVD) (see Section 12.2).265 proved for the treatment of post-partum depression. No information
Furthermore, inadvertent conception during statin therapy does is available on its safety in patients with CVD. Zuranolone is excreted in
not require pregnancy termination but should prompt close follow- the milk and lactation should be avoided in the absence of safety
up. Bile acid binding sequestrants265 and LDL apheresis265 can be data.279
considered in women with familial hypercholesterolaemia. PCSK9
inhibitors and ezetimibe are not recommended during pregnancy
5.2.12. Obstetric drugs in patients with due to lack of clinical data.266 Bempedoic acid has a strong contra-
cardiovascular disease
indication and therefore women are recommended contraception
during its use. Drugs for inducing ovulation, including follicle-stimulating hormone and
luteinizing hormone or combinations, are associated with an increased
risk of deep vein thrombosis (DVT) and PE, due to the sharp rise in oes-
5.2.9. Beta-adrenergic blocking agents
trogen levels during follicle recruitment,280 but no other immediate car-
Beta-blocker use during early pregnancy has not been associated with
diovascular side effects are known.
an increased risk of congenital malformations.250,267,268 Recent data
from ROPAC indicate higher SGA rates in women with beta-blocker
exposure (15.3% vs 9.3%, P < .001). With metoprolol as reference, la- 5.3. Internet databases
betalol (0.2, 95% CI 0.1–0.4) was the least likely to cause SGA, and See Supplementary data online, Internet databases.
atenolol (2.3, 95% CI 1.1–4.9) the most.12 Labetalol and lipophilic
drugs (metoprolol, propranolol, carvedilol) are preferred due to
5.4. List of drugs
high first-pass metabolism, as well as beta-1-selective drugs (bisopro-
lol, metoprolol), which reduce the risk of hypoglycaemia in addition to See Supplementary data online, Table S4.
Downloaded
from

by
guest
on
22
January
2026

4494 E S C G u id e l in e s
(cid:18)(cid:12)(cid:25)(cid:24)(cid:21)(cid:10)(cid:23)(cid:9)(cid:21)(cid:14)(cid:27)(cid:26)(cid:14)(cid:27)
(cid:31)(cid:31)(cid:3)(cid:29)(cid:28)(cid:21)(cid:7)(cid:15)(cid:24)(cid:27)(cid:19)(cid:5)(cid:29)(cid:25)(cid:12)(cid:23)(cid:22)(cid:19)(cid:29)(cid:24)(cid:16)(cid:26)(cid:25)(cid:27)(cid:24)(cid:27)(cid:24) (cid:31)(cid:31)(cid:3)(cid:29)(cid:28)(cid:21)(cid:7)(cid:15)(cid:24)(cid:27)(cid:19)(cid:5)(cid:29)(cid:25)(cid:12)(cid:23)(cid:22)(cid:19)(cid:29)(cid:24)(cid:16)(cid:26)(cid:25)(cid:27)(cid:24)(cid:27)(cid:24)
(cid:31) (cid:10)(cid:9)(cid:8)(cid:7)(cid:6)(cid:23)(cid:22)(cid:10)(cid:4)(cid:3)(cid:23)(cid:22)(cid:21)(cid:28)(cid:29)(cid:20)(cid:27)(cid:24)(cid:27)(cid:24) (cid:31) (cid:10)(cid:4)(cid:3)(cid:21)
(cid:18)(cid:25)(cid:25)(cid:17)(cid:16)(cid:24)(cid:17)(cid:15)(cid:21)(cid:26)(cid:14)
(cid:31)(cid:31)(cid:10)(cid:17)(cid:29)(cid:20)(cid:27)(cid:12)(cid:16)(cid:20)(cid:29)(cid:23)(cid:22)(cid:11)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:27)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)(cid:20)(cid:21)(cid:17)(cid:27)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)(cid:26)(cid:25)(cid:27)(cid:26)(cid:25)(cid:21)(cid:20)(cid:27)(cid:24)(cid:27)(cid:24)(cid:23) (cid:31)(cid:31)(cid:10)(cid:17)(cid:29)(cid:20)(cid:27)(cid:12)(cid:16)(cid:20)(cid:29)(cid:23)(cid:22)(cid:11)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:27)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)(cid:20)(cid:21)(cid:17)(cid:27)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)(cid:26)(cid:25)(cid:27)(cid:26)(cid:25)(cid:21)(cid:20)(cid:27)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)(cid:17)(cid:16)„(cid:27)(cid:31)(cid:16)(cid:20)(cid:23)
(cid:17)(cid:16)„(cid:27)(cid:31)(cid:16)(cid:20)(cid:23)(cid:22)’(cid:29)(cid:19)(cid:21)(cid:16)(cid:20)(cid:16)(cid:17)(cid:29) ’(cid:29)(cid:19)(cid:21)(cid:16)(cid:20)(cid:16)(cid:17)(cid:29)
(cid:31)(cid:30)(cid:1)(cid:27)(cid:28)(cid:21)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)(cid:26)(cid:25)(cid:27)(cid:26)(cid:21)(cid:14)(cid:29)(cid:20)(cid:27)(cid:20)(cid:29)(cid:23)(cid:22)(cid:17)(cid:27)(cid:14)(cid:29)(cid:28)(cid:16)(cid:24)(cid:16)(cid:17)(cid:29) (cid:31)(cid:30)(cid:1)(cid:27)(cid:28)(cid:21)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)(cid:26)(cid:25)(cid:27)(cid:26)(cid:21)(cid:14)(cid:29)(cid:20)(cid:27)(cid:20)(cid:29)(cid:23)(cid:22)(cid:17)(cid:27)(cid:14)(cid:29)(cid:28)(cid:16)(cid:24)(cid:16)(cid:17)(cid:29)(cid:23)(cid:22)—(cid:13)(cid:16)(cid:20)(cid:16)(cid:17)(cid:16)(cid:20)(cid:29)
(cid:31) (cid:10)(cid:11)(cid:16)(cid:27)(cid:17)(cid:21)(cid:25)(cid:27)(cid:20)(cid:29)(cid:23)(cid:22)(cid:17)(cid:16)(cid:12)(cid:27)(cid:26)‘(cid:25)(cid:21)(cid:11)(cid:16)(cid:17)(cid:29)(cid:23)(cid:22)(cid:17)(cid:25)(cid:27)(cid:20)(cid:29)(cid:17)(cid:21)(cid:25)(cid:27)(cid:20)(cid:29)(cid:23)(cid:22)(cid:21)(cid:28)(cid:29)(cid:20)(cid:27)(cid:24)(cid:27)(cid:24) (cid:31) (cid:10)(cid:11)(cid:16)(cid:27)(cid:17)(cid:21)(cid:25)(cid:27)(cid:20)(cid:29)(cid:23)(cid:22)(cid:17)(cid:16)(cid:12)(cid:27)(cid:26)‘(cid:25)(cid:21)(cid:11)(cid:16)(cid:17)(cid:29)(cid:23)(cid:22)(cid:17)(cid:25)(cid:27)(cid:20)(cid:29)(cid:17)(cid:21)(cid:25)(cid:27)(cid:20)(cid:29)
(cid:8)(cid:26)(cid:25)(cid:9)(cid:21)(cid:12)(cid:15)(cid:16)(cid:12)(cid:5)(cid:26)(cid:24)(cid:17)(cid:21)(cid:27)(cid:14)(cid:23)(cid:4)(cid:14)(cid:27)(cid:27)(cid:23)(cid:14)(cid:5)(cid:27)(cid:10)(cid:21)(cid:3)(cid:10)(cid:23)(cid:21)(cid:7)(cid:9)(cid:21)(cid:10)(cid:26)(cid:24)(cid:21)(cid:12)(cid:7)(cid:14)(cid:2)
(cid:31)(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:27)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)(cid:26)(cid:25)(cid:27)(cid:26)(cid:25)(cid:21)(cid:20)(cid:27)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)(cid:20)(cid:21)(cid:17)(cid:27)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)’(cid:29)(cid:19)(cid:21)(cid:16)(cid:20)(cid:16)(cid:17)(cid:29) (cid:31)(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:27)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)(cid:26)(cid:25)(cid:27)(cid:26)(cid:25)(cid:21)(cid:20)(cid:27)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)(cid:20)(cid:21)(cid:17)(cid:27)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)’(cid:29)(cid:19)(cid:21)(cid:16)(cid:20)(cid:16)(cid:17)(cid:29)(cid:23)(cid:22)
(cid:12)(cid:26)(cid:16)(cid:25)(cid:27)(cid:20)(cid:27)(cid:24)(cid:21)(cid:19)(cid:28)(cid:27)(cid:20)(cid:29)
(cid:31)(cid:30)(cid:1)(cid:27)(cid:28)(cid:21)(cid:24)(cid:27)(cid:24) (cid:31)(cid:30)(cid:1)(cid:27)(cid:28)(cid:21)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)(cid:19)(cid:21)(cid:20)(cid:17)(cid:29)(cid:12)(cid:21)(cid:25)(cid:28)(cid:21)(cid:20)
(cid:31) (cid:10) (cid:16)(cid:20)(cid:9) ‰(cid:8) (cid:16)(cid:15)(cid:7)(cid:6) (cid:16)(cid:23) (cid:28)(cid:22)(cid:10) (cid:27)(cid:4) (cid:25)(cid:12)(cid:3) (cid:23)(cid:22)(cid:23) (cid:30)(cid:22)(cid:10) (cid:4)(cid:4) (cid:10)(cid:2) (cid:23)(cid:6) (cid:22)(cid:1)(cid:23)(cid:22)(cid:17) (cid:127)(cid:16) (cid:129)(cid:12) (cid:141)(cid:27) (cid:143)(cid:26) (cid:7)‘ (cid:6)(cid:23)(cid:25) (cid:22)(cid:11)(cid:21)(cid:11) (cid:21)(cid:18)(cid:16)(cid:17) (cid:21)(cid:29) (cid:19)(cid:23) (cid:21)(cid:22)(cid:17) (cid:11)(cid:16)(cid:25) (cid:28)(cid:29) (cid:29)(cid:19) (cid:20)(cid:28) (cid:23)(cid:22) (cid:22)(cid:25) (cid:21)(cid:29) (cid:28)(cid:20) (cid:29)(cid:16) (cid:20)(cid:20) (cid:27)(cid:24)(cid:27)(cid:24) (cid:31) (cid:11)(cid:10)(cid:4) (cid:21)(cid:3) (cid:18)(cid:21) (cid:21)(cid:23) (cid:19)(cid:22)(cid:17) (cid:21)(cid:16) (cid:11)(cid:12)(cid:27) (cid:28)(cid:26) (cid:29)‘ (cid:20)(cid:25)(cid:21)(cid:11)(cid:16)(cid:17)(cid:29)(cid:23)(cid:22)(cid:17)(cid:16)(cid:25)(cid:29)(cid:19)(cid:28)(cid:22)(cid:25)(cid:29)(cid:20)(cid:16)(cid:20)(cid:22)(cid:16)(cid:20)‰(cid:16)(cid:15)(cid:16)(cid:28)(cid:27)(cid:25)(cid:12)(cid:23)(cid:22)(cid:1)(cid:127)(cid:129)(cid:141)(cid:143)(cid:7)(cid:6)(cid:23)
(cid:8)(cid:17)(cid:26)(cid:7)(cid:7)(cid:27)(cid:20)(cid:12)(cid:5)(cid:26)(cid:24)(cid:17)(cid:21)(cid:27)(cid:14)(cid:23)(cid:4)(cid:14)(cid:27)(cid:27)(cid:23)(cid:14)(cid:5)(cid:27)(cid:10)(cid:21)(cid:3)(cid:10)(cid:23)(cid:21)(cid:7)(cid:9)(cid:21)(cid:10)(cid:26)(cid:24)(cid:21)(cid:12)(cid:7)(cid:14)(cid:2)
(cid:31)(cid:31)–(cid:13)(cid:16)(cid:20)(cid:16)(cid:17)(cid:16)(cid:20)(cid:29)(cid:23)(cid:22)(cid:20)(cid:21)(cid:17)(cid:27)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)(cid:26)(cid:25)(cid:27)(cid:26)(cid:25)(cid:21)(cid:20)(cid:27)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)’(cid:29)(cid:19)(cid:21)(cid:16)(cid:20)(cid:16)(cid:17)(cid:29) (cid:31)(cid:31)Œ(cid:25)(cid:27)(cid:26)(cid:25)(cid:21)(cid:20)(cid:27)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)’(cid:29)(cid:19)(cid:21)(cid:16)(cid:20)(cid:16)(cid:17)(cid:29)(cid:23)(cid:22)—(cid:13)(cid:16)(cid:20)(cid:16)(cid:17)(cid:16)(cid:20)(cid:29)
(cid:31)(cid:30)(cid:30)(cid:29)(cid:31)(cid:16)(cid:24)(cid:29)(cid:28)(cid:16)(cid:20)(cid:29) (cid:31)(cid:30)(cid:2)(cid:21)(cid:17)(cid:27)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)(cid:22)(cid:11)(cid:29)(cid:31)(cid:16)(cid:24)(cid:29)(cid:28)(cid:16)(cid:20)(cid:29)
(cid:8)(cid:12)(cid:25)(cid:12)(cid:7)(cid:26)(cid:25)(cid:16)(cid:23)(cid:26)(cid:25)(cid:24)(cid:27)(cid:25)(cid:16)(cid:23)(cid:9)(cid:21)(cid:14)(cid:27)(cid:26)(cid:14)(cid:27)
(cid:31)(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:27)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)(cid:19)(cid:21)(cid:25)(cid:18)(cid:29)(cid:17)(cid:16)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)(cid:24)(cid:21)(cid:15)(cid:29)(cid:28)(cid:21)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)(cid:14)(cid:13)(cid:25)(cid:27)(cid:12)(cid:29)(cid:11)(cid:16)(cid:17)(cid:29)(cid:23) (cid:31)(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:27)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)(cid:19)(cid:21)(cid:25)(cid:18)(cid:29)(cid:17)(cid:16)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)(cid:24)(cid:21)(cid:15)(cid:29)(cid:28)(cid:21)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)(cid:24)(cid:27)€(cid:7)(cid:17)(cid:27)(cid:12)(cid:29)(cid:22)(cid:10)(cid:1)(cid:10)(cid:23)(cid:22)
(cid:18)(cid:29)(cid:25)(cid:21)(cid:26)(cid:21)(cid:11)(cid:16)(cid:24)(cid:23)(cid:22)(cid:24)(cid:27)€(cid:7)(cid:17)(cid:27)(cid:12)(cid:29)(cid:22)(cid:10)(cid:1)(cid:10) (cid:18)(cid:29)(cid:25)(cid:21)(cid:26)(cid:21)(cid:11)(cid:16)(cid:24)(cid:23)(cid:22)(cid:14)(cid:13)(cid:25)(cid:27)(cid:12)(cid:29)(cid:11)(cid:16)(cid:17)(cid:29)
(cid:31)(cid:30)(cid:9)(cid:24)(cid:27)(cid:26)(cid:16)(cid:17)(cid:27)„(cid:25)(cid:29)(cid:24)(cid:23)(cid:22)(cid:15)(cid:16)(cid:12)(cid:27)(cid:26)(cid:25)(cid:27)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)(cid:12)(cid:28)(cid:21)(cid:28)(cid:16)(cid:20)(cid:12)(cid:22)ˆ(cid:16)(cid:14)(cid:22)(cid:29)(cid:12)(cid:28)(cid:21)(cid:15)(cid:24)(cid:16)(cid:12)‰(cid:29)(cid:17)(cid:22)(cid:10)(cid:1)(cid:9)‚…Š (cid:31)(cid:30)(cid:3)(cid:16)(cid:12)(cid:27)(cid:26)(cid:25)(cid:27)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)Œ(cid:9)(cid:1)ƒŽ(cid:7)(cid:6)
(cid:31) (cid:10)(cid:28)(cid:29)(cid:20)(cid:27)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)(cid:17)(cid:16)(cid:24)(cid:28)(cid:16)(cid:21)‹(cid:29)(cid:11)(cid:23)(cid:22)(cid:25)(cid:21)(cid:20)(cid:27)(cid:24)(cid:21)‹(cid:16)(cid:20)(cid:29)(cid:23)(cid:22)Œ(cid:9)(cid:1)ƒŽ(cid:7)(cid:6)(cid:23)(cid:22)(cid:29)‹(cid:29)(cid:28)(cid:16)(cid:11)(cid:16)(cid:15)(cid:29) (cid:31) (cid:1)(cid:28)(cid:21)(cid:28)(cid:16)(cid:20)(cid:12)(cid:23)(cid:22)(cid:25)(cid:21)(cid:20)(cid:27)(cid:24)(cid:21)‹(cid:16)(cid:20)(cid:29)(cid:23)(cid:22)(cid:29)‹(cid:29)(cid:28)(cid:16)(cid:11)(cid:16)(cid:15)(cid:29)(cid:23)(cid:22)(cid:17)(cid:16)(cid:24)(cid:28)(cid:16)(cid:21)‹(cid:29)(cid:11)
(cid:28)(cid:27)(cid:26)(cid:25)(cid:24)(cid:23)(cid:22)(cid:26)(cid:21)(cid:20)(cid:19)(cid:25)(cid:27)
(cid:31)(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:27)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)(cid:26)(cid:25)(cid:27)(cid:26)(cid:25)(cid:21)(cid:20)(cid:27)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)(cid:19)(cid:21)(cid:25)(cid:18)(cid:29)(cid:17)(cid:16)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)(cid:24)(cid:21)(cid:15)(cid:29)(cid:28)(cid:21)(cid:24)(cid:27)(cid:24)(cid:23) (cid:31)(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:27)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)(cid:26)(cid:25)(cid:27)(cid:26)(cid:25)(cid:21)(cid:20)(cid:27)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)(cid:19)(cid:21)(cid:25)(cid:18)(cid:29)(cid:17)(cid:16)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)(cid:24)(cid:21)(cid:15)(cid:29)(cid:28)(cid:21)(cid:24)(cid:27)(cid:24)(cid:23)
(cid:14)(cid:13)(cid:25)(cid:27)(cid:12)(cid:29)(cid:11)(cid:16)(cid:17)(cid:29) (cid:14)(cid:13)(cid:25)(cid:27)(cid:12)(cid:29)(cid:11)(cid:16)(cid:17)(cid:29)(cid:23)(cid:22)(cid:10)(cid:9)(cid:8)(cid:7)(cid:6)(cid:23)(cid:22)(cid:12)(cid:26)(cid:16)(cid:25)(cid:27)(cid:20)(cid:27)(cid:24)(cid:21)(cid:19)(cid:28)(cid:27)(cid:20)(cid:29)
(cid:31)(cid:30)(cid:3)(cid:16)(cid:12)(cid:27)(cid:26)(cid:25)(cid:27)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)‰‘(cid:17)(cid:25)(cid:21)(cid:24)(cid:21)‹(cid:16)(cid:20)(cid:29)(cid:23)(cid:22)(cid:16)(cid:12)(cid:27)(cid:12)(cid:27)(cid:25)(cid:15)(cid:16)(cid:17)(cid:29)(cid:22)(cid:17)(cid:16)(cid:20)(cid:16)(cid:28)(cid:25)(cid:21)(cid:28)(cid:29)(cid:23) (cid:31)(cid:30)(cid:3)(cid:16)(cid:12)(cid:27)(cid:26)(cid:25)(cid:27)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)(cid:19)(cid:21)(cid:20)(cid:17)(cid:29)(cid:12)(cid:21)(cid:25)(cid:28)(cid:21)(cid:20)
„(cid:24)‘(cid:19)(cid:29)(cid:25)(cid:16)(cid:20)(cid:22)(cid:28)(cid:25)(cid:16)(cid:20)(cid:16)(cid:28)(cid:25)(cid:21)(cid:28)(cid:29)
(cid:31) (cid:10)(cid:9)(cid:8)(cid:7)(cid:6)(cid:23)(cid:22)(cid:10)(cid:4)(cid:3)(cid:23)(cid:22)(cid:10)(cid:4)(cid:2)(cid:6)(cid:23)(cid:22)(cid:30)(cid:4)(cid:10)(cid:23)(cid:22)(cid:1)(cid:127)(cid:129)(cid:141)(cid:143)(cid:7)(cid:6)(cid:23)(cid:22)(cid:16)(cid:18)(cid:21)(cid:15)(cid:25)(cid:21)(cid:17)(cid:16)(cid:20)(cid:29)(cid:23) (cid:31) (cid:6)(cid:18)(cid:21)(cid:15)(cid:25)(cid:21)(cid:17)(cid:16)(cid:20)(cid:29)(cid:23)(cid:22)(cid:21)(cid:24)(cid:16)(cid:12)(cid:5)(cid:16)(cid:25)(cid:29)(cid:20)(cid:23)(cid:22)(cid:10)(cid:4)(cid:3)(cid:21)(cid:23)(cid:22)(cid:10)(cid:4)(cid:2)(cid:6)(cid:23)(cid:22)(cid:1)(cid:127)(cid:129)(cid:141)(cid:143)(cid:7)(cid:6)
(cid:21)(cid:24)(cid:16)(cid:12)(cid:5)(cid:16)(cid:25)(cid:29)(cid:20)(cid:23)(cid:22)(cid:21)(cid:28)(cid:29)(cid:20)(cid:27)(cid:24)(cid:27)(cid:24)
(cid:28)(cid:27)(cid:26)(cid:25)(cid:24)(cid:23)(cid:24)(cid:25)(cid:26)(cid:7)(cid:14)(cid:5)(cid:20)(cid:26)(cid:7)(cid:24)(cid:26)(cid:24)(cid:21)(cid:12)(cid:7)(cid:23)(cid:4)(cid:21)(cid:15)(cid:15)(cid:19)(cid:7)(cid:12)(cid:14)(cid:19)(cid:5)(cid:5)(cid:25)(cid:27)(cid:14)(cid:14)(cid:26)(cid:7)(cid:24)(cid:14)(cid:2)
(cid:31)(cid:31)(cid:10) (cid:28)(cid:21)‹ (cid:19)(cid:21) (cid:25)(cid:28) (cid:27)‰ (cid:24)(cid:16)(cid:16) (cid:11)(cid:27)(cid:26) (cid:13)(cid:25) (cid:12)(cid:16)(cid:20)(cid:29)(cid:23)(cid:22)(cid:19)(cid:27)(cid:25)(cid:28)(cid:16)(cid:19)(cid:27)(cid:12)(cid:28)(cid:29)(cid:25)(cid:27)(cid:16)(cid:17)(cid:12)(cid:23)(cid:22)(cid:19)‘(cid:19)(cid:24)(cid:27)(cid:12)(cid:26)(cid:27)(cid:25)(cid:16)(cid:20)(cid:29)(cid:23) (cid:31)(cid:31)(cid:10)‹(cid:21)(cid:28)‰(cid:16)(cid:27)(cid:26)(cid:25)(cid:16)(cid:20)(cid:29)(cid:23)(cid:22)(cid:19)(cid:27)(cid:25)(cid:28)(cid:16)(cid:19)(cid:27)(cid:12)(cid:28)(cid:29)(cid:25)(cid:27)(cid:16)(cid:17)(cid:12)(cid:23)(cid:22)(cid:19)‘(cid:19)(cid:24)(cid:27)(cid:12)(cid:26)(cid:27)(cid:25)(cid:16)(cid:20)(cid:29)
(cid:31)(cid:30)(cid:1)(cid:16)(cid:25)(cid:27)(cid:24)(cid:16)(cid:11)(cid:13)(cid:12) (cid:31)(cid:30)(cid:141)(cid:21)(cid:19)(cid:25)(cid:27)(cid:24)(cid:16)(cid:11)(cid:13)(cid:12)(cid:23)(cid:22)(cid:12)(cid:16)(cid:25)(cid:27)(cid:24)(cid:16)(cid:11)(cid:13)(cid:12)
(cid:31) (cid:30)‘(cid:19)(cid:27)(cid:26)‰(cid:29)(cid:20)(cid:27)(cid:24)(cid:21)(cid:28)(cid:29)(cid:22)ˆ“(cid:7)€(cid:5)(cid:22)(cid:26)(cid:25)(cid:29)(cid:7)(cid:26)(cid:25)(cid:29)„(cid:20)(cid:21)(cid:20)(cid:19)‘(cid:22)(cid:21)(cid:20)(cid:17) (cid:31) (cid:30)‘(cid:19)(cid:27)(cid:26)‰(cid:29)(cid:20)(cid:27)(cid:24)(cid:21)(cid:28)(cid:29)(cid:23)(cid:22)(cid:29)(cid:18)(cid:29)(cid:25)(cid:27)(cid:24)(cid:16)(cid:11)(cid:13)(cid:12)
”•(cid:22)(cid:28)(cid:25)(cid:16)(cid:11)(cid:29)(cid:12)(cid:28)(cid:29)(cid:25)Š(cid:23)(cid:22)(cid:29)(cid:18)(cid:29)(cid:25)(cid:27)(cid:24)(cid:16)(cid:11)(cid:13)(cid:12)
(cid:28)(cid:16)(cid:5)(cid:27)(cid:25)(cid:24)(cid:27)(cid:7)(cid:14)(cid:21)(cid:12)(cid:7)
(cid:31)(cid:31)(cid:30) (cid:11)(cid:29) (cid:29)(cid:28) (cid:28)‰ (cid:27)‘ (cid:26)(cid:24) (cid:25)(cid:17) (cid:27)(cid:27) (cid:24)(cid:27)(cid:26) (cid:24)(cid:21) (cid:23)(cid:22)(cid:23) (cid:21)(cid:22)(cid:20) (cid:11)(cid:16)(cid:14) (cid:24)(cid:29) (cid:27)(cid:17) (cid:17)(cid:16) (cid:16)(cid:26) (cid:26)(cid:16) (cid:16)(cid:20) (cid:20)(cid:29) (cid:29)(cid:23)(cid:22)(cid:24)(cid:21)(cid:15)(cid:29)(cid:28)(cid:21)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)(cid:26)(cid:25)(cid:27)(cid:26)(cid:25)(cid:21)(cid:20)(cid:27)(cid:24)(cid:27)(cid:24)(cid:23) (cid:31)(cid:31)(cid:10)(cid:11)(cid:24)(cid:27)(cid:17)(cid:16)(cid:26)(cid:16)(cid:20)(cid:29)(cid:23)(cid:22)(cid:24)(cid:21)(cid:15)(cid:29)(cid:28)(cid:21)(cid:24)(cid:27)(cid:24)(cid:23)(cid:22)(cid:10)(cid:9)(cid:8)(cid:7)(cid:6)
(cid:31)(cid:30)(cid:157)‘(cid:17)(cid:25)(cid:21)(cid:24)(cid:21)‹(cid:16)(cid:20)(cid:29)(cid:23)(cid:22)‰‘(cid:17)(cid:25)(cid:27)(cid:19)‰(cid:24)(cid:27)(cid:25)(cid:27)(cid:28)‰(cid:16)(cid:21)‹(cid:16)(cid:17)(cid:29)(cid:23)(cid:22)(cid:16)(cid:20)(cid:17)(cid:21)(cid:26)(cid:21)(cid:11)(cid:16)(cid:17)(cid:29) (cid:31)(cid:30)(cid:157) (cid:11)‘ (cid:29)(cid:17) (cid:28)‰(cid:25)(cid:21) ‘(cid:24) (cid:24)(cid:21) (cid:17)‹ (cid:27)(cid:16)(cid:20) (cid:26)(cid:29) (cid:21)(cid:23) (cid:22)(cid:22) ˆ‰ (cid:17)‘ (cid:29)(cid:17) (cid:26)(cid:25) (cid:25)(cid:27) (cid:29)(cid:19) (cid:12)‰ (cid:12)(cid:24) (cid:16)(cid:27) (cid:27)(cid:25) (cid:20)(cid:27) Š(cid:28) (cid:23)(cid:22)‰ (cid:19)(cid:21)(cid:16)(cid:21) (cid:20)‹ (cid:17)(cid:16)(cid:17) (cid:29)(cid:29) (cid:12)(cid:23) (cid:21)(cid:22)(cid:16) (cid:25)(cid:20) (cid:28)(cid:17) (cid:21)(cid:20)(cid:21)(cid:26)(cid:21)(cid:11)(cid:16)(cid:17)(cid:29)(cid:23)
(cid:31) (cid:10)(cid:9)(cid:8)(cid:7)(cid:6)(cid:23)(cid:22)(cid:10)(cid:4)(cid:3)(cid:23)(cid:22)(cid:21)(cid:24)(cid:16)(cid:12)(cid:5)(cid:16)(cid:25)(cid:29)(cid:20)(cid:23)(cid:22)(cid:21)(cid:28)(cid:29)(cid:20)(cid:27)(cid:24)(cid:27)(cid:24) (cid:31) (cid:10)(cid:24)(cid:16)(cid:12)(cid:5)(cid:16)(cid:25)(cid:29)(cid:20)(cid:23)(cid:22)(cid:19)(cid:24)(cid:27)(cid:20)(cid:16)(cid:17)(cid:16)(cid:20)(cid:29)(cid:23)(cid:22)(cid:10)(cid:4)(cid:3)(cid:21)
(cid:6)(cid:19)(cid:20)(cid:15)(cid:12)(cid:7)(cid:26)(cid:25)(cid:16)(cid:23)(cid:26)(cid:25)(cid:24)(cid:27)(cid:25)(cid:21)(cid:26)(cid:20)(cid:23)(cid:17)(cid:16)(cid:5)(cid:27)(cid:25)(cid:24)(cid:27)(cid:7)(cid:14)(cid:21)(cid:12)(cid:7)
(cid:31)(cid:31)(cid:6)(cid:24)(cid:27)(cid:26)(cid:25)(cid:27)(cid:12)(cid:28)(cid:23)(cid:22)(cid:12)(cid:16)(cid:24)(cid:17)(cid:29)(cid:20)(cid:21)‡(cid:24) (cid:31)(cid:31)(cid:1)(cid:16)(cid:24)(cid:17)(cid:29)(cid:20)(cid:21)‡(cid:24)(cid:23)(cid:22)(cid:16)(cid:24)(cid:27)(cid:26)(cid:25)(cid:27)(cid:12)(cid:28)
(cid:31)(cid:30)(cid:4)(cid:16)(cid:27)(cid:19)(cid:16)„(cid:13)(cid:21)(cid:28)(cid:23)(cid:22)(cid:15)(cid:27)(cid:12)(cid:29)(cid:20)(cid:28)(cid:21)(cid:20)
(cid:29) (cid:3) (cid:18)(cid:29)(cid:27) (cid:25)(cid:12) (cid:16)(cid:29) (cid:19)(cid:16)(cid:20) „(cid:28) (cid:13)(cid:21) (cid:21)(cid:20) (cid:28)(cid:23)(cid:22)(cid:21)(cid:11)(cid:15)(cid:25)(cid:16)(cid:12)(cid:29)(cid:20)(cid:28)(cid:21)(cid:20)(cid:23)(cid:22)(cid:25)(cid:16)(cid:27)(cid:19)(cid:16)„(cid:13)(cid:21)(cid:28)(cid:23)(cid:22)(cid:12)(cid:29)(cid:24)(cid:29)(cid:31)(cid:16)(cid:26)(cid:21)„(cid:23) (cid:31) (cid:10)(cid:11)(cid:15)(cid:25)(cid:16)(cid:12)(cid:29)(cid:20)(cid:28)(cid:21)(cid:20)(cid:23)(cid:22)(cid:12)(cid:29)(cid:24)(cid:29)(cid:31)(cid:16)(cid:26)(cid:21)„
(cid:13)(cid:17)(cid:25)(cid:12)(cid:15)(cid:11)(cid:12)(cid:24)(cid:21)(cid:10)(cid:23)(cid:9)(cid:21)(cid:14)(cid:12)(cid:25)(cid:9)(cid:27)(cid:25)(cid:14)
(cid:31)(cid:31)(cid:129)(cid:30)(cid:144)(cid:157)(cid:23)(cid:22) (cid:157)(cid:23)(cid:22)(cid:24)(cid:27)€(cid:7)(cid:17)(cid:27)(cid:12)(cid:29)(cid:22)(cid:10)(cid:1)(cid:10) (cid:31)(cid:31)(cid:129)(cid:30)(cid:144)(cid:157)(cid:23)(cid:22)(cid:24)(cid:27)€(cid:7)(cid:17)(cid:27)(cid:12)(cid:29)(cid:22)(cid:10)(cid:1)(cid:10)(cid:23)(cid:22)‚ƒ(cid:10)(cid:23)(cid:22) (cid:157)
(cid:31)(cid:30)‚ƒ(cid:10)(cid:23)(cid:22)(cid:19)(cid:24)(cid:27)(cid:26)(cid:16)(cid:17)(cid:27)„(cid:25)(cid:29)(cid:24)(cid:23)(cid:22)(cid:14)(cid:27)(cid:20)(cid:17)(cid:21)(cid:26)(cid:21)(cid:25)(cid:16)(cid:20)(cid:13)(cid:31)(cid:23)(cid:22)(cid:21)(cid:24)(cid:28)(cid:29)(cid:26)(cid:24)(cid:21)(cid:12)(cid:29) (cid:31)(cid:30)(cid:9)(cid:24)(cid:27)(cid:26)(cid:16)(cid:17)(cid:27)„(cid:25)(cid:29)(cid:24)(cid:23)(cid:22)(cid:29)(cid:26)(cid:28)(cid:16)‡(cid:15)(cid:21)(cid:28)(cid:16)(cid:17)(cid:29)(cid:23)(cid:22)(cid:17)(cid:21)(cid:15)(cid:16)„(cid:21)(cid:28)(cid:25)(cid:21)(cid:20)(cid:23)(cid:22)(cid:25)(cid:16)(cid:18)(cid:21)(cid:25)(cid:27)(cid:31)(cid:21)(cid:15)(cid:21)(cid:20)
(cid:31) …†(cid:10)(cid:9)(cid:15)(cid:23)(cid:22)(cid:28)(cid:16)(cid:19)(cid:21)„(cid:25)(cid:29)(cid:24)(cid:27)(cid:25) (cid:31) (cid:10)(cid:26)(cid:16)(cid:31)(cid:21)(cid:15)(cid:21)(cid:20)(cid:23)(cid:22)(cid:29)(cid:17)(cid:27)(cid:31)(cid:21)(cid:15)(cid:21)(cid:20)(cid:23)(cid:22)(cid:28)(cid:16)(cid:19)(cid:21)„(cid:25)(cid:29)(cid:24)(cid:27)(cid:25)
(cid:1)(cid:26)(cid:20)(cid:127)(cid:19)(cid:20)(cid:26)(cid:25)(cid:23)(cid:17)(cid:27)(cid:26)(cid:25)(cid:24)(cid:23)(cid:9)(cid:21)(cid:14)(cid:27)(cid:26)(cid:14)(cid:27)
(cid:31)(cid:31)(cid:3)(cid:29)(cid:28)(cid:21)(cid:7)(cid:15)(cid:24)(cid:27)(cid:19)(cid:5)(cid:29)(cid:25)(cid:12)(cid:23)(cid:22)(cid:17)(cid:16)(cid:13)(cid:25)(cid:29)(cid:28)(cid:16)(cid:19)(cid:12)(cid:23)(cid:22)(cid:129)(cid:30)(cid:144)(cid:157)(cid:23)(cid:22) (cid:157)(cid:22)ˆ(cid:24)(cid:21)(cid:15)(cid:27)(cid:13)(cid:25)Š (cid:31)(cid:31)(cid:3)(cid:29)(cid:28)(cid:21)(cid:7)(cid:15)(cid:24)(cid:27)(cid:19)(cid:5)(cid:29)(cid:25)(cid:12)(cid:23)(cid:22)(cid:17)(cid:16)(cid:13)(cid:25)(cid:29)(cid:28)(cid:16)(cid:19)(cid:12)(cid:23)(cid:22)(cid:129)(cid:30)(cid:144)(cid:157)(cid:23)(cid:22)‚ƒ(cid:10)
(cid:31)(cid:30)‚ƒ(cid:10)(cid:22)ˆ(cid:16)(cid:20)(cid:22)(cid:19)(cid:21)(cid:12)(cid:29)(cid:22)(cid:27)(cid:14)(cid:22)(cid:11)(cid:29)(cid:19)‰(cid:21)(cid:20)(cid:16)(cid:19)(cid:21)(cid:24)(cid:22)(cid:18)(cid:21)(cid:24)(cid:18)(cid:29)(cid:12)(cid:23)(cid:22)(cid:12)(cid:29)(cid:29)(cid:22)(cid:12)(cid:26)(cid:29)(cid:19)(cid:16)‡(cid:19)
(cid:16)(cid:20)(cid:17)(cid:16)(cid:19)(cid:21)(cid:28)(cid:16)(cid:27)(cid:20)(cid:12)Š
Figure 6 Choice of medication during pregnancy (left) and during lactation and breastfeeding (right). ACE-I, angiotensin-converting enzyme inhibitor; ARB,
angiotensin receptor blocker; ARNI, angiotensin receptor/neprilysin inhibitor; ASA, acetylsalicylic acid; ASCVD, atherosclerotic cardiovascular disease; DOAC,
direct oral anticoagulant; LMWH, low-molecular-weight heparin; MRA, mineralocorticoid receptor antagonist; PCSK9-I, proprotein convertase subtilisin/kexin
type 9 inhibitor; SGLT2-I, sodium–glucose co-transporter-2 inhibitors; UFH, unfractionated heparin; VKA, vitamin K antagonist; wk, week.
First/safest choice in pregnancy, lactation and breastfeeding. Second choice in pregnancy, lactation, and breastfeeding. Evidence of foetal or infant
toxicity or no data on safety. aExcept candesartan. bSee text for details.
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4495
6. Pregnancy in women with needed. The two most used anti-arrhythmic drugs in previous studies,
beside beta-blockers, were flecainide and sotalol. Both drugs have a
cardiomyopathies and primary
long record of safety. However, sotalol should be used with caution
arrhythmia syndromes in women with reduced ejection fraction (EF) and with careful cor-
rected QT interval (QTc) monitoring.60 Sotalol also has a beta-blocker
6.1. Cardiomyopathies effect, necessitating monitoring of foetal growth.286,287 Amiodarone is
contraindicated in pregnancy. In women at high arrhythmic risk, an ICD
Cardiomyopathies are characterized by disease-specific structural ab-
should be implanted, preferably before pregnancy (see Section 12.4).
normalities and increased risk of ventricular and supraventricular ar-
Two large studies of women with ARVC showed that pre-pregnancy
rhythmias. The risk associated with pregnancy in a woman with
phenotypical severity, rather than pregnancy itself, was the primary risk
cardiomyopathy can be estimated using the mWHO 2.0 classification
factor. Pregnancy was uneventful in the overwhelming majority.288,289
(Table 6). Pre-pregnancy, women with cardiomyopathies should be
Pregnancy did not seem to accelerate long-term progression of the
clinically evaluated to optimize treatment, avoid contraindicated drugs,
ARVC phenotype.288 and assess the risk of heart failure and arrhythmias. Indicated proce-
dures, including implantable cardioverter defibrillator (ICD) implant-
ation, should be performed before pregnancy. 60 6.1.3. Hypertrophic cardiomyopathy
Genetic counselling is recommended before pregnancy to explain Hypertrophic cardiomyopathy290 is the most common inherited cardiomy-
the probability of genetic transmission, risks for the mother, foetus, opathy and is often caused by variants in sarcomeric genes.60 Phenocopies
and child, and the possibilities of pre-implantation and pre-natal genetic such as Anderson–Fabry disease and Danon disease290 are X-linked and
testing (Table 7).60,281 Women with cardiomyopathies should be man- therefore the cardiac phenotype tends to be milder and occurs later in
aged by the Pregnancy Heart Team, including a cardiologist with ex- life in females than males, making pregnancy usually uneventful.291–293
pertise in cardiomyopathies and arrhythmias. Despite higher maternal mortality in women with HCM compared
with the general population, absolute maternal mortality is low (0.5%)
6.1.1. Dilated cardiomyopathy and non-dilated left and confined to women at particularly high risk (Table 6).294,295 Data
ventricular cardiomyopathy from the ROPAC registry showed that despite overall good outcomes,
23% of pregnant women with HCM developed major cardiac events, in-
In women with dilated cardiomyopathy (DCM) and non-dilated left ven-
cluding VT (10%) and AF (1.7%), mostly in women already identified as
tricle (LV) cardiomyopathy (NDLVC), severe systolic LV dysfunction,
high risk prior to pregnancy.296 A recent systematic review including
New York Heart Association (NYHA) functional class III/IV, RV failure,
1624 women confirmed low neonatal mortality (0.2%) and stillbirths
sustained ventricular arrhythmias, AF, and/or severe mitral valve regurgi-
(1%) in pregnant women with HCM.297 A study including 242 women
tation (MR) are high-risk criteria for major adverse cardiovascular events
during pregnancy.282 In contrast, women with mild LV dysfunction, good with HCM found that pregnancy was not a modifier of the long-term
outcomes and pregnancy was well tolerated.298 Risk factors for ma-
functional status, no arrhythmias, and no history of cardiac events are
likely to have an uncomplicated pregnancy.282 jor adverse cardiovascular events were advanced NYHA class and
higher age at diagnosis.298 Left atrium (LA) diameter as a risk factor
Therapy should be modified before pregnancy. ACE-Is, ARBs,
has been reported with conflicting results.298,299
mineralocorticoid receptor antagonists (MRAs), sacubitril/valsartan, and
SGLT2 inhibitors are all contraindicated during pregnancy. Pre-pregnancy
risk stratification should include temporary withdrawal of contraindicated 6.1.3.1. Treatment of hypertrophic cardiomyopathy in pregnancy
medication with close monitoring (see Section 12.6 Heart failure). Ongoing beta-blocker therapy should be continued during pregnancy.
Beta-blockers should be continued with close monitoring of foetal growth. Atenolol should be replaced before pregnancy (Section 5.2.6). Atrial fib-
If anticoagulation is needed for AF or evidence of an intracardiac thrombus, rillation is poorly tolerated in HCM patients in general due to the risk of
LMWH should be used (see Section 5 for dosing regimens). haemodynamic decompensation, and medical or electrical cardiover-
Data about genotype-specific management during pregnancy are sion of AF during pregnancy should be considered. Beta-blockers
scarce but one study evaluated the risk of pregnancy and progression should be started during pregnancy when new symptoms occur [e.g.
of cardiomyopathy in women with lamin A/C (LMNA) P/LP variants.283 due to left ventricular outflow tract obstruction (LVOTO)], for rate
A small subset of women experienced arrhythmias during pregnancy al- control in AF, and to suppress ventricular arrhythmias. Verapamil is
though a history of pregnancy was not associated with long-term ad- the second choice of drug when beta-blockers are not tolerated.
verse disease progression.283
More information is included in Sections 7, 12.4, and 12.6. 6.1.3.2. Left ventricular outflow tract obstruction
Left ventricular outflow tract (LVOT) gradients may increase slightly
6.1.2. Arrhythmogenic right ventricular during pregnancy and were previously associated with increased car-
cardiomyopathy diac events including arrhythmias and HF.300 However, subsequent
Several observational studies and registries have shown that pregnan- studies have not confirmed this association.296,298
cies in women with arrhythmogenic right ventricular cardiomyopathy In women with obstructive HCM, it is recommended to evaluate gra-
(ARVC) are generally well tolerated with good foetal outcomes and dient in basal condition, with exercise and the Valsalva manoeuvre, be-
no cardiac mortality when receiving optimal surveillance and ther- fore pregnancy and with only the medications allowed during
apy.284,285 Delivery was usually vaginal and appeared safe. Sustained pregnancy, to identify those needing septal reduction therapy before
ventricular arrhythmias were reported in 5% of pregnancies and HF pregnancy.60 Disopyramide may cause uterine contractions and is not
in 13%. Neither increased arrhythmia burden or ICD shocks were ob- recommended in pregnancy and should be discontinued unless the ben-
served.284 Beta-blocker therapy should be continued during pregnancy efits outweigh foetal risk. Data on the safety of alcohol septal ablation
(with the exception of atenolol) or could be started in pregnancy if during pregnancy are limited to a few case reports.60,301,302
Downloaded
from

by
guest
on
22
January
2026

4496 E S C G u id e l in e s
Myosin inhibitors (e.g. mavacamten) have not been tested in preg-
Arrhythmogenic right ventricular cardiomyopathy
nancy and animal studies have shown foetal toxicity.303 Therefore,
Flecainide, in addition to beta-blockers, should be
contraception is recommended while on this treatment. Mavacamten
considered as the anti-arrhythmic drug of choice in IIa C
may interact with hormonal contraception and therefore adding intra-
pregnant women with ARVC.148
uterine or barrier contraception to hormonal contraception may be
considered. Myosin inhibitor treatment should be discontinued at least Sotalol may be considered as an anti-arrhythmic drug
6 months before planning pregnancy304 (see Supplementary data in pregnant women with ARVC, with careful
online, Table S4). evaluation of QTc and while monitoring for foetal IIb C
bradycardia and foetal growth and neonate
hypoglycaemia.
6.1.4. Hypertrabeculation of the left ventricle
Hypertrophic cardiomyopathy
Hypertrabeculation in isolation identified during pregnancy can be the
simple consequence of an increased preload, can resolve after preg- It is recommended to use the same risk stratification
nancy, and cannot be used to make a diagnosis of cardiomyopathy.60 protocol for ventricular arrhythmias in pregnant
I C
Patients with hypertrabeculation and associated HCM, DCM, or women with HCM as for non-pregnant women with
NDLVC should follow the same recommendation as patients with HCM.43
the specific cardiomyopathy.60 It is recommended to start beta-blockersc in women
with HCM who develop symptoms due to outflow I C
tract obstruction or arrhythmia during pregnancy.43
6.1.5. Labour and delivery in cardiomyopathies
It is recommended that women with HCM with
Labour and delivery may be associated with acute pain, adrenaline re-
symptomatic LV dysfunction (EF <50%) and or
lease, and need for urgent administration of anaesthetic drugs, and
therefore haemodynamic monitoring and continuous telemetry moni- severe LVOTO (≥50 mmHg) wishing to become I C
toring during and after delivery is often warranted. In the absence of ob- pregnant are counselled by the Pregnancy Heart
stetric contraindications, vaginal delivery is generally recommended. Team regarding the high risk of pregnancy-related
Neuraxial anaesthesia reduces pain and therefore reduces adrenergic adverse events.294,295
activation and arrhythmic risk. Cardioversion for AF should be considered in
IIa C
In HCM, peripheral vasodilatation is poorly tolerated in women pregnant women with HCM.43,305
with severe LVOT obstruction (LVOTO) and therefore epidural Disopyramide may be considered in pregnant
and spinal anaesthesia should be applied cautiously. Low-risk women with HCM only when the potential benefits IIb C
LVOTO cases may have a spontaneous labour and vaginal delivery. outweigh the risk of uterine contractions.305,306
Caesarean section may be the preferred option in women with severe
Myosin inhibitors are not recommended in women
LVOTO. III C
during pregnancy due to lack of safety data.303,304
AF, atrial fibrillation; ARVC, arrhythmogenic right ventricular cardiomyopathy; CMP,
Recommendation Table 5 — Recommendations for
cardiomyopathy; DCM, dilated cardiomyopathy; ECG, electrocardiogram; EF, ejection
cardiomyopathies and pregnancy
fraction; HCM, hypertrophic cardiomyopathy; HF, heart failure; LV, left ventricular;
LVOTO, left ventricular outflow tract obstruction; NYHA, New York Heart
Recommendations Classa Levelb Association; QTc, corrected QT interval; VKA, vitamin K antagonist.
aClass of recommendation.
Clinical cardiological surveillance (ECG, bLevel of evidence.
echocardiogram, and Holter ECG monitoring) is cExcept for atenolol.
I C
recommended during pregnancy in women with
CMPs, depending on individual risk.
6.2. Primary arrhythmia syndromes
Vaginal delivery is recommended in most women
In general, women with primary arrhythmia syndromes tolerate preg-
with CMPs, unless there are obstetric indications for
nancy well. Genetic counselling is recommended before pregnancy,
caesarean section, severe HF (EF <30% and/or
as discussed in Section 6.1. A complete clinical re-evaluation, optimiza-
NYHA class III/IV), uncontrolled arrhythmias, or I C
tion of treatment, and ICD evaluation should be undertaken prior to
severe outflow obstruction (≥50 mmHg) in women
pregnancy.252 Indicated treatment should be continued throughout
with HCM, or in women presenting in labour on
pregnancy and in the post-partum period.
VKAs.60
Continuation of beta-blockersc should be considered
6.2.1. Long QT syndrome
during pregnancy in women with CMPs, with close IIa C
follow-up of foetal growth.60 Long QT syndrome (LQTS) is the most common channelopathy.307 All pa-
tients with LQTS should take beta-blockers, with propranolol and nadolol
Dilated cardiomyopathy
being the most effective.308 Additional therapies include left cardiac sympa-
In women with DCM and worsening of EF during thetic denervation309 and mexiletine for LQT3252 and LQT2.310,311 The
pregnancy, counselling on the risk of recurrence
I C f o e t a l r i s k o f m e x il e t in e t r e a t m e n t i s u n k n o w n , a n d d e c i s io n s on treatment
during a subsequent pregnancy is recommended in all during pregnancy should be a shared decision with the woman.
cases, even after recovery of LV function.43 Retrospective studies312–316 show that women with LQTS were not at
Continued higher risk of cardiac events during pregnancy itself, but had an increased risk
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4497
in the post-partum period (up to 12 months), especially for those with study published, involving 96 women and 228 pregnancies, did not
LQT2. Beta-blocker therapy was associated with risk reduction in all the show an increased risk of cardiac events during pregnancy and the post-
studies. Women with LQTS should therefore start beta-blockers at preg- partum period.326
nancy or continue beta-blockers at pre-pregnancy dose, with propranolol Beta-blockers are the mainstay of therapy, with additive flecainide if
or nadolol as drugs of choice. Beta-blockers should be continued in the post- needed.322,327 Nadolol and propranolol are beta-blockers of choice and
partum period, particularly in the case of women with LQT2 due to the in- should be continued during pregnancy and lactation. As in LQTS, the
creased arrhythmic risk. It should be noted that nadolol has a higher excre- higher excretion of nadolol in breast milk should be noted (Section
tion in breast milk than propranolol, with a relative infant dose of 4%–7%.317 6.2.1). Left cardiac sympathetic denervation is a valuable anti-
Therefore, nadolol is generally not the preferred beta-blocker during lacta- arrhythmic option that should be performed in experienced centres
tion. However, arrhythmic risk can be high in LQTS, and nadolol is one of the before pregnancy if indicated.328 Implantable cardioverter defibrillators
drugs of choice; thereofore, a careful weighting of benefit against harm is ap- are indicated in a minority of patients with CPVT.
propriate. Change of beta-blocker therapy after delivery should be avoided,
as this is a vulnerable phase. Therefore, a change from nadolol to propran- 6.2.4. Short QT syndrome
olol should ideally be evaluated before pregnancy. High dosages of nadolol Short QT syndrome (SQTS) is a rare channelopathy characterized by
during lactation may require monitoring of the infant for bradycardia. short QT and increased risk of life-threatening arrhythmias and
Women with LQTS should always avoid QT-prolonging drugs (see AF.329 There are no case reports or studies published on pregnancy
www.crediblemeds.org)318. Women with LQTS should be promptly in women with SQTS. When choosing an anti-arrhythmic drug during
treated for hypokalaemia and hypomagnesaemia, which is relevant in pregnancy, quinidine is the best option in the absence of more robust
pregnancy-related hyperemesis, causing electrolyte disturbances and data.330
failure to absorb oral medications. All anti-emetic medications are
QT-prolonging. Electrocardiogram monitoring should be performed
6.2.5. Labour and delivery in primary arrhythmia
if anti-emetic therapy is absolutely required.
syndromes
Long QT syndrome can manifest very early in life, even during the foe-
In all primary arrhythmia syndromes, delivery should be planned with
tal period, and can be a cause of stillbirth319,320 (Section 4.5.1). A neonatal
heart rhythm monitoring, electrolyte control, and post-operative
ECG should be performed post-delivery and after 2 weeks to avoid over-
ECG monitoring until all anaesthetic drugs have been eliminated.
diagnosis due to transiently prolonged QT interval during the first 7–10
Labour and delivery may be associated with acute pain, adrenaline
days of life.321 Genetic screening for familiar genetic variants should be
release, and urgent administration of anaesthetic drugs, and therefore
performed as soon as possible (e.g. from chordal blood). If the newborn
continuous telemetry monitoring is often warranted. In the absence
is affected by LQTS, beta-blocker therapy should be started immediately.
of obstetric contraindications, vaginal delivery is generally recom-
mended. Neuraxial anaesthesia reduces pain and therefore adrenergic
6.2.2. Brugada syndrome
activation which is specifically important in LQTS and CPVT. Women
Men with Brugada syndrome (BrS) are more often symptomatic than
with LQTS and CPVT should continue beta-blocker therapy during la-
women.322 The only retrospective study on pregnant women with
bour and delivery. In women with CPVT, it is reasonable to keep
BrS did not show an increased risk of cardiac events during pregnancy
the heart rate under the threshold for premature ventricular contrac-
and the post-partum period.323 All patients with BrS should avoid con- tion onset during delivery, typically 100–110 b.p.m.331,332 Anaesthetic
traindicated drugs (see www.brugadadrugs.org),324 large meals, or ex-
drugs for LQTS should be selected according to the CredibleMeds
cess alcohol, and promptly treat fever and its causes.325 If there are
website (www.crediblemeds.org).
symptoms during pregnancy, quinidine therapy should be considered In BrS, propofol and local anaesthetics with sodium-blocking agents
with monitoring of hepatic function and blood count in the mother. (e.g. lidocaine) carry a theoretical risk of triggering arrhythmias. Case
reports have indicated uneventful delivery with neuraxial anaesthesia
6.2.3. Catecholaminergic polymorphic ventricular in women with BrS.333 Thiopental and inhalation anaesthesia have so
tachycardia far not been associated with adverse events.324,333 Anaesthestic drugs
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is should be chosen according the BrugadaDrugs website (www.
mainly caused by P/LP in the RYR2 gene.252 The only retrospective brugadadrugs.org).
Recommendation Table 6 — Recommendations for primary arrhythmia syndromes and pregnancy (see Evidence
Tables 4–6)
Recommendations Classa Levelb
Monitoring and treatment of hypokalaemia and hypomagnesaemia is recommended in pregnant women with primary arrhythmia
I C
syndromes suffering from hyperemesis.334
Long QT syndrome
Beta-blockersc, with pre-pregnancy dose and with nadolol and propranolol as drugs of choice, are recommended during pregnancy in
I B
women with LQTS.312–316,335
It is recommended to continue beta-blocker therapy during lactation in women with LQTS to reduce arrhythmic risk.148,336 I B
Pre-pregnancy beta-blocker dose of nadolol or propranolol, is recommended in women with LQT2, particularly in the post-partum period,
I B
which represents a high-risk period for life-threatening arrhythmias.148,313,315
Continued
Downloaded
from

by
guest
on
22
January
2026

4498 E S C G u id e l in e s
In women carrying a LQTS P/LP variant and who are phenotype-negative, use of beta-blockersc during pregnancy, post-partum, and
IIa C
lactation should be considered.148
Left cardiac sympathetic denervation should be considered before pregnancy in high-risk woman with LQTS who are not adequately
IIa C
protected by pharmacological therapies or who have appropriate ICD shocks despite optimal medical therapy.252
Brugada syndrome
Quinidine therapy should be considered in pregnant women with BrS who have arrhythmic events during pregnancy.337,338 IIa C
Catecholaminergic polymorphic ventricular tachycardia
Beta-blockersc, with pre-pregnancy dose and with nadolol and propranolol as drugs of choice, are recommended during pregnancy and
I C
lactation in women with CPVT.43,148,252
Flecainide, in addition to beta-blockers, is recommended in women with CPVT who experience cardiac events such as syncope, VT, or
I C
cardiac arrest during pregnancy.
It is recommended that women with CPVT who are stable on beta-blockers (nadolol or propranolol as drugs of choice) and flecainide
I C
before pregnancy continue both drugs during pregnancy and post-partum.
The use of beta-blockersc during pregnancy and lactation should be considered in phenotype-negative women with a CPVT P/LP variant.148 IIa C
Left cardiac sympathetic denervation should be considered before pregnancy in high-risk women with CPVT who are not adequately
IIa C
protected by pharmacological therapies or with appropriate ICD shocks despite optimal medical therapy.252
Short QT syndrome
It should be considered to continue quinidine therapy in women with SQTS throughout pregnancy and the post-partum period.148 IIa C
Quinidine therapy should be considered in pregnant women with SQTS and arrhythmic events during pregnancy.148 IIa C
BrS, Brugada syndrome; CPVT, catecholaminergic polymorphic ventricular tachycardia; ICD, implantable cardioverter defibrillator; LQTS, long QT syndrome, LQT2, long QT syndrome type
2; P/LP, pathogenic/likely pathogenic; SQTS, short QT syndrome; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
cExcept for atenolol.
7. Peripartum cardiomyopathy endothelial dysfunction and damage, and subsequently leads to HF.
Blocking prolactin with the dopamine D2 receptor agonist bromocrip-
7.1. Epidemiology tine has emerged as a potential disease-specific therapy for
PPCM.344,349–352 Additionally, the systemic or local increase in other
Peripartum cardiomyopathy is a potentially life-threatening condition
anti-angiogenic factors, such as the soluble fms-like tyrosine kinase-1
defined as HF with reduced left ventricular ejection fraction (LVEF)
(sFlt-1) receptor, contributes to both local and widespread vascular
<45%, without any other cause of HF, that occurs mainly during the
dysfunction.353
peripartum period or in the months following delivery, termination,
or miscarriage.339 Peripartum cardiomyopathy is essentially a diagnosis
7.3. Diagnosis and clinical interventions
of exclusion and requires urgent management.
Worldwide, PPCM is a complication of 1 of 2000 births,340 but inci- Peripartum cardiomyopathy may present as subtle manifestations
dence rates vary depending on the geographical region, ethnicity, and but most women with PPCM present with acute heart failure
socioeconomic factors, with an incidence of 1–4/1000 births in the (AHF) with severe symptoms (NYHA III/IV). Mild to moderate symp-
United States of America341,342 and 10/1000 births in the north- tomatic cases of PPCM are often mistaken for physiological changes
western region of Nigeria.343 Recent data from 49 countries showed associated with pregnancy, especially in the post-partum period.
that most women presented with PPCM in the post-partum Myocarditis is a differential diagnosis and should be excluded by
stage.344–346 Risk factors for PPCM are shown in Figure 7. CMR.354 Women with PPCM and pre-eclampsia had a higher risk
of adverse neonatal outcome but also a higher likelihood of left ven-
tricular recovery (LVEF ≥50%).15 Diagnostic measures in a woman
7.2. Mechanisms
with suspected PPCM should include ECG, NPs, and echocardiog-
Recent trials suggest a ‘multiple hit’ theory for developing PPCM, with raphy. The management strategy should be discussed within the
an accumulation of genetic and environmental risk factors (Figure 7). An Pregnancy Heart Team, considering maternal and foetal outcomes
overrepresentation of genetic variants in TTN, FLNC, BAG3, and DSP (Figure 7). Foetal prematurity and low birth weight are common in
genes have been found in up to 15% of women with PPCM, with mothers with PPCM, and children of these mothers have a 3.4 times
TTN truncating variants being the most common.347,348 The prevalence higher incidence of cardiovascular disease and 5 times higher
of these four genes in women with PPCM was comparable to the mortality.355
prevalence in DCM cohorts, supporting the similarity between PPCM Treatment of AHF caused by PPCM follows the main principles
and DCM. Genetic testing should therefore be considered in women of AHF management during and after pregnancy (Section 12.6).
with PPCM. Mechanical circulatory support should be considered in women with
There is growing evidence that several pathophysiological mechan- persistent cardiogenic shock despite medical treatment.356,357
isms in PPCM converge on a common pathway, which involves inflam- Most medications used in the management of HF are foetotoxic and
mation, unbalanced oxidative stress, and the generation of the thus contraindicated during pregnancy (i.e. ACE-Is, ARBs, MRAs, and
anti-angiogenic 16 kDa prolactin. The 16 kDa prolactin induces SGLT2 inhibitors).339 In the post-partum period, full HF treatment
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4499
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:29)(cid:25)(cid:24)(cid:23)(cid:22)(cid:21)(cid:26)(cid:29)(cid:20)(cid:28)(cid:19)(cid:23)(cid:18)(cid:19)(cid:27)(cid:26)(cid:25)(cid:17)(cid:18)(cid:22)(cid:16)(cid:31)(cid:31)(cid:15)(cid:14)(cid:13)
(cid:12)(cid:30)(cid:11)(cid:10)(cid:28)(cid:25)(cid:28)(cid:19)(cid:10)
(cid:21)(cid:20)(cid:19)(cid:18)(cid:17)(cid:16)(cid:19)(cid:15)(cid:25)(cid:14)(cid:13)(cid:12)(cid:25)(cid:15)(cid:30)(cid:29)(cid:13)(cid:15)(cid:25)(cid:16)(cid:11)(cid:25)(cid:10)(cid:26)(cid:14)(cid:27)(cid:17)(cid:25)(cid:11)(cid:14)(cid:30)(cid:9)(cid:28)(cid:27)(cid:26)(cid:25)(cid:8)(cid:30)(cid:17)(cid:10)(cid:25)(cid:27)(cid:26)(cid:12)(cid:28)(cid:7)(cid:26)(cid:12)(cid:25)(cid:6)(cid:5)(cid:4)(cid:31)(cid:25)(cid:3)(cid:22)(cid:2)(cid:1)(cid:25)(cid:8)(cid:30)(cid:17)(cid:10)(cid:16)(cid:28)(cid:17)(cid:25)(cid:14)(cid:13)(cid:20)(cid:25)(cid:16)(cid:17)(cid:10)(cid:26)(cid:27)(cid:25)(cid:26)(cid:127)(cid:18)(cid:9)(cid:14)(cid:30)(cid:13)(cid:14)(cid:129)(cid:9)(cid:26)(cid:25)(cid:7)(cid:14)(cid:28)(cid:15)(cid:26)(cid:25)(cid:17)(cid:10)(cid:14)(cid:17)
(cid:16)(cid:7)(cid:7)(cid:28)(cid:27)(cid:25)(cid:12)(cid:28)(cid:27)(cid:30)(cid:13)(cid:29)(cid:25)(cid:17)(cid:10)(cid:26)(cid:25)(cid:18)(cid:26)(cid:27)(cid:30)(cid:18)(cid:14)(cid:27)(cid:17)(cid:28)(cid:19)(cid:25)(cid:18)(cid:26)(cid:27)(cid:30)(cid:16)(cid:12)(cid:25)(cid:16)(cid:27)(cid:25)(cid:30)(cid:13)(cid:25)(cid:17)(cid:10)(cid:26)(cid:25)(cid:19)(cid:16)(cid:13)(cid:17)(cid:10)(cid:15)(cid:25)(cid:11)(cid:16)(cid:9)(cid:9)(cid:16)(cid:8)(cid:30)(cid:13)(cid:29)(cid:25)(cid:12)(cid:26)(cid:9)(cid:30)(cid:23)(cid:26)(cid:27)(cid:20)(cid:141)(cid:25)(cid:17)(cid:26)(cid:27)(cid:19)(cid:30)(cid:13)(cid:14)(cid:17)(cid:30)(cid:16)(cid:13)(cid:25)(cid:16)(cid:27)(cid:25)(cid:19)(cid:30)(cid:15)(cid:7)(cid:14)(cid:27)(cid:27)(cid:30)(cid:14)(cid:29)(cid:26)(cid:25)
(cid:9)(cid:28)(cid:8)(cid:7)(cid:22)(cid:6)(cid:26)(cid:21)(cid:25)(cid:19)(cid:29)(cid:8)
Ž(cid:14)(cid:9)(cid:13)(cid:28)(cid:17)(cid:27)(cid:30)(cid:17)(cid:30)(cid:16)(cid:13)(cid:25) ’(cid:26)(cid:16)(cid:29)(cid:27)(cid:14)(cid:18)(cid:10)(cid:30)(cid:7)(cid:14)(cid:9)(cid:25)(cid:27)(cid:26)(cid:29)(cid:30)(cid:16)(cid:13)(cid:25)
(cid:31)(cid:14)(cid:19)(cid:30)(cid:9)(cid:20)(cid:25)(cid:10)(cid:30)(cid:15)(cid:17)(cid:16)(cid:27)(cid:20) Ž(cid:28)(cid:9)(cid:17)(cid:30)(cid:18)(cid:14)(cid:27)(cid:30)(cid:17)(cid:20)(cid:141)(cid:25)(cid:19)(cid:28)(cid:9)(cid:17)(cid:30)(cid:18)(cid:9)(cid:26)(cid:25)(cid:18)(cid:27)(cid:26)(cid:29)(cid:13)(cid:14)(cid:13)(cid:7)(cid:30)(cid:26)(cid:15)(cid:25)
’(cid:26)(cid:13)(cid:26)(cid:17)(cid:30)(cid:7)(cid:25)(cid:143)“(cid:6)(cid:143)(cid:25)(cid:23)(cid:14)(cid:27)(cid:30)(cid:14)(cid:13)(cid:17)(cid:15)(cid:25)(cid:30)(cid:13)(cid:25)”‰Ž(cid:25)(cid:29)(cid:26)(cid:13)(cid:26)(cid:15) (cid:31)(cid:26)(cid:27)(cid:17)(cid:30)(cid:9)(cid:30)(cid:17)(cid:20)€(cid:14)(cid:15)(cid:15)(cid:30)(cid:15)(cid:17)(cid:26)(cid:12)(cid:25)(cid:17)(cid:27)(cid:26)(cid:14)(cid:17)(cid:19)(cid:26)(cid:13)(cid:17)(cid:15)(cid:25)
(cid:143)(cid:27)(cid:26)(cid:23)(cid:30)(cid:16)(cid:28)(cid:15)(cid:25)(cid:143)(cid:143)‰Ž (cid:21)(cid:19)(cid:16)„(cid:30)(cid:13)(cid:29)(cid:25)
(cid:144)(cid:29)(cid:26)(cid:25)(cid:3) ƒ(cid:25)(cid:16)(cid:27)(cid:25)•(cid:22)ƒ(cid:25)(cid:20)(cid:26)(cid:14)(cid:27)(cid:15)(cid:25) ”(cid:30)(cid:14)(cid:129)(cid:26)(cid:17)(cid:26)(cid:15)(cid:141)(cid:25)(cid:10)(cid:20)(cid:18)(cid:26)(cid:27)(cid:17)(cid:26)(cid:13)(cid:15)(cid:30)(cid:16)(cid:13)(cid:141)(cid:25)(cid:18)(cid:27)(cid:26)€(cid:26)(cid:7)(cid:9)(cid:14)(cid:19)(cid:18)(cid:15)(cid:30)(cid:14)(cid:25)
(cid:4)(cid:17)(cid:10)(cid:13)(cid:30)(cid:7)(cid:30)(cid:17)(cid:20)(cid:25) (cid:143)(cid:27)(cid:16)(cid:9)(cid:16)(cid:13)(cid:29)(cid:26)(cid:12)(cid:25)(cid:28)(cid:15)(cid:26)(cid:25)(cid:16)(cid:11)(cid:25)(cid:17)(cid:16)(cid:7)(cid:16)(cid:9)(cid:20)(cid:17)(cid:30)(cid:7)(cid:25)(cid:129)(cid:26)(cid:17)(cid:14)€(cid:14)(cid:29)(cid:16)(cid:13)(cid:30)(cid:15)(cid:17)(cid:15)(cid:25)
(cid:5)(cid:10)(cid:4)(cid:30)(cid:8)(cid:25)(cid:28)(cid:3)(cid:26)(cid:25)(cid:28)(cid:19)(cid:10)(cid:8)
(cid:143)(cid:10)(cid:20)(cid:15)(cid:30)(cid:7)(cid:14)(cid:9) (cid:4)(cid:9)(cid:26)(cid:7)(cid:17)(cid:27)(cid:16)(cid:7)(cid:14)(cid:27)(cid:12)(cid:30)(cid:16)(cid:29)(cid:27)(cid:14)(cid:19)(cid:25) ‹(cid:14)(cid:17)(cid:27)(cid:30)(cid:28)(cid:27)(cid:26)(cid:17)(cid:30)(cid:7) Œ€(cid:27)(cid:14)(cid:20)(cid:25) (cid:4)(cid:7)(cid:10)(cid:16)(cid:7)(cid:14)(cid:27)(cid:12)(cid:30)(cid:16)(cid:29)(cid:27)(cid:14)(cid:18)(cid:10)(cid:20)(cid:25) ‰Ž‘(cid:14)(cid:25)
(cid:26)(cid:127)(cid:14)(cid:19)(cid:25) (cid:18)(cid:26)(cid:18)(cid:17)(cid:30)(cid:12)(cid:26)(cid:25)
(cid:14)(cid:26)(cid:10)(cid:26)(cid:3)(cid:30)(cid:23)(cid:30)(cid:10)(cid:25)(cid:22)(cid:2)(cid:18)(cid:22)(cid:31)(cid:29)(cid:30)(cid:3)(cid:10)(cid:26)(cid:10)(cid:21)(cid:18)(cid:22)(cid:1)(cid:30)(cid:26)(cid:29)(cid:25)(cid:22)(cid:127)(cid:30)(cid:26)(cid:23)
(cid:31)(cid:29)(cid:30)(cid:3)(cid:10)(cid:26)(cid:10)(cid:21)(cid:18) (cid:31)(cid:19)(cid:8)(cid:25)(cid:141)(cid:27)(cid:26)(cid:29)(cid:25)(cid:24)(cid:23)
(cid:144)(cid:12)(cid:157)(cid:28)(cid:15)(cid:17)(cid:26)(cid:12)(cid:25)(cid:14)(cid:7)(cid:28)(cid:17)(cid:26)(cid:25) (cid:31)(cid:25) ‡(cid:11)(cid:25)(cid:13)(cid:16)(cid:25)(cid:27)(cid:26)(cid:23)(cid:26)(cid:27)(cid:15)(cid:30)(cid:129)(cid:9)(cid:26)(cid:25)(cid:7)(cid:14)(cid:28)(cid:15)(cid:26)(cid:25)(cid:30)(cid:15)(cid:25)(cid:11)(cid:16)(cid:28)(cid:13)(cid:12)(cid:141)(cid:25)(cid:7)(cid:16)(cid:13)(cid:17)(cid:30)(cid:13)(cid:28)(cid:26)(cid:25) (cid:31)(cid:25)(cid:17)(cid:27)(cid:26)(cid:14)(cid:17)(cid:19)(cid:26)(cid:13)(cid:17)
(cid:17)(cid:27)(cid:26)(cid:14)(cid:17)(cid:19)(cid:26)(cid:13)(cid:17)(cid:25)
…(cid:27)(cid:16)(cid:19)(cid:16)(cid:7)(cid:27)(cid:30)(cid:18)(cid:17)(cid:30)(cid:13)(cid:26)(cid:25)(cid:30)(cid:13)(cid:25)(cid:14)(cid:12)(cid:12)(cid:30)(cid:17)(cid:30)(cid:16)(cid:13)(cid:25)(cid:17)(cid:16)(cid:25)(cid:16)(cid:18)(cid:17)(cid:30)(cid:19)(cid:14)(cid:9)(cid:25) (cid:31)(cid:25)(cid:17)(cid:27)(cid:26)(cid:14)(cid:17)(cid:19)(cid:26)(cid:13)(cid:17)(cid:25)
ˆ‰(cid:9)(cid:14)(cid:15)(cid:15)(cid:25)‡‡(cid:129)Š
(cid:143)(cid:27)(cid:16)(cid:18)(cid:10)(cid:20)(cid:9)(cid:14)(cid:7)(cid:17)(cid:30)(cid:7)(cid:25)(cid:14)(cid:13)(cid:17)(cid:30)(cid:7)(cid:16)(cid:14)(cid:29)(cid:28)(cid:9)(cid:14)(cid:17)(cid:30)(cid:16)(cid:13)(cid:25)(cid:30)(cid:11)(cid:25)(cid:129)(cid:27)(cid:16)(cid:19)(cid:16)(cid:7)(cid:27)(cid:30)(cid:18)(cid:17)(cid:30)(cid:13)(cid:26)(cid:25)(cid:29)(cid:30)(cid:23)(cid:26)(cid:13)
ˆ‰(cid:9)(cid:14)(cid:15)(cid:15)(cid:25)‡‡(cid:14)Š(cid:25)
(cid:129)(cid:24)(cid:25)(cid:21)(cid:19)(cid:23)(cid:30)(cid:8)
(cid:2)€‚ƒ(cid:1)(cid:25)(cid:16)(cid:11)(cid:25)(cid:8)(cid:16)(cid:19)(cid:26)(cid:13)(cid:25)(cid:15)(cid:10)(cid:16)(cid:8)(cid:25)(cid:6)(cid:5)(cid:4)(cid:31)(cid:25)(cid:27)(cid:26)(cid:7)(cid:16)(cid:23)(cid:26)(cid:27)(cid:20)(cid:25)(cid:129)(cid:20)(cid:25)‚(cid:25)(cid:19)(cid:16)(cid:13)(cid:17)(cid:10)(cid:15)
(cid:21)(cid:28)(cid:129)(cid:15)(cid:17)(cid:14)(cid:13)(cid:17)(cid:30)(cid:14)(cid:9)(cid:25)(cid:23)(cid:14)(cid:27)(cid:30)(cid:14)(cid:17)(cid:30)(cid:16)(cid:13)(cid:25)(cid:14)(cid:7)(cid:7)(cid:16)(cid:27)(cid:12)(cid:30)(cid:13)(cid:29)(cid:25)(cid:17)(cid:16)(cid:25)(cid:26)(cid:17)(cid:10)(cid:13)(cid:30)(cid:7)(cid:25)(cid:129)(cid:14)(cid:7)„(cid:29)(cid:27)(cid:16)(cid:28)(cid:13)(cid:12)(cid:25)(cid:14)(cid:13)(cid:12)(cid:25)(cid:29)(cid:26)(cid:16)(cid:29)(cid:27)(cid:14)(cid:18)(cid:10)(cid:30)(cid:7)(cid:14)(cid:9)(cid:25)(cid:27)(cid:26)(cid:29)(cid:30)(cid:16)(cid:13)(cid:25)(cid:8)(cid:30)(cid:17)(cid:10)(cid:25)
(cid:8)(cid:16)(cid:27)(cid:15)(cid:26)(cid:25)(cid:16)(cid:28)(cid:17)(cid:7)(cid:16)(cid:19)(cid:26)(cid:25)(cid:30)(cid:13)(cid:25)…(cid:9)(cid:14)(cid:7)„(cid:25)(cid:8)(cid:16)(cid:19)(cid:26)(cid:13)(cid:25)(cid:30)(cid:13)(cid:25)(cid:17)(cid:10)(cid:26)(cid:25)†(cid:13)(cid:30)(cid:17)(cid:26)(cid:12)(cid:25)(cid:21)(cid:17)(cid:14)(cid:17)(cid:26)(cid:15)(cid:25)(cid:14)(cid:13)(cid:12)(cid:25)(cid:14)(cid:19)(cid:16)(cid:13)(cid:29)(cid:25)(cid:8)(cid:16)(cid:19)(cid:26)(cid:13)(cid:25)(cid:30)(cid:13)(cid:25)(cid:9)(cid:26)(cid:15)(cid:15)
(cid:12)(cid:26)(cid:23)(cid:26)(cid:9)(cid:16)(cid:18)(cid:26)(cid:12)(cid:25)(cid:7)(cid:16)(cid:28)(cid:13)(cid:17)(cid:27)(cid:30)(cid:26)(cid:15)(cid:25)(cid:8)(cid:16)(cid:27)(cid:9)(cid:12)(cid:8)(cid:30)(cid:12)(cid:26)(cid:25)
Figure 7 Risk factors and management of peripartum cardiomyopathy. CMR, cardiac magnetic resonance imaging; HF, heart failure; LVEF, left ventricular
ejection fraction; P/LP, pathogenic/likely pathogenic; PPCM, peripartum cardiomyopathy. aIn specific cases.
can be initiated, except if lactation and breastfeeding are necessary for lactation, which enables the possibility of full HF treatment of the
nutritional reasons, in which case ARBs and SGLT2 inhibitors should be mother that is not breastfeeding. The downsides of stopping lactation
avoided. Spironolactone is considered safe (see Section 5.2.7 and as PPCM treatment include psychological implications for the mother
Figure 7). and the source of nutrition for the infant. These considerations indicate
In addition to HF treatment, the prolactin production suppressing that women with moderate and severe HF in PPCM are the preferred
agent bromocriptine may be considered in women with PPCM candidates for bromocriptine treatment. A recent multi-centre rando-
(Figure 7).358–360 A secondary effect of bromocriptine is stopping mized study comparing two different bromocriptine dosages in women
Downloaded
from

by
guest
on
22
January
2026

4500 E S C G u id e l in e s
with severe PPCM (2.5 mg daily for 1 week vs 5 mg daily for 2 weeks Recommendation Table 7 — Recommendations for
followed by 2.5 mg daily for 6 weeks) observed a high LV recovery peripartum cardiomyopathy (see Evidence Table 7)
rate at 6 months. No significant differences were observed between
treatment over 1 week and 8 weeks, suggesting that a 1 week addition Recommendations Classa Levelb
of bromocriptine to standard heart failure treatment would be benefi-
Counselling for women with PPCM about the risk of
cial.358 There are limited data on the use of bromocriptine in pregnant
recurrence during a subsequent pregnancy and about
women with PPCM and cardiogenic shock.339,361 Personalized bromo- I C
contraception is recommended in all cases, even
criptine treatment, with dose adjustments to effectively suppress pro-
after recovery of LV function (LVEF >50%).355,369
lactin, may be a viable therapeutic option in these specific cases. Adding
Adding at least prophylactic LMWH treatment to
LMWH (in prophylactic doses at a minimum) to bromocriptine should
be considered to reduce the thromboembolic risk.362 bromocriptine treatment in women with PPCM IIa C
should be considered.358,362,372,373
Genetic counselling and testing should be considered
IIa C
7.4. Outcomes in women with PPCM.60
Risk stratification is crucial to determine the appropriate level of care for When a reversible course of HF is assumed,
women diagnosed with PPCM (Figure 7). Key indicators to identify indi- treatment in accordance with HF guidelines should
viduals at risk of complications include LVEF <30%, LV end-diastolic be considered for at least 12 months after complete IIa C
diameter >60 mm, biventricular dysfunction, ECG QT interval prolonga- LV recovery (normalization of LV volumes and
tion, delayed diagnosis, and Middle Eastern or African ethnicity and/or EF).339,345,368,374
geography.344 Additional parameters such as age (>40 or <20 years),
Bromocriptine treatment may be considered in
antepartum diagnosis, haemodynamic parameters at presentation, and
addition to optimal HF treatment to enhance
cardiac biomarkers can further refine risk stratification. IIb B
recovery of LV function in women with PPCM.358–
PPCM may cause ventricular tachyarrhythmias and patients should 360,366,375,376
therefore be monitored.363,364 As ∼50% of women with PPCM recover
The use of a WCD may be considered in women
within 1 year after delivery, a wearable cardioverter defibrillator (WCD) IIb C
with PPCM and LVEF <35%.377
for pregnant women with LVEF <35% at risk of sudden cardiac death
may be considered to provide bridging therapy to recovery.365,366 EF, ejection fraction; HF, heart failure; LMWH, low-molecular-weight heparin; LV, left
Myocardial recovery after PPCM, defined as LVEF >50%, has been ventricle; LVEF, left ventricular ejection fraction; PPCM, peripartum cardiomyopathy;
WCD, wearable cardioverter defibrillator.
shown to occur in 46% (25%–62% according to geographical region)
aClass of recommendation.
of women at 6 months.16 Full HF treatment should be given during the bLevel of evidence.
first year after complete LV function recovery. Stepwise discontinuation
of HF therapy may be considered after 1 year if complete myocardial re-
covery is achieved, assuming that no genetic predisposition has been
identified.339,367 However, recent data indicated higher risk of LVEF re- 8. Pregnancy in women with
lapse during subsequent pregnancies in PPCM women who had discon- aortopathies
tinued their HF medication.368 Left ventricular assist device (LVAD) or
heart transplantation have been reported in up to 10% of PPCM cases, Acute arterial dissection during pregnancy occurs in 5.5/100 000 live
with inferior survival rates compared to other age-adjusted heart trans- births, with the aorta being the third most frequent location (19.8%)
plant recipients.340 after coronary artery dissection (38.2%) and vertebral artery dissection
Outcomes after PPCM differ globally.344 The EURObservational (22.9%).378 A large cohort study reported an aortic dissection rate of
Research Programme’s (EORP) PPCM registry reported low mortality 5.5 per million women during pregnancy and post-partum, compared
rates369 of 2.4% 1 month after diagnosis.370 However, the mortality with 1.4 per million during the equivalent period 1 year later.40
rate at 6 months was 6%, with HF and cardiac arrest as the most fre- Although rare, acute aortic syndromes carry high foetal and maternal
quent causes of death.16 At 1 year follow-up, death from any cause oc- morbidity and mortality risks.378,379 Arterial dissections occur ante-
curred in 8% of women, with regional variations (Europe 5%, Africa 6%, natally in 15%, intrapartum in 23%, and post-partum in 62% of cases.378
Asia–Pacific 9%, Middle East 19%; P < .001).17 Most pregnancy-related aortic dissections occur in women who are un-
Women with a previous PPCM diagnosis face a notably elevated risk aware of their underlying aortic disease380 and events rarely occur in
of poor outcomes. In the most recent EORP paper following women women who have been monitored according to guidelines.7 The risk
with subsequent pregnancies after PPCM, risk of maternal mortality of peripartum dissection in more distal aortic segments remains after
was lower than in previous reports, at 2% at 198 days after delivery.368 prior aortic root replacement.381 The mechanism for dissection during
More than mild LV dysfunction before a new pregnancy increases the risk pregnancy is unclear. Given the high post-partum prevalence, haemo-
of LVEF deterioration, but also women with recovered LV functions re- dynamic changes alone do not fully explain the increased risk and hor-
mained at risk of relapse.368 In women planning a new pregnancy after a monal influences are likely involved.
previous PPCM and with only mild LV dysfunction, stress echo without
contraindicated HF medication may be helpful to further stratify risk.
8.1. Women with heritable thoracic aortic
Having a good contractile reserve after HF medication has been discon-
tinued may be an encouraging prognostic sign.371 If planning a new preg- disease
nancy after PPCM, discontinuation of beta-blocking therapy may not be The number of genes associated with heritable thoracic aortic disease
advisable, and restarting beta-blocking therapy may be beneficial at a sub- (HTAD) is steadily increasing. Although there is clear evidence for an
sequent pregnancy, irrespective of baseline LV systolic function.368 increased risk of aortic dissection in HTAD, recent data from the
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4501
ROPAC III study showed that the aortic dissection incidence rate (3.5%) with vascular Ehlers–Danlos syndrome should be counselled on preg-
in pregnant women with HTAD was lower than previously reported.382 nancy risk and monitored by a Pregnancy Heart Team.
Phenotypes and outcomes between different genes and variants vary,
are of clinical importance, and impose differences in management with
8.1.4. Non-syndromic heritable thoracic aortic
regard to the extent of imaging, surveillance, and referral for sur-
diseases
gery.62,383 Clinical and genetic entities for which data are available are
The number of genes linked to non-syndromic heritable thoracic aortic
discussed below and included in Figure 8.
diseases (nsHTAD) is growing, including those rarely associated with
extra-aortic features such as MYLK, ACTA2, MYH11, and PRKG1.401,402
8.1.1. Marfan syndrome
For most cases, specific pregnancy management recommendations are
Marfan syndrome (MFS) is caused by P/LP variants in FBN1. limited. Pragmatically, prophylactic surgery in nsHTAD is recommended
Pregnancy-associated cardiovascular events include aortic and coronary at a diameter >45 mm. In women with variants in PRKG1, certain ACTA2
artery dissection as well as rapid aortic growth necessitating surgery.384 variants, or additional risk factors that carry a high dissection risk at small
Aortic event rates can reach up to 10%. Although type A dissections diameters, such as hypertension or family history of dissection at smaller
mainly occur in undiagnosed women, often with aortic diameters ex- diameters, surgery may be considered at lower diameters (>40 mm).386
ceeding surgical thresholds,389 type B dissections remain unpredictable
and can occur even after prophylactic root replacement.390 Women di-
8.1.5. Aortic disease with no identifiable (likely)
agnosed earlier in life have a lower risk of dissection.391 More dissections
pathogenic variant
occur during the post-partum period than during pregnancy or at deliv-
ery.384,392 Event rates and overall maternal mortality are low in women It is unclear whether young women with known aortic disease in whom
under guidelines-based follow-up.7,390 Studies have shown stable aortic genetic screening fails to identify a P/LP variant truly have a lower dis-
root diameters during pregnancy in women with diameters between 40 section risk than those with a known variant. The term ‘sporadic aneur-
and 45 mm.384,393 No significant difference in aortic events is noted be- ysm’ is discouraged, as an aneurysm may stem from a heritable disorder
tween ever-pregnant and never-pregnant women,384,392 but most data even without a family history. Recent data from a large cohort of type A
come from patients in highly controlled environments. aortic dissection patients <30 years of age showed a near dichotomy
between HTAD and unknown hypertension as probable dissection
causes.403
8.1.2. Loeys–Dietz syndrome
Loeys–Dietz syndrome (LDS) is linked to P/LP variants in six genes:
8.2. Turner syndrome
TGFBR1, TGFBR2, SMAD2, SMAD3, TGFB2, and TGFB3. Aortic outcomes
in LDS vary by gene and variant,64 leading to gene-specific recommenda- Approximately 50% of women with Turner syndrome (TS) have
tions for aortic root surgery thresholds.62,383,388 Planned pregnancy is a cardiovascular manifestations, including aortic dilatation, bicuspid aortic
known risk factor, but data on dissection risk during pregnancy, including valve (BAV), aortic coarctation, elongated aortic arch, and partial ab-
diameters at dissection, are limited. Cases of type B dissection after aortic normal pulmonary venous return.404,405 All women with TS present
root replacement have been reported.394 A higher incidence of haemor- a generalized arteriopathy and TS itself is an independent risk factor
rhagic events, reported in earlier studies,395 was not corroborated in a for thoracic aortic dilatation. Aortic dissection risk (85% type A and
recent ROPAC III study.382 Although pregnancy data for women with 15% type B) increases with increasing diameters and can be reduced
LDS are sparse, recent reports suggest favourable maternal and foetal by following treatment guidelines.406–409 Risk factors include hyperten-
outcomes with appropriate counselling and surveillance.395 The lack of sion, BAV, and coarctation. In women with TS and an aortic size index
data about aortic diameters at dissection during pregnancy limits high- (ASI) ≥25 mm/m2, aortic height index ≥25 mm/m or a z-score >4, the
level recommendations for prophylactic aortic root surgery thresholds. increased dissection risk and the option of surgery before pregnancy
should be discussed with the patient and the Pregnancy Heart Team,
taking the other risk factors into account.410–412 Spontaneous preg-
8.1.3. Vascular Ehlers–Danlos syndrome
nancy can occur in women with mosaic TS, but assisted fertility tech-
With a reported pregnancy-related mortality rate of 5% and life-
niques are now more common. Timely cardiovascular evaluation
threatening vascular events in up to 10% of pregnancies, women with
before fertility treatment is very important. Higher rates of adverse
vascular Ehlers–Danlos syndrome undeniably have high-risk pregnan-
events during pregnancy and post-partum have been reported cies.396 Pregnancy-related complications include vascular dissection
including hypertensive disease, gestational diabetes, haemorrhage, and
or rupture, uterine rupture, perineal tears, haemorrhage, and prema-
SGA babies.413,414 Caesarean section rates of up to 67% have been
ture birth. However, pregnancy and delivery do not seem to affect
reported.414
overall survival rates in women with vascular Ehlers–Danlos syn-
drome.397 The risk may be lower for some women with specific genetic
variants, null mutations, and normal vascular imaging.398,399 Celiprolol is 8.3. Bicuspid aortic valve disease
recommended (also in normotensive women), given the very high risk Available data for patients with BAV indicate a low risk of aortic events
of dissections and the benefit demonstrated in non-pregnant popula- if the aorta is <45 mm. Data on pregnancy in women with diameters of
tions.7 Shared decision-making is crucial for these women. A ROPAC 45–50 mm are limited.7,415 Recent data on patients with BAV demon-
study included four women with vascular Ehlers–Danlos syndrome strate a higher risk of dissection in those with a ‘root phenotype’ com-
who experienced pregnancy without adverse maternal events.7 Based pared to those with a primarily ascending aorta involvement.416,417
on data from a recent systematic review, caesarean section at 37 weeks When counselling these patients, it is important to note that BAV
should be scheduled to avoid obstetrical complications.400 Women does not exclude the possibility of nsHTAD.
Downloaded
from

by
guest
on
22
January
2026

4502 E S C G u id e l in e s
8.4. Aortic aneurysms other than root or 8.6. Management
ascending aorta Women with aortic disease should be managed by a multidisciplinary
team with experts from both the Pregnancy Heart Team and the aor-
Currently there are no recommendations for prophylactic surgery be-
tic team who are experienced in diagnostic pathways, medical and sur-
fore conceiving except for the aortic root and ascending aorta. Recently
gical management of aortopathies in the ante-, peri-, and post-partum
published guidelines recommended surgery for the undissected aortic
arch, descending and abdominal aorta at 50 mm in patients with periods. Institutional protocols for the management of pregnancy-
Marfan syndrome,62 but no specific guidelines for management in preg- related aortic events should be available and a shared-decision model
needs to be applied. Imaging of the entire aorta (CT or CMR) in wo-
nancy are available.
men with known or suspected aortic disease is recommended and
can reasonably be performed for most clinical scenarios within the
8.5. Aortic dissection
6 months prior to pregnancy. CMR without gadolinium is recom-
Data about pregnancy in women with a history of aortic dissection are mended in pregnant women with known aortopathy, without pre-
scarce. ROPAC II and III included 11 and 9 women, respectively, with a pregnancy imaging. In all women with aortic disease, strict blood
previous dissection and reported no maternal mortality. However, two pressure control is recommended. Specific target values for this spe-
women in ROPAC III had a recurrent aortic event.7,382 Adverse events cific situation have not been studied—in the general population
are likely low in women with a history of traumatic or iatrogenic dissec- it is recommended that treated systolic blood pressure values be tar-
tion and probably also for those with a maximum aortic diameter of geted to 120–129 mmHg to reduce CVD, provided the treatment is
<40 mm and documented stable follow-up. Obviously there is a selec- well tolerated.388,418 In women with genetic aortopathies, treatment
tion bias, as many women with complex aortic disease choose not to with beta-blockers throughout pregnancy should be considered
have children independent of the risk of progression of aortic disease. with foetal growth monitoring. Women who used beta-blockers
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:24)(cid:23)(cid:22)(cid:21)(cid:23)
(cid:20)(cid:19)(cid:30)(cid:18)(cid:17)(cid:30)(cid:26) (cid:16)(cid:8)(cid:7)(cid:14)(cid:6)(cid:31)(cid:30)(cid:29)(cid:28)(cid:5)
(cid:6)(cid:2)(cid:25)(cid:24)(cid:20)(cid:20)(cid:14)(cid:1)(cid:5)
(cid:16)(cid:8)(cid:7)(cid:14)(cid:6)(cid:31)(cid:30)(cid:29)(cid:28)(cid:5)(cid:14)(cid:4)(cid:21)(cid:22)(cid:27)(cid:14)(cid:30)(cid:21)(cid:20)(cid:3)(cid:14)(cid:13)(cid:24)(cid:23)(cid:22)(cid:29)(cid:30)(cid:20)(cid:24) (cid:129)(cid:141)(cid:7)(cid:143)(cid:27)(cid:26)(cid:31)(cid:30)(cid:25)(cid:28)(cid:24)(cid:23) € ‚
(cid:6)(cid:2)(cid:25)(cid:24)(cid:20)(cid:20)(cid:14)(cid:1)(cid:1)(cid:127)(cid:5) (cid:6)(cid:2)(cid:25)(cid:24)(cid:20)(cid:20)(cid:14)(cid:1)(cid:5) (cid:6)(cid:2)(cid:25)(cid:24)(cid:20)(cid:20)(cid:14)(cid:1)(cid:5)
(cid:144)(cid:20)(cid:157) (cid:141)(cid:14)(cid:4)(cid:21)(cid:22)(cid:27)(cid:14)(cid:30)(cid:21)(cid:20)(cid:3)(cid:14)(cid:13)(cid:24)(cid:23)(cid:22)(cid:29)(cid:30)(cid:20)(cid:24) (cid:144)(cid:20)(cid:157) (cid:141) (cid:141)(cid:14)(cid:4)„(cid:29)(cid:14)(cid:31)„(cid:129)(cid:31)(cid:14)(cid:12)(cid:24)(cid:30)(cid:21)(cid:24)(cid:144)(cid:22)
(cid:6)(cid:2)(cid:25)(cid:24)(cid:20)(cid:20)(cid:14)(cid:1)(cid:1)(cid:127)(cid:5) (cid:6)(cid:2)(cid:25)(cid:24)(cid:20)(cid:20)(cid:14)(cid:1)(cid:5) (cid:6)(cid:2)(cid:25)(cid:24)(cid:20)(cid:20)(cid:14)(cid:1)(cid:5)
(cid:129)(cid:141)(cid:7)(cid:143)(cid:27)(cid:26)(cid:31)(cid:30)(cid:25)(cid:28)(cid:24)(cid:23) (cid:129)(cid:141)(cid:7)(cid:143)(cid:27)(cid:26)(cid:31)(cid:30)(cid:23)(cid:24)(cid:30)(cid:22)(cid:21)(cid:20)(cid:19)(cid:18)(cid:17)(cid:16)(cid:23)(cid:24)(cid:22)
(cid:6)(cid:2)(cid:25)(cid:24)(cid:20)(cid:20)(cid:14)(cid:1)(cid:1)(cid:127)(cid:5) (cid:6)(cid:2)(cid:25)(cid:24)(cid:20)(cid:20)(cid:14)(cid:1)(cid:1)(cid:24)(cid:5)
€ ‚(cid:14)(cid:4)(cid:21)(cid:22)(cid:27)(cid:14)(cid:30)(cid:21)(cid:20)(cid:3)(cid:14)(cid:13)(cid:24)(cid:23)(cid:22)(cid:29)(cid:30)(cid:20)(cid:127)
(cid:6)(cid:2)(cid:25)(cid:24)(cid:20)(cid:20)(cid:14)(cid:1)(cid:1)(cid:24)(cid:5)
(cid:11)(cid:10)(cid:14)(cid:9)(cid:9) (cid:11)…(cid:14)(cid:9)(cid:9) …(cid:10)(cid:14)(cid:9)(cid:9)
‚(cid:24)(cid:18)(cid:21)(cid:144)(cid:24)(cid:25)(cid:14)(cid:15)(cid:17)(cid:25)(cid:21)(cid:12)(cid:17)(cid:30)(cid:26) ‚(cid:24)(cid:18)(cid:21)(cid:144)(cid:24)(cid:25)(cid:14)(cid:15)(cid:17)(cid:25)(cid:21)(cid:12)(cid:17)(cid:30)(cid:26)(cid:14)(cid:4)(cid:21)(cid:22)(cid:27)
(cid:6)(cid:2)(cid:25)(cid:24)(cid:20)(cid:20)(cid:14)(cid:1)(cid:5) (cid:17)(cid:28)(cid:21)(cid:15)(cid:19)(cid:30)(cid:24)(cid:25)(cid:14)(cid:24)(cid:144)(cid:24)(cid:17)(cid:20)(cid:22)(cid:27)(cid:17)(cid:20)(cid:21)(cid:24)(cid:14)(cid:24)(cid:144)(cid:15)
(cid:24)(cid:144)(cid:14)(cid:17)ƒ(cid:28)(cid:17)(cid:15)(cid:21)(cid:22)(cid:17)(cid:15)(cid:14)(cid:20)(cid:17)(cid:23)(cid:29)(cid:144)(cid:15)(cid:14)(cid:20)(cid:22)(cid:24)(cid:18)(cid:17)
(cid:6)(cid:2)(cid:25)(cid:24)(cid:20)(cid:20)(cid:14)(cid:1)(cid:1)(cid:24)(cid:5)
(cid:2)(cid:24)(cid:17)(cid:20)(cid:24)(cid:30)(cid:17)(cid:24)(cid:144)(cid:14)(cid:20)(cid:17)(cid:23)(cid:22)(cid:21)(cid:29)(cid:144) (cid:2)(cid:24)(cid:17)(cid:20)(cid:24)(cid:30)(cid:17)(cid:24)(cid:144)(cid:14)(cid:20)(cid:17)(cid:23)(cid:22)(cid:21)(cid:29)(cid:144)
(cid:6)(cid:2)(cid:25)(cid:24)(cid:20)(cid:20)(cid:14)(cid:1)(cid:1)(cid:127)(cid:5) (cid:6)(cid:2)(cid:25)(cid:24)(cid:20)(cid:20)(cid:14)(cid:1)(cid:1)(cid:24)(cid:5)
(cid:16)(cid:29)(cid:15)(cid:17)(cid:14)(cid:29)(cid:13)
(cid:15)(cid:17)(cid:25)(cid:21)(cid:12)(cid:17)(cid:30)(cid:26)
Figure 8 Thresholds for prophylactic surgical treatment prior to pregnancy of aortic root/ascending aneurysm (above the line) and recommended mode of
delivery according to aortic diameter (below the line). BAV, bicuspid aortic valve; LDS, Loeys–Dietz syndrome; MFS, Marfan syndrome, nsHTAD, non-
syndromic heritable thoracic aortic disease; P/LP, pathogenic/likely pathogenic; TAD, thoracic aortic disease; w/o, without. aRisk factors: family history of
dissection, rapid aortic growth (≥3 mm/year), uncontrolled hypertension. bRoot phenotype to be added to the other risk factors. Based on Narula
et al.,384 Wallace et al.,385 Regalado et al.,386 Jondeau et al.,387 Mazzolai et al.,388 and Isselbacher et al.62.
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4503
throughout pregnancy in the ROPAC III study gave birth to infants 8.7. Cardiac surgery during pregnancy
with a significantly lower birth weight than women who did not.382
Prophylactic cardiac surgery in women who are planning a pregnancy is far
Specific thresholds for pre-conception aortic root surgery are illu-
more common than urgent or emergency surgery during pregnancy.
strated in Figure 8.
Aortic surgery is the most frequently performed procedure during preg-
The mode of delivery needs to be informed by the patient’s history,
nancy, followed by surgery for aortic and mitral valve disease. Key
presence and type of gene/variant, and aortic diameter. The primary
pregnancy-related pathologies include prosthetic valve thrombosis and
aim of intrapartum management in women with aortic disease is to re-
endocarditis. The decision to perform surgery with extracorporeal circula-
duce the cardiovascular stress of labour and delivery. Caesarean section
tion and cardioplegic arrest during pregnancy is highly individualized with no
may be considered in women with a maximum diameter of >45 mm specific guidelines available. A recent meta-analysis421 reported a maternal
and those with a history of dissection. In women with an aortic diam- mortality rate of 7.3% consistent across trimesters, and no difference in ma-
eter <40 mm, vaginal delivery is recommended. In women with MFS, ternal mortality if caesarean section was performed. Overall foetal mortal-
LDS, and vascular Ehlers–Danlos syndrome, pre-delivery anaesthesi- ity was 26.5%, lowest during third trimester surgeries (10.3%). Caesarean
ology consultation is recommended to consider precautions for dural section before surgery significantly reduces foetal mortality. The decision
ectasia and scoliosis (including possible previous surgery).419 In general, to perform a caesarean section prior to surgery should be based on foetal
an individualized approach is favoured.383 Given the peak risk of a dis- viability and the level of medical care available rather than on a fixed gesta-
section at day 6 post-partum, it may be appropriate for women to stay tional age. This is particularly crucial in acute type A aortic dissection.
in hospital for 1 week post-partum.420 Hypothermic distal circulatory arrest increases foetal mortality.422
Recommendation Table 8 — Recommendations for aortopathies, cardiac surgery, and pregnancy
Recommendations Classa Levelb
Counselling
It is recommended that women with aortic disease have counselling about the risk of aortic dissection in pregnancy and the post-partum
I C
period.404,423
It is recommended that women with a history of aortic dissection or -surgery have pre-pregnancy counselling about the high risk by an
extended Pregnancy Heart Teamc considering the presence and type of genetic variant, aortic morphology, growth rate, and aetiology of I C
aortic dissection.7,381,424
It is recommended that women with vascular Ehlers–Danlos syndrome wishing to become pregnant are counselled regarding the very high
risk of pregnancy-related adverse events by a multidisciplinary team, considering family history, genetic variant, and previous vascular I C
events.7,396,397,425
Imaging
Imaging of the entire aortad (CT or CMR) is recommended before pregnancy in women with known or suspected aortic disease.390,424,426 I C
In women with aortic dilatation related to BAV, imaging (with TTE, and CMR/CT if needed) of the aortic root, ascending aorta, and
I C
descending aorta (to rule out coarctation) is recommended before pregnancy.427,428
In women with low-risk aortic disease (mWHO 2.0 classes II and II–III), one-time echocardiographic imaging between 20 and 30 weeks of
I C
gestation and imaging at 6 months post-partum is recommended.393,429
In women with moderate to high-risk aortic disease (mWHO 2.0 classes III and IV), repeated echocardiographic imaging every 4–12 weeks
I C
(depending on diagnosis and severity of dilatation) is recommended during pregnancy and until 6 months post-partum.393,429,430
CMR (without gadolinium) imaging of the entire aorta is recommended in pregnant women at risk of or with known aortic dilatation who
I C
have not had recent pre-pregnancy cross sectional imaging.135
Treatment—medical
When a woman with known aortic dilatation, history of dissection, or P/LP variant associated with aortic disease becomes pregnant, strict
I C
and individualized BP control is recommended.431,432
Beta-blocker therapye throughout pregnancy and in the post-partum period is recommended in women with MFS and other HTADs.433 I C
Celiprolol is recommended in women with vascular Ehlers–Danlos syndrome during pregnancy and lactation.434 I C
Treatment—intervention/surgical
It is recommended that indications for pre-pregnancy aortic root and/or ascending aortic surgery are guided by aortic morphology,
I C
underlying pathology, family history, genetic variant, previous vascular events, and patient’s preference.62,383
It is recommended that centres managing pregnancies in women with moderate to high-risk aortic disease (mWHO 2.0 class III/IV) can
I C
provide cardiovascular surgery in case of peripartum adverse events.435,436
Specific conditions
In women with MFS and aortic root diameters >45 mm, surgery before pregnancy is recommended.380,424 I C
In women with LDS with P/LP variants in TGFBR1, TGFBR2, and aortic root diameters ≥45 mm, surgery before pregnancy is
I C
recommended.437–439
Continued
Downloaded
from

by
guest
on
22
January
2026

4504 E S C G u id e l in e s
In women with nsHTAD with P/LP variants in MYH11, ACTA2, PRKG1, or MYLK, and aortic root diameters ≥45 mm, surgery before
I C
pregnancy is recommended.385,386,440
In women with BAV and aortic root or ascending aortic diameter ≥50 mm, surgery before pregnancy is recommended.441,442 I C
In women without an identifiable P/LP variant with aortic root or ascending aortic diameters ≥50 mm, surgery before pregnancy is
I C
recommended.
In women with HTAD and aortic arch, descending aortic, or abdominal aortic diameters ≥50 mm, surgery before pregnancy should be
IIa C
considered.392,443
In women with LDS with P/LP variants in TGFB2, TGFB3, SMAD2, and SMAD3, and aortic root diameters ≥45 mm, surgery before pregnancy
IIa C
should be considered.437–439
In women with BAV and root phenotype or family history of aortic aneurysm or dissection, surgery before pregnancy should be considered
IIa C
if the aorta is ≥45 mm.
In women without an identifiable P/LP variant with aortic root or ascending aortic aneurysm ≥45 mm, surgery before pregnancy should be
considered in the presence of a family history of aortic aneurysm, aortic dissection, uncontrolled arterial hypertension, or on patient’s IIa C
preference.
In women with MFS and aortic root diameters between 40 and 45 mm, surgery before pregnancy may be considered if risk factors (growth
IIb C
>3 mm/year, family history of aortic dissection) are present.444
In women with LDS with P/LP variants in TGFBR1 or TGFBR2 and aortic root diameters ≥40 mm, surgery before pregnancy may be
IIb C
considered.387,437,445,446
In women with nsHTAD and aortic root diameters ≥40–44 mm, surgery before pregnancy may be considered depending on the genetic
IIb C
variant, family history, and aortic growth rate.385,386,440
Delivery
In women with an aorta <40 mm, vaginal delivery is recommended.163 I C
In women with vascular Ehlers–Danlos syndrome, caesarean section at 37 weeks is recommended for obstetrical reasons.400 I C
In women with an aorta 40–45 mm, vaginal delivery with epidural anaesthesia and an expedited second stage should be considered. IIa C
In women with an aorta ≥45 mm, caesarean section should be considered. IIa C
In women with acute, subacute, or chronic aortic dissection, caesarean section should be considered. IIa C
In women with an aorta 40–45 mm, caesarean section may be considered. IIb C
The use of ergometrine post-delivery is not recommended in women with aortopathy. III C
Cardiac surgery during pregnancy
Delivery before cardiac surgery should be considered as soon as the foetus is viable, taking gestational age, comorbidities, and the available
IIa C
level of neonatal care into account.163,421,435,447
Cardiac surgery may be considered during pregnancy when conservative and medical therapy has failed, and in situations that threaten the
IIb C
mother’s life or that are not amenable to percutaneous treatment.
BAV, bicuspid aortic valve; BP, blood pressure; CMR, cardiovascular magnetic resonance imaging; CT, computed tomography; HTAD, heritable thoracic aortic disease; LDS, Loeys–Dietz
syndrome; MFS, Marfan syndrome; mWHO, modified World Health Organization; nsHTAD, non-syndromic heritable thoracic aortic disease; P/LP, pathogenic/likely pathogenic; TTE,
transthoracic echocardiogram.
aClass of recommendation.
bLevel of evidence.
cExtended Pregnancy Heart Team: regular team + multidisciplinary aortic team—see also Section 4.1.
dIn women with vascular Ehlers–Danlos syndrome and LDS, imaging should encompass the entire aorta, including supra-aortic vessels as well as iliac and femoral arteries.
eSee Section 5.2.9 for beta-blocker choice.
9. Pregnancy in women with known to disease complexity (13% in severe, 5%–6% in less-complex lesions).
Arrhythmia rates were low overall (2%). Women with uncorrected
congenital heart disease
ACHD more often have maternal and foetal complications.451
Women with ACHD experiencing complications during pregnancy
Congenital heart disease is present in 0.8%–0.9% of live births, with signifi-
cant geographical variation.448,449 Nowadays, most children born with con- and post-partum may also be at higher risk of late cardiac events.451
Pre-pregnancy evaluation should at least include routine blood tests,
genital heart disease reach fertile age, even those with complex lesions,
ECG, TTE, and cardiopulmonary exercise testing. As mentioned in
making adult congenital heart disease (ACHD) one of the most frequent
CVDs during pregnancy.450 Discussions about family planning, contracep- Section 4, the increased transmission risk should be discussed, and gen-
etic counselling should be offered.452 The level and timing of the pre-
tion, pregnancy risk (mWHO 2.0—see Table 6), and life expectancy are es-
sential and should start early, preferably during the transition to adult life.2 pregnancy cardiovascular evaluation and follow-up during pregnancy
In the prospective ROPAC registry, most women with ACHD (n = depend on the mWHO 2.0 class (see Table 6), taking the anatomical
3295) had a relatively favourable pregnancy outcome, with an overall and functional status into account.
mortality rate of 0.2% and trends improving from 2007 to 2017.2 Optimization of cardiac status and any comorbidities should take place
Heart failure rates were low in ROPAC, with differences according prior to pregnancy. This includes guideline-directed elective surgery or/and
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4505
intervention of significant haemodynamic lesions (native or residual),21 as and delivery. High-risk women or those with HF symptoms during
well as optimizing medical therapy and healthy lifestyle choices. pregnancy or delivery should be considered for intensive (cardiac)
The timing and mode of delivery should be decided by the care admission for haemodynamic monitoring.183 For more details
Pregnancy Heart Team, for all women with a condition of mWHO about managing the various delivery stages, including post-partum,
2.0 class II–III or above. In general, vaginal delivery is the preferred de- see Sections 4.5 and 4.6.1.
livery mode in women with ACHD.163 Post-partum monitoring should A summary of relevant disease-specific considerations, maternal and
be individualized based on the woman’s underlying ACHD, risk or foetal complications, monitoring, and management during pregnancy
presence of arrhythmias and/or HF, and the course during pregnancy are listed in Table 12.
Table 12 Risks, monitoring, and management during pregnancy and delivery in women with congenital heart disease
ACHD Maternal Risk Obstetric and foetal Monitoring Pregnancy management and
risk delivery
Left ventricular outflow tract obstruction (LVOTO)
Coarctation of the • ↑ Complication risk if residual • ↑ Miscarriage rate453 • Close BP monitoring • Treat hypertensiona
aorta obstruction (gradient • Pre-term birth and low —also early • Consider bed rest, hospital
>20 mmHg, aortic lumen birth weight in 9%9 post-partum admission and stenting in case of
<12 mm), clinical signs of HF, • Pre-pregnancy CMR severe symptomatic
LVEF <40%, NYHA class>19 and treatment of (re)coarctation (including
• ↑ Risk of aortic dissection residual lesions454 refractory hypertension or
(if aneurysm present) maternal/foetal compromise)455
• Uncontrolled hypertension9 • Vaginal delivery preferred unless
aneurysm, HF, severe hypertension
Subvalvular, valvular and supravalvular aortic stenosis: see Section 12.5.1b and Section 8.3c for BAV related aortic disease.
Women with serial left heart obstructive lesions have higher maternal cardiovascular event rates.456
Shunt lesions
ASD • Low risk in (un)repaired ASD • Rare457 Unrepaired and • Large and/or haemodynamically
(if no PAH)457 • Unrepaired ASD 457,458: uncomplicated ASD: significant ASD: closure
Unrepaired ASD: • SGA (21%) consider TTE at pre-pregnancy21
• ↑ Risk of arrhythmia (4%)457 • Foetal/perinatal 28–32 weeks457 • Unrepaired ASD:
• Paradoxical embolism mortality (2%–3%) • Consider ASA or prophylactic
(2%–5%)457,458 • Pre-eclampsia (7%) LMWHd for paradoxical
embolism prevention
• Consider device closure in
pregnancy only for recurrent
stroke on medical therapy
VSD and patent Low risk in small or repaired No evidence for ↑ risk Unrepaired and Vaginal delivery is preferred
ductus arteriosus lesions with normal LV and no uncomplicated VSD:
PAHe consider TTE at
28–32 weeks
AVSD • Low risk in repaired AVSD • Offspring mortality in Unrepaired and • Residual shunt: see ASD and/or
without significant residual 6% primarily due to uncomplicated AVSD: VSD
lesions recurrence of the consider TTE at • ↑ AV valve regurgitation and/or HFf
• Arrhythmia and ↑ AV valve congenital heart 28–32 weeks • PAHe
regurgitation and HF if disease459 ↑ FU frequency in • Delivery: see ASD and VSD
residual left AV valve significant valve
regurgitation459,460 regurgitation, PAH, ↓
• ↑ Paradoxical emboli risk in ventricular function, or ↑
unoperated (partial) AVSD NYHA class461
Pulmonary valve and RVOT disease
RVOTO/PV stenosis • Mild to moderate: low risk • Very low complication • Mild to moderate: Pre-pregnancy severe RVOTO (Doppler
• Severe: RV failure and risk462,463 • TTE at 28–32 weeks peak gradient>64 mmHg) or/and any
arrhythmia21 • Severe stenosis: signs of right HF:
Continued
Downloaded
from

by
guest
on
22
January
2026

4506 E S C G u id e l in e s
• (Bi)monthly TTE • Intervention (at any level of the
(focused on RV RVOT)21
function) Severe symptomatic PV stenosis (not
responding to bed rest and conservative
management):
• Consider transcatheter balloon
valvotomy21
Consider caesarean section in severe
RVOTO/PV stenosis463
PV regurgitation • ↑ Risk when impaired RV • Premature birth463 Bimonthly TTE if severe
function462 PV regurgitation and ↓
RV function
Post pulmonary valve • Low risk463–466 • Very low complication TTE at 28–32 weeks Vaginal delivery is preferred
replacement (surgical risk462,463
or transcatheter
without severe
stenosis/regurgitation)
Repaired TOF
• Low risk if no residual • 15% risk of foetal and • First trimester and at • RV failure management:
lesions467 obstetric complications, 28–32 weeks FU with Bed rest and diuretics
• ↑ Risk of arrhythmia and HF mainly pre-term delivery TTE (increase FU • Arrhythmia managementg
(7%–10%) if pulmonary and low birth weight467 depending on • Severe PV stenosis/regurgitation:
regurgitation, ↓ RV function, • Low foetal mortality functional status) see above
severe RVOTO467,468 (0.7%)467 • Vaginal delivery is preferred
• Recurrence risk in the Consider caesarean section in severe
offspring in 22q11 RVOTO/PV stenosis
deletion syndrome: 50%
Ebstein anomaly
• Overall MACE rate in • Foetal risk is related to ↓ • Mild to moderate: • Severe tricuspid regurgitation with
ROPAC 9.9% maternal CO and baseline and 28–32 HF can usually be managed
• Low risk in mild/ moderate cyanosis3,469: weeks assessment with medically
Ebstein • Miscarriage TTE and ECG • Treat arrhythmias promptlyg
• (Very) high risk when • Pre-term birth • Severe: monthly/ • Appropriate pre-pregnancy
pre-pregnancy HF, cyanosis (20%–24%) bimonthly TTE & ECG counselling about very high risk of
due to atrial shunt • Neonatal death (3%) • Monitor for MACE when HF and/or cyanosis
• ↑ Arrhythmia risk due to • PPH arrhythmias if
accessory pathways469 • Recurrence risk (5%) palpitations
Transposition of the great arteries
TGA after atrial • High pregnancy risk—MACE • Foetal risks associated • According to • Pre-pregnancy counselling about
switch (Mustard or rate up to 28% in with maternal CO and anatomical and very high risk if NYHA class III/IV,
Senning) and CCTGA retrospective series470— saturation functional status: TTE systemic RV EF <40%, more than
lower risk in ROPAC6: Atrial • Pre-term birth (21%) every 1–3 months and moderate tricuspid regurgitation,
and ventricular arrhythmias in • Low birth weight serial NP or treated HF472,473,475
6.7%, HF in 10% (18%–21%)6,472,473 • Holter monitoring if • Treat HF primarily with medical
• Atrial arrhythmias often • Rare foetal and neonatal palpitations therapyh
poorly tolerated death (1%)474 • Promptly treat arrhythmiag
• Baffle leaks may lead to • PPH (7%)6 • Consider prolonged post-partum
desaturation and paradoxical monitoring (48–72 h) and early
embolism471 post-partum FU given the ↑ risk of
• Predictors of MACE: post-partum HF
symptoms of HF before No clear evidence for long-term
pregnancy and systemic RV EF deterioration or ↑ cardiovascular
<40%6 events associated with pregnancy6,476
TGA with arterial • Low risk • Low rate of prematurity • Consider TTE at 20 • Vaginal delivery is preferred
switch • Ventricular arrhythmias or foetal loss474,477 weeks • Surgery before pregnancy when the
(2.5%–7%), HF (2%–4%)8 • Intensify if ↓ ventricular neo-aortic root is >55 mm21,478or if
function, ↑ aortic severe aortic regurgitationf
Continued
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4507
regurgitation and ↑
aortic dilatation
Single ventricle physiology palliated with Fontan circulation
High pregnancy risk ↑ Very high foetal • According to • Pre-pregnancy counselling about
CV events479: complication risk:479–483 anatomical and very high risk especially if any risk
• Supraventricular arrhythmias • Low live birth rate (56%) functional status: TTE factor (see maternal risk)
(8%–11%) • Miscarriages (45%–54%) every 1–3 months and • Pregnancy may be well tolerated
• HF (4%–14%) • SGA (20%–55%) serial NP484 and successful in a subset of
Risk factors:479 • Premature birth (59%– • FU in specialized women with single ventricle and
• Oxygen saturations <85% 72%) ACHD centre Fontan circulation without
• ↓ Ventricular function • Neonatal death (5%– complications479,480,485–487
• Arrhythmias 18%) • ASA and/or LMWH (depending on
• Significant valvular disease Obstetric risk: the presence of complications)
• NYHA class III/IV • Hypertension (14%) should be considered in shared
• FALD • PPH (13%) decision484
• Atrial tachyarrhythmias should be
promptly treated with
cardioversioni
Labour/delivery with preload dependent
circulation:461
• Epidural with slow titration
• Labour in left lateral decubitus
position
• Low thresholds for assisted second
stage (↓ Valsalva duration)
• i.v. air filter (if fenestration or
significant venovenous collaterals)
Unrepaired cyanotic ACHD (without pulmonary hypertension)
HF, thrombosis, arrhythmia and Degree of maternal FU in expert centre • Pre-pregnancy counselling about
endocarditis in ≥15%488 hypoxaemia is the most very high risk especially if maternal
important predictor of resting saturation <85%489
foetal outcome: • i.v. air filter
10% foetal loss if resting
maternal blood saturation
>90%,
chance of a live birth 12% if
maternal oxygen
saturation<85%489
ACHD, adult congenital heart disease; ASA, acetylsalicylic acid; ASD, atrial septal defect; AV, atrioventricular; AVSD, atrioventricular septal defect; BAV, bicuspid aortic valve; BP, blood
pressure; CCTGA, congenitally corrected transposition of the great arteries; CMR, cardiovascular magnetic resonance; CO, cardiac output; CV, cardiovascular; ECG, electrocardiogram;
EF, ejection fraction; FALD, Fontan-associated liver disease; FU, follow-up; HF, heart failure; i.v., intravenous; LMWH, low-molecular-weight heparin; LV, left ventricle; LVEF, left
ventricular ejection fraction; LVOTO, left ventricular outflow tract obstruction; MACE: major adverse cardiovascular events; NP, natriuretic peptide; NYHA, New York Heart
Association; PAH, pulmonary arterial hypertension; PPH, post-partum haemorrhage; PV, pulmonary valve; ROPAC, Registry of Pregnancy and Cardiac Disease; RV, right ventricle,
RVOTO, right ventricle outflow tract obstruction; SGA, small for gestational age; TGA, transposition of the great arteries; TOF, tetralogy of Fallot; TTE, transthoracic echocardiogram;
VSD, ventricle septal defect.
↑ increase ↓ decrease.
aRefer to Section 12.3 Hypertensive disorders.
bRefer to Section 12.5.1 Stenotic native valve lesions.
cRefer to Section 8.3 Bicuspid aortic valve disease.
dRefer to Section 5 Drugs during pregnancy and lactation.
eRefer to Section 10 Pregnancy in women with pulmonary arterial hypertension.
fRefer to Section 12.5.2 Regurgitant native valve lesions.
gRefer to Section 12.4 Arrhythmias.
hRefer to Section 12.6 Heart failure.
iRefer to Section 12.4.3 Cardioversion, ablation, and device implantation and implantable cardioverter defibrillator management.
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

4508 E S C G u id e l in e s
Recommendation Table 9 — Recommendations for 10.1.1. Maternal and foetal risk
congenital heart disease and pregnancy (see Evidence
Although there is no safe cut-off for elevated pulmonary artery pres-
Table 8)
sure and risk, pregnancies with mild PAH and vasoreactive PAH
seem to have better maternal and foetal outcomes than those with
Recommendations Classa Levelb
moderate to severe PAH.141,496–498 Women with severe PAH, non-
Vaginal delivery is recommended in most women vasoreactive idiopathic PAH, and Eisenmenger syndrome have the high-
I B
with ACHD.161,163 est risk of maternal and foetal mortality.496,497,499–502 As the clinical
It is recommended that all women with Fontan course of PAH during pregnancy remains associated with unforesee-
circulation who wish to become pregnant receive able risks and pregnancy may accelerate PAH progression, all women
with PAH496 wishing to become pregnant should be counselled by a
counselling from the Pregnancy Heart Team I C
multidisciplinary team regarding the very high risk of pregnancy-related
regarding the high risk of pregnancy-related adverse
events.479,480,484,486,487 adverse events.
Women with Eisenmenger syndrome are unlikely to tolerate preg-
It is recommended that women with a systemic RV
nancy due to additional risks of RV failure and paradoxical emboli.
(Mustard/Senning or congenitally corrected TGA), in
Chronic cyanosis may worsen due to systemic vasodilatation during
NYHA class III/IV, systemic ventricular dysfunction
pregnancy, an increased right-to-left shunt, and decreased pulmonary
(EF <40%), or severe TR wishing to become I C
blood flow.
pregnant are counselled by the Pregnancy Heart
Foetal and neonatal mortality risk is high in women with PAH, main-
Team regarding the high risk of pregnancy-related ly related to pre-term delivery, reduced maternal CO, and/or hypox-
adverse events.473–475 aemia.503 Miscarriage is common. If oxygen saturation is >90%, there
In women with significant haemodynamic lesions, is usually a better foetal outcome (10% foetal loss). If oxygen satur-
discussion about guideline-directed interventions is I C ation is <85%, miscarriage, IUGR, prematurity, and foetal death are
recommended prior to pregnancy. common (live birth rate of only 12%).504,505
ACHD, adult congenital heart disease; EF, ejection fraction; NYHA, New York Heart
Association; RV, right ventricle; TGA, transposition of the great arteries; TR, tricuspid 10.1.2. Counselling and contraception
regurgitation.
aClass of recommendation. Women of childbearing potential with PAH should be counselled
bLevel of evidence. at the time of diagnosis about the very high risk and uncertainties as-
sociated with becoming pregnant. Clear advice against becoming
pregnant, including referral for psychological support if needed,
10. Pregnancy in women with
and clear contraceptive advice are required, taking into account the
pulmonary arterial hypertension woman’s individual needs. Reduced efficacy of hormonal contracep-
tives should be carefully considered and discussed with women trea-
Pulmonary hypertension (PH) is defined as a mean pulmonary ted with ERAs, as well as the addition of barrier methods for
arterial pressure >20 mmHg, derived from invasive right-heart cath- contraception.490,493
eterization, and is classified by aetiology and pathophysiology.490
Pulmonary arterial hypertension (PAH) is pre-capillary PH character-
ized by a pulmonary vascular resistance >2 Wood units and pulmon- 10.1.3. Management during pregnancy
ary arterial wedge pressure ≤15 mmHg. Untreated, idiopathic PAH When pregnancy occurs, termination should be discussed. Rigorous
results in death within a median of 2.8 years, but with PAH therapies, planning with the optimization of targeted PAH therapies and close
median survival extends to over 7 years.491,492 There is a preponder- monitoring are key in managing women with PAH who wish to con-
ance of females in the incidence of PAH, and this includes women of tinue with the pregnancy after appropriate counselling on the high ma-
childbearing age. The first clinical manifestations may be seen in ternal and foetal risks.
pregnancy.493 Bed rest may be required in symptomatic women, and it may be ap-
Women with PAH should be managed by a Pregnancy Heart Team, propriate to avoid additional risk factors (such as air travel). Right-heart
and a PH expert experienced in diagnostic pathways, medical treat- catheterization can be performed to assist management in women
ment, and anticoagulation management from the ante- to the peri- showing deterioration.
and post-partum period. Diuretics may be needed in women with HF, and iron deficiency
should be treated.43 It is recommended to stop ERAs, riociguat, and
selexipag because of potential or unknown teratogenicity.43,490
10.1. Pre-existing pulmonary arterial
PAH therapies that can be used during pregnancy include
hypertension
phosphodiesterase-5 inhibitors and prostacyclin analogues. Sildenafil
In women with PAH, maternal and foetal outcomes vary according to the is used in the vast majority of women and is combined with a prosta-
PAH subset. With improved treatment of PAH and a multidisciplinary cyclin analogue depending on the disease severity. The subset of wo-
approach during pregnancy and the peri-partum period, maternal mor- men with true vasodilator responsiveness who are well controlled on
tality has declined but remains high, ranging from 11% to 25%.2,490,494,495 CCB therapy should continue taking this during pregnancy.43,490,506
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4509
In women with Eisenmenger syndrome, caution is warranted when Recommendation Table 10 — Recommendations for
administering drugs that may lead to sudden systemic vasodilation or pulmonary arterial hypertension and pregnancy
a risk of paradoxical air embolism (i.v. line filters should be used for
i.v. therapies). Thromboembolism is a major risk, and anticoagulation Recommendations Classa Levelb
regimens (type and dosage) should be considered individually, balan-
It is recommended that women of childbearing
cing the risk of bleeding vs VTE at each stage of pregnancy. LMWH
potential with PAH wishing to become pregnant are
is most commonly used. Regular follow-up is advisable, initially every
counselled by a multidisciplinary team regarding the
2–4 weeks and then weekly in the third trimester. Women need to be I C
very high risk of pregnancy-related adverse events,
monitored for increasing hypoxaemia and symptoms of HF, including
encouraging a shared decision-making process about
breathlessness, syncope, and congestion. Regular echocardiography
whether to become pregnant.490
and blood testing, including NP levels, can provide evidence of HF
It is recommended to provide clear contraceptive
where appropriate.
advice to women of childbearing potential with I C
PAH.490
10.2. New diagnosis in pregnancy
For women with PAH requiring pregnancy
The usual diagnostic algorithm as per the 2022 ESC/ERS Guidelines
termination, it is recommended to perform this in I C
for the diagnosis and treatment of pulmonary hypertension should
PH centres.490 be followed in a pregnant woman with suspected PAH. Right-heart
Right-heart catheterization should be considered
catheterization should be considered if there is diagnostic uncer-
during pregnancy if there is diagnostic uncertainty or IIa C
tainty in identifying de novo PAH in pregnancy and to assist with im-
portant therapeutic decisions.490 If this is required, it should be to assist with important therapeutic decisions.490
performed in a specialized centre. An individualized approach is re- Endothelin receptor antagonists, riociguat, and
quired for starting PAH therapies. Many centres start therapy with selexipag are not recommended during III C
oral sildenafil. Close follow-up by an experienced Pregnancy Heart pregnancy.490,508,509
Team with a PH expert is needed and prompt escalation of PAH
PAH, pulmonary arterial hypertension; PH, pulmonary hypertension.
therapy, usually with i.v. epoprostenol, is indicated depending on aClass of recommendation.
the disease severity. bLevel of evidence.
11. Venous thromboembolism in
10.3. Delivery in women with pulmonary
arterial hypertension pregnancy and post-partum
A detailed delivery plan, including the optimal mode and timing of de-
11.1. Epidemiology and maternal risk
livery, should be provided on a timely basis by the Pregnancy Heart
Team with a PH expert. Early delivery, with careful tracking of foetal Venous thromboembolism includes PE and DVT. The pooled incidence of
growth, is often required in women with progressive, decompensated pregnancy-related VTE (including post-partum) is 1.2 per 1000 deliver-
HF not responding to PAH therapies and to reduce the risk of an un- ies510, and it is a major cause of pregnancy-related morbidity and mortal-
planned birth outside an expert centre.245 Therapeutic LMWH ity.510 Pregnancy-related VTE has a fatality rate of 0.68% and a recurrence
should be stopped 24 h prior to any mode of delivery to reduce rate (during pregnancy and post-partum) of 4.27%, which is higher post-
the risk of maternal haemorrhage. Caesarean section providing for partum.510 A documented assessment of VTE risk factors is recom-
a more controlled delivery may be preferred over vaginal deliv- mended before or in early pregnancy. The VTE risk is highest in the third
ery.494,507 Regional anaesthesia is usually favoured over general trimester and in the first 6 weeks post-partum.510 Mortality in
anaesthesia. pregnancy-related VTE is associated with CVD, hypertension, twin gesta-
tion, pre-term birth, caesarean section, transfusion, and black ethnicity.511
10.3.1. Peri- and post-partum monitoring
11.2. Risk factors for pregnancy-related
Due to the rapid changes in haemodynamics, the post-partum period is
venous thromboembolism
particularly high risk, with the majority of maternal mortality occurring
after delivery.245 During delivery and post-delivery, women should be Pregnancy is accompanied by physiological changes leading to an
monitored in the intensive care setting with ECG, pulse oximetry, increased VTE risk. First, increased procoagulant activity as well as de-
CO monitoring, meticulous fluid balance with central venous pressure creased physiological anticoagulant and fibrinolytic activity result in a hy-
monitoring, and optimization of RV function all important determinants percoagulable state.512,513 Second, the expanding uterus causes
of a good outcome. Women remain at high risk for many months after mechanical compression of the inferior vena cava and the pelvic veins,
delivery, and individualized counselling is required to discuss the need leading to impeded venous flow.512,513 In addition, non-pregnancy-
for ongoing therapies and the avoidance of future pregnancies. In wo- related and pregnancy- or delivery-related conditions may modify the in-
men with severe PAH and those who had complications during preg- dividual VTE risk (see Supplementary data online, Table S5).
nancy and/or delivery, optimization of PAH therapies should be In pregnancy, as well as in the early post-partum period, an emerging
prioritized over lactation. suspicion of VTE requires immediate diagnostic clarification.
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

4510 E S C G u id e l in e s
11.3. Prevention of venous needs to be confirmed by future studies. In morbidly obese women,
thromboembolism weight-based prophylactic dosing (considering anti-factor Xa measure-
ment) instead of fixed dosing might be more appropriate.198
Thromboprophylaxis follows an individualized risk assessment weighing
the VTE risk against the bleeding risk ante- and post-partum.
11.3.2. Pregnant women with prior indication for
long-term anticoagulation
11.3.1. Pregnant women with no prior indications for
In case of pre-existing oral anticoagulation therapy due to previous
long-term anticoagulation
VTE, oral anticoagulation (DOAC or VKA) should be replaced by
If prevention and treatment of VTE are initiated in the antepartum per- LMWH at recognition of pregnancy.517
iod, continuation for up to 6 weeks post-partum should be considered.
In women with low-risk thrombophilia without a history of VTE, rou- 11.4. Management of acute venous
tine antepartum thromboprophylaxis is not required.514 In women
thromboembolism
with a history of VTE or a high-risk thrombophilia, medical thrombo-
prophylaxis is recommended (Table 13). In women with ovarian hyper- 11.4.1. Clinical presentation and diagnosis
stimulation syndrome after in vitro fertilization, thromboprophylaxis is 11.4.1.1. Deep vein thrombosis
recommended during the first trimester.515,516 The expanding uterus potentially reduces the blood flow in the iliocaval
The drug class of choice for the prevention and treatment of veins. In addition, a constitutional narrowing of the left-sided common
pregnancy-related VTE is LMWH.517,518 Fondaparinux may be consid- iliac vein between the spine and the crossing artery could contribute to
ered as an alternative. A randomized controlled trial comparing a an increased risk of left-sided iliofemoral thrombosis.520 The clinical
weight-adjusted intermediate-dose LMWH with a fixed low-dose LEFt criteria (L = Left, symptoms in the left leg; E = Edema, calf circum-
LMWH regimen found that weight adjustment did not reduce the ference difference ≥2 cm; Ft = First trimester of presentation) may be
risk of recurrent VTE in the combined ante- and post-partum peri- used to identify low risk of pregnancy-related DVT.521,522 In pregnant
ods.519 Post-hoc analyses suggested a higher efficacy of weight-adjusted women with suspicion of acute DVT, immediate diagnostic clarification
intermediate-dose LMWH in the post-partum period only, but this is indicated (Figure 9).
Table 13 Reasons for antepartum/post-partum thromboprophylaxis
Medical conditions Antepartum thromboprophylaxis Post-partum thromboprophylaxis
History of unprovoked VTE
History of hormone-associated VTE
Homozygous factor V Leiden mutation
Heterozygous factor V Leiden mutation
Homozygous prothrombin gene mutation a
Heterozygous prothrombin gene mutation
Antithrombin deficiency
a a
Antiphospholipid syndrome b
Protein C or S deficiency a
Combined thrombophilia
Adapted from Nichols et al.213 under the terms of the Creative Commons Attribution-NonCommercial-No Derivatives License (CC BY NC ND).
VTE, venous thromboembolism.
= yes; = no; = no clear evidence to administer or not—to be individualized.
aWith family history of VTE (to be considered without family history of VTE).
bWith history of VTE or pregnancy loss.
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4511
Suspicion of pregnancy-related
Deep vein thrombosis
Administration of first therapeutic dose of LMWH
if anticipated diagnostic delay
(Class IIa)
Venous ultrasound
compression ultrasound of infrainguinal veins and ultrasound of iliac veins
Positive Inconclusive Negative
Serial venous ultrasound scans
Positive Negative
(2 exams within 7 days)
or MR-venography
Diagnosis of DVT No DVT
Consultation with
Pregnancy Heart Team
Therapeutic
including a vascular
dose LMWH AND
specialist and
(Class I)
a haematologist
(Class I)
Figure 9 Algorithm for the diagnosis and treatment of deep vein thrombosis during pregnancy. DVT, deep vein thrombosis; LMWH, low-molecular-weight
heparin, MR, magnetic resonance. Adapted from Chan et al.523
11.4.1.2. Pulmonary embolism YEARS criteria absent <1000 µg/L).526 Another meta-analysis confirmed
Clinical signs and symptoms of PE in pregnancy do not differ from those of the value of including D-dimer in a diagnostic algorithm to rule out PE in
PE in non-pregnant women. The diagnostic approach in haemodynamically pregnant women with suspicion of PE (Figure 10).527
stable pregnant women with suspicion of PE aims to reduce the need for
computed tomography pulmonary angiography (CTPA) by implementing 11.4.2. Treatment of venous thromboembolism
additional diagnostic strategies, such as clinical features, D-dimer, and ven- in pregnancy
ous ultrasound. Levels of D-dimer increase physiologically up to 39% per In pregnant women with a suspicion of VTE, anticoagulation with thera-
trimester.524 A multinational study demonstrated the efficiency of a diag- peutic LMWH should be commenced immediately, even before imaging,
nostic strategy involving clinical probability, D-dimer measurements until the diagnosis of VTE is either excluded or confirmed. In pregnant wo-
(threshold <500 µg/L), and peripheral venous compression ultrasound men with confirmed acute VTE, therapeutic anticoagulation with weight-
to reduce the need for CTPA.525 Using both the YEARS criteria (1, clinical adjusted LMWH based on early pregnancy weight is recommended by
signs of acute DVT; 2, haemoptysis; 3, PE is the most likely diagnosis) and using either a twice-daily or a once-daily regimen, each one resulting in
adapted D-dimer thresholds allows a further reduction in the need for a therapeutic daily dose518 (see also Section 5.2.1). Currently, there is in-
CTPA (D-dimer threshold if YEARS criteria present <500 µg/L, if sufficient evidence to favour once- or twice-daily regimens.217,218,518
Downloaded
from

by
guest
on
22
January
2026

4512 E S C G u id e l in e s
A Stable patient with clinical suspicion of pulmonary embolism
Administration of first therapeutic dose of LMWH
if anticipated diagnostic delay AND D-Dimer
(Class IIa)
Positive Negative
Venous ultrasound
compression ultrasound of infrainguinal veins and ultrasound of iliac veins
Positive Negative or inconclusive
if CTPA not available
Negative Chest X-ray Inconclusive Negative
CTPA
Perfusion lung scan
Positive Positive
Diagnosis of DVT No PE Diagnosis of PE No PE
Therapeutic Consultation with Pregnancy Heart
dose Team including a vascular specialist
AND
LMWH and a haematologist
(Class I) (Class I)
B
Unstable patient with suspicion of pregnancy-related pulmonary embolism
Consultation with
Administration of first
Pregnancy Heart Team
therapeutic dose of
including a vascular specialist AND AND TTE
UFH or LMWH
and a haematologist
(Class IIa)
(Class I)
RV dysfunction No RV dysfunction
CTPA
Positive Negative
Diagnosis of PE Search for alternative
causes of instability
Therapeutic dose Evaluation of
AND
anticoagulation reperfusion strategy
Figure 10 Algorithm for the diagnosis and treatment of pulmonary embolism in pregnancy in stable (A) and unstable women (B). CTPA, computed tom-
ography pulmonary angiography; DVT, deep vein thrombosis; LMWH, low-molecular-weight heparin; PE, pulmonary embolism; RV, right ventricle; TTE,
transthoracic echocardiogram; UFH, unfractionated heparin. Adapted from Barrios et al.528 with permission from Elsevier.
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4513
Despite fluctuations of anti-factor Xa levels during pregnancy, routine 12. Pregnancy in women with
anti-factor Xa monitoring does not affect clinical outcomes and should
acquired heart disease
only be considered in women with renal insufficiency or obesity.211–213
Fondaparinux may be considered as an alternative. In unstable pregnant
12.1. Acute chest pain in pregnancy
women with PE, UFH may be used in the initial phase of therapeutic
anticoagulation. Diagnostic evaluation for chest pain in pregnant women
After delivery, therapeutic-dose anticoagulation should be administered follows the same protocol as in non-pregnant women, including
for a minimum of 6 weeks, up to an overall duration of 3 months, except clinical examination, ECG, biomarkers and echocardiography
for cases in which an indefinite duration of anticoagulation is indi- (Figure 11).207,537,538 Importantly, spontaneous coronary artery
cated.510,529 LMWH or VKAs may be given during lactation. A more de- dissection (SCAD) is a more prevalent cause of chest pain during
tailed discussion of anticoagulants in the lactation period can be found in pregnancy and in the early post-partum period than in non-
Section 5. Thrombolytic or interventional treatment of PE is not recom- pregnant women.539
mended in the peripartum period and should only be considered in women Treatment and management of the specific differential diagnoses
with high-risk PE after consultation with a specialized multidisciplinary should follow established respective guidelines. The specificity of
team. In pregnant women with acute iliofemoral DVT, interventional D-dimer is reduced during pregnancy540,541 and women should not
thrombus removal should not routinely be performed. Data on the effect- undergo chest CT based solely on D-dimer levels (Section 11). In sus-
iveness and risks of the placement of temporary inferior vena cava filters pected acute aortic syndromes, there should be a low threshold for
for the prevention of PE in pregnant women are limited but appear to aortic CT and consultation with the aortic team in emergencies
be comparable to non-pregnant women. Due to limited data and potential (Section 8).542
complications associated with the inferior vena cava filters, their placement
should be limited to recurrent VTE despite appropriate anticoagulation or
12.2. Coronary artery disease
contraindication to therapeutic-dose anticoagulation therapy.530,531
12.2.1. Acute coronary syndrome
12.2.1.1. Coronary artery disease epidemiology and aetiology
11.5. Management of delivery and the
Acute coronary syndromes (ACS) are a major cause of maternal
post-partum period
death in developed countries, accounting for 20% of cardiovascular
For pregnant women receiving a prophylactic dose of anticoagulation, deaths.543 The risk of ACS is three to four times higher in pregnant
there is no specific need for a planned delivery. However, pregnant wo- women than in non-pregnant women of reproductive age,544 and
men receiving a therapeutic dose of anticoagulation need a planned de- mortality is estimated at 5%.545 Because the age at giving birth is
livery with prior discontinuation of LMWH to prevent spontaneous increasing overall, ACS in pregnancy may become more com-
delivery in a period of full anticoagulation. Details for the management mon.546 Although ACS can occur at any stage of pregnancy, it is
of anticoagulation during pregnancy and delivery, including for VTE, are more common in the third trimester or post-partum.544 Classic
provided in Sections 4.5.6. and 5.2.1. ASCVD risk factors are associated with ACS during pregnancy.
Recommendation Table 11 — Recommendations for venous thromboembolic diseases and pregnancy (see Evidence
Tables 9 and 10)
Recommendations Classa Levelb
For pregnant or post-partum women at high riskc of VTE, a prophylactic fixed dose of LMWH is recommended over a higher
I B weight-adjusted dose to reduce the risk of VTE.519
In pregnant women or women in the post-partum period with suspicion of VTE (DVT and/or PE), an immediate formal diagnostic
I B
assessment with validated methods is recommended and should not be postponed.525,526
In pregnant women or women in the post-partum period with newly diagnosed VTE (DVT and/or PE), the involvement of the Pregnancy
I C
Heart Team, including a vascular specialist and a haematologist, is recommended.
In pregnant or post-partum women with a diagnosis of VTE without haemodynamic instability, anticoagulation is recommended by using
I C
therapeutic-dose LMWH based on early pregnancy body weight.212,532
In pregnant women or women in the post-partum period with a strong clinical suspicion of VTE, initiation of treatment with a therapeutic
IIa C
dose of LMWH should be considered until the presence of VTE has been ruled out or confirmed.
In pregnant or post-partum women with a diagnosis of acute high-risk PE,d a catheter-based reperfusion strategy or systemic thrombolysis
IIa C
should be considered.533–535
In pregnant or post-partum women with a diagnosis of acute high-risk PE,d surgical thrombectomy may be considered as an alternative to a
IIb C
catheter-based approach or systemic thrombolysis.533–535
DVT, deep vein thrombosis; LMWH, low-molecular-weight heparin; PE, pulmonary embolism; VTE, venous thromboembolism.
aClass of recommendation.
bLevel of evidence.
cSee Supplementary data online, Table S5 for VTE risk factors.
dAccording to the Pulmonary Embolism Severity Index from the 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism.536
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

4514 E S C G u id e l in e s
Management of chest pain during pregnancy and up to 6 months post-partum
• Check for vital signs
• Perform: ECG, hs-cTn, TTE
• Assess: week of gestation, cardiovascular risk factors, previous CAD, DVT, family history of DVT/PE,
family history of aortic disease
Suspicion of
Other cause of Acute coronary Pulmonary Acute aortic
chest pain syndrome embolism syndrome
Check differential diagnoses e.g.: CT
• Myocarditis and pericarditis
• Gastroesophageal reflux
• Amniotic fluid embolism Go to
• Musculoskeletal pain algorithm Consult aortic
team
on PE
Non-high risk High-risk Very high-risk
a
Selective Inpatient Immediate
invasive strategy invasive strategy invasive strategy
Diagnosis of
ASCVD SCAD MINOCA Takotsubo
Haemodynamically
Haemodynamically Additional
unstable or
stable examinations
ongoing ischaemia
PCIb or CABG or
PCIb or urgent Conservative
conservative
CABG management
management
Figure 11 Management of chest pain during pregnancy and within 6 months post-partum. ASCVD, atherosclerotic cardiovascular disease; B-blocker, beta-
blocker; CABG, coronary artery bypass graft; CAD, coronary artery disease; CT, computed tomography; DVT, deep venous thrombosis; ECG, electrocar-
diogram; EF, ejection fraction; hs-cTn, high sensitivity cardiac troponin; i.v., intravenous; MINOCA, myocardial infarction with non-obstructive coronary ar-
teries; o.d., once a day; PCI, percutaneous coronary intervention; PE; pulmonary embolism; SCAD, spontaneous coronary artery dissection; TTE,
transthoracic echocardiogram. aIn patients without very high or high-risk features and a low index of suspicion for unstable angina. bDual anti-platelet therapy:
clopidogrel: loading dose of 300–600 mg orally, followed by an oral maintenance dose of 75 mg o.d. Aspirin: loading dose of 150–300 mg orally or 75–250 mg
i.v. if oral ingestion is not possible, followed by an oral maintenance dose of 75–100 mg o.d.
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4515
Additional risk factors are pre-eclampsia, thrombophilia, transfu- antiplatelet therapy with aspirin.563,566 Women with a history of
sion, post-partum infection, multiparity, and PPH. Pregnancies SCAD should be carefully counselled regarding the risk of recurrent
that required fertility treatment have not been shown to have an events in subsequent pregnancy.567,568
increased risk of ACS.547
Pregnancy-associated SCAD is the single most frequent cause of ACS 12.2.2. Coronary artery interventions
during pregnancy and post-partum (43%),548 followed by atherosclerotic
The indications for acute revascularization are comparable to those
lesion (27%), coronary embolism (17%), and vasospasm (2%).239
for non-pregnant women. In patients with high or very high-risk ACS,
Coronary thromboembolism may be due to pregnancy-related hyper-
immediate coronary angiography and PCI, if indicated, are recom-
coagulability and paradoxical embolization.549 Vasospasm has been asso- mended.557 Moreover, an early invasive strategy with coronary angiog-
ciated with the use of ergot derivatives prescribed for lactation
raphy is recommended for pregnant women with a confirmed or a
suppression or to treat PPH.549
working diagnosis of non-ST-elevation ACS (NSTE ACS) and with a
high index of suspicion for unstable angina. In atherosclerotic lesions557
12.2.1.2. Presentation and diagnosis PCI is indicated when there is ongoing or recurrent chest pain, haemo-
Clinical presentation of ACS in pregnancy is the same as in the non- dynamic instability, or ongoing ischaemia due to functionally significant
pregnant population. However, pregnant women with SCAD tend coronary stenoses or acute occlusions.122
to have a more severe clinical presentation than women with The choice of coronary stents should not be different from that for
non-SCAD ACS.550–553 non-pregnant women. Duration of DAPT should follow recommenda-
An ACS in pregnancy should be suspected in women presenting with tions for non-pregnant patients with an individual approach considering is-
cardiac arrest, acute onset chest pain, dyspnoea, ischaemic changes on chaemic and delivery-related risks, including bleeding risk during delivery
ECG, or elevated cardiac biomarkers.551,554 Diagnostic evaluation and neuraxial anaesthesia. Stents approved for short DAPT may be pre-
should follow ACS strategies (Figure 11).555–557 Major ischaemic ECG ferred during pregnancy in specific cases according to gestational age and
changes due to pregnancy itself are not expected (Figure 1). timing of delivery. In the case of coronary embolism, thrombo-aspiration
Invasive coronary angiography during pregnancy should be reserved and/or a simple angioplasty can be performed.43,569 Invasive procedures
for those with ACS, or when other diagnostic methods are inappropri- should follow the ALARA principle (see Section 4.3.5).
ate. ECG changes, such as transient ST-segment depression and T-wave Systemic thrombolysis may be an alternative reperfusion strategy if
inversion can be normal during pregnancy, but a serum troponin rise timely PCI is not available. Recombinant tissue plasminogen activator
suggests myocardial injury as in non-pregnant women. ST elevation is does not cross the placenta but can induce bleeding complications, in-
not normal in pregnancy and warrants urgent attention.558 cluding subplacental.
ST-elevation myocardial infarction (STEMI) in pregnant women in-
volves the anterior wall in 70%–80% of cases.239,558 In more than half 12.2.3. Chronic coronary syndromes in pregnancy
the cases, a reduction of LVEF <40% is observed, leading to a high in- Pregnant women with chronic coronary syndromes (CCS) are at high
cidence of complications.20 Myocardial infarction with non-obstructive risk of adverse maternal and foetal outcomes: 32% have cardiovascular
coronary arteries (MINOCA) should be considered a working diagnosis complications (including 9% with ischaemic cardiovascular complica-
warranting further investigation.559 tions) and there is 2% maternal mortality.570 The CARPREG II score,
now also included in the mWHO 2.0 classification (Table 6, Section
12.2.1.3. Pregnancy-associated spontaneous coronary artery 4), highlights the high risk of CCS as a predictor of maternal complica-
dissection tions. When counselling women with CCS, pregnancy can preferably be
Pregnancy-associated SCAD affects 1.81 per 100 000 pregnancies560 considered when there is no residual ischaemia or LV dysfunction 12
months after an index event.
and may occur at any time during or after pregnancy, although >70%
occur early post-partum, most commonly within the first week.550
Multiple predisposing factors have been described, including oestrogen 12.2.4. Management and delivery
and progesterone surges causing structural changes to the coronary tu- Women with ACS or CCS should be managed by a Pregnancy Heart
nica media. SCAD predominantly occurs in the left-sided coronaries, Team. Treatment should be tailored to the underlying pathophysiology,
with multivessel involvement.561 although foetal considerations may affect the choice of therapy.50,571
Percutaneous coronary intervention (PCI) in SCAD is associated All pregnant women with ACS and their foetus should be monitored
with an increased risk of complications, particularly iatrogenic dissec- at an intensive cardiac care unit.
tion and haematoma extension.562 For this reason, a conservative ap- The mode of delivery in a patient with gestational ACS or CCS
proach to revascularization is advised in clinically stable women with should be determined by obstetric considerations and the clinical status
SCAD without active or ongoing ischaemia.539,563 If SCAD involves of the mother. A vaginal delivery is indicated in most women with ob-
the left main coronary artery or proximal vessels, a coronary artery by- structive coronary artery disease (CAD). Vaginal delivery eliminates the
pass graft (CABG) may be considered depending on technical consid- potential risks associated with general anaesthesia and a major surgical
erations and local expertise.539 A multidisciplinary team should procedure. Clopidogrel must be withheld a minimum of 5 days before
decide whether the patient is a candidate for PCI or CABG. neuraxial anaesthesia to reduce the risk of epidural hematoma.572 An
Optimal medical management following SCAD is unknown but is elective caesarean section avoids a long or stressful labour and allows
currently being investigated in an ongoing clinical trial.562 Limited obser- better control of the time of delivery. A plan for emergency delivery
vational data suggest that beta-blockers (e.g. labetalol) and avoiding of a potentially viable foetus in case of sudden maternal deterioration
hypertension may be associated with a lower risk of recurrent should also be established. An arbitrary minimum time to delivery in
SCAD.564,565 The role of antiplatelet therapies in conservatively mana- stable women is at 2 weeks after ACS.18
ged SCAD has been controversial, with evidence favouring single Lipid-lowering and antiplatelet therapy are described in Section 5.
Downloaded
from

by
guest
on
22
January
2026

4516 E S C G u id e l in e s
Recommendation Table 12 — Recommendations for coronary artery disease and pregnancy (see Evidence Table 11)
Recommendations Classa Levelb
In pregnant women with chest pain, it is recommended to exclude life-threatening cardiovascular conditions, including PE, ACS (including
I C
SCAD), and acute aortic syndrome.538,539
It is recommended to manage pregnant women with ACS in the same way as non-pregnant women, including diagnostic investigations and
I C
interventions.557
Low-dose ASA is recommended as the antiplatelet treatment of choice during pregnancy and lactation when single antiplatelet treatment is
I B
indicated.573–579
If DAPT is required, clopidogrel is recommended as the P2Y12 inhibitor of choice during pregnancy.239 I C
The duration of DAPT (aspirin and clopidogrel) in pregnant women undergoing coronary stent implantation is recommended to be the
I C
same as in non-pregnant women, with an individual approach considering ischaemic risk and delivery-related bleeding risks.239
A vaginal delivery should be considered in most pregnant women with ACS, depending on LV function and clinical symptoms. IIa C
Continuation of statins may be considered during pregnancy in women with established ASCVD.580–582 IIb C
ACS, acute coronary syndrome; ASA, acetylsalicylic acid; ASCVD, atherosclerotic cardiovascular disease; DAPT, dual antiplatelet therapy; LV, left ventricular; PE, pulmonary embolism; SCAD,
spontaneous coronary artery dissection.
aClass of recommendation.
bLevel of evidence.
12.3. Hypertensive disorders hypertension (chronic hypertension), gestational hypertension, and pre-
Hypertensive disorders of pregnancy are the second most common med- eclampsia (Table 14). Over recent years an upward incidence trend has
ical complications (after PPH), affecting 5%–15% of pregnancies world- been observed due to older age at first childbirth and rising prevalence
wide, and are a major cause of maternal, foetal, and neonatal morbidity of obesity.586,587 Maternal risks include placental abruption, stroke,
and mortality.583 Hypertensive disorders in pregnancy include pre-existing multiple organ failure, and disseminated intravascular coagulation.588
Table 14 Hypertensive disorders of pregnancy
A. Pre-existing (chronic) hypertension
Hypertension which either precedes pregnancy or develops before 20 weeks gestation, usually persisting >6 weeks post-partum, and which may be associated with
proteinuria.
(1) Primary hypertension
(2) Secondary hypertension
(3) White-coat hypertension
(4) Masked hypertension
B. Gestational hypertension
Hypertension which develops after 20 weeks gestation and usually resolves within 6 weeks post-partum.
Transient gestational hypertension
Usually detected in the clinic but then settles with repeated BP measurements taken over several hours; associated with a 40% risk of developing true gestational
hypertension or pre-eclampsia in the remainder of the pregnancy, thus requiring careful follow-up.
C. Pre-eclampsia
Gestational hypertension accompanied by one or more of the following new-onset conditions at or after 20 weeks gestation:
• Proteinuria [urinary albumin excretion in a 24 h urine sample >0.3 g/day or UACR in a random spot urine sample >30 mg/mmol (0.3 mg/mg)]
• Other maternal organ dysfunction including:
• Acute kidney injury (serum creatinine ≥90 μmol/L; 1 mg/dL)
• Liver dysfunction (elevated ALT or AST >40 IU/L; >0.67 μkat/L with or without right upper quadrant or epigastric abdominal pain)
• Neurological complications (e.g. eclampsia/convulsions, altered mental status, blindness, stroke, clonus, severe headaches, persistent visual scotomata)
• Haematological complications (platelet count <150 000/μL, disseminated intravascular coagulation, haemolysis)
• Uteroplacental dysfunction (IUGR, abnormal umbilical artery Doppler waveform analysis, or stillbirth).
D. Pre-existing hypertension + superimposed pre-eclampsia
Pre-existing hypertension associated with any of the above maternal organ dysfunctions consistent with pre-eclampsia or a further increase in BP with new-onset
proteinuria.
E. Antenatally unclassifiable hypertension
When BP is first recorded after 20 weeks gestation and hypertension is diagnosed, reassessment is necessary at or after 6 weeks post-partum. If hypertension
resolves, it should be reclassified as gestational hypertension, whereas if hypertension persists, it should be reclassified as pre-existing/chronic hypertension.
Based on Mancia et al.584 and McEvoy et al.585
ALT, alanine transaminase; AST, aspartate aminotransferase; BP, blood pressure; IUGR, intrauterine growth restriction; UACR, urine albumin–creatinine ratio.
5202CSE©
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4517
The foetus is at high risk of IUGR prematurity, and intrauterine death useful in the management of high-risk pregnant women with hyperten-
(25%, 27%, and 4%, respectively, in cases of pre-eclampsia).589 sion and those with diabetic or hypertensive nephropathy.593,594 Either
home BP monitoring or office BP measurements may be used alterna-
tively or complementarily to diagnose hypertensive disorders during
12.3.1. Definition and classification of hypertension in pregnancy in women at risk of pre-eclampsia.
pregnancy However, among pregnant women with pre-existing or gestational
Hypertension in pregnancy is typically defined as systolic blood pres- hypertension, home BP monitoring is not associated with better BP
sure (BP) of ≥140 mmHg and/or diastolic BP of ≥90 mmHg,585 control compared with scheduled office BP measurements.584,595,596
measured using repeated BP readings in the office or hospital on Either can be used for BP monitoring.595,596
two separate occasions or ≥15 min apart in severe hypertension
(≥160/110 mmHg).584,590
12.3.2.2. Laboratory tests
Basic laboratory investigations recommended for monitoring hyperten-
sive disorders of pregnancy include urinalysis, blood count, haemato-
12.3.1.1. Pre-eclampsia/eclampsia
crit, liver enzymes, serum creatinine, and serum uric acid. All
Pre-eclampsia is defined as gestational hypertension complicated by
pregnant women should be assessed for proteinuria in early pregnancy
new onset of the laboratory or clinical changes reported in Table 14
to detect pre-existing renal disease and, in the second half of pregnancy,
at or after 20 weeks. Eclampsia is defined as the new onset of seizures to screen for pre-eclampsia.43
or coma in a pregnant woman with pre-eclampsia.584,585
In addition to basic laboratory tests, the following investigations may
The combination of haemolysis, thrombocytopenia, and elevated
be considered:
transaminases defines HELLP syndrome, which is usually considered
to be a variant of pre-eclampsia.43 Risk factors for pre-eclampsia are de- • Ultrasound of the adrenals, and plasma and urinary fractionated me-
scribed in Table 15. tanephrine assays.
• Doppler ultrasound of uterine arteries (after 20 weeks of gestation).597
• A ratio of soluble fms-like tyrosine kinase-1 (sFlt-1) to placental
Table 15 Risk factors for pre-eclampsia growth factor (PlGF) of <38 can be used to reliably exclude the de-
velopment of pre-eclampsia over the next 7 days when clinically
High risk factors for pre-eclampsia suspected.43,598
Hypertensive disorders during a previous pregnancy
If women with chronic hypertension are suspected of developing
Chronic hypertension
pre-eclampsia, testing for PlGF may help rule out pre-eclampsia be-
Chronic kidney disease tween 20 and 36 weeks.599,600
Type 1 or type 2 diabetes mellitus
Autoimmune diseases such as systemic lupus erythematosus or
12.3.3. Management of hypertension in pregnancy
antiphospholipid syndrome
Management of hypertension in pregnancy depends on the woman’s
Assisted reproductive therapy in the current pregnancy
BP and gestational age, and the presence of associated maternal and foe-
Moderate risk factors for pre-eclampsia tal risk factors.601,602 In pregnant women with BP >160/110 mmHg, hos-
Nulliparity pital admission is recommended603 (Figure 12A). If BP is ≥140–159/90–
Age ≥40 years 99 mmHg, BP control is mandatory with a BP target of <140/90 mmHg.
Pregnancy interval of more than 10 years In two large trials,583,604 tight diastolic BP control (<85–90 mmHg) in
BMI ≥35 kg/m2 at the first visit women with pre-existing hypertension was superior to less tight dia-
Family history of pre-eclampsia stolic BP control (<100–105 mmHg) and caused no harm.
Multi-foetal pregnancy In pregnant women with diagnosed hypertension, blood tests, clinical
examination, and assessment of proteinuria are mandatory and should
Based on Mancia et al.584 and McEvoy et al.585 be repeated regularly.599 If a urine dipstick is positive or borderline for
BMI, body mass index.
proteinuria, and symptoms and laboratory tests (including biomarker
assessment) are indicative of pre-eclampsia, the diagnosis of pre-
12.3.2. Diagnosis and risk assessment eclampsia can be made and hospital admission is recommended where
there are clinical concerns.599
12.3.2.1. Blood pressure measurement
Maternal BP should be assessed at each encounter and should be measured
in the sitting position (or the left lateral recumbent position during labour) 12.3.3.1. Non-pharmacological management
with an appropriately sized arm cuff at heart level and using Korotkoff V for Pregnant women with hypertension should be advised to follow a
diastolic BP. Mercury sphygmomanometers remain the gold standard for BP healthy lifestyle including physical activity, smoking cessation, a healthy
measurement in pregnancy as automatic devices tend to under-record BP diet, and control of body weight. Lifestyle changes before and during
and are unreliable in severe pre-eclampsia. Only automatic devices specific- pregnancy may ameliorate both maternal and foetal risks.605 Salt re-
ally validated for pregnancy should be used.584,591 striction is not advised to reduce hypertensive disorders during preg-
The diagnosis of hypertension in pregnancy by ambulatory BP mon- nancy, but it is reasonable for women with pre-existing hypertension
itoring is superior to office BP measurements or home BP monitoring to continue with a low sodium diet.584 Unless contraindicated, aerobic
for the prediction of pregnancy outcomes.584,592 Ambulatory BP mon- exercise should be recommended in pregnant women with hyperten-
itoring avoids unnecessary treatment of white-coat hypertension, and is sion to maintain ideal body weight and reduce adverse pregnancy
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

4518 E S C G u id e l in e s
outcomes.606 Obese women are advised to avoid an increase in weight 12.3.3.2.2. Pre-eclampsia. Pre-eclampsia may require hospital admis-
of more than ∼7 kg from pre-conception.601 sion, but not all women will require ongoing hospitalization and care
Calcium supplements are recommended for the prevention of pre- should be individualized (Figure 12B and Figure 12C). Women with
eclampsia in women with a low dietary intake of calcium (<600 mg/ at least one high-risk factor or two moderate-risk factors for pre-
day),607 where low-dose calcium supplementation (<1 g/day) has eclampsia (Table 15) should be advised to take 75–150 mg aspirin daily
been shown to be as effective as high-dose (≥1 g/day).608 at bedtime from week 12 to week 36/37.599,610 We advise discontinu-
ation of low-dose aspirin at week 36/37 when the aspirin indication is
12.3.3.2. Pharmacological treatment pre-eclampsia.
12.3.3.2.1. Mild hypertension (BP 140/90 – 159/109 mmHg). In Pre-eclampsia with severe features (severe hypertension with or
mild gestational hypertension it seems reasonable to initiate treatment without proteinuria, any hypertension grade with neurological, haem-
at BP values of 140/90 mmHg,583,609 whereas a diastolic BP reduction atological, or cardiovascular complications, liver dysfunction, or renal
to <80 mmHg is not recommended. dysfunction) should be managed with a magnesium sulfate infusion
Methyldopa, beta-blockers (most data are available for labetalol), to prevent eclampsia, in addition to early delivery.43,611 Magnesium
and dihydropyridine CCBs (most data are available for nifedipine) toxicity can present with cardiac effects, including ECG interval
are the drugs of choice for mild gestational and pre-existing changes (prolonged PR, QRS, and QT intervals) at magnesium levels
hypertension.584 of 2.5–5 mmol/L, and can progress to atrioventricular (AV) nodal con-
ACE-Is, ARBs, and direct renin inhibitors are strictly contraindicated. duction block, bradycardia, hypotension, and cardiac arrest at levels of
Diuretics are not advised in gestational hypertension and pre-eclampsia, 6–10 mmol/L. If magnesium toxicity is suspected, it is recommended
due to the reduction of intravascular volume and reduction of uteropla- to stop the magnesium infusion and give 30 mL i.v. calcium gluco-
cental perfusion and thereby possible foetal adverse effects.
nate.612–614
Management of pregnant women with hypertension
BP 140/90 to 159/109 mmHg BP ≥160/≥110 mmHg
Admission to hospital
Do not admit routinely
(Class I)
Proteinuria or maternal organ dysfunction or
uteroplacental dysfunctiona
Pre-eclampsia
Evaluate level of care
Aim for BP <140/90 mmHg
(Class I)
Regular monitoringb
Figure 12A Management of hypertension and pre-eclampsia in the emergency ward. BP, blood pressure; N, no; Y, yes.
a See Figure 12B.
b See Figure 12C.
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4519
Hypertension (BP ≥140/90 mmHg)
Evaluate
Proteinuria
Albumin/creatinine Protein/creatinine
OR
ratio ≥8 mg/mmol ratio ≥30 mg/mmol
OR
One or more clinical features of pre-eclampsia
Symptoms Laboratory
• Headache • Haemolysis
• Vision problems • Deterioration of renal
• Breathing problems function
• Severe pain below • Abnormal liver tests
the ribs • Falling platelet count
• Vomiting
• Oedema
• Trouble urinating
OR
Uteroplacental dysfunction (foetal growth restriction,
abnormal umbilical artery Doppler waveform analysis,
or stillbirth)
Biomarker
Inconclusive
sFlt-1/PIGF ≥85
Positive or PIGF <12 pg/mL
Positive
Pre-eclampsia diagnosed
Figure 12B Proteinuria assessment and diagnosis of pre-eclampsia. BP, blood pressure; PlGF, placental growth factor; sFLt-1, soluble fms-like tyrosine
kinase-1.
Downloaded
from

by
guest
on
22
January
2026

4520 E S C G u id e l in e s
Monitoring and treatment of hypertension and pre-eclampsia
Monitoring
Hypertension Pre-eclampsia
BP 140/90−159/109 BP ≥160/110 BP 140/90−159/109 BP ≥160/110
mmHg mmHg mmHg mmHg
BP monitoring schedule
At least every 48 h
Once or twice Every Every
(more frequently
a week 15−30 min 15−30 min
if admitted)
Screening for proteinuria
Once or twice
Daily Only repeat if clinically indicated
a week
Blood tests: full blood count, liver function, renal function
Once a week
Offer PIGF-based testing once, Twice a week 3 times a week
if pre-eclampsia is suspected
Treatment
i.v. labetalol, i.v. nicardipine,
p.o. labetalola or metoprololb i.v. urapidil, i.v. Mg++
(Class I)
(Class I)
p.o. methyldopac p.o. nifedipined
(Class I) (Class I)
Figure 12C Monitoring and treatment of hypertension and pre-eclampsia. Mg, magnesium; PlGF, placental growth factor; p.o., per oral.
aLabetalol 100 mg p.o. b.i.d. bMetoprolol 100 mg p.o. b.i.d. cMethyldopa 250 mg p.o. b.i.d./t.i.d. dNifedipine 5–10 mg p.o. 10 mg p.o. if >160/110 mmHg.
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4521
12.3.3.2.3. Severe hypertension (BP ≥160/110 mmHg). In severe increasing every 3–5 min to a maximum dose of 100 μg/min, in com-
hypertension, assessment and gradual BP reduction to <160/ bination with diuretics.43,611
110 mmHg is mandatory in a hospital setting. Continuous cardiotoco-
graphic monitoring is also compulsory. The selection of antihyperten-
12.3.4. Hypertension and delivery
sive drugs and the route of administration depend on initial diagnosis,
expected delivery time, presence or absence of pre-eclampsia, and A recent randomized controlled trial from the United Kingdom found
the preferences and experience of the attending physicians.43,611 that once a diagnosis of pre-eclampsia was made in women with late
pre-term pre-eclampsia (34–37 weeks), there was a lower rate of ma-
Recent comprehensive meta-analyses comparing commonly used anti-
ternal morbidity and less severe maternal hypertension when delivery
hypertensive drugs (e.g. oral nifedipine, labetalol, methyldopa)
was planned to occur within the next 48 h.620 However, a greater pro-
(Figure 12C) showed they had similar efficacy in lowering BP in severe
portion of neonates were admitted to the neonatal intensive care unit
hypertension in pregnancy, with nifedipine showing superiority in some
compared to mothers who were managed from an earlier stage.
studies (see Section 5.2.6).43,253,254,611,615 Nifedipine also has the advan-
Decisions around timing of delivery should be individualized considering
tage of wider distribution, availability, and lower pricing. Available data
both maternal and foetal well-being. If well managed hypertension
showed that hydralazine is less effective than other drugs and is asso-
alone, delivery should be planned around 39 weeks of gestation.
ciated with more side effects.616 Hydralazine is therefore a second-line
When choosing the mode of delivery, the clinical scenario should
option to be used only if other drugs are not available.
take into consideration the current gestational age and a full foetal as-
In cases of pre-eclampsia with severe features, persistent severe
sessment, as well as the preference of the mother. If induction of la-
hypertension, or recurrent severe hypertension despite orally admi-
bour is to be considered, continuous foetal monitoring is required.
nistered agents, i.v. administration of labetalol (or nicardipine) is ad-
Women with severe pre-eclampsia benefit from neuraxial anaesthesia
vised. Intravenous urapidil can also be used but may not be available to reduce the hypertensive response to pain. Additionally, an epidural
in all countries.611,617,618 Sodium nitroprusside is the drug of last re- will provide adequate anaesthesia should a caesarean delivery be
sort because prolonged treatment is associated with an increased required.
risk of foetal cyanide poisoning.619 The drug of choice when After delivery, methyldopa should be avoided due to the risk of
pre-eclampsia is associated with pulmonary oedema is nitroglycerine post-partum depression. Methyldopa should be stopped within 2
(glyceryl trinitrate), given as an i.v. infusion of 5 μg/min, gradually days after delivery and changed to an alternative treatment.
Recommendation Table 13 — Recommendations for hypertensive disorders and pregnancy (see Evidence Tables
12–17)
Recommendations Classa Levelb
It is recommended to aim for systolic BP <140 mmHg and diastolic BP <90 mmHg in pregnant women.583,585,609 I B
Systolic BP ≥160 mmHg or diastolic BP ≥110 mmHg in a pregnant woman is an emergency, and treatment in a hospital setting is
I C
recommended.43,584
Low-dose aspirin (75–150 mg daily) is recommended in women at moderate or high risk of pre-eclampsia (i.e. at least one high-risk factor or
I A
two moderate-risk factors for pre-eclampsia) from weeks 12 to 36/37.610,621,622
In women with gestational hypertension, initiation of drug treatment is recommended at systolic BP ≥140 mmHg or diastolic BP
I B
≥90 mmHg.c583–585,609
Methyldopa is recommended for the treatment of hypertension in pregnancy.623,624 I B
Labetalol, metoprolol, and dihydropyridine CCBs are recommended for the treatment of hypertension in pregnancy.623 I C
In severe hypertension, drug treatment with i.v. labetalol, urapidil, nicardipine, or oral short acting nifedipine or methyldopa is
I C
recommended for acute reduction in blood pressure.625,626 Intravenous hydralazine is a second-line option.
In pre-eclampsia associated with pulmonary oedema, nitroglycerine given as an i.v. infusion is recommended.627 I C
In women with pre-eclampsia without severe features, delivery is recommended at 37 weeks.620,628 I B
It is recommended to expedite delivery in women with pre-eclampsia associated with adverse markers such as haemostatic disorders.629 I C
In women with gestational hypertension, delivery is recommended at 39 weeks.620,628 I B
Ambulatory BP or home BP monitoring should be considered to exclude white-coat and masked hypertension, which are common in
IIa C
pregnancy.
Home BP monitoring may be considered as an adjunct to office BP measurements in pregnant women to detect new-onset hypertension or
IIb B
for monitoring BP control.595,596
BP, blood pressure; CCB, calcium channel blocker; i.v, intravenous.
aClass of recommendation.
bLevel of evidence.
cOffice BP measurements.
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

4522 E S C G u id e l in e s
(cid:3)(cid:26)(cid:26)(cid:10)(cid:12)(cid:27)(cid:10)(cid:9)(cid:20)(cid:25)(cid:28)(cid:17)(cid:20)(cid:19)(cid:17)(cid:8)(cid:26)(cid:24)(cid:18)(cid:19)(cid:25)(cid:19)(cid:16)(cid:12)
(cid:23)(cid:26)(cid:24)(cid:18)(cid:19)(cid:25)(cid:19)(cid:16)(cid:12)(cid:22)(cid:26)(cid:24)(cid:11)(cid:25)(cid:27)(cid:24)(cid:14)(cid:17)(cid:16)(cid:10)(cid:25)(cid:19)(cid:18)(cid:24)(cid:28)
(cid:23)(cid:26)(cid:24)(cid:22)(cid:24)(cid:21)(cid:20)(cid:28)(cid:27)(cid:20)(cid:19)(cid:18)(cid:17)(cid:16)(cid:15)(cid:19)(cid:14)(cid:20)(cid:27)(cid:20)(cid:15)(cid:19)(cid:28)
(cid:20)(cid:19)(cid:17)(cid:27)(cid:26)(cid:20)(cid:18)(cid:18)(cid:24)(cid:26)(cid:28)(cid:17)(cid:25)(cid:19)(cid:14)(cid:17)(cid:9)(cid:15)(cid:14)(cid:30)(cid:11)(cid:25)(cid:27)(cid:15)(cid:26)(cid:28)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:27)(cid:24)(cid:28) (cid:143)(cid:11)(cid:24)(cid:16)(cid:27)(cid:26)(cid:20)(cid:16)(cid:25)(cid:11)
(cid:13)(cid:15)(cid:26)(cid:15)(cid:19)(cid:25)(cid:26)(cid:12)(cid:17)(cid:25)(cid:26)(cid:27)(cid:24)(cid:26)(cid:12)(cid:17)(cid:14)(cid:20)(cid:28)(cid:24)(cid:25)(cid:28)(cid:24) (cid:1)(cid:24)(cid:25)(cid:26)(cid:27)(cid:17)(cid:26)(cid:25)(cid:27)(cid:24)
(cid:13)(cid:15)(cid:19)(cid:18)(cid:24)(cid:19)(cid:20)(cid:27)(cid:25)(cid:11)(cid:17)(cid:10)(cid:24)(cid:25)(cid:26)(cid:27)(cid:17)(cid:14)(cid:20)(cid:28)(cid:24)(cid:25)(cid:28)(cid:24) (cid:3)(cid:30)(cid:27)(cid:15)(cid:9)(cid:25)(cid:27)(cid:20)(cid:28)(cid:9)
(cid:13)(cid:25)(cid:26)(cid:14)(cid:20)(cid:15)(cid:9)(cid:12)(cid:15)(cid:8)(cid:25)(cid:27)(cid:10)(cid:20)(cid:24)(cid:28) (cid:143)(cid:16)(cid:27)(cid:15)(cid:8)(cid:20)(cid:16)(cid:17)(cid:25)(cid:16)(cid:27)(cid:20)(cid:6)(cid:20)(cid:27)(cid:12)
(cid:7)(cid:25)(cid:11)(cid:6)(cid:30)(cid:11)(cid:25)(cid:26)(cid:17)(cid:10)(cid:24)(cid:25)(cid:26)(cid:27)(cid:17)(cid:14)(cid:20)(cid:28)(cid:24)(cid:25)(cid:28)(cid:24)
(cid:13)(cid:10)(cid:25)(cid:19)(cid:19)(cid:24)(cid:11)(cid:15)(cid:8)(cid:25)(cid:27)(cid:10)(cid:20)(cid:24)(cid:28)
(cid:1)(cid:15)(cid:26)(cid:9)(cid:15)(cid:19)(cid:25)(cid:11)
(cid:2)(cid:24)(cid:28)(cid:27)(cid:26)(cid:15)(cid:18)(cid:24)(cid:19)(cid:28)
(cid:1)(cid:25)(cid:24)(cid:9)(cid:15)(cid:14)(cid:12)(cid:19)(cid:25)(cid:9)(cid:20)(cid:16)
(cid:13)(cid:7)(cid:17)(cid:26)(cid:20)(cid:28)(cid:5)(cid:17)(cid:4)(cid:25)(cid:16)(cid:27)(cid:15)(cid:26)(cid:28)
(cid:13)(cid:25)(cid:26)(cid:14)(cid:20)(cid:25)(cid:16)(cid:17)(cid:15)(cid:30)(cid:27)(cid:8)(cid:30)(cid:27)
(cid:3)(cid:18)(cid:24)(cid:20)(cid:19)(cid:18)
(cid:7)(cid:24)(cid:19)(cid:27)(cid:26)(cid:20)(cid:16)(cid:30)(cid:11)(cid:25)(cid:26)(cid:17)(cid:24)(cid:19)(cid:14)(cid:22)(cid:14)(cid:20)(cid:25)(cid:28)(cid:27)(cid:15)(cid:11)(cid:20)(cid:16)(cid:17)(cid:6)(cid:15)(cid:11)(cid:30)(cid:9)(cid:24)
(cid:2)(cid:29)(cid:24)(cid:28)(cid:20)(cid:27)(cid:12)
(cid:13)(cid:25)(cid:26)(cid:14)(cid:20)(cid:25)(cid:16)(cid:17)(cid:129)(cid:25)(cid:11)(cid:11)(cid:17)(cid:28)(cid:27)(cid:26)(cid:24)(cid:28)(cid:28)
(cid:1)(cid:12)(cid:8)(cid:24)(cid:26)(cid:27)(cid:24)(cid:19)(cid:28)(cid:20)(cid:15)(cid:19)
(cid:3)(cid:27)(cid:26)(cid:20)(cid:25)(cid:11)(cid:17)(cid:28)(cid:20)(cid:141)(cid:24)
(cid:127)(cid:20)(cid:25)(cid:29)(cid:24)(cid:27)(cid:24)(cid:28)
(cid:3)(cid:30)(cid:27)(cid:15)(cid:19)(cid:15)(cid:9)(cid:20)(cid:16)
(cid:23)(cid:11)(cid:25)(cid:28)(cid:9)(cid:25)(cid:17)(cid:16)(cid:25)(cid:27)(cid:24)(cid:16)(cid:10)(cid:15)(cid:11)(cid:25)(cid:9)(cid:20)(cid:19)(cid:24)
(cid:16)(cid:15)(cid:19)(cid:16)(cid:24)(cid:19)(cid:27)(cid:26)(cid:25)(cid:27)(cid:20)(cid:15)(cid:19)(cid:28)
(cid:157)(cid:24)(cid:27)(cid:25)(cid:29)(cid:15)(cid:11)(cid:20)(cid:16)
(cid:144)(cid:10)(cid:12)(cid:26)(cid:15)(cid:27)(cid:15)(cid:21)(cid:20)(cid:16)(cid:15)(cid:28)(cid:20)(cid:28)
(cid:143)(cid:11)(cid:24)(cid:16)(cid:27)(cid:26)(cid:15)(cid:11)(cid:12)(cid:27)(cid:24)(cid:17)(cid:16)(cid:10)(cid:25)(cid:19)(cid:18)(cid:24)(cid:28)
Figure 13 Arrhythmogenesis in pregnant women. CV; cardiovascular.
12.4. Arrhythmias 12.4.1. Supraventricular arrhythmias
12.4.1.1. New-onset narrow QRS tachycardia
The number of pregnant women presenting with arrhythmia is rising
due to increasing age at pregnancy and cardiovascular risk factors New-onset narrow QRS (<120 ms) tachycardias in pregnancy are
such as obesity, hypertension, diabetes, and CAD in pregnant wo- treated according to haemodynamic stability. In all cases with
men.630 Haemodynamic, metabolic, and hormonal changes, and haemodynamic instability caused by any supraventricular tachycardia
changes in autonomic function may contribute to increased arrhythmo- (SVT) including AF and AFL, synchronized, direct current cardiover-
genesis during pregnancy and women with prior history of arrhythmia sion is indicated (Figure 14).631 The foetal heart rate should be closely
may experience worsening of symptoms during pregnancy monitored after cardioversion.632 In haemodynamically stable nar-
(Figure 13).630 Arrhythmia may have serious effects on the health of row QRS tachycardias, the use of vagal manoeuvres (modified
both the mother and the foetus and should be treated similarly to ar- Valsalva manoeuvre, carotid sinus massage) may terminate an atrio-
rhythmias in non-pregnant women. ventricular (nodal) re-entry tachycardia (AV(N)RT) arrhythmia.633
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4523
Management of narrow QRS tachycardia in pregnant women
Haemodynamically
Haemodynamically stable SVT
unstable SVT
Vagal manoeuvres:
Electrical cardioversion Valsalva manoeuvre, i.v. adenosinea
(Class I) carotid sinus massage (Class I)
(Class I)
Pad position:
If sinus rhythm
sterno-apical/
not achieved
antero-posterior
Avoid breast tissue
i.v. beta-blockersb
i.v. verapamild
Foetal heart rate e.g. metoprololc OR
(Class IIa)
monitoring (Class I)
Figure 14 Management of narrow QRS tachycardia in pregnant women. i.v., intravenous; SVT, supraventricular tachycardia. aAdenosine 6–18 mg bolus.
bAtenolol contraindicated. cMetoprolol 2.5–15 mg. dVerapamil 2.5–10 mg bolus over 5 min.
If these manoeuvres fail, i.v. adenosine (6–18 mg bolus) is recom- Rapid atrioventricular conduction of AF may have serious haemo-
mended for termination of AV(N)RT. Intravenous beta-1-selective dynamic consequences for both mother and foetus. Atrial fibrillation
blockers (preferably metoprolol) can be administered for all SVTs, during pregnancy is associated with increased maternal death.639
which either terminate the SVT or slow AV conduction and thereby Atrial flutter in pregnant women most often occurs in the presence
the ventricular rate.634 Intravenous beta-1-selective blockers (meto- of ACHD or valvular heart disease (VHD) and in metabolic distur-
prolol), non-dihydropyridine CCBs (verapamil), and digoxin can be bances such as thyrotoxicosis or electrolyte disturbances.
used safely.635 In stable patients without structural heart disease, fle- Direct current cardioversion in pregnancy is required in haemo-
cainide and ibutilide may be considered for termination of AF and dynamically unstable patients with monitoring of foetal heart rate
AFL (Figure 15). In patients with congenital disease, synchronized, (Figure 15).250,268,271 Rhythm control is the preferred AF treatment
direct current cardioversion may be preferred. strategy during pregnancy. For women with structurally normal hearts,
anti-arrhythmic drugs (e.g. flecainide and sotalol, see Section 5.2.5) are
12.4.1.2. Atrial fibrillation including anticoagulation not associated with foetal harm, although sotalol’s beta-blocker effect
The incidence of arrhythmias among pregnant women is increasing, necessitates monitoring of foetal growth.250,268,271 There are minimal
with AF being the most clinically relevant.252,271,636 Atrial enlargement data on the use of propafenone during pregnancy, but this sodium chan-
during pregnancy is accompanied by increased atrial function and both nel blocker may be considered if flecainide is not available. Intravenous
size and function of the LA reverse after normal pregnancy.637 Atrial ibutilide or flecainide may be considered for termination of AFL and AF
fibrillation is more frequent in pregnant women at older age, with in haemodynamically stable patients.640
high BMI638, with ACHD, or with predisposing acquired conditions The indication for anticoagulation with LMWH before cardioversion
(e.g. hypertension, HF).637 Compared to women <25 years of age, or the need for transoesophageal echocardiography should be evalu-
the odds ratio (OR) of AF episodes was 5.2 in women aged ≥40, and ated as in non-pregnant women and be maintained for at least 4 weeks
the OR was higher in the third compared to the first trimester.638 after cardioversion.636,641
Downloaded
from

by
guest
on
22
January
2026

4524 E S C G u id e l in e s
Management of atrial fibrillation and atrial flutter in pregnant women
Haemodynamically AF/AFL with pre-excitation Haemodynamically
unstable AF/AFL and high ventricular rates stable AF/AFL
Electrical cardioversion Severe structural
(Class I) heart disease
Pharmacological
Acute rate control
cardioversion
i.v.
i.v.
beta-blockersa i.v. flecainidee
OR verapamilc
e.g. metoprololb (Class IIb)
(Class IIa)
(Class I)
OR
i.v. digoxind Avoid amiodarone or i.v. ibutilidef
(Class IIa) dronedarone (Class IIb)
Figure 15 Management of atrial fibrillation and atrial flutter in pregnancy. AF, atrial fibrillation; AFL, atrial flutter; i.v., intravenous; N, no; SVT, supraven-
tricular tachycardia; Y, yes. aAtenolol: contraindicated. bMetoprolol: 2.5–15 mg. cVerapamil: 2.5–10 mg bolus over 5 min. dDigoxin: 0.5 mg bolus, 0.75–1.5 mg
over 24 h in divided doses. eFlecainide: 2 mg/kg over 10 min. fIbutilide: <60 kg: 0.01 mg/kg over 10 min, repeated after 10 min if necessary; ≥60 kg: 1 mg over
10 min, repeated after 10 min if necessary.
When a rate control strategy is needed in the case of (long-standing) pregnancy.643,644 DOACs are contraindicated in pregnancy. The pres-
persistent or permanent AF, beta-blockers, verapamil, or digoxin ence of mechanical valves or moderate to severe mitral stenosis require
should be used, also in combination, taking into consideration the con- VKA (see Section 5.2.1 and Section 12.5).
comitant conditions affecting the mother.271,642
Atrial fibrillation is a strong risk factor for cardioembolic events,
and the hypercoagulable state of pregnancy may increase this risk. In 12.4.1.3. Pre-existing supraventricular tachycardia
pregnant women with persistent or permanent AF, the decision to an- In women with AVNRT, atrioventricular re-entry tachycardia (AVRT),
ticoagulate is the same as in non-pregnant women and depends on the and focal atrial tachycardia (FAT), chronic oral prophylaxis can be
risk of thromboembolic events according to the CHA DS -VA score achieved with beta-blockers (metoprolol) or verapamil. For women
2 2
[congestive heart failure, hypertension, age ≥75 (doubled), diabetes, with drug-refractory SVT or who have a contraindication to these
stroke (doubled), vascular disease, age 65–74].643 The CHA DS -VA drugs, flecainide or sotalol are reasonable alternatives, as is propafe-
2 2
score threshold of ≥2 to anticoagulate has not been validated in none if flecainide is not available.
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4525
In pregnant women with AVRT and Wolff–Parkinson–White (WPW) mented AF, with known orthodromic AVRT, and with intermittent
syndrome, arrhythmia episodes can be prevented by using oral flecainide, pre-excitation, long-term AV blockade is acceptable for prevention.
or propafenone when flecainide is not available. When AV-nodal blocking If catheter ablation treatment is necessary, it should be performed by
agents are used in WPW syndrome and AF occurs, the risk of rapid ven- experienced operators in a centre equipped with non-fluoroscopic
tricular rates is increased. However, in pregnant women without docu- mapping techniques (Section 12.4.3.2).
Recommendation Table 14 — Recommendations for supraventricular tachycardia and pregnancy
Acute management of SVT and AF Classa Levelb
Immediate electrical cardioversion is recommended for acute treatment of SVT with haemodynamic instability. I C
Vagal manoeuvres and i.v. adenosine are recommended for conversion of haemodynamically stable supraventricular tachycardias.645 I C
Intravenous beta-blockersc (e.g. metoprolol) are recommended as the first-line option for acute rate control in pregnant women with AF or
I C
AF with preserved LVEF and rapid ventricular rate.646
Intravenous digoxin or verapamil (if preserved LVEF) should be considered as a second-line option for initial rate control in pregnant
IIa C
women with AF or AFL and rapid ventricular rate.635
Ibutilide or flecainide may be considered for termination of AF and AFL in pregnant women without structural heart disease.640,647 IIb C
Long-term management of SVT and AF
Therapeutic anticoagulation with LMWH is recommended for pregnant women with persistent or permanent AF at elevated
I C
thromboembolic risk.636,641
Beta-1-selective blockersc are recommended for rate control in pregnant women with AF, AFL, or FAT.146,271,648 I C
Beta-1-selective blockersc or verapamil are recommended for the prevention of SVT in women without pre-excitation on resting
I C
ECG.146,268,649
Flecainide or propafenone are recommended for the prevention of arrhythmias in pregnant women with WPW syndrome.650 I C
Digoxin or verapamil should be considered for rate control in pregnant women with AF, AFL, or FAT when beta-blockers fail or are not
IIa C
tolerated.146,271,645
Flecainide, in addition to beta-blockers, should be considered for long-term AF rhythm control in pregnancy.250,268,271,640 IIa C
Sotalol may be considered for rhythm management of AF and AFL with controlling for pro-arrhythmic risk factors as in non-pregnant
IIb C
women.651
Catheter ablation may be considered in pregnant women with recurrent, long symptomatic SVT, or with contraindications to
IIb C
pharmacological therapies.
AF, atrial fibrillation; AFL, atrial flutter; ECG, electrocardiogram; FAT, focal atrial tachycardia; i.v., intravenous; LMWH, low-molecular-weight heparin; LVEF, left ventricular ejection fraction;
SVT, supraventricular tachycardia; WPW, Wolff–Parkinson–White.
aClass of recommendation.
bLevel of evidence.
cExcept for atenolol.
12.4.2. Ventricular arrhythmias Recommendations on the acute management of ventricular arrhyth-
New-onset VT and ventricular fibrillation (VF) arising during pregnancy mias during pregnancy are described in the 2022 ESC Guidelines for the
are rare (18 per 100 000 pregnancy-related hospitalizations).652 The management of patients with ventricular arrhythmias and the preven-
most common type of VT in pregnant women is idiopathic VT originating tion of sudden cardiac death, and are depicted in Figure 16.252
from the right ventricular outflow tract (RVOT) (Figure 16). When new-
onset VT develops during the last 6 weeks of pregnancy or during the first 12.4.3. Cardioversion, ablation, and device
month post-partum, underlying PPCM should be excluded.370 implantation, and implantable cardioverter
The use of amiodarone is not recommended in pregnancy and defibrillator management
should be limited to women with refractory or life-threatening arrhyth-
12.4.3.1. Electrical cardioversion
mias that cannot be controlled with any other anti-arrhythmic therapy.
Electrical cardioversion is safe and effective in all pregnancy phases as it
If administered, it requires close monitoring for potential side effects in
does not affect foetal circulation or induce foetal arrhythmia. In preg-
the foetus, such as bradycardia or IUGR.
nancy there are no changes in transthoracic impedance compared to
In women with known underlying substrates for VT, beta-blockers
non-pregnant women,660 and shock energies delivered should there-
are recommended for prevention of VT.148,252 In case of refractoriness
fore be the same as in non-pregnant patients. The foetal heart rate
or contraindications to beta-blockers, anti-arrhythmic therapy with fle-
should be monitored after cardioversion.631,632,661,662
cainide, sotalol, or quinidine is recommended, with the choice of drug
based on the underlying cardiac substrate (Figure 16).148,252 Idiopathic
RVOT-VT can be prevented with beta-blockers or verapamil.653 12.4.3.2. Catheter ablation
When this is ineffective, flecainide654 or sotalol650,655–659 are safe op- Catheter ablation in pregnant women should preferably be performed
tions to consider for prophylaxis of idiopathic RVOT-VT. after the first trimester in a centre with experience in non-fluoroscopic
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

4526 E S C G u id e l in e s
electro-anatomical mapping and catheter navigation systems.663–665 12.4.3.3. Device implantation
Catheter ablation for drug-refractory and poorly tolerated VT or for An ICD is indicated in pregnant women who are at high risk of sudden
recurrent drug-refractory AVNRT, AVRT, FAT, cavotricuspid isthmus- cardiac death.252 Implantation of a device is not associated with a high-
dependent AFL, and certain benign right-sided VTs may be considered er risk of major complications and can be performed safely,667,668 par-
to avoid potentially harmful anti-arrhythmic drug effects during preg- ticularly after 8 weeks of gestation. During implantation, radiation
nancy, although it has no role in AF.664,666 exposure should be minimized following the ALARA principle (see
Management of ventricular tachycardia in pregnancy
Electrical cardioversion
(Class I)
Pharmacological acute conversion and/or management of recurrent VT/VF
Unknown/ i.v. beta-blockers
other aetiology (routine usage)
Structural heart i.v. beta-blockers i.v. procainamide
disease (routine usage) (Class IIa)
Idiopathic i.v. beta-blockers i.v adenosine
RVOT-VT (Class IIa) (Class IIa)
i.v verapamil
Fascicular VT
(Class IIa)
CPVT i.v. beta-blockers
(Class I)
Long QT or Remove i.v. beta-blockers i.v. Mg++/K+
Torsade de precipitating (e.g. propranolol)
Pointes VT factors (Class I) Overdrive
pacing
Brugada p.o. quinidine
i.v. isoproterenol
syndrome (Class IIa)
Idiopathic VF i.v. isoproterenol p.o. quinidine i.v. verapamil
Failure of pharmacologic conversion/control
Figure 16 Management of ventricular tachycardias in pregnancy. CPVT, catecholaminergic polymorphic ventricular tachycardia; i.v., intravenous; N, no;
RVOT, right ventricular outflow tract; VF, ventricular fibrillation; VT, ventricular tachycardia; Y, yes. See Supplementary data online (Table S6) for medication
dosages. Adapted from Zeppenfeld et al.252.
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4527
Section 4.3.5) or with non-fluoroscopic imaging techniques.669 appropriate ICD shock caused by ventricular tachyarrhythmias. In case
Women with an ICD should maintain their regular ICD care through- of tachyarrhythmia, triggering events such as HF, electrolyte abnormal-
out pregnancy.669 ities, ischaemia, or infectious disease should be ruled out, as with non-
pregnant women. Depending on the underlying cause, therapy consists
of device reprogramming or initiating or adapting anti-arrhythmic drug
12.4.3.4. Implantable cardioverter defibrillator management therapy. In the case of drug-refractory arrhythmias or serious anti-
Routine ICD interrogation and guidance are recommended prior to de- arrhythmic drug side effects, catheter ablation may be considered in ex-
livery. Management of pregnant women with an ICD or pacemaker is perienced centres.664
summarized in Figures 17 and 18. Most data indicate that maternal ICD shocks do not have major foe-
Women with structural heart disease are at higher risk of atrial and tal adverse effects.668,671 The approach to pregnant women presenting
ventricular tachyarrhythmias during pregnancy.670 Consequently, preg- with ICD shocks is no different from non-pregnant women
nant women with ICDs may present with either an inappropriate shock (Figure 18).252
(due to e.g. lead defects, new-onset supraventricular tachyarrhythmias, A WCD may be considered when pregnant women have an ICD in-
or technical issues such as T-wave oversensing or noise sensing) or an dication from reversible conditions.365,672–674
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:30)(cid:29)(cid:26)(cid:25)(cid:24)(cid:25)(cid:23)(cid:22)
(cid:21)(cid:20)(cid:29)(cid:19)(cid:19)(cid:31)(cid:30)(cid:29)(cid:26)(cid:25)(cid:24)(cid:25)(cid:23)(cid:22)(cid:19)(cid:18)(cid:29)(cid:24)(cid:30)(cid:17)(cid:19)(cid:21)(cid:29)(cid:24)(cid:16)(cid:19)(cid:15)(cid:25)(cid:23)(cid:14)(cid:13)(cid:12)(cid:15)(cid:25)(cid:26)(cid:19)(cid:24)(cid:25)(cid:19)(cid:29)(cid:14)(cid:29)(cid:23)(cid:17)(cid:30)(cid:11)(cid:27)(cid:20)(cid:22)(cid:10)(cid:15)(cid:11)(cid:14)(cid:11)(cid:26)(cid:15)(cid:10)(cid:17)(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:31)(cid:24)(cid:23)(cid:31)(cid:22)(cid:21)(cid:20)(cid:28)(cid:26)(cid:20)(cid:23)(cid:25)(cid:31)(cid:22)(cid:21)
(cid:19)(cid:18)(cid:23)(cid:19)(cid:17)(cid:18)(cid:22)(cid:21)(cid:16)(cid:31)(cid:19)(cid:18)(cid:23)(cid:16)(cid:21)(cid:17)(cid:21)(cid:15)(cid:14)(cid:31)(cid:17)(cid:21)(cid:25)(cid:31)(cid:25)(cid:23)(cid:26)(cid:22)(cid:20)(cid:23)(cid:18)(cid:14)(cid:31)(cid:28)(cid:13)(cid:31)(cid:17)(cid:31)(cid:12)(cid:28)(cid:11)(cid:17)(cid:21)(cid:31)(cid:12)(cid:22)(cid:10)(cid:29)(cid:31)(cid:17)(cid:31)(cid:19)(cid:17)(cid:15)(cid:23)(cid:11)(cid:17)(cid:9)(cid:23)(cid:18)(cid:31)(cid:28)(cid:18)(cid:31)(cid:8)(cid:7)(cid:6)
(cid:31)(cid:8)(cid:21)(cid:22)(cid:10)(cid:22)(cid:17)(cid:10)(cid:23)(cid:31)(cid:28)(cid:18)(cid:31)(cid:17)(cid:25)(cid:17)(cid:19)(cid:10)(cid:31)(cid:17)(cid:21)(cid:10)(cid:22)(cid:17)(cid:18)(cid:18)(cid:29)(cid:14)(cid:10)(cid:29)(cid:11)(cid:22)(cid:15)(cid:31)(cid:25)(cid:18)(cid:27)(cid:16)(cid:31)(cid:10)(cid:29)(cid:23)(cid:18)(cid:17)(cid:19)(cid:14)
(cid:31)(cid:30)(cid:29)(cid:26)(cid:25)(cid:24)(cid:25)(cid:23)(cid:22)
(cid:1)(cid:7)(cid:24)(cid:14)(cid:13)(cid:24)(cid:17)(cid:29)(cid:19)(cid:8)(cid:13)(cid:25)(cid:23)(cid:17)(cid:15)(cid:11)(cid:25)(cid:19)(cid:11)(cid:8)(cid:19)(cid:27)(cid:24)(cid:23)(cid:29)(cid:16)(cid:24)(cid:5)(cid:29)(cid:30)(cid:143)(cid:3)(cid:6)(cid:2)(cid:127)(cid:19)(cid:24)(cid:17)(cid:10)(cid:10)(cid:23)(cid:18)(cid:14)(cid:31)(cid:30)(cid:10)(cid:17)(cid:10)(cid:27)(cid:30)(cid:3)(cid:31)(cid:30)(cid:23)(cid:21)(cid:30)(cid:22)(cid:21)(cid:16)(cid:3)(cid:31)(cid:19)(cid:17)(cid:15)(cid:22)(cid:21)(cid:16)(cid:31)(cid:17)(cid:21)(cid:25)(cid:31)(cid:22)(cid:11)(cid:19)(cid:23)(cid:25)(cid:17)(cid:21)(cid:15)(cid:23)
(cid:28)(cid:13)(cid:31)(cid:10)(cid:29)(cid:23)(cid:31)(cid:26)(cid:23)(cid:17)(cid:25)(cid:30)(cid:3)(cid:31)(cid:23)(cid:20)(cid:17)(cid:26)(cid:27)(cid:17)(cid:10)(cid:22)(cid:28)(cid:21)(cid:31)(cid:28)(cid:13)(cid:31)(cid:30)(cid:10)(cid:28)(cid:18)(cid:23)(cid:25)(cid:31)(cid:17)(cid:18)(cid:18)(cid:29)(cid:14)(cid:10)(cid:29)(cid:11)(cid:22)(cid:17)(cid:31)(cid:23)(cid:19)(cid:22)(cid:30)(cid:28)(cid:25)(cid:23)(cid:30)
(cid:144)(cid:23)(cid:20)(cid:29)(cid:12)(cid:13)(cid:14)(cid:29)(cid:19)(cid:30)(cid:29)(cid:26)(cid:13)(cid:14)(cid:24)(cid:30)(cid:19)(cid:8)(cid:11)(cid:14)(cid:14)(cid:11)(cid:4)(cid:28)(cid:13)(cid:27)(cid:19)(cid:7)(cid:15)(cid:10)(cid:15)(cid:17)(cid:10)(cid:19)(cid:25)(cid:27)(cid:18)(cid:22)(cid:21)(cid:16)(cid:31)(cid:23)(cid:21)(cid:10)(cid:22)(cid:18)(cid:23)(cid:31)(cid:19)(cid:18)(cid:23)(cid:16)(cid:21)(cid:17)(cid:21)(cid:15)(cid:14)
(cid:9)(cid:12)(cid:16)(cid:15)(cid:10)(cid:10)(cid:15)(cid:11)(cid:25)(cid:19)(cid:8)(cid:11)(cid:30)(cid:19)(cid:12)(cid:29)(cid:14)(cid:15)(cid:7)(cid:29)(cid:30)(cid:22)
(cid:6)(cid:11)(cid:25)(cid:17)(cid:15)(cid:25)(cid:13)(cid:11)(cid:13)(cid:10)(cid:19)(cid:30)(cid:20)(cid:22)(cid:17)(cid:20)(cid:16)(cid:19)(cid:16)(cid:11)(cid:25)(cid:15)(cid:17)(cid:11)(cid:30)(cid:15)(cid:25)(cid:26)(cid:19)(cid:8)(cid:11)(cid:30)(cid:19)(cid:20)(cid:15)(cid:26)(cid:20)(cid:19)(cid:30)(cid:15)(cid:10)(cid:5)(cid:19)(cid:4)(cid:11)(cid:16)(cid:29)(cid:25)(cid:24)
(cid:3)(cid:6)(cid:2)
(cid:1)(cid:7)(cid:24)(cid:14)(cid:13)(cid:24)(cid:17)(cid:29)(cid:127)
(cid:9)(cid:12)(cid:24)(cid:27)(cid:17)(cid:24)(cid:17)(cid:15)(cid:11)(cid:25)(cid:19)(cid:11)(cid:8)(cid:19)(cid:27)(cid:30)(cid:11)(cid:26)(cid:30)(cid:24)(cid:16)(cid:16)(cid:15)(cid:25)(cid:26)(cid:19)(cid:11)(cid:8)(cid:19)(cid:17)(cid:20)(cid:29)(cid:19)(cid:3)(cid:6)(cid:2)(cid:19)(cid:10)(cid:28)(cid:31)(cid:11)(cid:22)(cid:21)(cid:22)(cid:11)(cid:22)(cid:141)(cid:23)(cid:31)(cid:10)(cid:29)(cid:23)(cid:31)(cid:18)(cid:22)(cid:30)(cid:9)(cid:31)(cid:28)(cid:13)(cid:31)(cid:22)(cid:21)(cid:17)(cid:19)(cid:19)(cid:18)(cid:28)(cid:19)(cid:18)(cid:22)(cid:17)(cid:10)(cid:23)
(cid:30)(cid:29)(cid:28)(cid:15)(cid:9)(cid:30)(cid:31)(cid:25)(cid:27)(cid:18)(cid:22)(cid:21)(cid:16)(cid:31)(cid:25)(cid:23)(cid:26)(cid:22)(cid:20)(cid:23)(cid:18)(cid:14)(cid:143)(cid:31)(cid:127)(cid:129)(cid:31)(cid:10)(cid:29)(cid:23)(cid:18)(cid:17)(cid:19)(cid:14)(cid:31)(cid:141)(cid:28)(cid:21)(cid:23)(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:31)(cid:24)(cid:23)(cid:31)(cid:10)(cid:27)(cid:18)(cid:21)(cid:23)(cid:25)(cid:31)(cid:28)(cid:144)(cid:3)(cid:31)(cid:28)(cid:21)(cid:26)(cid:14)(cid:31)(cid:10)(cid:29)(cid:23)(cid:31)(cid:127)(cid:157)
(cid:10)(cid:29)(cid:23)(cid:18)(cid:17)(cid:19)(cid:14)(cid:31)(cid:141)(cid:28)(cid:21)(cid:23)(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:31)(cid:24)(cid:23)(cid:31)(cid:17)(cid:20)(cid:17)(cid:22)(cid:26)(cid:17)(cid:24)(cid:26)(cid:23)(cid:24)
(cid:5)(cid:4)
(cid:31)(cid:14)(cid:24)(cid:23)(cid:15)(cid:25)(cid:26)(cid:19)(cid:11)(cid:8)(cid:19)(cid:16)(cid:24)(cid:26)(cid:25)(cid:29)(cid:17)(cid:19)(cid:11)(cid:7)(cid:29)(cid:30)(cid:19)(cid:3)(cid:6)(cid:2)(cid:19)(cid:157)(cid:24)(cid:17)(cid:17)(cid:29)(cid:30)(cid:22)(cid:31)(cid:10)(cid:28)(cid:31)(cid:10)(cid:23)(cid:11)(cid:19)(cid:28)(cid:18)(cid:17)(cid:18)(cid:22)(cid:26)(cid:14)(cid:31)(cid:30)(cid:27)(cid:30)(cid:19)(cid:23)(cid:21)(cid:25)(cid:31)(cid:8)(cid:7)(cid:6)(cid:31)(cid:10)(cid:29)(cid:23)(cid:18)(cid:17)(cid:19)(cid:14)(cid:31)(cid:22)(cid:13)
(cid:21)(cid:23)(cid:15)(cid:23)(cid:30)(cid:30)(cid:17)(cid:18)(cid:14)(cid:2)(cid:31)(cid:129)(cid:29)(cid:22)(cid:30)(cid:31)(cid:22)(cid:30)(cid:31)(cid:17)(cid:21)(cid:31)(cid:17)(cid:26)(cid:10)(cid:23)(cid:18)(cid:21)(cid:17)(cid:10)(cid:22)(cid:20)(cid:23)(cid:31)(cid:10)(cid:28)(cid:31)(cid:25)(cid:23)(cid:20)(cid:22)(cid:15)(cid:23)(cid:31)(cid:19)(cid:18)(cid:28)(cid:16)(cid:18)(cid:17)(cid:11)(cid:11)(cid:22)(cid:21)(cid:16)
(cid:129)(cid:11)(cid:16)(cid:29)(cid:25)(cid:19)(cid:4)(cid:15)(cid:17)(cid:20)(cid:19)(cid:27)(cid:24)(cid:23)(cid:15)(cid:25)(cid:26)(cid:28)(cid:12)(cid:29)(cid:27)(cid:29)(cid:25)(cid:12)(cid:29)(cid:25)(cid:23)(cid:22)(cid:127)(cid:31)(cid:22)(cid:21)(cid:31)(cid:15)(cid:17)(cid:30)(cid:23)(cid:31)(cid:28)(cid:13)(cid:31)(cid:23)(cid:26)(cid:23)(cid:15)(cid:10)(cid:18)(cid:28)(cid:30)(cid:27)(cid:18)(cid:16)(cid:23)(cid:18)(cid:14)(cid:3)(cid:31)(cid:27)(cid:30)(cid:23)(cid:31)(cid:24)(cid:22)(cid:19)(cid:28)(cid:26)(cid:17)(cid:18)(cid:31)(cid:11)(cid:28)(cid:25)(cid:23)(cid:31)(cid:10)(cid:28)
(cid:17)(cid:20)(cid:28)(cid:22)(cid:25)(cid:31)(cid:22)(cid:21)(cid:10)(cid:23)(cid:18)(cid:13)(cid:23)(cid:18)(cid:23)(cid:21)(cid:15)(cid:23)(cid:2)(cid:31)(cid:6)(cid:28)(cid:31)(cid:21)(cid:28)(cid:10)(cid:31)(cid:19)(cid:18)(cid:28)(cid:16)(cid:18)(cid:17)(cid:11)(cid:31)(cid:17)(cid:31)(cid:25)(cid:23)(cid:20)(cid:22)(cid:15)(cid:23)(cid:31)(cid:22)(cid:21)(cid:31)(cid:6)(cid:5)(cid:5)(cid:1)(cid:127)(cid:5)(cid:5)(cid:31)(cid:11)(cid:28)(cid:25)(cid:23)(cid:3)(cid:31)(cid:17)(cid:30)(cid:31)(cid:10)(cid:29)(cid:23)(cid:18)(cid:23)(cid:31)(cid:22)(cid:30)(cid:31)(cid:17)(cid:31)(cid:18)(cid:22)(cid:30)(cid:9)(cid:31)(cid:28)(cid:13)
(cid:4)(cid:31)(cid:28)(cid:21)(cid:31)(cid:129)(cid:31)(cid:19)(cid:29)(cid:23)(cid:21)(cid:28)(cid:11)(cid:23)(cid:21)(cid:17)
(cid:9)(cid:8)(cid:17)(cid:29)(cid:30)(cid:19)(cid:12)(cid:29)(cid:14)(cid:15)(cid:7)(cid:29)(cid:30)(cid:22)
(cid:19)(cid:141)(cid:29)(cid:27)(cid:30)(cid:11)(cid:26)(cid:30)(cid:24)(cid:16)(cid:16)(cid:15)(cid:25)(cid:26)(cid:31)(cid:28)(cid:13)(cid:31)(cid:10)(cid:29)(cid:23)(cid:31)(cid:19)(cid:17)(cid:15)(cid:23)(cid:11)(cid:17)(cid:9)(cid:23)(cid:18)(cid:1)(cid:8)(cid:7)(cid:6)(cid:31)(cid:10)(cid:28)(cid:31)(cid:22)(cid:10)(cid:30)(cid:31)(cid:28)(cid:18)(cid:22)(cid:16)(cid:22)(cid:21)(cid:17)(cid:26)(cid:31)(cid:30)(cid:10)(cid:17)(cid:10)(cid:27)(cid:30)
Figure 17 Management of pacemaker and implantable cardioverter defibrillator and pregnancy. b.p.m., beats per minute; ICD, implantable cardioverter
defibrillator; VF, ventricular fibrillation; VT, ventricular tachycardia. aPatients with an increase in arrhythmias during pregnancy, history of ventricular tachyar-
rhythmias. bSingle zone configuration: VT detection at 250 b.p.m., prolonged detection duration, e.g. 30 out of 40 beats.
Downloaded
from

by
guest
on
22
January
2026

4528 E S C G u id e l in e s
Management of implantable cardioverter defibrillator shocks during pregnancy
ICD interrogation
Appropriate shocks Inappropriate shocks
VT/VF Programmer available
Haemodynamically Position magnet
stable over the ICD
Device
reprogramming
Identify and Start advanced
treat triggers life support
(see related
section)
Anti-arrhythmic
Reprogramme Reprogramme
drug therapy
to discriminate to avoid T-wave
(see related section)
SVT oversensing
If serious
side effects or
drug refractoriness,
consider catheter
ablation
(Class IIb)
Figure 18 Management of implantable cardioverter defibrillator shocks in pregnancy. ICD, implantable cardioverter defibrillator; N, no; SVT, supraven-
tricular tachycardia; VF, ventricular fibrillation; VT, ventricular tachycardia; Y, yes.
Recommendation Table 15 — Recommendations for For acute conversion of haemodynamically stable
ventricular tachycardia, device implantation, catheter
sustained VTs during pregnancy, i.v. beta-blocker,
ablation, and pregnancy
adenosine (idiopathic RVOT-VT), verapamil
IIa C
Recommendations Classa Levelb (fascicular VT), procainamide, or overdrive
ventricular pacing (ICD lead) should be
Immediate electrical cardioversion is recommended considered.252,653,676–678
for both unstable and stable ventricular I C
When performing catheter ablation during
tachycardias.252
pregnancy, the use of non-fluoroscopic mapping and IIa C
Beta-blockers or verapamil are recommended for navigation systems should be considered.663–665
I C
the prevention of idiopathic sustained VT.
Catheter ablation with electro-anatomical mapping
If an ICD, pacemaker, or resynchronization therapy systems may be considered in experienced centres in
device is indicated during pregnancy, implantation is the case of sustained drug-refractory, recurrent, and/ IIb C
I C
recommended with optimal radiation or poorly tolerated VT if there are no other
protection.667,675
alternatives.
In idiopathic RVOT-VT, flecainide should be
ICD, implantable cardioverter defibrillator; i.v., intravenous; RVOT, right ventricular
considered if beta-blockers fail, to prevent IIa C
outflow tract; VT ventricular tachycardia.
recurrence. aClass of recommendation.
bLevel of evidence.
Continued
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4529
12.4.4. Cardiac arrest Because most of the underlying causes of cardiac arrest in pregnancy
Maternal cardiac arrest occurs in 8/100 000 hospitalizations in the United tend to be reversible, pregnant women have better outcomes than non-
States of America679 and 7.6/100 000 pregnancies in the Netherlands.680 pregnant women.684 Basic cardiac arrest resuscitation principles apply
Haemorrhage and anaesthetic complications are the most common to pregnant women, although some differences should be consid-
overall causes of cardiac arrest,681 and HF, ACS, arrhythmias, aortic dis- ered.684 If cardiac arrest occurs beyond 20 weeks of pregnancy, left lat-
section, and PE are the most common cardiovascular causes of cardiac eral manual displacement of the uterus or left lateral position of the
arrest.682,683 woman is indicated to avoid aortocaval compression (Figure 19).684,685
Chest compressions should be according to basic life support guidelines.
Management of cardiac arrest in pregnancy
Potential aetiology
• Anaesthetic complications • Amniotic fluid embolism
• Bleeding • Pulmonary embolism
• Cardiovascular causes • Eclampsia
• Drugs
Maternal interventions Obstetric interventions
Not pregnancy-specific Pregnancy-specific
If no ROSC after
Airway management Continuous manual 4 min of resuscitation
efforts and foetus
left uterus
is viable, immediate
Drug choices displacement
caesarean
and doses as in (Class I)
section
non-pregnant
(Class IIa)
(Class I)
i.v. access
above diaphragm
Chest compressions Neonatal Team (Class I)
as in non-pregnant
(Class I)
In women with Mg++
infusion (pre-eclampsia):
Defibrillation protocol
Stop Mg++ infusion and
as in non-pregnant
administer calcium
(Class I)
gluconatea
Anterolateral
defibrillator pad
In resuscitated
placement with the
pregnant women,
lateral pad placed
temperature control on
under the breast
an individual basis
(Class I)
Figure 19 Management of cardiac arrest in pregnancy. i.v., intravenous; ROSC, return of spontaneous circulation. a30 mL calcium gluconate 10% solution.
Downloaded
from

by
guest
on
22
January
2026

4530 E S C G u id e l in e s
In post-arrest care, the full left lateral decubitus position is recom- 12.4.5.2. Atrioventricular block
mended. The use of device-assisted chest compressions in pregnancy Mobitz type I AV block is common in pregnant women and rarely
is currently not recommended due to lack of data.684 Importantly, no progresses during pregnancy.691 There are no data on progression
drugs should be withheld because of concerns about teratogen- of congenital AV conduction block during pregnancy and vaginal
icity.614,686 Foetal monitoring after cardiac arrest is mandatory. delivery does not cause extra risk for mothers who are asymp-
Emergency caesarean section should be immediately prepared for tomatic, haemodynamically stable, and have a normal cardiac anat-
and considered when initial resuscitation fails.682 If this is not feasible, omy and function.691 Prophylactic placement of temporary
rapid maternal transfer is advised to an appropriate clinical setting pacemaker wires is not usually indicated but is an individualized
with uninterrupted resuscitation. decision.
Recommendation Table 16 — Recommendations for 12.4.5.3. Management of sinus node dysfunction and
cardiac arrest and pregnancy
atrioventricular block
Recommendation Classa Levelb In acute, life-threatening settings, bradycardia should be treated as in
non-pregnancy. Isoproterenol can be used when benefits outweigh
Continuous manual left uterine displacement during risks. It is not known if it is excreted in human milk. Pacing indications
CPR in pregnant women (≥20 weeks) with cardiac (temporary and permanent) do not differ between pregnant and
I C
arrest is recommended to relieve aortocaval non-pregnant women and can be found in the 2021 ESC
compression.614 Guidelines on cardiac pacing and cardiac resynchronization ther-
It is recommended to establish i.v. access above the apy.692 Pacemakers can be implanted safely during pregnancy using
diaphragm to ensure that the i.v. therapy is not I C standard methods with minimal fluoroscopy or non-fluoroscopic
obstructed by the gravid uterus.614
methods.675,693–695
It is recommended to perform the same chest
compressions and defibrillation protocols in I C
pregnant as in non-pregnant women.554,614,687 Recommendation Table 17 — Recommendation for
congenital atrioventricular block and pregnancy
Anterolateral defibrillator pad placement is
recommended with the lateral pad placed under the I C Recommendation Classa Levelb
breast.614,660
In pregnant women with asymptomatic congenital
It is recommended that no drugs are withheld in
AV block, normal cardiac anatomy and function, a
pregnant women with cardiac arrest due to concerns I C
of teratogenicity.686 narrow QRS complex, and ventricular rate III C
(≥50 b.p.m.), a prophylactic temporary pacemaker
Immediate caesarean section at the site of the arrest
during delivery is not recommended.691
should be considered and immediately prepared if
ROSC has not been achieved in the mother after AV, atrioventricular; b.p.m., beats per minute; QRS, Q, R, and S waves.
4 min of resuscitative efforts and if the foetus is IIa C aClass of recommendation.
bLevel of evidence.
viable, taking gestational age, comorbidities, and
the available level of medical care into
account.614,688,689
12.5. Valvular heart disease
CPR, cardiopulmonary resuscitation; i.v, intravenous; ROSC, return of spontaneous
circulation. During childbearing years VHD is usually either congenital or rheumatic
aClass of recommendation. in cause. Complications during pregnancy include new-onset AF, which
bLevel of evidence. can lead to deterioration in cardiac function, an increased risk of
thromboembolic events, and heart failure.696,697 Women with valve
disease should have access to pre-conception counselling and their car-
12.4.5. Bradycardia diac condition should be optimized. This may include pre-pregnancy
12.4.5.1. Sinus node dysfunction intervention or surgery for those with symptoms or severe disease
(Figure 20), in keeping with the 2021 ESC/EACTS Guidelines for the
Sinus bradycardia due to sinus node dysfunction is uncommon in
management of valvular heart disease.698 Dedicated tools for risk strati-
pregnant women who do not have structural heart disease. In
fication may be needed in the setting of rheumatic heart disease.697
the second trimester, symptomatic bradycardia may occur as a re-
sult of a reduction in systemic resistance, but this rarely requires
treatment. Symptomatic bradycardia during pregnancy may be 12.5.1. Stenotic native valve lesions
caused by the supine hypotensive syndrome, defined as a systolic Stenotic valve lesions limit the ability to increase CO during pregnancy.
BP decrease of >15 mmHg due to compression of the inferior The result of this may be presentation with symptoms for the first time
vena cava by the uterus.690 Management depends on the underlying during pregnancy. Serial TTE in pregnancy will usually demonstrate an
cause, severity of symptoms, and potential risks to both the mother increase in valve gradient of up to 50% due to the normal
and the foetus. pregnancy-related increase in CO.699
5202CSE©
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4531
12.5.1.1. Mitral valve stenosis Despite this, maternal mortality is rare for those under expert
Mitral valve stenosis is a common cause of HF during pregnancy.11 Mild care.703 The risk of sudden death in those with severe stenosis is in-
stenosis is usually well tolerated.11 However, symptoms may occur if creased but difficult to quantify. BAV-associated aortopathy is dis-
the valve area is <1.5 cm2. Maternal mortality in mitral stenosis is higher cussed in Section 8.3.
in those with NYHA >II, systolic pulmonary arterial pressure (PAP)
>30 mmHg, severe stenosis, older age, and in low-income coun- 12.5.1.2.1. Management. Medical therapy has a limited role in
tries11,696,700 (Figure 20). Foetal risks include increased rates of prema- symptomatic aortic stenosis. Diuretics may help those with HF or
ture delivery, IUGR, and foetal death, especially in highly symptomatic high filling pressures, but caution should be exercised. In women
mothers (NYHA III/IV).701 with severe symptomatic aortic stenosis, rest and possibly hospital ad-
mission should be considered. Intervention should be considered in
12.5.1.1.1. Management. Diagnosis is as per usual criteria.698 women with persisting symptoms including angina or with new ST
During pregnancy, valve area by 2D-planimetry is thought to be changes on ECG. In symptomatic pregnant women with severe aortic
more reliable than flow-dependent measures, because higher stroke stenosis not responding to medical therapy, non-surgical options such
volume and tachycardia will increase the measured gradient across as balloon valvuloplasty or transcatheter aortic valve implantation
the valve.702 Mitral valve anatomy, especially the presence of subval- (TAVI) may be considered during pregnancy.705,706 Procedures
var involvement or the presence of MR, is important if considering should be performed in an experienced valve centre. If no catheter-
intervention. based options are available, surgical valve replacement or repair is re-
If signs or symptoms of PH are present, activity restriction should be commended. If the foetus is at a viable gestation, taking account of
suggested, and beta-blockers and/or diuretics should be started. other comorbidities and the available level of neonatal care, delivery
Anticoagulation regimens should be individualized. Therapeutic antic- should occur prior to valve intervention. These complex decisions
oagulation with full therapeutic-dose LMWH or VKA (see Section 5) should be discussed with the full Pregnancy Heart Team.707 Cardiac
is indicated in those with AF, left atrial clot, or a previous embolism. surgery with cardiopulmonary bypass is associated with at least a
Anticoagulation should be considered in those with significant mitral 20% risk of foetal loss.708
stenosis, spontaneous echo contrast in the LA, dilated LA with left atrial Vaginal delivery is the preferred mode of delivery for the majority of
volume index >60 mL/mL2, or those in HF. women. In those with severe symptomatic aortic stenosis, caesarean
delivery should be considered. Early post-partum HF may develop.
For pulmonary stenosis, see Section 9 on congenital heart disease.
12.5.1.1.2. Interventions. Pre-pregnancy intervention should be con-
sidered in those with significant stenosis (valve area <1.5 cm2). Before
12.5.2. Regurgitant native valve lesions
and during pregnancy, percutaneous mitral balloon commissurotomy is
the primary intervention in those who remain in NYHA III/IV or with Valve regurgitation is generally better tolerated than valve stenosis in
severe PAP elevation despite medical therapy.703 Balloon techniques pregnancy. Increased maternal and foetal event rates can be seen in
are highly successful during pregnancy unless there is complex subvalvar those with severe regurgitation.709
involvement. Closed commissurotomy is rarely used but is an alterna-
tive. Open valve surgery should only be used when there is a risk to ma- 12.5.2.1. Mitral and aortic valve regurgitation
ternal life and other options are not possible or have failed.704 Women with valve regurgitation and either symptoms or LV
dysfunction incur an increased risk of HF, occurring in 20%–25%
12.5.1.1.3. Delivery. Vaginal delivery is the preferred option. of those with at least moderate regurgitation.182,710 Acute regurgitant
Caesarean section is preferred in cases of severe mitral stenosis and lesions are often less well tolerated than chronic regurgitation.710
for those with refractory HF. Delivery is a time of increased risk of
HF and thrombotic events.182 12.5.2.1.1. Management. Diuretics can be used in those with severe
symptomatic mitral or aortic regurgitation. Cardiac surgery is rarely re-
12.5.1.1.4. Post-partum. Close monitoring is needed in the days follow- quired during pregnancy. Vaginal delivery is preferred unless the
ing delivery and diuretics may be required to treat fluid overload. The long- mother is in refractory HF.
term outcome depends on the risk of valve progression and the success of
commissurotomy if performed. Lifelong follow-up is required. 12.5.2.2. Arrhythmogenic mitral valve prolapse
Arrhythmic mitral valve prolapse (AMVP) is defined as the presence of
12.5.1.2. Valvular aortic stenosis mitral valve prolapse and arrhythmia symptoms or signs, such as fre-
Bicuspid aortic valve disease is a common cause of valvular aortic stenosis in quent ventricular premature contractions or complex ventricular ar-
women of childbearing age. The outcome is related to the baseline severity rhythmias.711 The arrhythmias may arise from myocardial fibrosis
of the stenotic lesion. Women with severe stenosis and those with symp- resulting from prolonged and increased stretch of papillary muscles
toms prior to pregnancy have a 1 in 4 risk of developing HF during preg- and of the inferolateral LV wall by the prolapsing valves.
nancy.703 Exercise testing and measurement of NP can be used to Several reports have included female sex as a risk factor for severe
stratify risk prior to pregnancy. Those with symptomatic severe aortic sten- arrhythmic events.711 Other risk factors include syncope, the pres-
osis should be offered intervention prior to pregnancy. Risk-stratifying ence of mitral annular disjunction, late gadolinium enhancement
those with asymptomatic aortic stenosis is more challenging. Left ventricu- on CMR, complex ventricular arrhythmias, including non-sustained
lar systolic dysfunction, or effort limitation on exercise testing, indicate that ventricular tachycardia, syncope, T-wave inversions in the inferolat-
intervention before pregnancy should be considered.698 eral ECG leads, bi-leaflet mitral valve prolapse, and reduced LVEF.
Women with severe aortic stenosis contemplating pregnancy should Little is known about the effect of pregnancy in women with AMVP,
be counselled regarding the risks and offered surgery if they prefer. but altered loading conditions may lead to increased tension in mitral
Downloaded
from

by
guest
on
22
January
2026

4532 E S C G u id e l in e s
valve apparatus and thereby increased risk of ventricular arrhythmias. centre with experience in AMVP and with periodic Holter monitoring
A recent publication indicated increased arrhythmic risk during preg- to identify a potential increase in arrhythmic burden.711 Risk stratification
nancy in women with AMVP and life-threatening ventricular for ICD implantation should follow the consensus for AMVP in general.711
arrhythmias.712
It is recommended that women with AMVP undergo pre-conception
counselling and optimization of medication. Medical treatment includes 12.5.2.3. Tricuspid regurgitation
anti-arrhythmic therapy with, for example, beta-blockers and/or flecai- Medical treatment for tricuspid regurgitation is usually not required
nide.713 If started pre-pregnancy, treatment should continue during preg- but during pregnancy diuretics and medication for rhythm manage-
nancy with close follow-up and arrhythmic monitoring. A pregnant ment may be needed. Surgery for isolated TR in pregnancy is rarely
woman with AMVP should be monitored during pregnancy at a tertiary indicated except for the setting of endocarditis.
(cid:7)(cid:23)(cid:22)(cid:24)(cid:21)(cid:25)(cid:10)(cid:27)(cid:14)(cid:21)(cid:23)(cid:14)(cid:21)(cid:25)(cid:27)(cid:17)(cid:25)(cid:11)(cid:29)(cid:21)(cid:8)(cid:17)(cid:23)(cid:17)(cid:26)(cid:16)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:24)(cid:23)(cid:22)(cid:24)(cid:21) (cid:20)(cid:19)(cid:22)(cid:18)(cid:30)(cid:17)(cid:23)(cid:29)(cid:16)(cid:25)(cid:24)(cid:23)(cid:22)(cid:24)(cid:21)
(cid:15)(cid:28)(cid:21)(cid:17)(cid:30)(cid:14)(cid:27)(cid:14) Stenosis
(cid:18)(cid:17)(cid:16)(cid:20)(cid:23)(cid:28)(cid:30)(cid:23)(cid:19)(cid:25)(cid:20)(cid:15)(cid:30)(cid:14)(cid:25)(cid:15)(cid:13)(cid:25)(cid:12)(cid:11)(cid:15)(cid:27)(cid:19)(cid:25)(cid:30)(cid:22)(cid:23)(cid:17)(cid:21)(cid:30)(cid:15)(cid:30) (cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:27)(cid:26)(cid:25)(cid:24)(cid:23)(cid:27)(cid:27)(cid:25)(cid:22)(cid:21)(cid:27)(cid:23)(cid:20)(cid:28)(cid:22)(cid:23)(cid:19)
(cid:127)(cid:21)(cid:19)(cid:23)(cid:20)(cid:28)(cid:22)(cid:23)(cid:25)(cid:22)(cid:21)(cid:25)(cid:30)(cid:23)(cid:9)(cid:23)(cid:20)(cid:23)(cid:25)(cid:30)(cid:22)(cid:23)(cid:17)(cid:21)(cid:30)(cid:15)(cid:30) (cid:10)(cid:26)(cid:11)(cid:1)(cid:22)(cid:21)(cid:11)(cid:28)(cid:22)(cid:15)(cid:16)
(cid:10)(cid:26)(cid:11)(cid:1)(cid:22)(cid:21)(cid:11)(cid:28)(cid:22)(cid:15)(cid:16) (cid:10)(cid:23)(cid:9)(cid:23)(cid:20)(cid:23)(cid:25)(cid:8)(cid:7)(cid:6)
(cid:10)(cid:23)(cid:9)(cid:23)(cid:20)(cid:23)(cid:25)(cid:129)(cid:7)(cid:6) (cid:5)(cid:15)(cid:27)(cid:28)(cid:22)(cid:23)(cid:19)(cid:25)(cid:20)(cid:15)(cid:4)(cid:3)(cid:22)(cid:25)(cid:28)(cid:22)(cid:20)(cid:15)(cid:29)(cid:11)
(cid:141)(cid:143)(cid:17)(cid:21)(cid:20)(cid:11)(cid:28)(cid:27)(cid:25)(cid:144)(cid:157) (cid:2)(cid:20)(cid:15)(cid:21)(cid:20)(cid:25)(cid:28)(cid:20)(cid:20)(cid:3)(cid:26)(cid:22)(cid:3)(cid:11)(cid:15)(cid:28)
(cid:5)(cid:15)(cid:27)(cid:28)(cid:22)(cid:23)(cid:19)(cid:25)(cid:28)(cid:21)(cid:20)(cid:22)(cid:28)
Regurgitation
Regurgitation (cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:27)(cid:26)(cid:25)(cid:24)(cid:23)(cid:27)(cid:27)(cid:25)(cid:22)(cid:21)(cid:27)(cid:23)(cid:20)(cid:28)(cid:22)(cid:23)(cid:19)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:27)(cid:26)(cid:25)(cid:24)(cid:23)(cid:27)(cid:27)(cid:25)(cid:22)(cid:21)(cid:27)(cid:23)(cid:20)(cid:28)(cid:22)(cid:23)(cid:19) (cid:2)(cid:21)(cid:21)(cid:20)(cid:25)(cid:8)(cid:7)(cid:25)(cid:13)(cid:29)(cid:17)(cid:16)(cid:22)(cid:15)(cid:21)(cid:17)
(cid:10)(cid:26)(cid:11)(cid:1)(cid:22)(cid:21)(cid:11)(cid:28)(cid:22)(cid:15)(cid:16)
(cid:5)(cid:15)(cid:27)(cid:28)(cid:22)(cid:23)(cid:19)(cid:25)(cid:129)(cid:7)(cid:25)(cid:24)(cid:15)(cid:22)(cid:3)(cid:25)(cid:15)(cid:11)(cid:1)(cid:28)(cid:15)(cid:20)(cid:23)(cid:19)
(cid:30)(cid:26)(cid:30)(cid:22)(cid:21)(cid:27)(cid:15)(cid:16)(cid:25)(cid:13)(cid:29)(cid:17)(cid:16)(cid:22)(cid:15)(cid:21)(cid:17)
(cid:5)(cid:15)(cid:27)(cid:28)(cid:22)(cid:23)(cid:19)(cid:25)(cid:28)(cid:21)(cid:20)(cid:22)(cid:28)
(cid:13)(cid:27)(cid:28)(cid:29)(cid:23)(cid:22)(cid:25)(cid:24)(cid:23)(cid:22)(cid:24)(cid:21)
(cid:15)(cid:28)(cid:21)(cid:17)(cid:30)(cid:14)(cid:27)(cid:14)
(cid:6)(cid:15)(cid:4)(cid:3)(cid:25)(cid:30)(cid:29)(cid:30)(cid:1)(cid:15)(cid:16)(cid:15)(cid:21)(cid:17)(cid:25)(cid:15)(cid:13)(cid:25)(cid:20)(cid:15)(cid:30)(cid:14)(cid:25)(cid:21)(cid:13)
(cid:20)(cid:3)(cid:23)(cid:29)(cid:11)(cid:28)(cid:22)(cid:15)(cid:16)(cid:25)(cid:19)(cid:15)(cid:30)(cid:23)(cid:28)(cid:30)(cid:23)
(cid:10)(cid:26)(cid:11)(cid:1)(cid:22)(cid:21)(cid:11)(cid:28)(cid:22)(cid:15)(cid:16)
(cid:12)(cid:29)(cid:27)(cid:26)(cid:19)(cid:14)(cid:11)(cid:27)(cid:10)(cid:25)(cid:24)(cid:23)(cid:22)(cid:24)(cid:21)
(cid:10)(cid:23)(cid:9)(cid:23)(cid:20)(cid:23)(cid:25)(cid:30)(cid:22)(cid:23)(cid:17)(cid:21)(cid:30)(cid:15)(cid:30)
(cid:5)(cid:15)(cid:27)(cid:28)(cid:22)(cid:23)(cid:19)(cid:25)(cid:27)(cid:23)(cid:13)(cid:22)(cid:25)(cid:28)(cid:22)(cid:20)(cid:15)(cid:29)(cid:11)
Stenosis
(cid:6)(cid:15)(cid:4)(cid:3)(cid:25)(cid:2)(cid:141)(cid:10)(cid:2)
(cid:8)(cid:28)(cid:20)(cid:23)(cid:25)(cid:28)(cid:30)(cid:25)(cid:17)(cid:28)(cid:22)(cid:15)(cid:9)(cid:23)(cid:25)(cid:27)(cid:23)(cid:30)(cid:15)(cid:21)(cid:17)
(cid:157)(cid:21)(cid:11)(cid:1)(cid:27)(cid:23)€(cid:25)(cid:30)(cid:29)(cid:143)(cid:9)(cid:28)(cid:27)(cid:9)(cid:29)(cid:27)(cid:28)(cid:20)(cid:25)(cid:19)(cid:15)(cid:30)(cid:23)(cid:28)(cid:30)(cid:23)
(cid:10)(cid:26)(cid:11)(cid:1)(cid:22)(cid:21)(cid:11)(cid:28)(cid:22)(cid:15)(cid:16) (cid:141)(cid:20)(cid:20)(cid:3)(cid:26)(cid:22)(cid:3)(cid:11)(cid:15)(cid:28)
(cid:27)(cid:29)(cid:15)(cid:19)(cid:25)(cid:20)(cid:23)(cid:22)(cid:23)(cid:17)(cid:22)(cid:15)(cid:21)(cid:17)
(cid:129)(cid:15)(cid:9)(cid:23)(cid:20)(cid:25)(cid:19)(cid:15)(cid:30)(cid:23)(cid:28)(cid:30)(cid:23) (cid:9)(cid:21)(cid:8)(cid:19)(cid:29)(cid:8)(cid:27)(cid:28)(cid:23)(cid:28)(cid:27)(cid:30)(cid:17)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:27)(cid:26)(cid:25)(cid:24)(cid:23)(cid:27)(cid:27)(cid:25)(cid:22)(cid:21)(cid:27)(cid:23)(cid:20)(cid:28)(cid:22)(cid:23)(cid:19)
Regurgitation (cid:144)€(cid:16)(cid:27)(cid:29)(cid:19)(cid:23)(cid:25)(cid:127)(cid:28)(cid:20)(cid:13)(cid:28)(cid:17)(cid:25)(cid:30)(cid:26)(cid:17)(cid:19)(cid:20)(cid:21)(cid:11)(cid:23)‚
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:27)(cid:26)(cid:25)(cid:24)(cid:23)(cid:27)(cid:27)(cid:25)(cid:22)(cid:21)(cid:27)(cid:23)(cid:20)(cid:28)(cid:22)(cid:23)(cid:19) (cid:16)(cid:21)(cid:17)(cid:17)(cid:23)(cid:16)(cid:22)(cid:15)(cid:9)(cid:23)(cid:25)(cid:22)(cid:15)(cid:30)(cid:30)(cid:29)(cid:23)(cid:25)(cid:19)(cid:15)(cid:30)(cid:23)(cid:28)(cid:30)(cid:23)
(cid:5)(cid:15)(cid:27)(cid:28)(cid:22)(cid:23)(cid:19)(cid:25)(cid:129)(cid:7)(cid:25)(cid:24)(cid:15)(cid:22)(cid:3)(cid:25)(cid:19)(cid:26)(cid:30)(cid:13)(cid:29)(cid:17)(cid:16)(cid:22)(cid:15)(cid:21)(cid:17)
Poor RV function
(cid:127)(cid:15)(cid:22)(cid:20)(cid:28)(cid:27)(cid:25)(cid:9)(cid:28)(cid:27)(cid:9)(cid:23)(cid:25)(cid:1)(cid:20)(cid:21)(cid:27)(cid:28)(cid:1)(cid:30)(cid:23)(cid:25)(cid:24)(cid:15)(cid:22)(cid:3)(cid:25)
Ebstein anomaly
(cid:9)(cid:23)(cid:17)(cid:22)(cid:20)(cid:15)(cid:16)(cid:29)(cid:27)(cid:28)(cid:20)(cid:25)(cid:28)(cid:20)(cid:20)(cid:3)(cid:26)(cid:22)(cid:3)(cid:11)(cid:15)(cid:28)
Figure 20 Valvular heart disease and pregnancy. ECG, electrocardiogram; LV, left ventricle; LVH, left ventricular hypertrophy; PASP, pulmonary arterial
systolic pressure; RV, right ventricle; RVH, right ventricular hypertrophy. Red flags indicate high-risk features.
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4533
Recommendation Table 18 — Recommendations for native valve disease and pregnancy
Recommendations Classa Levelb
Intervention is recommended before pregnancy in symptomatic patients with severe aortic stenosis.698 I C
Intervention is recommended before pregnancy in women with mitral stenosis and a valve area <1.5 cm2. 698,701,714 I C
In pregnant women with symptomatic mitral stenosis or pulmonary hypertension, restricted activities and beta-blockers are
I C
recommended.20
In pregnant women with mitral stenosis, diuretics are recommended when congestive symptoms persist despite beta-blockers.20 I C
Full therapeutic-dose anticoagulation is recommended in women with mitral stenosis complicated by AF, left atrial thrombus, or prior
I C
embolism.
Surgical treatment is recommended before pregnancy in women with severe aortic or mitral regurgitation with symptoms, impaired
I C
ventricular function, or marked ventricular dilatation.698,715
Diuretics are recommended in pregnant women with regurgitant lesions when symptoms or signs of congestion occur. I C
Intervention should be considered before pregnancy in those with asymptomatic severe aortic stenosis after counselling on the risks and
IIa C
benefits.698
Percutaneous mitral commissurotomy for mitral stenosis should be considered in pregnant women with severe symptoms or systolic
IIa C
pulmonary artery pressure >50 mmHg despite medical therapy.698
Valve surgery during pregnancy should only be considered when there is a maternal mortality risk and other treatment options have
IIa C
failed.421
In very selected symptomatic pregnant women with severe aortic stenosis not responding to medical therapy, non-surgical options such as
IIb C
balloon valvuloplasty or TAVI may be considered.716
AF, atrial fibrillation; TAVI, transcatheter aortic valve implantation.
aClass of recommendation.
bLevel of evidence.
12.5.3. Prosthetic valves valve implantation should be avoided when possible. Transcatheter
When a woman of childbearing age or a girl requires valve surgery, valve-in-valve intervention may have a role in extending the lifespan
careful consideration should be given to the possibility of future preg- of a failing bioprosthetic valve in a young woman contemplating preg-
nancies. When appropriate, the discussion regarding valve choice nancy. In a recent retrospective study of CARPREG data, 215 pregnan-
should involve the Pregnancy Heart Team. In general, valve repair, cies in 101 women who had implanted bioprosthetic valves prior to
valve-in-valve, or non-mechanical valves are preferable, avoiding the pregnancy were described. More than a quarter had some degree of
need for anticoagulation. Data from the ROPAC III study, focusing valvar dysfunction, although the time since the last valve replacement
on prosthetic valves, show that the chance of an uncomplicated preg- surgery was only 6 ± 3 years on average. Bioprosthetic valve dysfunc-
nancy with a live birth in women with a MHV was 54%, compared to tion was more than twice as common in women with left-sided as op-
79% in women with a tissue valve.177 Regional differences, especially be- posed to right-sided valves.719
tween high-income and low- and middle-income countries, need to be The chance of a pregnancy without serious adverse events and a live
acknowledged, as also indicated in a recent study from Madras in India birth in women with a bioprosthetic valve is 79%.177 When significant
(M-PAC registry) describing pregnancy outcomes in 70 women with a bioprosthetic dysfunction is present, the risk of complications can be
prosthetic heart valve.717 A very high foetal death rate and major ad- significant, especially if associated with severe stenosis or ventricular
verse cardiovascular events (MACE) rate (40% and 34%, respective- dysfunction. There is no compelling evidence that pregnancy is asso-
ly),717 including a high number of valve thromboses, is believed to ciated with accelerated valve deterioration.
relate not only to differences in organization of care, but also to under-
lying valvular disease, with more rheumatic heart disease in low- and 12.5.3.2. Mechanical valves
middle-income countries. The Ross procedure in aortic valve disease
Pregnant women with MHVs are exposed to a high risk of complica-
is an alternative option to be considered. In the absence of aortic dila-
tions (mWHO 2.0 risk classification ≥III). The chances of an event-free
tation, pregnancy risk is low after the Ross procedure.718
pregnancy with a live birth were only 58% in the initial ROPAC II study
and showed no improvement after 8 years in the ROPAC III study
12.5.3.1. Bioprosthetic valves (54%).177,204 Thrombotic complications occur in 9%–24% and bleeding
Prior to pregnancy, a full assessment of valve function should be complications in 20%–30% of the cases in the ROPAC III and a United
performed. Many women are on lifetime low-dose aspirin treatment, Kingdom study, respectively.176,177 Women with a mechanical valve in
and this should be continued during pregnancy unless there is a contra- the mitral position are especially at risk of adverse outcomes, including
indication. If there is severe valve dysfunction prior to pregnancy, mortality.177
reintervention should be considered. However, in this setting All women with MHVs should be fully counselled pre-pregnancy re-
the risk of pregnancy with the current valve dysfunction should be ba- garding the risks and benefits of the various anticoagulation regimens.
lanced against the risk of the new valve being proposed. Mechanical When planning the optimal anticoagulation strategy, logistical issues,
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

4534 E S C G u id e l in e s
such as access to timely anti-factor Xa level testing and maternal ability to therapeutic-dose LMWH throughout pregnancy. The management
adhere to treatment regimens, need to be considered. of anticoagulants during pregnancy in women with MHVs is summar-
ized in Figure 21.
12.5.3.2.1. Anticoagulation during pregnancy. The most effective
regimen in preventing maternal thrombotic complications is the con- 12.5.3.2.2. Mechanical valve thrombosis. Regular maternal cardiac
tinuous use of VKAs. Thrombotic events not only compromise the ultrasound should be performed during pregnancy to assess valve func-
mother but also jeopardize the baby.170,200,204,206,720,721 However, tion and rule out valve thrombosis. Imaging once per trimester will usu-
there remain concerns about the foetal impact of VKAs. Data from ally suffice unless there is pre-existing valve dysfunction or HF. Changes
the ROPAC III study indicated a higher risk of miscarriage in VKA in valve gradient that exceed the usual increase due to changing cardiac
users.177 As discussed in Section 5, the foetal risk of VKAs is in part output should be investigated. Symptoms such as new HF, embolic
dose-related. Although there is no safe dose for the foetus, event rates event, or syncope need urgent assessment. Changes in valve clicks
are reduced when lower doses of VKA are used.200 For these reasons, and new murmurs should also trigger investigation. Transthoracic and
continuation of VKAs should be considered when the risk of throm- transoesophageal echocardiography, fluoroscopy, and CT can all be
bosis is high and the dose required to achieve the target INR is low used to assess MHV leaflet movement.
(see Section 5). Target INRs are unchanged from non-pregnant va- Valve thrombosis has a high maternal mortality. Its management is
lues.698 INR monitoring should be weekly or every 2 weeks (see comparable with management in non-pregnant women. In a subacute
Section 5). setting, optimizing anticoagulation with UFH and re-establishing a
The alternative strategy is switching to therapeutic-dose LMWH therapeutic INR with VKA may be sufficient. Thrombolysis may be con-
(twice daily) until the 12th week of pregnancy with a monitoring sidered, especially in non-critically ill women, when surgery is not imme-
plan. The target peak levels of anti-factor Xa should be discussed in- diately available for critically ill women, and in right-sided prosthetic
dividually and vary between 1 and 1.2 IU/mL. The value of trough anti- valve thrombosis.698 Urgent intervention is often required in acute
factor Xa levels is less clear. Adjusting dosing to obtain levels of thrombosis with obstruction or severe regurgitation.722 This is asso-
>0.6 IU/mL has been suggested, however, with little evidence.170,216 ciated with high maternal and foetal risks. There is a clear survival bene-
Dosing regimens for therapeutic LMWH are provided in Section 5. fit for the foetus without increasing maternal mortality if cardiac
In women with a very high thrombotic risk, the addition of low-dose surgery is performed after caesarean section. Therefore, the optimal
acetylsalicylic acid (ASA) should be considered.170 In rare circum- treatment strategy, as determined by the Pregnancy Heart Team, will
stances, such as the unavailability of anti-factor Xa level testing, i.v. depend on type of valve involved, haemodynamic stability of the
UFH can be used. Target aPTT levels with a prolongation of ≥2 times mother, and gestational age.421
the control can be challenging to achieve and may require multiple ad-
justments of dosing and prolonged inpatient care. In the majority of 12.5.3.2.3. Anticoagulation during delivery in women with mechan-
cases, VKAs will be the favoured therapy in the second and third tri- ical heart valves. The management of delivery for women with
mesters to minimize the maternal risks after the period of embryo- MHV is discussed in Section 4.5.6. These are high-risk deliveries with sig-
genesis.176,204 Despite this, some women will choose to remain on nificant bleeding complications.
Recommendation Table 19 — Recommendations for prosthetic valves and pregnancy (see Evidence Table 18)
Recommendations Classa Levelb
A bioprosthetic valve is recommended (over a mechanical valve) in young women contemplating pregnancy requiring a valve prosthesis.177 I B
It is recommended that the type of valve surgery or intervention for a woman contemplating pregnancy is chosen in consultation with the
I C
Pregnancy Heart Team.
Women with mechanical heart valves
It is recommended that a care plan documenting the agreed anticoagulant strategy (including the decision to continue VKAs or converting to
therapeutic-dose LMWH in the first trimester) is in place for women of childbearing age with an MHV prior to pregnancy or as soon as I C
pregnancy is recognized.170
It is recommended that pregnant women with an MHV are managed by the Pregnancy Heart Team.170 I C
In pregnant women on VKAs, it is recommended to perform INR monitoring weekly or at a minimum every 2 weeks. I C
In pregnant women with MHVs on therapeutic-dose LMWH, it is recommended to check peak anti-factor Xa levels and to target levels
I C
according to individualized risk.
During the second and third trimesters until the 36th week, continuing VKAs should be considered in women with prosthetic heart valves at
IIa C
higher risk of thrombosis.
During the second and third trimesters, continuing LMWH with anti-factor Xa level monitoring and dose adjustment may be considered in
IIb C
women at lower risk of thrombosis.
LMWH is not recommended when anti-factor Xa level monitoring is not available. III C
INR, international normalized ratio; LMWH, low-molecular-weight heparin; MHV, mechanical heart valve; VKA, vitamin K antagonist.
aClass of recommendation.
bLevel of evidence.
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4535
Management of pregnant women with mechanical heart valves
by the Pregnancy Heart Team (Class I)
Good control of anticoagulation with therapeutic INRs
Pregnancy Heart Team decision
taking into account: Counsel that
pregnancy risks
• High risk of valve thrombosis are very high
(See box below)
Discuss pregnancy
• VKA dosea
alternatives
• Maternal choice
• No high-risk of valve • High-risk of valve
thrombosis (See box below) thrombosis (See box below)
• High dose VKA • Only if high VKA dose and/or
• Availability of no anti-factor Xa testing
anti-factor Xa testing available
• High-risk of valve thrombosis (See box below)
Continuous i.v. UFH
Dose-adjusted LMWH Continue VKA
(rarely used)
Pregnancy Heart Team decision taking into account:
• High risk of valve thrombosis (See box below)
• Maternal choice
Dose-adjusted LMWH, if
VKA, if higher risk VKA • Lower risk of valve thrombosis
of valve thrombosis
(usual care) • Availability of anti-factor Xa testing
(Class IIa)
(Class IIb)
Last 2 weeks of pregnancy and deliveryb
High risk of valve thrombosis
Right sided valves Previous thrombotic events
Mitral valve replacement Valve dysfunction especially
Atrial fibrillation stenosis
Poor LV function Other clotting risks (smoker)
Older generation valves
Figure 21 Management of anticoagulants during the different stages of pregnancy in women with mechanical heart valves. INR, international normalized
ratio; i.v., intravenous; LMWH, low-molecular-weight heparin; LV, left ventricle; N, no; UFH, unfractionated heparin; VKA, vitamin K antagonist; Y, yes. aSee
Table 10. bSee Figure 5 and Section 4.5.7.
)yhtapoyrbme
fo
ksir(
retsemirt
tsriF
retsemirt
driht/dnoceS
Downloaded
from

by
guest
on
22
January
2026

4536 E S C G u id e l in e s
12.5.4. Endocarditis prophylaxis refractory cardiogenic shock.339 In cardiogenic shock, urgent delivery by
Infective endocarditis during pregnancy is a rare yet severe event as- caesarean section with combined spinal/epidural analgesia or general an-
sociated with maternal and foetal morbidity and mortality. An increas- aesthesia is recommended.732–734
ing risk factor is represented by i.v. drug abuse associated with the Milder cases of acute HF can be treated with oral diuretics,
opioid epidemic in the United States of America.723 The most com- b1-selective beta-blockers (bisoprolol, metoprolol succinate), hydrala-
mon pathogens are Staphylococcus (74%) and Serratia (13%).724 A re- zine, and oral nitrates. Diuretics (loop diuretics and thiazides if re-
cent comparison across antepartum, delivery, and post-partum quired) should be used with caution due to a potential reduction in
maternity-associated infective endocarditis showed the 60-day mor- uterine blood flow, but may be necessary in pulmonary congestion
tality rate was highest in the delivery subgroup and the rate of valve or echocardiographic signs of high LV end-diastolic pressure.732
replacements was highest in post-partum cases.725 Antibiotics should
be given according to guidelines,178,726 laboratory data on culture and Recommendation Table 20 — Recommendations for
chronic and acute heart failure and pregnancy (see
antibiotic sensitivity, and the differential foetal toxicity of antibiotics
Evidence Table 19)
(see Section 5).
Chronic heart failure Classa Levelb
12.6. Heart failure
12.6.1. Chronic heart failure It is recommended that women with HFrEF are
advised about the risk of deterioration of cardiac I C
Heart failure complicates 11% of pregnancies in women with pre-existing
heart disease and has an in-hospital maternal mortality rate of 9%.2 function during pregnancy and peripartum.34
Specific pre-pregnancy counselling is needed for women with ventricular In pregnant women with HFrEF, it is recommended
dysfunction irrespective of the cause. As many HF medications are contra- that non-selective beta-blockers are switched to
indicated in pregnancy (see Section 5), modifying the drug regimen pre- beta-1-selective blockers (metoprolol, bisoprolol) I C
pregnancy should be part of pregnancy risk stratification, with reassessment with close maternal and foetal
after at least 3 months.727 Contractile reserve off HF therapy, measured by monitoring.733,734,738,739
stress echocardiography, can be used for reassessing ventricular function.371 Anticoagulation with therapeutic doses of LMWH is
Two peaks of HF deterioration occur in pregnancy: at 23–30 weeks and recommended in pregnant women with intracardiac I C
peri-delivery.182 Pre-conception counselling should include a discussion of thrombus or decreased LV function with EF <35%.216
management if there is a clinical deterioration during the first peak. Early de-
It is recommended to optimize HF guideline-directed
livery due to maternal cardiac deterioration will impact foetal outcomes.
medical therapy after delivery, taking contraindicated I C
Patients with mild ventricular dysfunction may tolerate pregnancy with drugs during lactation into accountc.339,734
no increase in symptoms. However, those with worse than mild ventricu-
Due to the high metabolic demands of lactation,
lar dysfunction (mWHO 2.0 class >II) (Table 6) require expert care from
avoiding lactation may be considered in women with IIb C
the Pregnancy Heart Team, with additional input from the advanced HF
severe HF.360,733
team including transplant and mechanical circulatory support experts.
ACE-Is, ARBs, ARNIs, MRAs, ivabradine, and SGLT2
Women with pre-existing severe HF (LVEF <30%, mWHO 2.0 class
IV) are at high risk of maternal morbidity and mortality and account for inhibitors are not recommended during pregnancy III C
up to 15% of maternal deaths globally.2,728 due to adverse foetal effects.
Assessment of patients with pre-existing HF includes regular assess- Acute heart failure
ment of symptoms, echocardiography, and NP at intervals determined
Inotropes and/or vasopressors are recommended in
by the severity of HF and other non-cardiac issues.
pregnant women with cardiogenic shock with
I C
levosimendan, dobutamine, and milrinone as
12.6.2. Acute heart failure (including cardiogenic shock) recommended agents.730
Acute heart failure can develop in women without pre-existing heart Urgent delivery with caesarean section is
disease as can be the case in PPCM (Section 7), or secondary in women
recommended in pregnant women with cardiogenic
with known cardiac disease such as cardiomyopathy, ischaemic heart
shock as soon as the foetus is viable, taking I C
disease, ACHD, and severe VHD. The diagnosis can be challenging be-
gestational age, comorbidities, and the available level
cause the symptoms and signs of AHF can be misinterpreted as changes
of medical care into account.689
due to pregnancy (Figure 22).349,729 Pregnant women presenting with
Early transfer of pregnant women in cardiogenic
AHF require urgent hospital admission. These patients should be re-
shock to a facility providing mechanical circulatory IIa C
ferred to an expert centre with established advanced HF care, including
support should be considered.345,740
on-site surgery and mechanical circulatory support or even a transplant
programme as backup. Preventing lactation may be considered in women
In case of cardiogenic shock, recommended inotropic agents include le- with severe HF due to the high metabolic demands of IIb B
vosimendan,730 dobutamine, and milrinone (Figure 22). Levosimendan is lactation.360
administered as a continuous infusion without an initial loading dose.
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI,
Dobutamine is an option, whereas adrenaline should be avoided. angiotensin receptor/neprilysin inhibitor; EF, ejection fraction; HF, heart failure; HFrEF, heart
Milrinone may be an alternative if benefits outweigh the risk, due to failure with reduced ejection fraction; LMWH, low-molecular-weight heparin; LV, left ventricle;
placental transfer (see Supplementary data online, Table S2). Mechanical MRA, mineralocorticoid receptor antagonist; SGLT2, sodium–glucose co-transporter-2.
aClass of recommendation.
circulatory support [preferably veno-arterial extracorporeal membrane bLevel of evidence.
oxygenation (VA-ECMO)731] should be considered in case of severe cSee Figure 6 and Supplementary data online, Table S2.
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4537
Management of acute heart failure and cardiogenic shock in pregnancy
and up to 6 months post-partum
Consider corticosteroids for foetal lung maturation if <35 weeks of gestation
Assess HF severitya
Severe HF or cardiogenic shock No severe HF or cardiogenic shock
Delivered
Oxygen optimization:
Preload optimization:
non-invasive mechanical
volume versus diuretics
ventilation
-initiate nitrates if
or invasive ventilation,
SBP >110 mmHg
if SpO2 <95%
ACE-I, ARB, Hydralazine,
Add inotropes and/or
ARNI, nitrate,
vasopressors; Urgent delivery
beta-blocker, beta-blocker,
levosimendan without by caesarean section
MRA, (bisoprolol,
loading dose, in case of cardiogenic
SGLT2-I, metoprolol
dobutamine or shock
diuretic succinate),
milrinone (Class I)
(Class I) diuretic
(Class I)
Ivabradine ACE-I, ARB,
ARNI, MRA
ivabradine,
and SGLT2-I
In PPCM (Class III)
If delivered:
Bromocriptineb
Consider
(Class IIb)
vaginal
delivery with
Anticoagulant therapy
epidural
(heparin/LMWH) to reduce
analgesia
thromboembolic events
(Class I)
if bromocriptine is used
(Class IIa)
MCS (preferably VA-ECMO or LVAD), in accordance
with local availability and team experience;
‘bridge-to-recovery’ or as ‘bridge-to-bridge’ in
case of refractory cardiogenic shock.
No recovery
Heart transplantation
Figure 22 Management of acute heart failure and cardiogenic shock in pregnancy and up to 6 months post-partum. ACE-I, angiotensin-converting enzyme
inhibitors; ARB, angiotensin receptor blockers; ARNI, angiotensin receptor/neprilysin inhibitor; b.p.m., beats per minute; HF, heart failure; HR, heart rate;
LMWH, low-molecular-weight heparin; LVAD, left ventricular assist device; MCS, mechanical circulatory support; MRA, mineralocorticoid receptor antag-
onist; PPCM, peripartum cardiomyopathy; SGLT2-I, sodium–glucose co-transporter-2 inhibitor; SBP, systolic blood pressure; SpO , oxygen saturation;
2
VA-ECMO, veno-arterial extracorporeal membrane oxygenation. aAssessment of heart failure severity: SBP <90 mmHg; HR >130 b.p.m. or <45 b.p.m.;
respiratory rate >25/min; SpO <90%; Blood lactate >2.0 mmol/L; low central–venous oxygen saturation <60% (if available); altered mental state; cold,
2
clammy, mottled skin; oliguria <0.5 mL/kg/h. bBromocriptine: starting dose 2.5 mg twice daily with up-titration if needed.
Downloaded
from

by
guest
on
22
January
2026

4538 E S C G u id e l in e s
Beta-blockers should be initiated and gradually up-titrated to the max- Recommendation Table 21 — Recommendations for
imum tolerated dose.345,357,732–734 ACE-Is, ARBs, ARNIs, MRAs, ivab- heart transplantation and pregnancy
radine, SGLT2 inhibitors, and atenolol are contraindicated during
pregnancy due to adverse effects on the foetus. Hydralazine and ni- Recommendations Classa Levelb
trates appear safe.43,345,357,733,734
It is recommended to postpone pregnancy until at
In the post-partum period, the use of ivabradine to control the heart
least 1 year after heart transplantation, taking I C
rate may be considered in addition to beta-blockers, or if there is a
individual risk factors into account.275,741
contraindication for beta-blockers.43,339,735,736 In HF with a reversible
In women with a heart transplant, it is recommended
cause, HF treatment in accordance with guidelines should be recom-
that immunosuppression serum drug levels are
mended for at least 12 months after full LV recovery, followed by grad-
ual tapering350 (see also Section 7). Women with pregnancy-associated monitored during pregnancy every 4 weeks until the I C
32nd week, then every 2 weeks until the 36th week,
HF should be counselled about the risks of recurrence in subsequent
pregnancies.737 then weekly until delivery, and for 6–12 months after
delivery to guide dosing.275
It is recommended to perform weekly monitoring of
donor-specific antibodies for at least 6–12 months I C
after delivery.275,741,749–751
12.7. Special populations
Paternal HLA testing prior to conception should be
12.7.1. Heart transplantation
considered due to the risk of developing IIa C
Successful pregnancies have been reported in women with heart donor-specific antibodies.746,747
transplantation, but these pregnancies carry a higher risk. Before
Mycophenolic acid therapy is not recommended in
transplantation and before a post-transplantation pregnancy, wo-
pregnancy and should be discontinued 6 weeks III C
men should be counselled about maternal and foetal risks, includ-
before conception.275,741
ing the risks of rejection, infection, graft dysfunction, and potential
teratogenicity of drugs. Based on the individual risk factors, it is HLA, human leucocyte antigen.
recommended to postpone pregnancy until at least 1 year after aClass of recommendation.
bLevel of evidence.
transplantation.275 Women with heart transplantation are at
higher risk of experiencing cardiometabolic complications during
pregnancy such as pre-eclampsia, gestational diabetes, hyperten- 12.7.2. Cardio-oncology
sion, decreased kidney function, and infections.741–745 The risk 12.7.2.1 Gestational cancer
of complications is lower in women with normal graft function Gestational cancer is defined as cancer that occurs during pregnancy or
and no signs of rejection. Pre-pregnancy evaluation should include within 12 months after delivery. The occurrence is ∼1 in 1000 pregnan-
standard assessments and, if clinically indicated, coronary angiog- cies, with a possible rise in incidence as maternal childbearing age in-
raphy, right-heart catheterization, and endomyocardial bi- creases. The most frequent cancers affecting pregnant women are
opsy.741–745 breast cancer, cervical and ovarian cancer, lymphoma, leukaemia, colo-
All drugs should be reviewed before pregnancy275 and mycopheno- rectal cancer, and melanoma.752–754 Women diagnosed with cancer
lic acid therapy275,741 should be avoided due to the teratogenic risk. In during pregnancy should be evaluated and considered by a multidiscip-
cases where the father has the same human leucocyte antigen (HLA) linary team. Both the effect of pregnancy on the cancer and the effect of
as the donated heart, there is a risk of developing donor-specific anti- the cancer on the pregnancy should be evaluated. Patients should be
bodies.746,747 Therefore, consideration should be given to performing followed in centres with neonatal units in case of premature delivery.
paternal HLA testing before conception. The baseline assessment prior to chemotherapy, and the monthly or
During pregnancy, changes in maternal metabolism can affect the bimonthly follow-up during chemotherapy, should include clinical history,
serum drug levels of immunosuppression therapy.748 Close monitoring physical examination, ECG, cardiac biomarkers, and TTE in the context of
of serum drug levels is recommended.275 Echocardiographic evalua- physiological haemodynamic changes during pregnancy.107,755,756 LVEF,
tions are recommended to assess graft function during pregnancy. NP serial measurements,756 and high-sensitivity cTn can be used for mon-
Foetal growth should be regularly evaluated due to the risk of lower itoring of cancer-therapy-related cardiac dysfunction (CTRCD).734,756
birth weight.745 Vaginal delivery should be considered in stable Chemotherapy given during the first trimester is associated with a high
patients.745 risk of malformation (up to 20%) and miscarriage. Chemotherapy is often
Close monitoring of cardiac function, immunosuppression, avoided after 34 weeks of gestation to provide a ≥3 week window be-
and donor-specific antibodies is necessary until 6–12 months after tween the last chemotherapy and delivery. Cytotoxic chemotherapies
delivery due to the risk of post-pregnancy rejection.275,741,749–751 provide different risk profiles during the second and third trimesters.752,754
Lactation may be possible in patients on immunosuppressive drugs, The suggested chemotherapy treatments for pregnant women with can-
depending on the type of medication (see Section 5.2.10). cer are summarized in the 2022 ESC Guidelines on cardio-oncology.757
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4539
12.7.2.2 Pregnancy in cancer survivors BP at 7 days.765 Methyldopa should be avoided because of the risk of
Improved cancer treatments have led to an increased number of wo- post-partum depression.602,766 Agents used for the management of
men with pregnancies after oncological therapy. Previous treatment acute, severe hypertension in the post-partum period are similar to
with anthracycline chemotherapy or chest radiotherapy implies a those used during pregnancy and include labetalol, hydralazine, and ni-
15-fold increased lifetime risk of developing HF. Furthermore, both fedipine (see Sections 5 and 12).767 For women with persistent hyper-
the cancer and the cancer treatment have an impact on fertility, preg- tension, antihypertensive therapy should be initiated with reference to
nancy outcomes, and cardiovascular health. The major risk factors for lactating status following current guidelines (see Section 5).584,585,767
cardiovascular events during pregnancy in cancer survivors include
CTRCD (28%; 47.4 times higher odds), younger age at cancer diagno- 13.1.2. Gestational diabetes mellitus
sis,758,759 higher cumulative doses of anthracycline, and greater dur- Gestational diabetes mellitus is characterized by glucose intolerance
ation between cancer treatment and first pregnancy.758,759 that is first recognized during pregnancy.768 Haemoglobin A1c testing
may help to identify women at high risk.768,769 Women with GDM
have a sharply increased risk of developing type 2 diabetes later in life
Recommendation Table 22 — Recommendations for
cardio-oncology and pregnancy and a significantly higher likelihood of experiencing adverse cardiovas-
cular events.770–772 Women with GDM are recommended to undergo
Recommendations Classa Levelb a formal oral glucose tolerance test (oGTT) 6–12 weeks post-partum
with a repeat assessment at 6–12 months (Figure 25). Thereafter, regu-
It is recommended that pregnant women with cancer
lar annual follow-up with glucose tolerance monitoring is recom-
who require cardiotoxic cancer therapy are jointly
I C
mended.773–775
managed by the Pregnancy Heart Team and the
cardio-oncology team.43
13.1.3. Pre-term birth
Cardiac troponin and NP measurements may be
Pre-term delivery occurs after 20 and before the completion of 37
considered at baseline and during anthracycline
IIb C weeks of gestation, regardless of birth weight. There are strong associa-
chemotherapy in pregnant women with
tions between pre-term delivery (alone or with pregnancy-related
cancer.734,756
hypertensive disorders), CVD, and mortality.771,772 Women with pre-
NP, natriuretic peptide. term deliveries are more likely to have an increasing BP trajectory after
aClass of recommendation. pregnancy and to be affected by accelerated atherosclerosis independ-
bLevel of evidence. ent of traditional CVD risk factors.776,777 The earlier pre-term delivery
occurs, the more strongly it is associated with hypertension and CVD in
later life. The relationship of pre-term birth to type 2 diabetes mellitus
13. Adverse pregnancy outcomes
and dyslipidaemia is inconsistent.
and long-term management
13.1.4. Small for gestational age
Adverse pregnancy outcomes (APO), including gestational hyperten-
sive disorders, pre-eclampsia, gestational diabetes mellitus (GDM), Delivering a SGA baby (weight <10th percentile) has not been consist-
small or large for gestational age babies, or pre-term birth are a group ently related to an increased CVD risk, but has been associated with
of interrelated disorders that share common pathways.760 Placental hypertension and diabetes.761,771,772 Conversely, large for gestational
dysfunction and oxidative stress in the context of cardiometabolic, gen- age babies (weight >90th percentile) have been reported to increase
etic, or environmental risk factors may cause APOs.761 A multidisciplin- maternal CVD risk, but the evidence is limited.761
ary care approach is essential (Figure 23)761,762 for optimizing
modifiable cardiovascular risk factors after all APOs.761,762 13.1.5. Pregnancy loss and placental abruption
Placental abruption, spontaneous pregnancy loss or stillbirth, and foetal
13.1. Adverse pregnancy outcomes loss after 28 weeks of gestation have been associated with an increased
13.1.1. Post-partum hypertensive disorders risk of future CVD, with a particularly high risk of hypertension and type
2 diabetes mellitus.771,778 One or more terminations are associated Hypertension in the post-partum period is most common in women
with a higher CVD risk, however, with limited evidence.779
with antenatal hypertensive disorders, but it can also develop de novo
in the post-partum period. New-onset or de novo post-partum pre-
13.2. Breastfeeding
eclampsia is increasingly recognized as an important contributor to ma-
ternal morbidity and mortality in the post-partum period (Figure 24).763 Breastfeeding fosters the recovery of maternal physiological systems to their
Women with pregnancy-related hypertensive disorders, most not- pre-conception state. Breastfeeding women have a better cardiometabolic
ably pre-eclampsia, have a higher incidence of several CVDs, including profile, and breastfeeding up to 12 months after childbirth has been shown
CAD, stroke, and HF.762,764 Treatment for uncomplicated post-partum to lower future risk of CVD and mortality,780–783 potentially due to lowered
hypertension (first 6 weeks after delivery) includes nifedipine and labe- BP.784–787 Longer breastfeeding periods are associated with better CVD out-
talol (metoprolol if labetalol is unavailable).764 A small randomized con- comes.782,784,788–790 The role of breastfeeding for women who experienced
trolled trial showed that administration of furosemide in the first 5 days an APO is less clear, but it also appears to have beneficial effects.789,791,792
post-partum in women with gestational hypertension and pre- There is inconclusive evidence about the beneficial effects of breastfeeding
eclampsia significantly reduced the prevalence of persistently elevated on the cardiovascular health of older women (i.e. aged ≥55 years).720,788,793,794
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

4540 E S C G u id e l in e s
(cid:19)(cid:29)(cid:20)(cid:18)(cid:17)(cid:29)(cid:20)(cid:16)(cid:15)(cid:30)(cid:15)(cid:23)(cid:14) (cid:19)(cid:29)(cid:20)(cid:16)(cid:15)(cid:30)(cid:15)(cid:23)(cid:14) (cid:19)(cid:26)(cid:24)(cid:13)(cid:18)(cid:17)(cid:30)(cid:29)(cid:13)(cid:22)(cid:12)
(cid:11)(cid:28)(cid:25)(cid:20)(cid:29)(cid:24)(cid:20)(cid:10)(cid:17)(cid:29)(cid:20)(cid:16)(cid:15)(cid:30)(cid:15)(cid:23)(cid:14)(cid:10) (cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:30)(cid:24)(cid:23)(cid:22)(cid:21)(cid:30)(cid:29)
(cid:26)(cid:22)(cid:13)(cid:23)(cid:26)(cid:12)(cid:20)(cid:24) (cid:28)(cid:27)(cid:24)(cid:26)(cid:29)(cid:28)(cid:20)(cid:29)(cid:24)
(cid:31)(cid:30)(cid:29)(cid:30)(cid:28)(cid:27)(cid:26)(cid:25)
(cid:24)(cid:23)(cid:22)(cid:30)(cid:21)(cid:28)(cid:30)(cid:29)(cid:25)(cid:27)(cid:20)(cid:30)(cid:19)(cid:18)(cid:27)(cid:25)(cid:17)(cid:21)(cid:18)(cid:30)(cid:21)(cid:25) (cid:24)(cid:23)(cid:22)(cid:30)(cid:21)(cid:28)(cid:30)(cid:29)(cid:25)(cid:27)(cid:17)(cid:29)
(cid:31)(cid:30)(cid:25)(cid:28)(cid:16)(cid:28)(cid:27)(cid:17)(cid:29)(cid:16)(cid:15)(cid:19)(cid:18)(cid:27)(cid:16)(cid:14)(cid:30)(cid:28)(cid:30)(cid:25) (cid:6)(cid:27)(cid:16)(cid:14)(cid:30)(cid:28)(cid:30)(cid:25)
(cid:3)(cid:16)(cid:21)(cid:18)(cid:27)(cid:17)(cid:12)(cid:30)(cid:28)(cid:16)(cid:14)(cid:17)(cid:15)(cid:27)(cid:26)
(cid:13)(cid:12)(cid:16)(cid:15)(cid:15)(cid:11)(cid:15)(cid:16)(cid:21)(cid:10)(cid:30)(cid:19)(cid:9)(cid:17)(cid:21) (cid:3)(cid:5)(cid:6)
(cid:21)(cid:27)(cid:25)(cid:1)(cid:19)(cid:9)(cid:16)(cid:26)(cid:28)(cid:17)(cid:21)(cid:25)
(cid:10)(cid:30)(cid:25)(cid:28)(cid:16)(cid:28)(cid:27)(cid:17)(cid:29)(cid:16)(cid:15)(cid:19)(cid:16)(cid:10)(cid:30) (cid:13)(cid:28)(cid:21)(cid:17)(cid:1)(cid:30)
(cid:8)(cid:21)(cid:30)(cid:28)(cid:30)(cid:21)(cid:12)(cid:19)(cid:18)(cid:30)(cid:15)(cid:27)(cid:20)(cid:30)(cid:21)(cid:23) (cid:24)(cid:30)(cid:16)(cid:21)(cid:28)(cid:19)(cid:9)(cid:16)(cid:27)(cid:15)(cid:7)(cid:21)(cid:30) (cid:127)(cid:29)(cid:20)(cid:27)(cid:21)(cid:17)(cid:29)(cid:12)(cid:30)(cid:29)(cid:28)
(cid:8)(cid:21)(cid:30)(cid:10)(cid:29)(cid:16)(cid:29)(cid:26)(cid:23)(cid:19)(cid:15)(cid:17)(cid:25)(cid:25) (cid:5)(cid:15)(cid:15)(cid:4)(cid:26)(cid:16)(cid:7)(cid:25)(cid:30)(cid:19)(cid:16)(cid:29)(cid:18)
(cid:8)(cid:15)(cid:16)(cid:26)(cid:30)(cid:29)(cid:28)(cid:16)(cid:15)(cid:19)(cid:16)(cid:14)(cid:21)(cid:7)(cid:22)(cid:28)(cid:27)(cid:17)(cid:29) (cid:3)(cid:2)(cid:6)(cid:19)(cid:12)(cid:17)(cid:21)(cid:28)(cid:16)(cid:15)(cid:27)(cid:28)(cid:23)
(cid:3)(cid:17)(cid:7)(cid:29)(cid:25)(cid:30)(cid:15)(cid:15)(cid:27)(cid:29)(cid:10)
(cid:6)(cid:30)(cid:15)(cid:27)(cid:20)(cid:30)(cid:21)(cid:23)(cid:19)(cid:22)(cid:15)(cid:16)(cid:29)(cid:29)(cid:27)(cid:29)(cid:10)
(cid:3)(cid:16)(cid:21)(cid:18)(cid:27)(cid:17)(cid:20)(cid:16)(cid:25)(cid:26)(cid:7)(cid:15)(cid:16)(cid:21) (cid:3)(cid:16)(cid:21)(cid:18)(cid:27)(cid:17)(cid:20)(cid:16)(cid:25)(cid:26)(cid:7)(cid:15)(cid:16)(cid:21)
(cid:12)(cid:17)(cid:29)(cid:27)(cid:28)(cid:17)(cid:21)(cid:27)(cid:29)(cid:10) (cid:21)(cid:27)(cid:25)(cid:1)(cid:19)(cid:16)(cid:25)(cid:25)(cid:30)(cid:25)(cid:25)(cid:12)(cid:30)(cid:29)(cid:28)
(cid:157)(cid:27)(cid:9)(cid:30)(cid:25)(cid:28)(cid:23)(cid:15)(cid:30)(cid:19)(cid:17)(cid:22)(cid:28)(cid:27)(cid:12)(cid:27) (cid:16)(cid:28)(cid:27)(cid:17)(cid:29)
(cid:8)(cid:21)(cid:30)(cid:10)(cid:29)(cid:16)(cid:29)(cid:26)(cid:23)(cid:19)(cid:24)(cid:30)(cid:16)(cid:21)(cid:28)(cid:19)(cid:129)(cid:30)(cid:16)(cid:12) (cid:8)(cid:21)(cid:27)(cid:12)(cid:16)(cid:21)(cid:23)(cid:19)(cid:26)(cid:16)(cid:21)(cid:30)(cid:19)(cid:22)(cid:144)(cid:23)(cid:25)(cid:27)(cid:26)(cid:27)(cid:16)(cid:29)
(cid:141)(cid:17)(cid:12)(cid:30)(cid:29)(cid:143)(cid:25)(cid:19)(cid:144)(cid:30)(cid:16)(cid:21)(cid:28)(cid:19)(cid:26)(cid:15)(cid:27)(cid:29)(cid:27)(cid:26)(cid:16)
Figure 23 Multidisciplinary approach of adverse pregnancy outcomes. CAD, coronary artery disease; CVD, cardiovascular disease. aSee Section 13.3 on
Women’s Heart Clinics.
13.3. Women’s Heart Clinics establishment of Women’s Heart Clinics focusing on women of all
Post-partum care is often segmented and only carried out by obste- ages with CVD are necessary to span the care up to post-partum.795
tricians. A longer duration of post-partum care, including cardiovas- Seamless communication between the various healthcare providers
cular risk assessment and counselling on CVD risk prevention, (e.g. obstetrician, cardiologist, internist, family physician) and multi-
is likely to lower the long-term risk of CVD in women with an disciplinary management of APOs is critical for long-term care and
APO (Figure 25).762,795 Pregnancy Heart Teams and the potential the woman’s future health.761,796,797
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4541
(cid:22)(cid:27)(cid:141)(cid:157)(cid:29)(cid:25)(cid:18)(cid:27)(cid:28)(cid:13)(cid:15)(cid:29)(cid:18)(cid:28)(cid:157)(cid:15)(cid:23)(cid:30)(cid:28)(cid:24)(cid:16)
(cid:9)(cid:17)(cid:15)(cid:27)(cid:30)(cid:28)(cid:27)(cid:25)(cid:18)(cid:26)(cid:29)(cid:25)
(cid:31)(cid:13)≥€‚ƒ(cid:8)„ƒ(cid:16)(cid:16)(cid:129)(cid:20)…
(cid:129)(cid:17)(cid:15)(cid:27)(cid:30)(cid:28)(cid:27)(cid:25)(cid:18)(cid:26)(cid:29)(cid:25)(cid:13)(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:141)(cid:26)(cid:28)(cid:9)(cid:29)(cid:24)(cid:28) (cid:129)(cid:17)(cid:15)(cid:27)(cid:30)(cid:28)(cid:27)(cid:25)(cid:18)(cid:26)(cid:29)(cid:25)(cid:13)(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)
(cid:18)(cid:26)(cid:20)(cid:25)(cid:18)(cid:13)(cid:29)(cid:5)(cid:13)(cid:29)(cid:30)(cid:20)(cid:23)(cid:25)(cid:13)(cid:1)(cid:17)(cid:18)(cid:5)(cid:24)(cid:25)(cid:19)(cid:28)(cid:26)(cid:29)(cid:25) (cid:18)(cid:26)(cid:20)(cid:25)(cid:18)(cid:13)(cid:29)(cid:5)(cid:13)(cid:29)(cid:30)(cid:20)(cid:23)(cid:25)(cid:13)(cid:1)(cid:17)(cid:18)(cid:5)(cid:24)(cid:25)(cid:19)(cid:28)(cid:26)(cid:29)(cid:25)
(cid:31)(cid:29)(cid:18)(cid:28)(cid:157)(cid:15)(cid:23)(cid:30)(cid:28)(cid:24)(cid:16)
(cid:9)(cid:17)(cid:15)(cid:27)(cid:30)(cid:28)(cid:27)(cid:25)(cid:18)(cid:26)(cid:29)(cid:25)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:24)(cid:30)(cid:26)(cid:23) (cid:22)(cid:27)(cid:24)(cid:30)(cid:29)(cid:21)(cid:29)(cid:20)(cid:26)(cid:19)(cid:23)(cid:21) (cid:14)(cid:27)(cid:30)(cid:24)(cid:16)(cid:13)(cid:21)(cid:23)(cid:12)(cid:29)(cid:30)(cid:23)(cid:28)(cid:29)(cid:30)(cid:17)
(cid:18)(cid:17)(cid:16)(cid:15)(cid:28)(cid:29)(cid:16)(cid:18) (cid:23)(cid:12)(cid:25)(cid:29)(cid:30)(cid:16)(cid:23)(cid:21)(cid:26)(cid:28)(cid:26)(cid:27)(cid:18)
†(cid:10)(cid:23)(cid:21)(cid:24)(cid:23)(cid:28)(cid:27)(cid:13)(cid:5)(cid:29)(cid:30)
(cid:6)(cid:19)(cid:24)(cid:28)(cid:27)(cid:13)(cid:5)(cid:23)(cid:28)(cid:28)(cid:17)(cid:13)(cid:21)(cid:26)(cid:10)(cid:27)(cid:30)
(cid:14)(cid:27)(cid:10)(cid:27)(cid:30)(cid:27)(cid:13)(cid:15)(cid:27)(cid:30)(cid:18)(cid:26)(cid:18)(cid:28)(cid:27)(cid:25)(cid:28)(cid:13) (cid:29)(cid:5)(cid:13)(cid:15)(cid:30)(cid:27)(cid:20)(cid:25)(cid:23)(cid:25)(cid:19)(cid:17)(cid:4)
(cid:30)(cid:26)(cid:20)(cid:9)(cid:28)(cid:13)(cid:24)(cid:15)(cid:15)(cid:27)(cid:30)(cid:13) (cid:11)(cid:27)(cid:30)(cid:27)(cid:12)(cid:30)(cid:23)(cid:21)(cid:13)(cid:10)(cid:27)(cid:25)(cid:29)(cid:24)(cid:18) (cid:3)(cid:9)(cid:30)(cid:29)(cid:16)(cid:12)(cid:29)(cid:19)(cid:17)(cid:28)(cid:29)(cid:15)(cid:27)(cid:25)(cid:26)(cid:23)(cid:2)(cid:13)
‡(cid:24)(cid:23)(cid:1)(cid:30)(cid:23)(cid:25)(cid:28)(cid:13)(cid:29)(cid:30)(cid:13) (cid:28)(cid:9)(cid:30)(cid:29)(cid:16)(cid:12)(cid:29)(cid:18)(cid:26)(cid:18)(cid:8)(cid:18)(cid:28)(cid:30)(cid:29)(cid:7)(cid:27) (cid:26)(cid:16)(cid:15)(cid:23)(cid:26)(cid:30)(cid:27)(cid:1)(cid:13)(cid:21)(cid:26)(cid:10)(cid:27)(cid:30)
(cid:27)(cid:15)(cid:26)(cid:20)(cid:23)(cid:18)(cid:28)(cid:30)(cid:26)(cid:19)(cid:13)(cid:15)(cid:23)(cid:26)(cid:25) (cid:5)(cid:24)(cid:25)(cid:19)(cid:28)(cid:26)(cid:29)(cid:25)(cid:2)
(cid:30)(cid:27)(cid:25)(cid:23)(cid:21)(cid:13)(cid:26)(cid:25)(cid:18)(cid:24)(cid:127)(cid:19)(cid:26)(cid:27)(cid:25)(cid:19)(cid:17)
(cid:143)(cid:28)(cid:9)(cid:27)(cid:30)(cid:13)(cid:23)(cid:27)(cid:28)(cid:26)(cid:29)(cid:21)(cid:29)(cid:20)(cid:26)(cid:27)(cid:18)(cid:13)(cid:27)(cid:144)(cid:19)(cid:21)(cid:24)(cid:1)(cid:27)(cid:1)
(cid:31)(cid:29)(cid:18)(cid:28)(cid:157)(cid:15)(cid:23)(cid:30)(cid:28)(cid:24)(cid:16)
(cid:15)(cid:30)(cid:27)(cid:157)(cid:27)(cid:19)(cid:21)(cid:23)(cid:16)(cid:15)(cid:18)(cid:26)(cid:23)(cid:8)
(cid:27)(cid:19)(cid:21)(cid:23)(cid:16)(cid:15)(cid:18)(cid:26)(cid:23)
Figure 24 Algorithm for the management of new-onset post-partum hypertension. BP, blood pressure.
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:24)
(cid:27)(cid:23)(cid:22)(cid:21)(cid:30)(cid:24)(cid:25)
…†(cid:10)(cid:9)(cid:25)(cid:9)(cid:24)(cid:19)(cid:21)(cid:19)(cid:30)(cid:29)
„(cid:24)(cid:19)(cid:3)(cid:30)(cid:24)(cid:4)(cid:22)(cid:21)(cid:30)(cid:24)(cid:25)(cid:22)(cid:7)(cid:24)(cid:27)(cid:26)(cid:19)(cid:28)(cid:25)(cid:24)
(cid:1)(cid:4)(cid:29)(cid:30)(cid:25)(cid:21)(cid:27)(cid:17)(cid:27)(cid:1)(cid:19)(cid:10)(cid:9)
(cid:11)(cid:25)(cid:17)(cid:19)(cid:26)(cid:25)(cid:24)(cid:4) (cid:143)(cid:22)€(cid:25)(cid:25)(cid:14)(cid:10) ‚(cid:22)ƒ(cid:22)(cid:144)(cid:157)(cid:22)€(cid:25)(cid:25)(cid:14)(cid:10) (cid:143)(cid:22)(cid:3)(cid:27)(cid:29)(cid:9)(cid:15)(cid:10) (cid:144)(cid:157)(cid:22)(cid:3)(cid:27)(cid:29)(cid:9)(cid:15)(cid:10)
(cid:129)(cid:25)(cid:141)(cid:21)(cid:15)(cid:25)(cid:21)(cid:14)(cid:22)(cid:25)(cid:26)(cid:25)(cid:24)(cid:4)
(cid:20)(cid:29)(cid:28)(cid:19)(cid:26)(cid:19)(cid:28)(cid:18)(cid:30)(cid:17)(cid:19)(cid:16)(cid:25)(cid:28)(cid:22)(cid:21)(cid:15)(cid:25)(cid:21)(cid:14)(cid:22)(cid:13)(cid:12)(cid:11)(cid:22)(cid:24)(cid:19)(cid:10)(cid:14)(cid:22)(cid:23)(cid:30)(cid:21)(cid:9)(cid:27)(cid:24) (cid:143)(cid:22)(cid:9)(cid:27)(cid:22)(cid:144)(cid:157)(cid:22)(cid:3)(cid:27)(cid:29)(cid:9)(cid:15)(cid:10)
(cid:13)(cid:17)(cid:30)(cid:10)(cid:10)(cid:22)(cid:20)(cid:20)(cid:30)
(cid:8)(cid:17)(cid:27)(cid:27)(cid:28)(cid:22)(cid:7)(cid:24)(cid:25)(cid:10)(cid:10)(cid:18)(cid:24)(cid:25)
(cid:6)(cid:17)(cid:18)(cid:21)(cid:27)(cid:10)(cid:25)(cid:22)(cid:17)(cid:25)(cid:26)(cid:25)(cid:17)(cid:10)
(cid:5)(cid:19)(cid:7)(cid:19)(cid:28)(cid:22)(cid:17)(cid:25)(cid:26)(cid:25)(cid:17)(cid:10)
(cid:8)(cid:27)(cid:28)(cid:4)(cid:22)(cid:3)(cid:30)(cid:10)(cid:10)(cid:22)(cid:19)(cid:29)(cid:28)(cid:25)(cid:2)
(cid:5)(cid:19)(cid:23)(cid:25)(cid:10)(cid:9)(cid:4)(cid:17)(cid:25)(cid:22)(cid:21)(cid:27)(cid:18)(cid:29)(cid:10)(cid:25)(cid:17)(cid:17)(cid:19)(cid:29)(cid:1)
(cid:127)(cid:3)(cid:27)(cid:9)(cid:19)(cid:27)(cid:29)(cid:30)(cid:17)(cid:22)(cid:10)(cid:9)(cid:24)(cid:25)(cid:10)(cid:10)
Figure 25 Algorithm for the management of adverse pregnancy outcomes. CVD, cardiovascular disease.
Downloaded
from

by
guest
on
22
January
2026

4542 E S C G u id e l in e s
Recommendation Table 23 — Recommendations for long-term effects of adverse pregnancy outcomes (see Evidence
Tables 20 and 21)
Recommendations Classa Levelb
It is recommended to undertake a cardiovascular risk assessment in women with APOs, to recognize and document APOs when CVD risk is
I B
evaluated in women, and to provide counselling on the importance of healthy lifestyle choices that optimize cardiovascular health.771,772
In women with persistent post-partum hypertension beyond 6 weeks to 3 months post-partum, initiation of antihypertensive therapy with
I B
reference to lactating status is recommended following current guidelines.584,602,798
In cases where adoption of healthy lifestyle choices alone is inadequate to control post-partum glucose levels, initiation of pharmacotherapy
I C
following current guidelines is recommended.773,774,799
It is recommended that women with a history of GDM undergo a formal oGTT 6–12 weeks post-partum with a repeat assessment at 6–12
I C
months and regular annual follow-up visits to screen for diabetes.773,774,800
Nifedipine and labetalol (metoprolol if labetalol is unavailable) are recommended as treatments for uncomplicated post-partum
I C
hypertension in the first 6 weeks after delivery.602,766,767
In women with a history of any APO, cardiovascular risk assessment should be considered at 3 months post-partum with repeat assessment
IIa C
at 6–12 months after implementation of appropriate lifestyle interventions, and regular long-term follow-up thereafter.761,795
Breastfeeding may be considered in order to lower the future cardiovascular risk in women with APOs.789,791,792 IIb C
APO, adverse pregnancy outcomes; CVD, cardiovascular disease; GDM, gestational diabetes mellitus; oGTT, oral glucose tolerance test.
aClass of recommendation.
bLevel of evidence.
14. Key messages • In a life-threatening situation, treatments such as defibrillation, in-
terventions, acute coronary revascularization, mechanical circula-
• A Pregnancy Heart Team should be involved in the risk assess- tory support, and medication should be the same as in
ment, counselling and management of women in mWHO 2.0 non-pregnant women, irrespective of contraindications.
class ≥II–III from pre-conception to the late post-partum. • The use of non-invasive imaging tests with ionizing radiation during
Each woman should have a detailed delivery plan agreed in pregnancy should only be performed when the benefits clearly out-
advance. weigh the maternal and foetal risk, and if the result will significantly
• In women with known CVD, a complete clinical re-evaluation modify the medical management.
should take place pre-pregnancy to estimate risk, optimize treat- • In women with LQTS and CPVT, the continuation of beta-blockers
ment, consider and evaluate the removal of contraindicated drugs, throughout pregnancy with monitoring of foetal growth is recom-
and reduce the probability of complications. mended (atenolol is the only contraindicated beta-blocker).
• Women and their partner (if any) should be offered structured Beta-blockers of choice are propranolol and nadolol.
psychosocial support during the entire trajectory, especially • In women with LQT2, post-partum is a distinct high-risk period,
for those at high risk and those considering pregnancy and therefore full dosage of beta-blockers is strongly recommended.
termination. • Genetic testing should be considered in PPCM.
• Women with known heritable cardiovascular disorders should be • In women with PPCM and DCM, subsequent pregnancy is not re-
counselled about the transmission risk, including the option for as- commended if LV function does not normalize.
sisted reproductive technology. • Genetic testing in women with aortic disease wishing to conceive is
• Management of women with CVD who are pregnant or wishing recommended and management should be based on the presence
to become pregnant should be individualized and performed ac- and type of P/LP variant.
cording to a shared decision-making model, respecting the woman’s • Women with the following ACHD lesions should be provided with
autonomy. expert counselling and education by a Pregnancy Heart Team, with
• Women in mWHO 2.0 class IV should be comprehensively clear and thorough discussion of the very high pregnancy risk and
counselled about the very high pregnancy risk, being careful the need for a shared decision-making process:
to promote a detailed and transparent dialogue about the
⚬ Systemic RV, in NYHA class III–IV, ventricular dysfunction
heightened maternal and foetal risks associated with pregnancy.
(EF <40%), more than moderate TR, or treated HF;
A shared decision-making process is essential, allowing for in-
⚬ A Fontan circulation and oxygen saturation <85%, reduced ven-
formed choices, including the consideration of pregnancy ter-
tricular function, severe arrhythmias, or in NYHA class III–IV.
mination if necessary.
• Vaginal delivery is the first choice for the majority of women with • There is no safe cut-off value for elevated pulmonary artery pres-
CVD. sure in pregnancy.
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4543
• Women of childbearing potential with PAH should be counselled at Peripartum cardiomyopathy
the time of diagnosis about the risks and uncertainties associated
• The potential for recovery of cardiac function in PPCM remains un-
with becoming pregnant.
clear and the risks in subsequent pregnancies are not well defined.
• Any suspicion of VTE, including DVT and PE, requires an immediate
formal assessment with validated diagnostic tests by a multidisciplin- Aortopathies
ary specialized team.
• More data are needed to correctly estimate the pregnancy risk in
• LMWH is the agent of choice for prophylaxis and treatment of VTE
women with previous aortic dissection and/or aortic root surgery.
in pregnancy.
• Risk factors for aortic dissection in the post-partum period are
• When treating women with HF during pregnancy, it should be
poorly understood, making counselling about this difficult.
noted that several drugs [ACE-Is, ARBs, direct renin inhibitors, sa-
• It is unclear whether a distinction between root and ascending
cubitril–valsartan (ARNIs), MRAs, and SGLT2 inhibitors] are not re-
phenotype in women with BAV should lead to a different threshold
commended. When inotropes or more advanced treatment is
for prophylactic surgery (as in non-pregnant women).
necessary, referral to an expert centre is recommended.
• When possible, mechanical valves should be avoided in girls and wo- Congenital heart disease
men of childbearing age.
• More data are needed to estimate the risk and the long-term effects
• Methyldopa, labetalol, and CCBs are recommended for the treat-
of pregnancy (including multiple pregnancies), especially in women
ment of hypertension in pregnancy.
with a Fontan circulation or univentricular hearts.
• Women at high or moderate risk of pre-eclampsia should be ad-
• Risk factors for the development of heart failure and arrhythmias vised to additionally take 75–100 mg of ASA daily from weeks 12
in pregnant women with (systemic) right-heart failure are poorly
to 36/37.
understood.
• After cardiac transplantation, it is recommended to postpone preg-
nancy for at least 1 year, taking individual risk factors into account. Pulmonary hypertension
• Women with APOs should be informed about long-term risks and
• Defining the optimal timing to start or escalate PAH therapies in
preventive strategies and offered appropriate follow-up, including
pregnancy complicated with PAH remains challenging.
psychosocial support (if necessary).
Venous thromboembolism
15. Gaps in evidence • Data on risk stratification of VTE in pregnancy are limited, specific-
ally in those with other pre-existing comorbidities.
Pre-pregnancy counselling and evaluation • Data on the use of anticoagulant agents (other than LMWH) are
limited, just as data on the efficacy and safety of inferior vena cava
• Data on the adverse effects of assisted reproductive treatment in
filters and catheter-based thrombectomy (in PE).
women with CVD are lacking.
Acquired heart disease
Diagnostic methods
• The foetal risks associated with the newer HF medications remain
• There is a lack of data on the safety of echocardiographic contrast unclear, particularly regarding exposure during different trimesters.
agents during pregnancy or lactation. • The optimal tools to stratify risk of recurrence for atherosclerotic
• There are controversial data on the use of gadolinium-based con- and SCAD ACS are unknown.
trast agents in pregnancy. • Physiopathological mechanisms of SCAD in pregnancy are
• There are no clear cut-offs for NT-proBNP levels during pregnancy. unknown.
• There are no normative values of cTnI and cTnT in pregnancy and • Optimal treatment of SCAD during pregnancy is not well
the post-partum period. established.
• There is a lack of data on normal lung ultrasound pattern during • There is scarce evidence about the necessity of using statins during
pregnancy. pregnancy in women with cardiovascular risk or established ASCVD.
• Optimal anticoagulation strategies for women with MHVs during
Drugs during pregnancy and lactation
pregnancy remain uncertain.
• Safety data of DOACs and antidotes (idarucizumab, andexanet alfa, • The role of anti-factor Xa level monitoring needs to be determined.
cirapantag) in pregnancy are lacking.
Women’s Heart Clinics
• Safety data of newer anti-arrhythmic drugs and rate-controlling
drugs (vernakalant, ivabradine, landiolol) in pregnancy are lacking. • Optimal strategies for surveillance and follow-up of women with
APOs are unclear.
• It is unclear how social determinants of health (the environmental
Cardiomyopathy and primary arrhythmia syndromes
factors that affect how people live, learn, and work) affect APOs.
• The available data on gene-specific management during pregnancy in • There is a need for studies exploring models of post-natal care,
different cardiomyopathies and primary arrhythmia syndromes are starting from the initial antenatal visit through to the end of the
limited. post-partum period.
Downloaded
from

by
guest
on
22
January
2026

4544 E S C G u id e l in e s
• Further research is needed to identify risk factors for 17. Evidence tables
pregnancy-related depression and poor health behaviour engage-
ment in women with CVD, enabling the development of tailored in- Evidence tables are available at European Heart Journal
terventions to improve their health and quality of life. online.
16. ‘What to do’ and ‘what not to
do’ messages from the Guidelines 18. Data availability statement
Table 16 lists all Class I and Class III recommendations from the text No new data were generated or analysed in support of this
alongside their level of evidence. research.
Table 16 ‘What to do’ and ‘what not to do’
Recommendations Classa Levelb
4. The Pregnancy Heart Team
Counselling, pregnancy risk assessment, contraception, assisted reproductive technology, and the involvement of a Pregnancy Heart
Team
It is recommended to perform a risk assessment in all women with CVD of childbearing age using the mWHO 2.0 classification. I C
A discussion by the Pregnancy Heart Team about the high risk of maternal mortality or morbidity and the related high foetal risk is
recommended for women with mWHO 2.0 class IV conditions, including a shared decision-making process for pregnancy termination, I C
involving psychological support.
It is recommended that women with CVD of mWHO 2.0 class II–III and above are evaluated and managed by a Pregnancy Heart Team from
I C
pre-pregnancy onwards through pregnancy and post-partum.
It is recommended that women with CVD of mWHO 2.0 class II and above, or those at risk of developing CVD, receive individualized advice
I C
to determine the most suitable contraception method, including emergency contraception.
Assessment by a clinical geneticist prior to pregnancy is recommended in women fulfilling diagnostic criteria for inherited cardiovascular
I C
disease to guide risk stratification and pre-natal genetic testing.
Pre-conception genetic counselling is recommended in couples with heritable CVD, whether genetic testing is being considered or not. It is
recommended that this counselling is provided by an appropriately trained healthcare professional within a multidisciplinary team that offers I C
psychological support and education to encourage decision-making.
It is recommended that single embryo transfer is performed in women with CVD. I C
It is recommended to offer women with CVD access to termination of pregnancy that is tailored to their cardiac condition to minimize the
I C
risks of the procedure.
Diagnostic methods in pregnancy
Transthoracic echocardiography is recommended as first-line imaging tool in any pregnant woman with unexplained or new cardiovascular
I C
signs or symptoms.
It is recommended to limit exposure to all medical ionizing radiation doses to ALARA levels. I C
It is recommended to keep the radiation dose to the foetus as low as possible (preferably <50 mGy), particularly if the foetus is in the field of
I C
view.
Timing and mode of delivery
Vaginal delivery is recommended in most women with CVD. I B
Routine induction of labour prior to 39 weeks is not recommended in women with stable CVD. III C
It is recommended that the timing of delivery is planned to ensure safe and effective peripartum anticoagulation. I C
It is recommended to discontinue VKAs and start therapeutic-dose LMWH or adjusted-dose i.v. UFH at the 36th week of gestation or 2
I C
weeks before the planned delivery.
In women at low risk on therapeutic-dose LMWH, neuraxial anaesthesia and vaginal delivery (or caesarean section for obstetric indications)
I C
is recommended 24 h after the last dose of LMWH.
In women at high risk, it is recommended to convert LMWH to i.v. UFH at least 36 h prior to delivery and stop the UFH infusion 4–6 h prior
I C
to anticipated delivery. The aPTT should be normal before regional anaesthesia.
If delivery starts while the mother is on VKAs or <2 weeks after discontinuation of VKAs, caesarean section is recommended for foetal
I C
protection.
Post-delivery, it is recommended that the decision to restart LMWH or UFH is made after discussion with the Pregnancy Heart Team and
I C
the woman who gave birth.
Continued
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4545
It is recommended to postpone the switch from heparin back to oral anticoagulants until 7–14 days post-partum when the wound area has
I C
healed, in consultation with the Pregnancy Heart Team.
5. Drugs during pregnancy and lactation
Direct oral anticoagulants and pregnancy
DOACs are not recommended during pregnancy. III C
6. Pregnancy in women with cardiomyopathies and primary arrhythmia syndromes
Cardiomyopathies and pregnancy
Clinical cardiological surveillance (ECG, echocardiogram, and Holter ECG monitoring) is recommended during pregnancy in women with
I C
CMPs, depending on individual risk.
Vaginal delivery is recommended in most women with CMPs, unless there are obstetric indications for caesarean section, severe HF
(EF <30% and/or NYHA class III/IV), uncontrolled arrhythmias, or severe outflow obstruction (≥50 mmHg) in women with HCM, or in I C
women presenting in labour on VKAs.
In women with DCM and worsening of EF during pregnancy, counselling on the risk of recurrence during a subsequent pregnancy is
I C
recommended in all cases, even after recovery of LV function.
It is recommended to use the same risk stratification protocol for ventricular arrhythmias in pregnant women with HCM as for
I C
non-pregnant women with HCM.
It is recommended to start beta-blockers in women with HCM who develop symptoms due to outflow tract obstruction or arrhythmia
I C
during pregnancy.
It is recommended that women with HCM with symptomatic LV dysfunction (EF <50%) and or severe LVOTO (≥50 mmHg) wishing to
I C
become pregnant are counselled by the Pregnancy Heart Team regarding the high risk of pregnancy-related adverse events.
Myosin inhibitors are not recommended in women during pregnancy due to lack of safety data. III C
Primary arrhythmia syndromes and pregnancy
Monitoring and treatment of hypokalaemia and hypomagnesaemia is recommended in pregnant women with primary arrhythmia
I C
syndromes suffering from hyperemesis.
Beta-blockers, with pre-pregnancy dose and with nadolol and propranolol as drugs of choice, are recommended during pregnancy in
I B
women with LQTS.
It is recommended to continue beta-blocker therapy during lactation in women with LQTS to reduce arrhythmic risk. I B
Pre-pregnancy dose beta-blocker of nadolol or propranolol are recommended in women with LQT2, particularly in the post-partum
I B
period, which represents a high-risk period for life-threatening arrhythmias.
Beta-blockers, with pre-pregnancy dose and with nadolol and propranolol as drugs of choice, are recommended during pregnancy and
I C
lactation in women with CPVT.
Flecainide, in addition to beta-blockers, is recommended in women with CPVT who experience cardiac events such as syncope, VT, or
I C
cardiac arrest, during pregnancy.
It is recommended that women with CPVT who are stable on beta-blockers (nadolol or propranolol as drugs of choice) and flecainide
I C
before pregnancy, continue both drugs also during pregnancy and post-partum.
7. Peripartum cardiomyopathy
Counselling for women with PPCM about the risk of recurrence during a subsequent pregnancy and about contraception is recommended
I C
in all cases, even after recovery of LV function (LVEF >50%).
8. Pregnancy in women with aortopathies
It is recommended that women with aortic disease have counselling about the risk of aortic dissection in pregnancy and the post-partum
I C
period.
It is recommended that women with a history of aortic dissection or -surgery have pre-pregnancy counselling about the high risk by an
extended Pregnancy Heart Team considering the presence and type of genetic variant, aortic morphology, growth rate, and aetiology of I C
aortic dissection.
It is recommended that women with vascular Ehlers–Danlos syndrome wishing to become pregnant are counselled regarding the very high
I C
risk of pregnancy-related adverse events by a multidisciplinary team, considering family history, genetic variant, and previous vascular events.
Imaging of the entire aorta (CT or CMR) is recommended before pregnancy in women with known or suspected aortic disease. I C
In women with aortic dilatation related to BAV, imaging (with TTE, and CMR/CT if needed) of the aortic root, ascending aorta, and
I C
descending aorta (to rule out coarctation) is recommended before pregnancy.
In women with low-risk aortic disease (mWHO 2.0 classes II and II–III), one-time echocardiographic imaging between 20 and 30 weeks of
I C
gestation and imaging at 6 months post-partum is recommended.
Continued
Downloaded
from

by
guest
on
22
January
2026

4546 E S C G u id e l in e s
In women with moderate to high-risk aortic disease (mWHO 2.0 classes III and IV), repeated echocardiographic imaging every 4–12 weeks
I C
(depending on diagnosis and severity of dilatation) is recommended during pregnancy and until 6 months post-partum.
CMR (without gadolinium) imaging of the entire aorta is recommended in pregnant women at risk of or with known aortic dilatation who
I C
have not had recent pre-pregnancy cross-sectional imaging.
It is recommended that centres managing pregnancies in women with moderate to high-risk aortic disease (mWHO 2.0 class III/IV) can
I C
provide cardiovascular surgery in case of peripartum adverse events.
When a woman with known aortic dilatation, history of dissection, or P/LP variant associated with aortic disease becomes pregnant, strict
I C
and individualized BP control is recommended.
Beta-blocker therapy throughout pregnancy and in the post-partum period is recommended in women with MFS and other HTADs. I C
Celiprolol is recommended in women with vascular Ehlers–Danlos syndrome during pregnancy and lactation. I C
It is recommended that indications for pre-pregnancy aortic root and/or ascending aortic surgery are guided by aortic morphology,
I C
underlying pathology, family history, genetic variant, previous vascular events, and patient’s preference.
In women with MFS and aortic root diameters >45 mm, surgery before pregnancy is recommended. I C
In women with LDS with P/LP variants in TGFBR1, TGFBR2, and aortic root diameters ≥45 mm, surgery before pregnancy is recommended. I C
In women with nsHTAD with P/LP variants in MYH11, ACTA2, PRKG1, or MYLK, and aortic root diameters ≥45 mm, surgery before
I C
pregnancy is recommended.
In women with BAV and aortic root or ascending aortic diameter ≥50 mm, surgery before pregnancy is recommended. I C
In women without an identifiable P/LP variant with aortic root or ascending aortic diameters ≥50 mm, surgery before pregnancy is
I C
recommended.
In women with an aorta <40 mm, vaginal delivery is recommended. I C
In women with vascular Ehlers–Danlos syndrome, caesarean section at 37 weeks is recommended for obstetrical reasons. I C
The use of ergometrine post-delivery is not recommended in women with aortopathy. III C
9. Pregnancy in women with known congenital heart disease
Vaginal delivery is recommended in most women with ACHD. I B
It is recommended that all women with Fontan circulation who wish to become pregnant receive counselling from the Pregnancy Heart
I C
Team regarding the high risk of pregnancy-related adverse events.
It is recommended that women with a systemic RV (Mustard/Senning or congenitally corrected TGA), in NYHA class III/IV, systemic
ventricular dysfunction (EF <40%), or severe TR wishing to become pregnant are counselled by the Pregnancy Heart Team regarding the I C
high risk of pregnancy-related adverse events.
In women with significant haemodynamic lesions, discussion about guideline-directed interventions is recommended prior to pregnancy. I C
10. Pregnancy in women with pulmonary arterial hypertension
It is recommended that women of childbearing potential with PAH wishing to become pregnant are counselled by a multidisciplinary team
regarding the very high risk of pregnancy-related adverse events, encouraging a shared decision-making process about whether to become I C
pregnant.
It is recommended to provide clear contraceptive advice to women of childbearing potential with PAH. I C
For women with PAH requiring pregnancy termination, it is recommended to perform this in PH centres. I C
Endothelin receptor antagonists, riociguat, and selexipag are not recommended during pregnancy. III C
11. Venous thromboembolism in pregnancy and post-partum
For pregnant or post-partum women at high risk of VTE, a prophylactic fixed dose of LMWH is recommended over a higher
I B
weight-adjusted dose to reduce the risk of VTE.
In pregnant women or women in the post-partum period with suspicion of VTE (DVT and/or PE), an immediate formal diagnostic
I B
assessment with validated methods is recommended and should not be postponed.
In pregnant women or women in the post-partum period with newly diagnosed VTE (DVT and/or PE), the involvement of the Pregnancy
I C
Heart Team, including a vascular specialist and a haematologist, is recommended.
In pregnant or post-partum women with a diagnosis of VTE without haemodynamic instability, anticoagulation is recommended by using
I C
therapeutic-dose LMWH based on early pregnancy body weight.
12. Pregnancy in women with acquired heart disease
Coronary artery disease and pregnancy
In pregnant women with chest pain, it is recommended to exclude life-threatening cardiovascular conditions, including PE, ACS (including
I C
SCAD), and acute aortic syndrome.
Continued
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4547
It is recommended to manage pregnant women with ACS in the same way as non-pregnant women, including diagnostic investigations and
I C
interventions.
Low-dose ASA is recommended as the antiplatelet treatment of choice during pregnancy and lactation when single antiplatelet treatment is
I B
indicated.
If DAPT is required, clopidogrel is recommended as the P2Y12 inhibitor of choice during pregnancy. I C
The duration of DAPT (aspirin and clopidogrel) in pregnant women undergoing coronary stent implantation is recommended to be the
I C
same as in non-pregnant women, with an individual approach considering ischaemic risk and delivery-related bleeding risks.
Hypertensive disorders and pregnancy
It is recommended to aim for systolic BP <140 mmHg and diastolic BP <90 mmHg in pregnant women. I B
Systolic BP ≥160 mmHg or diastolic BP ≥110 mmHg in a pregnant woman is an emergency, and treatment in a hospital setting is
I C
recommended.
Low-dose aspirin (75–150 mg daily) is recommended in women at moderate or high risk of pre-eclampsia (i.e. at least one high risk factor or
I A
two moderate risk factors for pre-eclampsia) from weeks 12 to 36/37.
In women with gestational hypertension, initiation of drug treatment is recommended at systolic BP ≥140 mmHg or diastolic
I B
BP ≥90 mmHg.
Methyldopa is recommended for the treatment of hypertension in pregnancy. I B
Labetalol, metoprolol, and dihydropyridine calcium channel blockers are recommended for the treatment of hypertension in pregnancy. I C
In severe hypertension, drug treatment with i.v. labetalol, urapidil, nicardipine, or oral short-acting nifedipine or methyldopa is
I C
recommended for acute reduction in blood pressure. Intravenous hydralazine is a second-line option.
In pre-eclampsia associated with pulmonary oedema, nitroglycerine given as an i.v. infusion is recommended. I C
In women with pre-eclampsia without severe features, delivery is recommended at 37 weeks. I B
It is recommended to expedite delivery in women with pre-eclampsia associated with adverse markers such as haemostatic disorders. I C
In women with gestational hypertension, delivery is recommended at 39 weeks. I B
Supraventricular tachycardia and pregnancy
Immediate electrical cardioversion is recommended for acute treatment of SVT with haemodynamic instability. I C
Vagal manoeuvres and i.v. adenosine are recommended for conversion of haemodynamically stable supraventricular tachycardias. I C
Intravenous beta-blockers (metoprolol) are recommended as the first-line option for acute rate control in pregnant women with AF or AF
I C
with preserved LVEF and rapid ventricular rate.
Therapeutic anticoagulation with LMWH is recommended for pregnant women with persistent or permanent AF at elevated
I C
thromboembolic risk.
Beta-1-selective blockers are recommended for rate control in pregnant women with AF, AFL, or FAT. I C
Beta-1-selective blockers or verapamil are recommended for the prevention of SVT in women without pre-excitation on resting ECG. I C
Flecainide or propafenone are recommended for the prevention of arrhythmias in pregnant women with WPW syndrome. I C
Ventricular tachycardia, device implantation, catheter ablation, and pregnancy
Immediate electrical cardioversion is recommended for both unstable and stable ventricular tachycardias. I C
Beta-blockers or verapamil are recommended for the prevention of idiopathic sustained VT. I C
If an ICD, pacemaker, or resynchronization therapy device is indicated during pregnancy, implantation is recommended with optimal
I C
radiation protection.
Cardiac arrest and pregnancy
Continuous manual left uterine displacement during CPR in pregnant women (≥20 weeks) with cardiac arrest is recommended to relieve
I C
aortocaval compression.
It is recommended to establish i.v. access above the diaphragm to ensure that the i.v. therapy is not obstructed by the gravid uterus. I C
It is recommended to perform the same chest compressions and defibrillation protocols in pregnant as in non-pregnant women. I C
Anterolateral defibrillator pad placement is recommended with the lateral pad placed under the breast. I C
It is recommended that no drugs are withheld in pregnant women with cardiac arrest due to concerns of teratogenicity. I C
Congenital atrioventricular block and pregnancy
In pregnant women with asymptomatic congenital AV block, normal cardiac anatomy and function, a narrow QRS complex, and ventricular
III C
rate (>50 b.p.m.), a prophylactic temporary pacemaker during delivery is not recommended.
Native valve disease and pregnancy
Intervention is recommended before pregnancy in symptomatic patients with severe aortic stenosis. I C
Intervention is recommended before pregnancy in women with mitral stenosis and a valve area <1.5 cm2. I C
Continued
Downloaded
from

by
guest
on
22
January
2026

4548 E S C G u id e l in e s
In pregnant women with symptomatic mitral stenosis or pulmonary hypertension, restricted activities and beta-blockers are recommended. I C
In pregnant women with mitral stenosis, diuretics are recommended when congestive symptoms persist despite beta-blockers. I C
Full therapeutic-dose anticoagulation is recommended in women with mitral stenosis complicated by AF, left atrial thrombus, or prior
I C
embolism.
Surgical treatment is recommended before pregnancy in women with severe aortic or mitral regurgitation with symptoms, impaired
I C
ventricular function, or marked ventricular dilatation.
Diuretics are recommended in pregnant women with regurgitant lesions when symptoms or signs of congestion occur. I C
Prosthetic valves and pregnancy
A bioprosthetic valve is recommended (over a mechanical valve) in young women contemplating pregnancy requiring a valve prosthesis. I B
It is recommended that the type of valve surgery or intervention for a woman contemplating pregnancy is chosen in consultation with the
I C
Pregnancy Heart Team.
It is recommended that a care plan documenting the agreed anticoagulant strategy (including the decision to continue VKAs or converting to
therapeutic-dose LMWH in the first trimester) is in place for women of childbearing age with an MHV prior to pregnancy or as soon as I C
pregnancy is recognized.
It is recommended that pregnant women with an MHV are managed by the Pregnancy Heart Team. I C
In pregnant women on VKAs, it is recommended to perform INR monitoring weekly or at a minimum every 2 weeks. I C
In pregnant women with MHVs on therapeutic-dose LMWH, it is recommended to check peak anti-factor Xa levels and to target levels
I C
according to individualized risk.
LMWH is not recommended when anti-factor Xa level monitoring is not available. III C
Chronic and acute heart failure and pregnancy
It is recommended that women with HFrEF are advised about the risk of deterioration of cardiac function during pregnancy and peripartum. I C
In pregnant women with HFrEF, it is recommended that non-selective beta-blockers are switched to beta-1-selective blockers (metoprolol,
I C
bisoprolol) with close maternal and foetal monitoring.
Anticoagulation with therapeutic doses of LMWH is recommended in pregnant women with intracardiac thrombus or decreased LV
I C
function with EF <35%.
It is recommended to optimize HF guideline-directed medical therapy after delivery, taking contraindicated drugs during lactation into
I C
account.
Urgent delivery with caesarean section is recommended in pregnant women with cardiogenic shock as soon as the foetus is viable, taking
I C
gestational age, comorbidities, and the available level of medical care into account.
Inotropes and/or vasopressors are recommended in pregnant women with cardiogenic shock with levosimendan, dobutamine, and
I C
milrinone as recommended agents.
ACE-Is, ARBs, ARNIs, MRAs, ivabradine, and SGLT2 inhibitors are not recommended during pregnancy due to adverse foetal effects. III C
Heart transplantation and pregnancy
It is recommended to postpone pregnancy until at least 1 year after heart transplantation, taking individual risk factors into account. I C
In women with a heart transplant, it is recommended that immunosuppression serum drug levels are monitored during pregnancy every 4
weeks until the 32nd week, then every 2 weeks until the 36th week, then weekly until delivery, and for 6–12 months after delivery to guide I C
dosing.
It is recommended to perform weekly monitoring of donor-specific antibodies for at least 6–12 months after delivery. I C
Mycophenolic acid therapy is not recommended in pregnancy and should be discontinued 6 weeks before conception. III C
Cardio-oncology and pregnancy
It is recommended that pregnant women with cancer who require cardiotoxic cancer therapy are jointly managed by the Pregnancy Heart
I C
Team and the cardio-oncology team.
13. Long-term effects of adverse pregnancy outcomes
It is recommended to undertake a cardiovascular risk assessment in women with APOs, to recognize and document APOs when CVD risk is
I B
evaluated in women, and to provide counselling on the importance of healthy lifestyle choices that optimize cardiovascular health.
In women with persistent post-partum hypertension beyond 6 weeks to 3 months post-partum, initiation of antihypertensive therapy with
I B
reference to lactating status is recommended following current guidelines.
In cases where adoption of healthy lifestyle choices alone is inadequate to control post-partum glucose levels, initiation of pharmacotherapy
I C
following current guidelines is recommended.
It is recommended that women with a history of GDM undergo a formal oGTT 6–12 weeks post-partum with a repeat assessment at 6–12
I C
months and regular annual follow-up visits to screen for diabetes.
Continued
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4549
Nifedipine and labetalol (metoprolol if labetalol is unavailable) are recommended as treatments for uncomplicated post-partum
I C
hypertension in the first 6 weeks after delivery.
ACE-I, angiotensin-converting enzyme inhibitor; ACHD, congenital heart disease; ACS, acute coronary syndrome; AF, atrial fibrillation; AFL, atrial flutter; ALARA, as low as reasonably
achievable; aPTT, activated partial thromboplastin time; APO, adverse pregnancy outcome; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor/neprilysin inhibitor; ASA,
acetylsalicylic acid; AV, atrioventricular; BAV, bicuspid aortic valve; BP, blood pressure; CMP; cardiomyopathy; CMR, cardiovascular magnetic resonance; CPR, cardiopulmonary
resuscitation; CPVT, catecholaminergic polymorphic ventricular tachycardia; CT, computed tomography; CVD, cardiovascular disease; DAPT, dual antiplatelet therapy; DCM, dilated
cardiomyopathy; DOAC, direct oral anticoagulant; DVT, deep vein thrombosis; ECG, electrocardiogram; EF, ejection fraction; FAT, focal atrial tachycardia; GDM, gestational diabetes
mellitus; HCM, hypertrophic cardiomyopathy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; HTAD, heritable thoracic aortic disease; ICD, implantable
cardioverter defibrillator; INR, international normalized ratio; i.v., intravenous; LDS, Loeys–Dietz syndrome; LMWH, low-molecular-weight heparin; LQT2, long QT syndrome type 2;
LQTS, long QT syndrome; LV, left ventricle; LVEF, left ventricular ejection fraction; LVOTO, left ventricular outflow tract obstruction; MFS, Marfan syndrome; MHV, mechanical heart
valve; MRA, mineralocorticoid receptor antagonist; mWHO, modified World Health Organization; nsHTAD, non-syndromic heritable thoracic aortic disease; NYHA, New York Heart
Association; oGTT, oral glucose tolerance test; PAH, pulmonary arterial hypertension; PE, pulmonary embolism; PH, pulmonary hypertension; P/LP, pathogenic/likely pathogenic; PPCM,
peripartum cardiomyopathy; RV, right ventricle; SCAD, spontaneous coronary artery dissection; SGLT2, sodium–glucose co-transporter-2; SVT, supraventricular tachycardia; TGA,
transposition of the great arteries; TR, tricuspid regurgitation; TTE, transthoracic echocardiogram; UFH, unfractionated heparin; VKA, vitamin K antagonist; VT, ventricular tachycardia;
VTE, venous thromboembolism; WPW, Wolff–Parkinson–White.
aClass of recommendation.
bLevel of evidence.
19. Author information Department of Cardiology, Vall d'Hebron University Hospital,
Barcelona, Spain; Oliver Schlager, Division of Angiology,
Author/Task Force Member Affiliations: Nina Eide Department of Medicine II, Medical University of Vienna, Vienna,
Hasselberg, Department of Cardiology, Oslo University Hospital, Austria; Florian S. Schoenhoff, Department of Cardiac Surgery,
Rikshospitalet, Oslo, Norway; Michèle de Hosson, Cardiology, Inselspital, University Hospital Bern, University of Bern, Bern,
Ghent University Hospital, Ghent, Belgium; Margarita Brida, Switzerland; Tommaso Simoncini, Department of Clinical and
Department of Rehabilitation and Sports Medicine, Faculty of Experimental Medicine, University of Pisa, Pisa, Italy; Françoise
Medicine, University of Rijeka, Rijeka, Croatia, and Adult Congenital Steinbach, ESC Patient Forum, Sophia Antipolis, France; Isabella
Heart Disease Centre, Royal Brompton and Harefield Trust and Sudano, Cardiology, University Hospital Zurich University Heart
Imperial College, London, United Kingdom; Silvia Castelletti, Center, Zurich, Switzerland, and University of Zurich, Switzerland;
Cardiology Department, IRCCS Istituto Auxologico Italiano, Milan, Lorna Swan, Scottish Adult Congenital Cardiac Service, Golden
Italy; Matthew Cauldwell, Obstetrics, St George’s Hospital, Jubilee National Hospital, Glasgow, United Kingdom; Anne Marie
London, United Kingdom; Elisabetta Cerbai, Department of Valente, Cardiology, Boston Children’s Hospital, Boston, MA,
Neurosciences, Psychology, Drug Research and Child Health, United States of America, and Medicine, Brigham and Women’s
University of Florence, Florence, Italy, and European Laboratory for Hospital, Boston, United States of America, MA, and Medicine and
Non-Linear Spectroscopy, LENS, Sesto Fiorentino, Italy; Lia Crotti, Pediatrics, Harvard Medical School, Boston, MA, United States of
Department of Cardiology, Cardiomyopathy Unit, Center for America.
Cardiac Arrhythmias of Genetic Origin and Laboratory of
Cardiovascular Genetics, IRCCS, Istituto Auxologico Italiano, Milan,
Italy, and Department of Medicine and Surgery, University of 20. Appendix
Milano-Bicocca, Milan, Italy; Natasja M.S. de Groot, Unit
Translational Electrophysiology, Department of Cardiology, Erasmus ESC Scientific Document Group
University Medical Center, Rotterdam, Netherlands; Mette-Elise Includes Document Reviewers and ESC National Cardiac Societies.
Estensen, Department of Cardiology, Oslo University Hospital, Document Reviewers: Werner Budts (CPG Review
Oslo, Norway; Eva S. Goossens, Centre for Research and Co-ordinator) (Belgium), Karen Sliwa (CPG Review Co-ordinator)
Innovation in Care, Department of Nursing and Midwifery, Faculty of (South Africa), Marianna Adamo (Italy), Elena Arbelo (Spain), Eloisa
Medicine and Health Sciences, University of Antwerp, Antwerp, Arbustini (Italy), Giuseppe Boriani (Italy), Antonio Brucato (Italy),
Belgium, and Department of Public Health and Primary Care, KU Sergio Buccheri (Sweden), Alessandra Bura Riviere (France), Pavel
Leuven, Leuven, Belgium, and Department of Patient Care, Antwerp Calda (Czech Republic), G.-Andrei Dan (Romania), Konstantinos
University Hospital, UZA, Antwerp; Bernhard Haring, Klinik für Dimopoulos (United Kingdom), Alexandra Frogoudaki (Greece),
Innere Medizin III, Saarland University, Homburg, Germany; Donata Estelle Gandjbakhch (France), Eva Gerdts (Norway), Sofie A Gevaert
Kurpas, Division of Research Methodology, Department of Nursing, (Belgium), Bruna Gigante (Sweden), Bettina Heidecker (Germany),
Wroclaw Medical University, Wroclaw, Poland; Carmel Borja Ibanez (Spain), Stefan James (Sweden), Mark Johnson (United
M. McEniery, Department of Medicine, University of Cambridge, Kingdom), Peter Jüni (United Kingdom), Jolanda Kluin (Netherlands),
Cambridge, United Kingdom; Sanne A.E. Peters, Julius Center for Lars Køber (Denmark), Konstantinos C. Koskinas (Switzerland), Greg
Health Sciences and Primary Care, University Medical Center Lip (United Kingdom), Emma F. Magavern (United Kingdom), Bill
Utrecht, Utrecht, Netherlands, and The George Institute for Global McEvoy (Ireland), Borislava Mihaylova (United Kingdom), Richard
Health, School of Public Health, Imperial College London, London, Mindham (United Kingdom), Inge Moelgaard (Denmark), Philip
United Kingdom, and The George Institute for Global Health, Moons (Belgium), Jens Cosedis Nielsen (Denmark), Ntobeko
University of New South Wales, Sydney, Australia; Amina A. B. Ntusi (South Africa), Agnes A. Pasquet (Belgium), Tatjana
Rakisheva, Cardiology Department, City Cardiology Center, Potpara (Serbia), Eva Prescott (Denmark), Bianca Rocca (Italy), Jolien
Almaty, Kazakhstan; Antonia Sambola, Acute Cardiac Care Unit, Roos-Hesselink (Netherlands), Xavier Rosselló (Spain), Anna Sannino
5202CSE©
Downloaded
from

by
guest
on
22
January
2026

4550 E S C G u id e l in e s
(Germany), Felix Tanner (Switzerland), Ulf Landmesser (Germany), ESC Clinical Practice Guidelines (CPG) Committee: Ulf
Ilonca Vaartjes (Netherlands), Christiaan Vrints (Belgium), Katja Landmesser (Chairperson) (Germany), Stefan James (Co-Chairperson)
Zeppenfeld (Netherlands), Dayenne Zwaagman (Netherlands) (Sweden), Marianna Adamo (Italy), Suleman Aktaa (United Kingdom),
ESC National Cardiac Societies actively involved in the review Folkert W. Asselbergs (Netherlands), Colin Baigent (United Kingdom),
process of the 2025 ESC Guidelines for the management of cardiovas- Michael A. Borger (Germany), Giuseppe Boriani (Italy), Margarita Brida
cular disease and pregnancy: (Croatia), Robert A. Byrne (Ireland), Estelle Gandjbakhch (France),
Albania: Albanian Society of Cardiology, Aurel Demiraj; Algeria: Bettina Heidecker (Germany), Anja Hennemuth (Germany), Borja
Algerian Society of Cardiology, Nora Henine; Armenia: Armenian Ibanez (Spain), Peter Jüni (United Kingdom), Gregory Y.H. Lip (United
Cardiologists Association, Hamlet G. Hayrapetyan; Austria: Kingdom), John William McEvoy (Ireland), Borislava Mihaylova (United
Austrian Society of Cardiology, Noemi Pavo; Azerbaijan: Kingdom), Inge Moelgaard (Denmark), Lis Neubeck (United Kingdom),
Azerbaijan Society of Cardiology, Gulane Aghayeva; Belgium: Eva Prescott (Denmark), Bianca Rocca (Italy), Xavier Rossello (Spain),
Belgian Society of Cardiology, Agnes A. Pasquet; Bosnia and Anna Sannino (Germany), Felix C. Tanner (Switzerland), Wojtek
Herzegovina: Association of Cardiologists of Bosnia and Wojakowski (Poland), Katja Zeppenfeld (Netherlands)
Herzegovina, Milan Gluhović; Bulgaria: Bulgarian Society of
Cardiology, Nina Gotcheva; Croatia: Croatian Cardiac Society,
21. References
Bosko Skoric; Cyprus: Cyprus Society of Cardiology, Maria
Karakyriou; Czechia: Czech Society of Cardiology, Zuzana 1.Bredy C, Deville F, Huguet H, Picot MC, De La Villeon G, Abassi H, et al. Which risk
Motovska; Denmark: Danish Society of Cardiology, Dorte score best predicts cardiovascular outcome in pregnant women with congenital heart
disease? Eur Heart J Qual Care Clin Outcomes 2023;9:177–83.  Guldbrand Nielsen; Egypt: Egyptian Society of Cardiology, Ghada
ehjqcco/qcac019
Youssef; Estonia: Estonian Society of Cardiology, Maarja Maser; 2.Roos-Hesselink J, Baris L, Johnson M, De Backer J, Otto C, Marelli A, et al. Pregnancy
Finland: Finnish Cardiac Society, Sanna Laurila; France: French outcomes in women with cardiovascular disease: evolving trends over 10 years in the
Society of Cardiology, Bernard Iung; Georgia: Georgian Society of ESC Registry Of Pregnancy And Cardiac disease (ROPAC). Eur Heart J 2019;40:
3848–55. 
Cardiology, Khatuna Jalabadze; Germany: German Cardiac Society,
3.van der Zande JA, Tutarel O, Ramlakhan KP, van der Bosch AE, Bordese R, Zengin E,
Stephanie Fichtner; Greece: Hellenic Society of Cardiology, et al. Pregnancy outcomes in women with Ebstein’s anomaly: data from the Registry Of
Alexandra Frogoudaki; Hungary: Hungarian Society of Cardiology, Pregnancy And Cardiac disease (ROPAC). Open Heart 2023;10:e002406. 
org/10.1136/openhrt-2023-002406
Olga Hajnalka Balint; Iceland: Icelandic Society of Cardiology, Þórdís
4.Wander G, van der Zande JA, Patel RR, Johnson MR, Roos-Hesselink J. Pregnancy in
Jóna Hrafnkelsdóttir; Ireland: Irish Cardiac Society, Paul F. Brennan; women with congenital heart disease: a focus on management and preventing the
Israel: Israel Heart Society, Rafael Kuperstein; Italy: Italian risk of complications. Expert Rev Cardiovasc Ther 2023;21:587–99. 
Federation of Cardiology, Gabriele Egidy Assenza; Kazakhstan: 1080/14779072.2023.2237886
5.Ramlakhan KP, Malhamé I, Marelli A, Rutz T, Goland S, Franx A, et al. Hypertensive
Association of Cardiologists of Kazakhstan, Gulnara Junusbekova;
disorders of pregnant women with heart disease: the ESC EORP ROPAC registry.
Kosovo (Republic of): Kosovo Society of Cardiology, Pranvera Eur Heart J 2022;43:3749–61. 
Ibrahimi; Kyrgyzstan: Kyrgyz Society of Cardiology, Saamay 6.Tutarel O, Baris L, Budts W, Gamal Abd-El Aziz M, Liptai C, Majdalany D, et al.
Pregnancy outcomes in women with a systemic right ventricle and transposition of
Abilova; Latvia: Latvian Society of Cardiology, Oskars Kalejs;
the great arteries results from the ESC-EORP Registry Of Pregnancy And Cardiac dis-
Lebanon: Lebanese Society of Cardiology, Georges Saadé; Libya:
ease (ROPAC). Heart 2022;108:117–23. 
Libyan Cardiac Society, Hanan Taher Bugaigis; Lithuania: 318685
Lithuanian Society of Cardiology, Jūratė Barysienė; Luxembourg: 7.Campens L, Baris L, Scott NS, Broberg CS, Bondue A, Jondeau G, et al. Pregnancy out-
come in thoracic aortic disease data from the Registry Of Pregnancy And Cardiac dis-
Luxembourg Society of Cardiology, Rouguiatou Sow; Malta: Maltese
ease. Heart 2021;107:1704–9. 
Cardiac Society, Maryanne Caruana; Moldova (Republic of): 8.Tutarel O, Ramlakhan KP, Baris L, Subirana MT, Bouchardy J, Nemes A, et al.
Moldavian Society of Cardiology, Lilia David; Morocco: Moroccan Pregnancy outcomes in women after arterial switch operation for transposition of
Society of Cardiology, Aatif Benyass; Netherlands: Netherlands the great arteries: results from ROPAC (Registry Of Pregnancy And Cardiac disease)
of the European Society of Cardiology EURObservational research programme. J Am
Society of Cardiology, Anastasia D. Egorova; North Macedonia:
Heart Assoc 2021;10:e018176. 
National Society of Cardiology of North Macedonia, Marijan 9.Ramlakhan KP, Tobler D, Greutmann M, Schwerzmann M, Baris L, Yetman AT, et al.
Bosevski; Norway: Norwegian Society of Cardiology, Elisabeth Pregnancy outcomes in women with aortic coarctation. Heart 2020;107:290–8.

Leirgul; Poland: Polish Cardiac Society, Olga Trojnarska; Portugal:
10.Baris L, Hakeem A, Moe T, Cornette J, Taha N, Farook F, et al. Acute coronary syn-
Portuguese Society of Cardiology, Rita Ilhão Moreira; Romania: drome and ischemic heart disease in pregnancy: data from the EURObservational
Romanian Society of Cardiology, Ruxandra Jurcut; San Marino: San Research Programme-European Society of Cardiology Registry of Pregnancy and
Marino Society of Cardiology, Marco Zavatta; Serbia: Cardiology Cardiac Disease. J Am Heart Assoc 2020;9:e015490. 
119.015490
Society of Serbia, Aleksandra Ilic; Slovakia: Slovak Society of
11.van Hagen IM, Thorne SA, Taha N, Youssef G, Elnagar A, Gabriel H, et al. Pregnancy
Cardiology, Juraj Dubrava; Slovenia: Slovenian Society of outcomes in women with rheumatic mitral valve disease: results from the Registry Of
Cardiology, Katja Prokšelj; Spain: Spanish Society of Cardiology, Pregnancy And Cardiac disease. Circulation 2018;137:806–16. 
CIRCULATIONAHA.117.032561
Milagros Pedreira Pérez; Sweden: Swedish Society of Cardiology,
12.Ramlakhan KP, Roos-Hesselink JW, Basso T, Greenslade J, Flint RB, Krieger EV, et al.
Christina Christersson; Switzerland: Swiss Society of
Perinatal outcomes after in-utero exposure to beta-blockers in women with heart dis-
Cardiology, Matthias Greutmann; Syrian Arab Republic: Syrian ease: data from the ESC EORP Registry Of Pregnancy And Cardiac disease (ROPAC).
Cardiovascular Association, Elias Barakat; Tunisia: Tunisian Society Int J Cardiol 2024;410:132234. 
13.Kodogo V, Viljoen C, Hoevelmann J, Chakafana G, Tromp J, Farhan HA, et al.
of Cardiology and Cardiovascular Surgery, Meriam Drissa; Türkiye:
Proteomic profiling in patients with peripartum cardiomyopathy: a biomarker study
Turkish Society of Cardiology, Alev Arat Ozkan; Ukraine: Ukrainian of the ESC EORP PPCM registry. JACC Heart Fail 2023;11:1708–25. 
Association of Cardiology, Olena I Mitchenko; United Kingdom of 10.1016/j.jchf.2023.07.028
Great Britain and Northern Ireland: British Cardiovascular 14.Tromp J, Jackson AM, Abdelhamid M, Fouad D, Youssef G, Petrie MC, et al.
Thromboembolic events in peripartum cardiomyopathy: results from the ESC
Society, Dawn L. Adamson; Uzbekistan: Association of
EORP PPCM registry. Eur J Heart Fail 2023;25:1464–6. 
Cardiologists of Uzbekistan, Feruza Zakirova 2871
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4551
15.Jackson AM, Petrie MC, Frogoudaki A, Laroche C, Gustafsson F, Ibrahim B, et al. 40.Kamel H, Roman MJ, Pitcher A, Devereux RB. Pregnancy and the risk of aortic dissec-
Hypertensive disorders in women with peripartum cardiomyopathy: insights from tion or rupture: a cohort-crossover analysis. Circulation 2016;134:527–33. 
the ESC EORP PPCM registry. Eur J Heart Fail 2021;23:2058–69.  org/10.1161/CIRCULATIONAHA.116.021594
1002/ejhf.2264 41.Cerneca F, Ricci G, Simeone R, Malisano M, Alberico S, Guaschino S. Coagulation and
16.Sliwa K, Petrie MC, van der Meer P, Mebazaa A, Hilfiker-Kleiner D, Jackson AM, et al. fibrinolysis changes in normal pregnancy. Increased levels of procoagulants and re-
Clinical presentation, management, and 6-month outcomes in women with peripar- duced levels of inhibitors during pregnancy induce a hypercoagulable state, combined
tum cardiomyopathy: an ESC EORP registry. Eur Heart J 2020;41:3787–97. https:// with a reactive fibrinolysis. Eur J Obstet Gynecol Reprod Biol 1997;73:31–6. 
doi.org/10.1093/eurheartj/ehaa455 org/10.1016/S0301-2115(97)02734-6
17.Jackson AM, Bauersachs J, Petrie MC, van der Meer P, Laroche C, Farhan HA, et al. 42.Pieper PG. Use of medication for cardiovascular disease during pregnancy. Nat Rev
Outcomes at one year in women with peripartum cardiomyopathy: findings from Cardiol 2015;12:718–29. 
43.Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková
the ESC EORP PPCM registry. Eur J Heart Fail 2024;26:34–42. 
R, De Bonis M, et al. 2018 ESC Guidelines for the management of cardiovascular dis-
1002/ejhf.3055
eases during pregnancy. Eur Heart J 2018;39:3165–241. 
18.Davis MB, Arendt K, Bello NA, Brown H, Briller J, Epps K, et al. Team-based care of
eurheartj/ehy340
women with cardiovascular disease from pre-conception through pregnancy and
44.Easter SR, Valente AM, Economy KE. Creating a multidisciplinary pregnancy heart
postpartum: JACC focus seminar 1/5. J Am Coll Cardiol 2021;77:1763–77. 
team. Curr Treat Options Cardiovasc Med 2020;22:3. 
org/10.1016/j.jacc.2021.02.033
020-0800-x
19.Opotowsky AR, Siddiqi OK, D’Souza B, Webb GD, Fernandes SM, Landzberg MJ.
45.Lucà F, Colivicchi F, Parrini I, Russo MG, Di Fusco SA, Ceravolo R, et al. The role of the
Maternal cardiovascular events during childbirth among women with congenital heart
pregnancy heart team in clinical practice. Front Cardiovasc Med 2023;10:1135294.
disease. Heart 2012;98:145–51. 

20.Elkayam U, Goland S, Pieper PG, Silverside CK. High-risk cardiac disease in pregnancy:
46.Miller HE, Do SC, Cruz G, Panelli DM, Leonard SA, Girsen A, et al. Addressing post-
part I. J Am Coll Cardiol 2016;68:396–410. 
partum contraception practices utilizing a multidisciplinary pregnancy heart team ap-
21.Baumgartner H, De Backer J, Babu-Narayan SV, Budts W, Chessa M, Diller GP, et al.
proach. AJOG Glob Rep 2022;2:100100. 
2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J
47.Sharma G, Ying W, Silversides CK. The importance of cardiovascular risk assessment
2021;42:563–645.  and pregnancy heart team in the management of cardiovascular disease in pregnancy.
22.Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009;33: Cardiol Clin 2021;39:7–19. 
130–7.  48.Stephens EH, Dearani JA, Overman DM, Deyle DR, Rose CH, Ashikhmina E, et al.
23.Sliwa K, Böhm M. Incidence and prevalence of pregnancy-related heart disease. Pregnancy heart team: a lesion-specific approach. J Thorac Cardiovasc Surg 2023;166:
Cardiovasc Res 2014;101:554–60.  221–30. 
24.Creanga AA, Syverson C, Seed K, Callaghan WM. Pregnancy-related mortality in the 49.Wolfe DS. Introduction to building the cardio-obstetric team. Clin Obstet Gynecol
United States, 2011–2013. Obstet Gynecol 2017;130:366–73.  2020;63:791–8. 
AOG.0000000000002114 50.Magun E, DeFilippis EM, Noble S, LaSala A, Waksmonski C, D’Alton ME, et al.
25.Kotit S, Yacoub M. Cardiovascular adverse events in pregnancy: a global perspective. Cardiovascular care for pregnant women with cardiovascular disease. J Am Coll
Glob Cardiol Sci Pract 2021;2021:e202105.  Cardiol 2020;76:2102–13. 
26.Majmundar M, Doshi R, Patel KN, Zala H, Kumar A, Kalra A. Prevalence, trends, and 51.van Hagen IM, Boersma E, Johnson MR, Thorne SA, Parsonage WA, Escribano Subías
outcomes of cardiovascular diseases in pregnant patients in the USA: 2010–19. Eur P, et al. Global cardiac risk assessment in the Registry Of Pregnancy And Cardiac dis-
Heart J 2023;44:726–37.  ease: results of a registry from the European Society of Cardiology. Eur J Heart Fail
27.Nair M, Nelson-Piercy C, Knight M. Indirect maternal deaths: UK and global perspec- 2016;18:523–33. 
tives. Obstet Med 2017;10:10–5.  52.Silversides CK, Grewal J, Mason J, Sermer M, Kiess M, Rychel V, et al. Pregnancy out-
28.WHO. The WHO Application of ICD-10 to Deaths During Pregnancy, Childbirth and comes in women with heart disease: the CARPREG II study. J Am Coll Cardiol 2018;71:
Puerperium: ICD MM.  (25 2419–30. 
August 2023, date last accessed). 53.American College of Obstetricians and Gynecologists’ Presidential Task Force on
29.Alkema L, Chou D, Hogan D, Zhang S, Moller AB, Gemmill A, et al. Global, regional, Pregnancy and Heart Disease and Committee on Practice Bulletins—Obstetrics.
and national levels and trends in maternal mortality between 1990 and 2015, with ACOG practice bulletin no. 212: pregnancy and heart disease. Obstet Gynecol 2019;
scenario-based projections to 2030: a systematic analysis by the UN maternal mortal- 133:e320–56. 
ity estimation inter-agency group. Lancet 2016;387:462–74.  54.Nana M, Stannard MT, Nelson-Piercy C, Williamson C. The impact of preconception
S0140-6736(15)00838-7 counselling on maternal and fetal outcomes in women with chronic medical condi-
30.MacDorman MF, Declercq E, Cabral H, Morton C. Recent increases in the U.S. mater- tions: a systematic review. Eur J Intern Med 2023;108:52–9. 
nal mortality rate: disentangling trends from measurement issues. Obstet Gynecol 2016; ejim.2022.11.003
55.Deng LX, Gleason LP, Awh K, Khan AM, Drajpuch D, Fuller S, et al. Too little too late?
128:447–55. 
Communication with patients with congenital heart disease about challenges of adult
31.Ferranti EP, Jones EJ, Hernandez TL. Pregnancy reveals evolving risk for cardiometa-
life. Congenit Heart Dis 2019;14:534–40.  bolic disease in women. J Obstet Gynecol Neonatal Nurs 2016;45:413–25. 
56.Ricci P, Dimopoulos K, Bouchard M, Zhiya CC, Meira VC, Pool D, et al. Transition to
org/10.1016/j.jogn.2016.02.004
adult care of young people with congenital heart disease: impact of a service on knowl-
32.Brown HL, Smith GN. Pregnancy complications, cardiovascular risk factors, and future
edge and self-care skills, and correlates of a successful transition. Eur Heart J Qual Care
heart disease. Obstet Gynecol Clin North Am 2020;47:487–95. 
Clin Outcomes 2023;9:351–7. 
ogc.2020.04.009
57.Bratt EL, Mora MA, Sparud-Lundin C, Saarijärvi M, Burström Å, Skogby S, et al.
33.CDC. Report From Nine Maternal Mortality Review Committees. 
Effectiveness of the STEPSTONES transition program for adolescents with congenital
view/cdc/51660 (12 December 2024, date last accessed).
heart disease—a randomized controlled trial. J Adolesc Health 2023;73:655–63. https://
34.Siu SC, Sermer M, Colman JM, Alvarez AN, Mercier LA, Morton BC, et al. Prospective
doi.org/10.1016/j.jadohealth.2023.02.019
multicenter study of pregnancy outcomes in women with heart disease. Circulation
58.de Hosson M, De Groote K, Hecke AV, De Wolf D, Vandekerckhove K, Mosquera LM,
2001;104:515–21. 
et al. Evaluation of a nurse-led multi-component transition program for adolescents
35.Drenthen W, Boersma E, Balci A, Moons P, Roos-Hesselink JW, Mulder BJ, et al.
with congenital heart disease. Patient Educ Couns 2024;118:108028. 
Predictors of pregnancy complications in women with congenital heart disease. Eur
10.1016/j.pec.2023.108028
Heart J 2010;31:2124–32.  59.Buys R, Cornelissen V, Van De Bruaene A, Stevens A, Coeckelberghs E, Onkelinx S,
36.Hossin MZ, Kazamia K, Faxén J, Rudolph A, Johansson K, Sandström A, et al. et al. Measures of exercise capacity in adults with congenital heart disease. Int J
Pre-existing maternal cardiovascular disease and the risk of offspring cardiovascular Cardiol 2011;153:26–30. 
disease from infancy to early adulthood. Eur Heart J 2024;45:4111–23.  60.Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al.
org/10.1093/eurheartj/ehae547 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J 2023;
37.Sanghavi M, Rutherford JD. Cardiovascular physiology of pregnancy. Circulation 2014; 44:3503–626. 
130:1003–8.  61.Balci A, Sollie-Szarynska KM, van der Bijl AG, Ruys TP, Mulder BJ, Roos-Hesselink JW,
38.Estensen ME, Beitnes JO, Grindheim G, Aaberge L, Smiseth OA, Henriksen T, et al. et al. Prospective validation and assessment of cardiovascular and offspring risk models
Altered maternal left ventricular contractility and function during normal pregnancy. for pregnant women with congenital heart disease. Heart 2014;100:1373–81. https://
Ultrasound Obstet Gynecol 2013;41:659–66.  doi.org/10.1136/heartjnl-2014-305597
39.Ouzounian JG, Elkayam U. Physiologic changes during normal pregnancy and delivery. 62.Isselbacher EM, Preventza O, Hamilton Black J, 3rd, Augoustides JG, Beck AW, Bolen
Cardiol Clin 2012;30:317–29.  MA, et al. 2022 ACC/AHA Guideline for the diagnosis and management of aortic
Downloaded
from

by
guest
on
22
January
2026

4552 E S C G u id e l in e s
disease: a report of the American Heart Association/American College of Cardiology 84.Greydanus DE, Dodich C. Pelvic inflammatory disease in the adolescent: a poignant,
Joint Committee on clinical practice guidelines. Circulation 2022;146:e334–482. https:// perplexing, potentially preventable problem for patients and physicians. Curr Opin
doi.org/10.1161/CIR.0000000000001106 Pediatr 2015;27:92–9. 
63.Wilde AAM, Semsarian C, Márquez MF, Shamloo AS, Ackerman MJ, Ashley EA, et al. 85.Upadhya KK. Emergency contraception. Pediatrics 2019;144:e20193149. 
European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia org/10.1542/peds.2019-3149
Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society 86.Gemzell-Danielsson K, Rabe T, Cheng L. Emergency contraception. Gynecol Endocrinol
(LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac dis- 2013;29:1–14. 
eases. Europace 2022;24:1307–67.  87.Jesam C, Cochon L, Salvatierra AM, Williams A, Kapp N, Levy-Gompel D, et al. A pro-
64.Regalado ES, Morris SA, Braverman AC, Hostetler EM, De Backer J, Li R, et al. spective, open-label, multicenter study to assess the pharmacodynamics and safety of
Comparative risks of initial aortic events associated with genetic thoracic aortic dis- repeated use of 30 mg ulipristal acetate. Contraception 2016;93:310–6. 
ease. J Am Coll Cardiol 2022;80:857–69.  10.1016/j.contraception.2015.12.015
65.Reuter C, Grove ME, Orland K, Spoonamore K, Caleshu C. Clinical cardiovascular gen- 88.Turok DK, Gero A, Simmons RG, Kaiser JE, Stoddard GJ, Sexsmith CD, et al.
etic counselors take a leading role in team-based variant classification. J Genet Couns Levonorgestrel vs. copper intrauterine devices for emergency contraception. N Engl
2018;27:751–60.  J Med 2021;384:335–44. 
66.Akolekar R, Beta J, Picciarelli G, Ogilvie C, D’Antonio F. Procedure-related risk of mis- 89.Mecdi Kaydirak M, Aslan E. Efficacy of nursing support in the pre- and postmedical ter-
carriage following amniocentesis and chorionic villus sampling: a systematic review and mination of pregnancy phases: a randomized study. Omega (Westport) 2021;84:51–68.
meta-analysis. Ultrasound Obstet Gynecol 2015;45:16–26.  
14636 90.Haberer K, Silversides CK. Congenital heart disease and women’s health across the life
67.Yeates L, McDonald K, Burns C, Semsarian C, Carter S, Ingles J. Decision-making and span: focus on reproductive issues. Can J Cardiol 2019;35:1652–63. 
experiences of preimplantation genetic diagnosis in inherited heart diseases: a qualita- 1016/j.cjca.2019.10.009
91.Lewis R, Tanton C, Mercer CH, Mitchell KR, Palmer M, Macdowall W, et al. tive study. Eur J Hum Genet 2022;30:187–93. 
Heterosexual practices among young people in Britain: evidence from three national
00963-1
surveys of sexual attitudes and lifestyles. J Adolesc Health 2017;61:694–702.  68.Dhalwani NN, Fiaschi L, West J, Tata LJ. Occurrence of fertility problems presenting to
org/10.1016/j.jadohealth.2017.07.004
primary care: population-level estimates of clinical burden and socioeconomic inequal-
92.Jatlaoui TC, Riley HEM, Curtis KM. The safety of intrauterine devices among young
ities across the UK. Hum Reprod 2013;28:960–8. 
women: a systematic review. Contraception 2017;95:17–39. 
des451
contraception.2016.10.006
69.Goualou M, Noumegni S, de Moreuil C, Le Guillou M, De Coninck G, Hoffmann C,
93.Mantha S, Karp R, Raghavan V, Terrin N, Bauer KA, Zwicker JI. Assessing the risk of
et al. Venous thromboembolism associated with assisted reproductive technology: a
venous thromboembolic events in women taking progestin-only contraception: a
systematic review and meta-analysis. Thromb Haemost 2023;123:283–94. 
meta-analysis. BMJ 2012;345:e4944. 
org/10.1055/s-0042-1760255
94.Dragoman MV, Tepper NK, Fu R, Curtis KM, Chou R, Gaffield ME. A systematic review
70.Kametas NA, McAuliffe F, Krampl E, Chambers J, Nicolaides KH. Maternal cardiac
and meta-analysis of venous thrombosis risk among users of combined oral contracep-
function in twin pregnancy. Obstet Gynecol 2003;102:806–15. 
tion. Int J Gynaecol Obstet 2018;141:287–94. 
1016/s0029-7844(03)00807-x
95.Morales A, Allain DC, Arscott P, James E, MacCarrick G, Murray B, et al. At the heart of
71.Ombelet W, Martens G, De Sutter P, Gerris J, Bosmans E, Ruyssinck G, et al. Perinatal
the pregnancy: what prenatal and cardiovascular genetic counselors need to know
outcome of 12,021 singleton and 3108 twin births after non-IVF-assisted reproduc-
about maternal heart disease. J Genet Couns 2017;26:669–88. 
tion: a cohort study. Hum Reprod 2006;21:1025–32. 
1007/s10897-017-0081-z
dei419
96.Sunitha M, Chandrasekharappa S, Brid SV. Electrocradiographic QRS axis, Q wave and
72.Glisic M, Shahzad S, Tsoli S, Chadni M, Asllanaj E, Rojas LZ, et al. Association between
T-wave changes in 2nd and 3rd trimester of normal pregnancy. J Clin Diagn Res 2014;8:
progestin-only contraceptive use and cardiometabolic outcomes: a systematic review
BC17–21. 
and meta-analysis. Eur J Prev Cardiol 2018;25:1042–52. 
97.Madras V, Challa N. Electrocardiographic variations during three trimesters of normal
2047487318774847
pregnancy. Int J Res Med Sci 2015;3:2218–22. 
73.Palacios S, Colli E, Regidor PA. Efficacy and cardiovascular safety of the new estrogen-
ijrms20150605
free contraceptive pill containing 4 mg drospirenone alone in a 24/4 regime. BMC
98.Uma V, Devi M. Electrocardiographic changes during the third trimester of pregnancy:
Womens Health 2020;20:218.  a cross sectional study. Sch J App Med Sci 2016;4:3054–7. 
74.Vink AS, Wilde AAM. Oral contraceptives and their effect on arrhythmogenesis in long
sjams.2016.v04i08.062
QT syndrome: does it matter? Heart Rhythm 2022;19:49–50.  99.Bello NA, Bairey Merz CN, Brown H, Davis MB, Dickert NW, El Hajj SC, et al.
hrthm.2021.08.007 Diagnostic cardiovascular imaging and therapeutic strategies in pregnancy: JACC focus
75.Goldenberg I, Younis A, Huang DT, Yoruk A, Rosero SZ, Cutter K, et al. Use of oral seminar 4/5. J Am Coll Cardiol 2021;77:1813–22. 
contraceptives in women with congenital long QT syndrome. Heart Rhythm 2022;19: 056
41–8.  100. American College of Obstetricians and Gynecologists’ Committee on Obstetric
76.Lidegaard Ø, Løkkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke Practice. Committee opinion no. 656: guidelines for diagnostic imaging during preg-
and myocardial infarction with hormonal contraception. N Engl J Med 2012;366: nancy and lactation. Obstet Gynecol 2016;127:e75–80. 
2257–66.  0000000000001316
77.Chen MJ, Jensen JT, Kaunitz AM, Achilles SL, Zatik J, Weyers S, et al. Tolerability and 101. Desai DK, Moodley J, Naidoo DP. Echocardiographic assessment of cardiovascular
safety of the estetrol/drospirenone combined oral contraceptive: pooled analysis of hemodynamics in normal pregnancy. Obstet Gynecol 2004;104:20–9. 
two multicenter, open-label phase 3 trials. Contraception 2022;116:44–50. https:// 10.1097/01.AOG.0000128170.15161.1d
doi.org/10.1016/j.contraception.2022.10.004 102. Sadaniantz A, Kocheril AG, Emaus SP, Garber CE, Parisi AF. Cardiovascular changes in
78.Dragoman M, Curtis KM, Gaffield ME. Combined hormonal contraceptive use among pregnancy evaluated by two-dimensional and Doppler echocardiography. J Am Soc
women with known dyslipidemias: a systematic review of critical safety outcomes. Echocardiogr 1992;5:253–8. 
Contraception 2016;94:280–7.  103. Mesa A, Jessurun C, Hernandez A, Adam K, Brown D, Vaughn WK, et al. Left ventricu-
79.WHO. Medical Eligibility Criteria for Contraceptive Use.  lar diastolic function in normal human pregnancy. Circulation 1999;99:511–7. https://
publications/i/item/9789241549158 (29 January 2025, date last accessed). doi.org/10.1161/01.CIR.99.4.511
80.Horton LG, Simmons KB, Curtis KM. Combined hormonal contraceptive use among 104. Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finstuen JA, Foster MC, et al. Guidelines
obese women and risk for cardiovascular events: a systematic review. Contraception for performing a comprehensive transthoracic echocardiographic examination in
2016;94:590–604.  adults: recommendations from the American Society of Echocardiography. J Am Soc
81.Siagian SN, Christianto C, Angellia P, Holiyono HI. The risk factors of acute coronary Echocardiogr 2019;32:1–64. 
syndrome in young women: a systematic review and meta-analysis. Curr Cardiol Rev 105. Porter TR, Mulvagh SL, Abdelmoneim SS, Becher H, Belcik JT, Bierig M, et al. Clinical
2023;19:e161122210969.  applications of ultrasonic enhancing agents in echocardiography: 2018 American
82.Abarbanell G, Tepper NK, Farr SL. Safety of contraceptive use among women with Society of Echocardiography guidelines update. J Am Soc Echocardiogr 2018;31:
congenital heart disease: a systematic review. Congenit Heart Dis 2019;14:331–40. 241–74. 
 106. Popescu MR, Bouariu A, Ciobanu AM, Gică N, Panaitescu AM. Pregnancy complica-
83.Lindley KJ, Bairey Merz CN, Davis MB, Madden T, Park K, Bello NA. Contraception and tions lead to subclinical maternal heart dysfunction—the importance and benefits of
reproductive planning for women with cardiovascular disease: JACC focus seminar 5/ follow-up using speckle tracking echocardiography. Medicina (Kaunas) 2022;58:296.
5. J Am Coll Cardiol 2021;77:1823–34.  
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4553
107. Savu O, Jurcuţ R, Giuşcă S, van Mieghem T, Gussi I, Popescu BA, et al. Morphological 131. Arbeid E, Demi A, Brogi E, Gori E, Giusto T, Soldati G, et al. Lung ultrasound pattern is
and functional adaptation of the maternal heart during pregnancy. Circ Cardiovasc normal during the last gestational weeks: an observational pilot study. Gynecol Obstet
Imaging 2012;5:289–97.  Invest 2017;82:398–403. 
108. ACOG committee opinion no. 650: physical activity and exercise during pregnancy 132. Hendriks BMF, Schnerr RS, Milanese G, Jeukens C, Niesen S, Eijsvoogel NG, et al.
and the postpartum period. Obstet Gynecol 2015;126:e135–42.  Computed tomography pulmonary angiography during pregnancy: radiation dose of
1097/AOG.0000000000001214 commonly used protocols and the effect of scan length optimization. Korean J Radiol
109. Wowdzia JB, Davenport MH. Cardiopulmonary exercise testing during pregnancy. 2019;20:313–22. 
Birth Defects Res 2021;113:248–64.  133. Committee opinion no. 723: guidelines for diagnostic imaging during pregnancy
110. Lui GK, Silversides CK, Khairy P, Fernandes SM, Valente AM, Nickolaus MJ, et al. Heart and lactation. Obstet Gynecol 2017;130:e210–6. 
rate response during exercise and pregnancy outcome in women with congenital heart 0000000000002355
disease. Circulation 2011;123:242–8.  134. Park K, Bairey Merz CN, Bello NA, Davis M, Duvernoy C, Elgendy IY, et al.
110.953380 Management of women with acquired cardiovascular disease from pre-conception
111. Mayama M, Yoshihara M, Uno K, Tano S, Takeda T, Ukai M, et al. Factors influencing through pregnancy and postpartum: JACC focus seminar 3/5. J Am Coll Cardiol 2021;
brain natriuretic peptide levels in healthy pregnant women. Int J Cardiol 2017;228: 77:1799–812. 
749–53.  135. Ray JG, Vermeulen MJ, Bharatha A, Montanera WJ, Park AL. Association between MRI
112. Sarma AA, Aggarwal NR, Briller JE, Davis M, Economy KE, Hameed AB, et al. The util- exposure during pregnancy and fetal and childhood outcomes. JAMA 2016;316:
ization and interpretation of cardiac biomarkers during pregnancy: JACC: advances ex- 952–61. 
pert panel. JACC Adv 2022;1:100064.  136. Bird ST, Gelperin K, Sahin L, Bleich KB, Fazio-Eynullayeva E, Woods C, et al.
113. Esbrand FD, Zafar S, Panthangi V, Cyril Kurupp AR, Raju A, Luthra G, et al. Utility of First-trimester exposure to gadolinium-based contrast agents: a utilization study of
N-terminal (NT)-brain natriuretic peptide (proBNP) in the diagnosis and prognosis of 4.6 million U.S. pregnancies. Radiology 2019;293:193–200. 
pregnancy associated cardiovascular conditions: a systematic review. Cureus 2022;14: radiol.2019190563
e32848.  137. Jabehdar Maralani P, Kapadia A, Liu G, Moretti F, Ghandehari H, Clarke SE, et al.
114. Sheikh M, Ostadrahimi P, Salarzaei M, Parooie F. Cardiac complications in pregnancy: a Canadian Association of Radiologists recommendations for the safe use of MRI
systematic review and meta-analysis of diagnostic accuracy of BNP and N-terminal during pregnancy. Can Assoc Radiol J 2022;73:56–67. 
pro-BNP. Cardiol Ther 2021;10:501–14.  08465371211015657
115. Afshani N, Moustaqim-Barrette A, Biccard BM, Rodseth RN, Dyer RA. Utility of B-type 138. Sachs HC. The transfer of drugs and therapeutics into human breast milk: an update on
natriuretic peptides in preeclampsia: a systematic review. Int J Obstet Anesth 2013;22: selected topics. Pediatrics 2013;132:e796–809. 
96–103.  1985
116. Chang SA, Khakh P, Janzen M, Lee T, Kiess M, Rychel V, et al. Trending cardiac biomar- 139. Cova MA, Stacul F, Quaranta R, Guastalla P, Salvatori G, Banderali G, et al. Radiological
kers during pregnancy in women with cardiovascular disease. Circ Heart Fail 2022;15: contrast media in the breastfeeding woman: a position paper of the Italian Society of
e009018.  Radiology (SIRM), the Italian Society of Paediatrics (SIP), the Italian Society of
117. Siegmund AS, Pieper PG, Bouma BJ, Rosenberg FM, Groen H, Bilardo CM, et al. Early Neonatology (SIN) and the Task Force on Breastfeeding, Ministry of Health, Italy.
N-terminal pro-B-type natriuretic peptide is associated with cardiac complications and Eur Radiol 2014;24:2012–22. 
function during pregnancy in congenital heart disease. Neth Heart J 2021;29:262–72. 140. Lee JS, Choi ES, Hwang Y, Lee KS, Ahn KH. Preterm birth and maternal heart disease: a
 machine learning analysis using the Korean national health insurance database. PLoS
118. Kampman MA, Balci A, van Veldhuisen DJ, van Dijk AP, Roos-Hesselink JW, One 2023;18:e0283959. 
Sollie-Szarynska KM, et al. N-terminal pro-B-type natriuretic peptide predicts cardio- 141. Piao C, Wang W-J, Deng Y, Wang K. Clinical outcomes of pulmonary hypertension in
vascular complications in pregnant women with congenital heart disease. Eur Heart J pregnancy among women with congenital heart disease in China. J Matern Fetal
2014;35:708–15.  Neonatal Med 2023;36:2183349. 
119. Shivvers SA, Wians FH Jr, Keffer JH, Ramin SM. Maternal cardiac troponin I levels dur- 142. Thaman R, Varnava A, Hamid MS, Firoozi S, Sachdev B, Condon M, et al. Pregnancy
ing normal labor and delivery. Am J Obstet Gynecol 1999;180:122–7.  related complications in women with hypertrophic cardiomyopathy. Heart 2003;89:
1016/S0002-9378(99)70161-4 752–6. 
120. Kumar R, De Jesus O. Radiation Effects on the Fetus. Treasure Island, FL: StatPearls 143. Mozumdar N, Rowland J, Pan S, Rajagopal H, Geiger MK, Srivastava S, et al. Diagnostic
Publishing, 2023. accuracy of fetal echocardiography in congenital heart disease. J Am Soc Echocardiogr
121. Wakeford R, Little MP. Risk coefficients for childhood cancer after intrauterine irradi- 2020;33:1384–90. 
ation: a review. Int J Radiat Biol 2003;79:293–309.  144. Moon-Grady AJ, Donofrio MT, Gelehrter S, Hornberger L, Kreeger J, Lee W, et al.
0955300031000114729 Guidelines and recommendations for performance of the fetal echocardiogram: an up-
122. Khaing PH, Buchanan GL, Kunadian V. Diagnostic angiograms and percutaneous cor- date from the American Society of Echocardiography. J Am Soc Echocardiogr 2023;36:
onary interventions in pregnancy. Interv Cardiol 2020;15:e04.  679–723. 
icr.2020.02 145. Gelson E, Johnson M. Effect of maternal heart disease on pregnancy outcomes. Expert
123. Ntusi NA, Samuels P, Moosa S, Mocumbi AO. Diagnosing cardiac disease during preg- Rev Obstet Gynecol 2010;5:605–17. 
nancy: imaging modalities. Cardiovasc J Afr 2016;27:95–103.  146. Halpern DG, Weinberg CR, Pinnelas R, Mehta-Lee S, Economy KE, Valente AM. Use of
CVJA-2016-022 medication for cardiovascular disease during pregnancy: JACC state-of-the-art review.
124. Damilakis J, Theocharopoulos N, Perisinakis K, Manios E, Dimitriou P, Vardas P, et al. J Am Coll Cardiol 2019;73:457–76. 
Conceptus radiation dose and risk from cardiac catheter ablation procedures. 147. Lees CC, Marlow N, van Wassenaer-Leemhuis A, Arabin B, Bilardo CM, Brezinka C,
Circulation 2001;104:893–7.  et al. 2 year neurodevelopmental and intermediate perinatal outcomes in infants
125. Dauer LT, Thornton RH, Miller DL, Damilakis J, Dixon RG, Marx MV, et al. Radiation with very preterm fetal growth restriction (TRUFFLE): a randomised trial. Lancet
management for interventions using fluoroscopic or computed tomographic guidance 2015;385:2162–72. 
during pregnancy: a joint guideline of the Society of Interventional Radiology and the 148. Joglar JA, Kapa S, Saarel EV, Dubin AM, Gorenek B, Hameed AB, et al. 2023 HRS expert
Cardiovascular and Interventional Radiological Society of Europe with endorsement consensus statement on the management of arrhythmias during pregnancy. Heart
by the Canadian Interventional Radiology Association. J Vasc Interv Radiol 2012;23: Rhythm 2023;20:e175–264. 
19–32.  149. Donofrio MT, Moon-Grady AJ, Hornberger LK, Copel JA, Sklansky MS, Abuhamad A,
126. Colletti PM, Lee KH, Elkayam U. Cardiovascular imaging of the pregnant patient. AJR et al. Diagnosis and treatment of fetal cardiac disease: a scientific statement from the
Am J Roentgenol 2013;200:515–21.  American Heart Association. Circulation 2014;129:2183–242. 
127. Webb JA, Thomsen HS, Morcos SK. The use of iodinated and gadolinium contrast 01.cir.0000437597.44550.5d
media during pregnancy and lactation. Eur Radiol 2005;15:1234–40.  150. Schlichting LE, Insaf TZ, Zaidi AN, Lui GK, Van Zutphen AR. Maternal comorbidities
10.1007/s00330-004-2583-y and complications of delivery in pregnant women with congenital heart disease.
128. Thomsen HS. European Society of Urogenital Radiology (ESUR) guidelines on the safe J Am Coll Cardiol 2019;73:2181–91. 
use of iodinated contrast media. Eur J Radiol 2006;60:307–13.  151. Rouse CE, Easter SR, Duarte VE, Drakely S, Wu FM, Valente AM, et al. Timing of de-
ejrad.2006.06.020 livery in women with cardiac disease. Am J Perinatol 2022;39:1196–203. 
129. Bourjeily G, Chalhoub M, Phornphutkul C, Alleyne TC, Woodfield CA, Chen KK. 10.1055/s-0040-1721716
Neonatal thyroid function: effect of a single exposure to iodinated contrast medium 152. Mishanina E, Rogozinska E, Thatthi T, Uddin-Khan R, Khan KS, Meads C. Use of labour
in utero. Radiology 2010;256:744–50.  induction and risk of cesarean delivery: a systematic review and meta-analysis. CMAJ
130. Krawczyk P, Jastrzębska A, Sałapa K, Szczeklik W, Andres J. Abnormal lung ultrasound 2014;186:665–73. 
pattern during labor: a prospective cohort pilot study. J Clin Ultrasound 2019;47:261–6. 153. Roos-Hesselink JW, Ruys TP, Stein JI, Thilén U, Webb GD, Niwa K, et al. Outcome of
 pregnancy in patients with structural or ischaemic heart disease: results of a registry of
Downloaded
from

by
guest
on
22
January
2026

4554 E S C G u id e l in e s
the European Society of Cardiology. Eur Heart J 2013;34:657–65.  178. Delgado V, Ajmone Marsan N, de Waha S, Bonaros N, Brida M, Burri H, et al. 2023
1093/eurheartj/ehs270 ESC Guidelines for the management of endocarditis. Eur Heart J 2023;44:
154. Mok T, Woods A, Small A, Canobbio MM, Tandel MD, Kwan L, et al. Delivery timing 3948–4042. 
and associated outcomes in pregnancies with maternal congenital heart disease at 179. D’Souza R, Ostro J, Shah PS, Silversides CK, Malinowski A, Murphy KE, et al.
term. J Am Heart Assoc 2022;11:e025791.  Anticoagulation for pregnant women with mechanical heart valves: a systematic review
155. Ramsey PS, Hogg BB, Savage KG, Winkler DD, Owen J. Cardiovascular effects of in- and meta-analysis. Eur Heart J 2017;38:1509–16. 
travaginal misoprostol in the mid trimester of pregnancy. Am J Obstet Gynecol 2000; ehx032
183:1100–2.  180. Leffert L, Butwick A, Carvalho B, Arendt K, Bates SM, Friedman A, et al. The Society for
156. Lee S, Cauldwell M, Wendler R. Cardiac effects of drugs used for induction of labour Obstetric Anesthesia and Perinatology Consensus Statement on the anesthetic man-
and prevention and treatment of postpartum haemorrhage. Int J Cardiol Congenit Heart agement of pregnant and postpartum women receiving thromboprophylaxis or higher
Dis 2021;5:100208.  dose anticoagulants. Anesth Analg 2018;126:928–44. 
157. Kilpatrick AW, Thorburn J. Severe hypotension due to intramyometrial injection of 0000000000002530
prostaglandin E2. Anaesthesia 1990;45:848–9.  181. Khedagi AM, Bello NA. Hypertensive disorders of pregnancy. Cardiol Clin 2021;39:
1990.tb14569.x 77–90. 
158. Cauldwell M, Steer PJ, Swan L, Uebing A, Gatzoulis MA, Johnson MR. The management 182. Ruys TP, Roos-Hesselink JW, Hall R, Subirana-Domènech MT, Grando-Ting J,
of the third stage of labour in women with heart disease. Heart 2017;103:945–51. Estensen M, et al. Heart failure in pregnant women with cardiac disease: data from
 the ROPAC. Heart 2014;100:231–8. 
159. NICE. Intrapartum Care for Women With Existing Medical Conditions or Obstetric 183. Canobbio MM, Warnes CA, Aboulhosn J, Connolly HM, Khanna A, Koos BJ, et al.
Complications and Their Babies.  Management of pregnancy in patients with complex congenital heart disease: a scien-
recommendations#management-of-the-third-stage-of-labour-for-women-with- tific statement for healthcare professionals from the American Heart Association.
heart-disease (8 June 2024, date last accessed). Circulation 2017;135:e50–87. 
160. Perloff J. Congenital Heart Disease in Adult. 2nd edn. Philadelphia, PA: Saunders 184. Giorgione V, Cauldwell M, Thilaganathan B. Pre-eclampsia and cardiovascular disease:
Company, 1998.
from pregnancy to postpartum. Eur Cardiol 2023;18:e42. 
161. Easter SR, Rouse CE, Duarte V, Hynes JS, Singh MN, Landzberg MJ, et al. Planned va-
2022.56
ginal delivery and cardiovascular morbidity in pregnant women with heart disease. Am J
185. ACOG committee opinion no. 756: optimizing support for breastfeeding as part of
Obstet Gynecol 2020;222:77.e1–e11. 
obstetric practice. Obstet Gynecol 2018;132:e187–96. 
162. Angeli L, Fieni S, Dall’Asta A, Ghi T, De Carolis S, Sorrenti S, et al. Mode of delivery and
0000000000002890
peripartum outcome in women with heart disease according to the ESC guidelines: an
186. Kitt JA, Fox RL, Cairns AE, Mollison J, Burchert HH, Kenworthy Y, et al. Short-term
Italian multicenter study. J Matern Fetal Neonatal Med 2023;36:2184221. 
postpartum blood pressure self-management and long-term blood pressure control:
org/10.1080/14767058.2023.2184221
a randomized controlled trial. Hypertension 2021;78:469–79. 
163. Ruys TP, Roos-Hesselink JW, Pijuan-Domènech A, Vasario E, Gaisin IR, Iung B, et al. Is a
HYPERTENSIONAHA.120.17101
planned caesarean section in women with cardiac disease beneficial? Heart 2015;101:
187. Cauldwell M, Von Klemperer K, Uebing A, Swan L, Steer PJ, Gatzoulis M, et al. Why is
530–6. 
post-partum haemorrhage more common in women with congenital heart disease? Int
164. Meng M-L, Arendt KW. Obstetric anesthesia and heart disease: practical clinical
J Cardiol 2016;218:285–90. 
considerations. Anesthesiology 2021;135:164–83. 
188. Wang Z, Liu J, Shuai H, Cai Z, Fu X, Liu Y, et al. Mapping global prevalence of depres-
0000000000003833
sion among postpartum women. Transl Psychiatry 2021;11:543. 
165. Hill NE, Granlund B. Anesthesia for Labor, Delivery, and Cesarean Section in High-Risk
1038/s41398-021-01663-6
Heart Disease. Treasure Island, FL: StatPearls Publishing, 2023.
189. Hutchens J, Frawley J, Sullivan EA. Quality of life and mental health of women who had
166. Rahmati J, Shahriari M, Shahriari A, Nataj M, Shabani Z, Moodi V. Effectiveness of spinal
cardiac disease in pregnancy and postpartum. BMC Pregnancy Childbirth 2022;22:797.
analgesia for labor pain compared with epidural analgesia. Anesth Pain Med 2021;11:

e113350. 
190. Donnenwirth JA, Hess R, Ross R. Post-traumatic stress, depression, and quality of life
167. Roofthooft E, Rawal N, Van de Velde M. Current status of the combined spinal–epi-
in women with peripartum cardiomyopathy. MCN Am J Matern Child Nurs 2020;45:
dural technique in obstetrics and surgery. Best Pract Res Clin Anaesthesiol 2023;37:
176–82. 
189–98. 
191. Rosman L, Salmoirago-Blotcher E, Cahill J, Wuensch KL, Sears SF. Depression and
168. Wise J. Maternity care: remifentanil is recommended as alternative to epidural in draft
health behaviors in women with peripartum cardiomyopathy. Heart Lung 2017;46:
guidance. BMJ 2023;381:946. 
363–8. 
169. NICE. Intrapartum Care. 
192. Roberts L, Davis GK, Homer CSE. Depression, anxiety, and post-traumatic stress dis-
care-pdf-66143897812933 (26 November 2024, date last accessed).
170. Lester W, Walker N, Bhatia K, Ciantar E, Banerjee A, Trinder J, et al. British Society for order following a hypertensive disorder of pregnancy: a narrative literature review.
Haematology guideline for anticoagulant management of pregnant individuals with Front Cardiovasc Med 2019;6:147. 
mechanical heart valves. Br J Haematol 2023;202:465–78.  193. Ramlakhan KP, Johnson MR, Roos-Hesselink JW. Pregnancy and cardiovascular dis-
18781 ease. Nat Rev Cardiol 2020;17:718–31. 
171. Hood C, Goldstein JN, Milling TJ, Refaai MA, Bajcic P, Goldstein B, et al. INR and vita- 194. Eke AC. An update on the physiologic changes during pregnancy and their impact on
min K-dependent factor levels after vitamin K antagonist reversal with 4F-PCC or plas- drug pharmacokinetics and pharmacogenomics. J Basic Clin Physiol Pharmacol 2022;33:
ma. Blood Adv 2023;7:2206–13.  581–98. 
172. Condeni MS, Weant KA, Neyens RR, Eriksson EA, Miano TA. Safety and efficacy of 195. Haas DM. Pharmacogenetics and individualizing drug treatment during pregnancy.
fixed versus variable-dose prothrombin complex concentrate for emergent reversal Pharmacogenomics 2014;15:69–78. 
of vitamin K antagonists: a systematic review and meta-analysis. Am J Emerg Med 196. Verstegen RHJ, Anderson PO, Ito S. Infant drug exposure via breast milk. Br J Clin
2024;77:91–105.  Pharmacol 2022;88:4311–27. 
173. Chai-Adisaksopha C, Hillis C, Siegal DM, Movilla R, Heddle N, Iorio A, et al. 197. Drugs and Lactation Database (LactMed). 
Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. NBK501922/ (29 January 2025, date last accessed).
A systematic review and meta-analysis. Thromb Haemost 2016;116:879–90.  198. Overcash RT, Somers AT, LaCoursiere DY. Enoxaparin dosing after cesarean delivery
org/10.1160/TH16-04-0266 in morbidly obese women. Obstet Gynecol 2015;125:1371–6. 
174. Schroeder M, Hogwood J, Gray E, Mulloy B, Hackett AM, Johansen KB. Protamine neu- AOG.0000000000000873
tralisation of low molecular weight heparins and their oligosaccharide components. 199. Xu Z, Fan J, Luo X, Zhang WB, Ma J, Lin YB, et al. Anticoagulation regimens during
Anal Bioanal Chem 2011;399:763–71.  pregnancy in patients with mechanical heart valves: a systematic review and
175. Thomas S, Makris M. The reversal of anticoagulation in clinical practice. Clin Med (Lond) meta-analysis. Can J Cardiol 2016;32:1248.e1–e9. 
2018;18:314–9.  11.005
176. Vause S, Clarke B, Tower CL, Hay C, Knight M. Pregnancy outcomes in women with 200. Steinberg ZL, Dominguez-Islas CP, Otto CM, Stout KK, Krieger EV. Maternal and fetal
mechanical prosthetic heart valves: a prospective descriptive population based study outcomes of anticoagulation in pregnant women with mechanical heart valves. J Am
using the United Kingdom Obstetric Surveillance System (UKOSS) data collection sys- Coll Cardiol 2017;69:2681–91. 
tem. BJOG 2017;124:1411–9.  201. Ferreira S, Costa R, Malveiro D, Vieira F, Tuna M. Warfarin embryopathy: balancing
177. van der Zande A, Ramlakhan K, Gnararaj J, Al Farhan H, Malhame I, Otto C, et al. maternal and fetal risks with anticoagulation therapy. Pediatr Neonatol 2018;59:
Pregnancy and anticoagulation in women with a prosthetic heart valve: data from 534–5. 
the ESC EORP Registry Of Pregnancy And Cardiac disease (ROPAC) III. Eur Heart J 202. Wainwright H, Beighton P. Warfarin embryopathy: fetal manifestations. Virchows Arch
2025,  2010;457:735–9. 
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4555
203. Soma-Pillay P, Nene Z, Mathivha TM, Macdonald AP. The effect of warfarin dosage on 226. Steinberg ZL, Krieger EV. Reply: the anticoagulation conundrum of mechanical heart
maternal and fetal outcomes in pregnant women with prosthetic heart valves. Obstet valves in pregnancy: should DOACs be considered? J Am Coll Cardiol 2017;70:
Med 2011;4:24–7.  3074–5. 
204. van Hagen IM, Roos-Hesselink JW, Ruys TP, Merz WM, Goland S, Gabriel H, et al. 227. Beyer-Westendorf J, Marten S. Reproductive issues in women on direct oral anticoa-
Pregnancy in women with a mechanical heart valve: data of the European Society of gulants. Res Pract Thromb Haemost 2021;5:e12512. 
Cardiology Registry Of Pregnancy And Cardiac disease (ROPAC). Circulation 2015; 228. Wang L, He K, Maxwell B, Grossman SJ, Tremaine LM, Humphreys WG, et al. Tissue
132:132–42.  distribution and elimination of [14C]apixaban in rats. Drug Metab Dispos 2011;39:
205. Hassouna A, Allam H. Limited dose warfarin throughout pregnancy in patients with 256–64. 
mechanical heart valve prosthesis: a meta-analysis. Interact Cardiovasc Thorac Surg 229. Bapat P, Kedar R, Lubetsky A, Matlow JN, Aleksa K, Berger H, et al. Transfer of dabi-
2014;18:797–806.  gatran and dabigatran etexilate mesylate across the dually perfused human placenta.
206. Güner A, Kalçık M, Gürsoy MO, Gündüz S, Astarcıoğlu MA, Bayam E, et al. Obstet Gynecol 2014;123:1256–61. 
Comparison of different anticoagulation regimens regarding maternal and fetal out- 230. Bapat P, Pinto LS, Lubetsky A, Berger H, Koren G. Rivaroxaban transfer across the
comes in pregnant patients with mechanical prosthetic heart valves (from the multi- dually perfused isolated human placental cotyledon. Am J Obstet Gynecol 2015;213:
center ANATOLIA-PREG registry). Am J Cardiol 2020;127:113–9.  710.e1–e6. 
1016/j.amjcard.2020.04.010 231. Beyer-Westendorf J, Tittl L, Bistervels I, Middeldorp S, Schaefer C, Paulus W, et al. Safety
207. Jakobsen C, Larsen JB, Fuglsang J, Hvas AM. Mechanical heart valves, pregnancy, and of direct oral anticoagulant exposure during pregnancy: a retrospective cohort study.
bleeding: a systematic review and meta-analysis. Semin Thromb Hemost 2023;49: Lancet Haematol 2020;7:e884–91. 
542–52.  232. Ueberham L, Hindricks G. Anticoagulation in special patient populations with atrial fib-
208. Schaefer C, Hannemann D, Meister R, Eléfant E, Paulus W, Vial T, et al. Vitamin K an- rillation. Herz 2021;46:323–8. 
tagonists and pregnancy outcome. A multi-centre prospective study. Thromb Haemost 233. Zhao Y, Arya R, Couchman L, Patel JP. Are apixaban and rivaroxaban distributed into
2006;95:949–57.  human breast milk to clinically relevant concentrations? Blood 2020;136:1783–5.
209. Clark SL, Porter TF, West FG. Coumarin derivatives and breast-feeding. Obstet Gynecol 
2000;95:938–40.  234. Datta P, Bramnik A, Rewers-Felkins K, Krutsch K, Baker T, Hale TW. Transfer of apix-
210. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:688–98.  aban into human milk. Obstet Gynecol 2021;137:1080–2. 
org/10.1056/NEJM199709043371007 0000000000004388
211. Friedrich E, Hameed AB. Fluctuations in anti-factor Xa levels with therapeutic enoxa- 235. Ayuk P, Kampouraki E, Truemann A, Sidgwick F, McDonald L, Bingham J, et al.
parin anticoagulation in pregnancy. J Perinatol 2010;30:253–7.  Investigation of dabigatran secretion into breast milk: implications for oral thrombo-
jp.2009.164 prophylaxis in post-partum women. Am J Hematol 2020;95:E10–3. 
212. McDonnell BP, Glennon K, McTiernan A, O’Connor HD, Kirkham C, Kevane B, et al. 1002/ajh.25652
Adjustment of therapeutic LMWH to achieve specific target anti-FXa activity does not 236. Wiesen MH, Blaich C, Müller C, Streichert T, Pfister R, Michels G. The direct factor Xa
affect outcomes in pregnant patients with venous thromboembolism. J Thromb inhibitor rivaroxaban passes into human breast milk. Chest 2016;150:e1–4. 
Thrombolysis 2017;43:105–11.  org/10.1016/j.chest.2016.01.021
213. Nichols KM, Henkin S, Creager MA. Venous thromboembolism associated with preg- 237. Saito J, Kaneko K, Yakuwa N, Kawasaki H, Yamatani A, Murashima A. Rivaroxaban con-
nancy: JACC focus seminar. J Am Coll Cardiol 2020;76:2128–41.  centration in breast milk during breastfeeding: a case study. Breastfeed Med 2019;14:
1016/j.jacc.2020.06.090 748–51. 
214. Butwick AJ, Bentley J, Leonard SA, Carmichael SL, El-Sayed YY, Stephansson O, et al. 238. Muysson M, Marshall K, Datta P, Rewers-Felkins K, Baker T, Hale TW. Rivaroxaban
Prepregnancy maternal body mass index and venous thromboembolism: a population- treatment in two breastfeeding mothers: a case series. Breastfeed Med 2020;15:
based cohort study. BJOG 2019;126:581–8.  41–3. 
215. Gigante B, Tamargo J, Agewall S, Atar D, Ten Berg J, Campo G, et al. Update on an- 239. Elkayam U, Jalnapurkar S, Barakkat MN, Khatri N, Kealey AJ, Mehra A, et al.
tithrombotic therapy and body mass. A clinical consensus statement of the ESC Pregnancy-associated acute myocardial infarction: a review of contemporary experi-
Working Group on cardiovascular pharmacotherapy and the ESC Working Group ence in 150 cases between 2006 and 2011. Circulation 2014;129:1695–702. https://
on thrombosis. Eur Heart J Cardiovasc Pharmacother 2024;10:614–183.  doi.org/10.1161/CIRCULATIONAHA.113.002054
org/10.1093/ehjcvp/pvae064 240. Argentiero D, Savonitto S, D’Andrea P, Iacovelli F. Ticagrelor and tirofiban in preg-
216. Pacheco LD, Saade G, Shrivastava V, Shree R, Elkayam U. Society for Maternal–Fetal nancy and delivery: beyond labels. J Thromb Thrombolysis 2020;49:145–8. 
Medicine consult series #61: anticoagulation in pregnant patients with cardiac disease. org/10.1007/s11239-019-01939-1
Am J Obstet Gynecol 2022;227:B28–43.  241. Serna Candel C, Hellstern V, Beitlich T, Aguilar Pérez M, Bäzner H, Henkes H.
217. Voke J, Keidan J, Pavord S, Spencer NH, Hunt BJ. The management of antenatal Management of a decompensated acute-on-chronic intracranial venous sinus throm-
venous thromboembolism in the UK and Ireland: a prospective multicentre obser- bosis. Ther Adv Neurol Disord 2019;12:1756286419895157. 
vational survey. Br J Haematol 2007;139:545–58.  1756286419895157
2141.2007.06826.x 242. Bauer ME, Bauer ST, Rabbani AB, Mhyre JM. Peripartum management of dual antipla-
218. Knight M. Antenatal pulmonary embolism: risk factors, management and outcomes. telet therapy and neuraxial labor analgesia after bare metal stent insertion for acute
BJOG 2008;115:453–61.  myocardial infarction. Anesth Analg 2012;115:613–5. 
219. Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical 0b013e31825ab374
heart valves: a systematic review of the literature. Arch Intern Med 2000;160:191–6. 243. Kuoni S, Steiner R, Saleh L, Lehmann R, Ochsenbein-Kölble N, Simões-Wüst AP.
 Safety assessment of the SGLT2 inhibitors empagliflozin, dapagliflozin and canagliflozin
220. De Carolis S, di Pasquo E, Rossi E, Del Sordo G, Buonomo A, Schiavino D, et al. during pregnancy: an ex vivo human placenta perfusion and in vitro study. Biomed
Fondaparinux in pregnancy: could it be a safe option? A review of the literature. Pharmacother 2024;171:116177. 
Thromb Res 2015;135:1049–51.  244. Muller DRP, Stenvers DJ, Malekzadeh A, Holleman F, Painter RC, Siegelaar SE. Effects
221. Dempfle CE, Koscielny J, Lindhoff-Last E, Linnemann B, Bux-Gewehr I, Kappert G, of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring
et al. Fondaparinux pre-, peri-, and/or postpartum for the prophylaxis/treatment of ven- outcomes: a systematic review of the evidence. Front Endocrinol (Lausanne) 2023;14:
ous thromboembolism (FondaPPP). Clin Appl Thromb Hemost 2021;27: 1215356. 
10760296211014575.  245. Hemnes AR, Kiely DG, Cockrill BA, Safdar Z, Wilson VJ, Al Hazmi M, et al. Statement
222. Mazzolai L, Hohlfeld P, Spertini F, Hayoz D, Schapira M, Duchosal MA. Fondaparinux is on pregnancy in pulmonary hypertension from the Pulmonary Vascular Research
a safe alternative in case of heparin intolerance during pregnancy. Blood 2006;108: Institute. Pulm Circ 2015;5:435–65. 
1569–70.  246. Cesta CE, Segovia Chacón S, Engeland A, Broe A, Damkier P, Furu K, et al. Use of sil-
223. Gerhardt A, Zotz RB, Stockschlaeder M, Scharf RE. Fondaparinux is an effective alter- denafil and other phosphodiesterase type 5 inhibitors among pregnant women in
native anticoagulant in pregnant women with high risk of venous thromboembolism Scandinavia. Acta Obstet Gynecol Scand 2021;100:2111–8. 
and intolerance to low-molecular-weight heparins and heparinoids. Thromb Haemost aogs.14251
2007;97:496–7.  247. Horng M, Mohammad I, Smith ZR, Awdish RL, Cajigas HR. Inhaled iloprost for chronic
224. Beyer-Westendorf J, Michalski F, Tittl L, Middeldorp S, Cohen H, Abdul Kadir R, et al. thromboembolic pulmonary hypertension (CTEPH) during pregnancy: a case report.
Pregnancy outcome in patients exposed to direct oral anticoagulants—and the chal- Pharmacotherapy 2016;36:e142–7. 
lenge of event reporting. Thromb Haemost 2016;116:651–8.  248. Tokgöz HC, Kaymaz C, Poci N, Akbal Ö Y, Öztürk S. A successful cesarean delivery
TH16-04-0305 without fetal or maternal morbidity in an eisenmenger patient with cor triatriatum si-
225. Sessa M, Mascolo A, Callréus T, Capuano A, Rossi F, Andersen M. Direct-acting oral nistrum, double-orifice mitral valve, large ventricular septal defect, and single ventricle
anticoagulants (DOACs) in pregnancy: new insight from VigiBase(®). Sci Rep 2019; who was under long-term bosentan treatment. Turk Kardiyol Dern Ars 2017;45:184–8.
9:7236.  
Downloaded
from

by
guest
on
22
January
2026

4556 E S C G u id e l in e s
249. Nauwelaerts N, Ceulemans M, Deferm N, Eerdekens A, Lammens B, Armoudjian Y, 272. Ryu RJ, Eyal S, Easterling TR, Caritis SN, Venkataraman R, Hankins G, et al.
et al. Case report: bosentan and sildenafil exposure in human milk—a contribution Pharmacokinetics of metoprolol during pregnancy and lactation. J Clin Pharmacol
from the ConcePTION project. Front Pharmacol 2022;13:881084.  2016;56:581–9. 
3389/fphar.2022.881084 273. Lip GY, Beevers M, Churchill D, Shaffer LM, Beevers DG. Effect of atenolol on birth
250. Duan L, Ng A, Chen W, Spencer HT, Nguyen J, Shen AY, et al. β-Blocker exposure in weight. Am J Cardiol 1997;79:1436–8. 
pregnancy and risk of fetal cardiac anomalies. JAMA Intern Med 2017;177:885–7. 274. de Bruin R, van Dalen SL, Franx SJ, Ramaswamy VV, Simons SHP, Flint RB, et al. The risk
 for neonatal hypoglycemia and bradycardia after beta-blocker use during pregnancy or
251. van der Zande JA, Cornette JMJ, Roos-Hesselink JW, Flint RB. Maternal, fetal, neonatal lactation: a systematic review and meta-analysis. Int J Environ Res Public Health 2022;19:
and breastmilk flecainide concentration during maternal therapy and lactation: a case 9616. 
report. Int Breastfeed J 2023;18:21.  275. Kittleson MM, DeFilippis EM, Bhagra CJ, Casale JP, Cauldwell M, Coscia LA, et al.
252. Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022 Reproductive health after thoracic transplantation: an ISHLT expert consensus state-
ESC Guidelines for the management of patients with ventricular arrhythmias and ment. J Heart Lung Transplant 2023;42:e1–42. 
the prevention of sudden cardiac death. Eur Heart J 2022;43:3997–4126.  009
org/10.1093/eurheartj/ehac262 276. Le HL, Francke MI, Andrews LM, de Winter BCM, van Gelder T, Hesselink DA. Usage
253. George R, Thomas C, Joy CA, Varghese B, Undela K, Adela R. Comparative efficacy of tacrolimus and mycophenolic acid during conception, pregnancy, and lactation, and
and safety of oral nifedipine with other antihypertensive medications in the manage- its implications for therapeutic drug monitoring: a systematic critical review. Ther Drug
ment of hypertensive disorders of pregnancy: a systematic review and meta-analysis Monit 2020;42:518–31. 
of randomized controlled trials. J Hypertens 2022;40:1876–86.  277. Coscia LA, Armenti DP, King RW, Sifontis NM, Constantinescu S, Moritz MJ. Update
1097/HJH.0000000000003233 on the teratogenicity of maternal mycophenolate mofetil. J Pediatr Genet 2015;4:
254. Easterling T, Mundle S, Bracken H, Parvekar S, Mool S, Magee LA, et al. Oral antihyper- 42–55. 
tensive regimens (nifedipine retard, labetalol, and methyldopa) for management of se- 278. Lebin LG, Novick AM. Selective serotonin reuptake inhibitors (SSRIs) in pregnancy: an
vere hypertension in pregnancy: an open-label, randomised controlled trial. Lancet updated review on risks to mother, fetus, and child. Curr Psychiatry Rep 2022;24:
2019;394:1011–21.  687–95. 
255. Yin J, Mei Z, Shi S, Du P, Qin S. Nifedipine or amlodipine? The choice for hypertension 279. Walkery A, Leader LD, Cooke E, VandenBerg A. Review of allopregnanolone agonist
during pregnancy: a systematic review and meta-analysis. Arch Gynecol Obstet 2022; therapy for the treatment of depressive disorders. Drug Des Devel Ther 2021;15:
306:1891–900.  3017–26. 
256. Coberger ED, Jensen BP, Dalrymple JM. Transfer of candesartan into human breast milk. 280. Henriksson P. Cardiovascular problems associated with IVF therapy. J Intern Med 2021;
Obstet Gynecol 2019;134:481–4.  289:2–11. 
257. Phelps DL, Karim A. Spironolactone: relationship between concentrations of dethioa- 281. Wallet T, Legrand L, Isnard R, Gandjbakhch E, Pousset F, Proukhnitzky J, et al.
cetylated metabolite in human serum and milk. J Pharm Sci 1977;66:1203.  Pregnancy and cardiac maternal outcomes in women with inherited cardiomyopathy:
org/10.1002/jps.2600660841 interest of the CARPREG II risk score. ESC Heart Fail 2024;11:1506–14. 
258. Saito J, Mito A, Yakuwa N, Kaneko K, Kawasaki H, Suzuki T, et al. Eplerenone levels in 10.1002/ehf2.14694
maternal serum, cord blood, and breast milk during pregnancy and lactation. Hypertens 282. Grewal J, Siu SC, Ross HJ, Mason J, Balint OH, Sermer M, et al. Pregnancy outcomes in
Res 2021;44:879–81.  women with dilated cardiomyopathy. J Am Coll Cardiol 2009;55:45–52. 
259. Gehlert J, Morton A. Eplerenone as a treatment for resistant hypertension in preg- 10.1016/j.jacc.2009.08.036
nancy. Obstet Med 2021;14:35–8.  283. Castrini AI, Skjølsvik E, Estensen ME, Almaas VM, Skulstad H, Lyseggen E, et al.
260. Gunganah K, Carpenter R, Drake WM. Eplerenone use in primary aldosteronism dur- Pregnancy and progression of cardiomyopathy in women with LMNA genotype-
ing pregnancy. Clin Case Rep 2016;4:81–2.  positive. J Am Heart Assoc 2022;11:e024960. 
261. Morton A, Laurie J. Eplerenone in the management of resistant hypertension with ob- 024960
structive sleep apnoea in pregnancy. Pregnancy Hypertens 2017;7:54–5.  284. Hodes AR, Tichnell C, Te Riele AS, Murray B, Groeneweg JA, Sawant AC, et al.
10.1016/j.preghy.2016.12.001 Pregnancy course and outcomes in women with arrhythmogenic right ventricular car-
262. Mulder J, Kusters DM, Roeters van Lennep JE, Hutten BA. Lipid metabolism during diomyopathy. Heart 2016;102:303–12. 
pregnancy: consequences for mother and child. Curr Opin Lipidol 2024;35:133–40. 285. Gandjbakhch E, Varlet E, Duthoit G, Fressart V, Charron P, Himbert C, et al. Pregnancy
263. FDA. FDA Requests Removal of Strongest Warning Against Using Cholesterol-Lowering and newborn outcomes in arrhythmogenic right ventricular cardiomyopathy/dysplasia.
Statins During Pregnancy; Still Advises Most Pregnant Patients Should Stop Taking Int J Cardiol 2018;258:172–8. 
Statins.  286. Ermakov S, Scheinman M. Arrhythmogenic right ventricular cardiomyopathy—antiar-
strongest-warning-against-using-cholesterol-lowering-statins-during-pregnancy (14 rhythmic therapy. Arrhythm Electrophysiol Rev 2015;4:86–9. 
August 2024, date last accessed). AER.2015.04.02.86
264. Mauricio R, Khera A. Statin use in pregnancy: is it time for a paradigm shift? Circulation 287. Ermakov S, Gerstenfeld EP, Svetlichnaya Y, Scheinman MM. Use of flecainide in com-
2022;145:496–8.  bination antiarrhythmic therapy in patients with arrhythmogenic right ventricular car-
265. Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, et al. diomyopathy. Heart Rhythm 2017;14:564–9. 
Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based ap- 010
proach from the writing committee of the American Society for Apheresis: the sev- 288. Castrini AI, Lie Ø, Leren IS, Estensen ME, Stokke MK, Klæboe LG, et al. Number of
enth special issue. J Clin Apher 2016;31:149–62.  pregnancies and subsequent phenotype in a cross-sectional cohort of women with ar-
266. Ardissino M, Slob EAW, Reddy RK, Morley AP, Schuermans A, Hill P, et al. Genetically rhythmogenic cardiomyopathy. Eur Heart J Cardiovasc Imaging 2019;20:192–8. https://
proxied low-density lipoprotein cholesterol lowering via PCSK9-inhibitor drug targets doi.org/10.1093/ehjci/jey061
and risk of congenital malformations. Eur J Prev Cardiol 2024;31:955–65.  289. Platonov PG, Castrini AI, Svensson A, Christiansen MK, Gilljam T, Bundgaard H, et al.
10.1093/eurjpc/zwad402 Pregnancies, ventricular arrhythmias, and substrate progression in women with ar-
267. Wu Y, Yao JW, Xu LJ, Chen M, Wan L. Risk of congenital malformations in offspring of rhythmogenic right ventricular cardiomyopathy in the Nordic ARVC registry.
women using β-blockers during early pregnancy: an updated meta-analysis of observa- Europace 2020;22:1873–9. 
tional studies. Br J Clin Pharmacol 2021;87:806–15.  290. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014
268. Bateman BT, Heide-Jørgensen U, Einarsdóttir K, Engeland A, Furu K, Gissler M, et al. ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the
β-Blocker use in pregnancy and the risk for congenital malformations: an international task force for the diagnosis and management of hypertrophic cardiomyopathy of
cohort study. Ann Intern Med 2018;169:665–73.  the European Society of Cardiology (ESC). Eur Heart J 2014;35:2733–79. 
269. Welzel T, Donner B, van den Anker JN. Intrauterine growth retardation in pregnant org/10.1093/eurheartj/ehu284
women with long QT syndrome treated with beta-receptor blockers. Neonatology 291. Licordari R, Trimarchi G, Teresi L, Restelli D, Lofrumento F, Perna A, et al. Cardiac
2021;118:406–15.  magnetic resonance in HCM phenocopies: from diagnosis to risk stratification and
270. Peltenburg PJ, Kallas D, Bos JM, Lieve KVV, Franciosi S, Roston TM, et al. An inter- therapeutic management. J Clin Med 2023;12:3481. 
national multicenter cohort study on β-blockers for the treatment of symptomatic jcm12103481
children with catecholaminergic polymorphic ventricular tachycardia. Circulation 292. Boucek D, Jirikowic J, Taylor M. Natural history of Danon disease. Genet Med 2011;13:
2022;145:333–44.  563–8. 
271. Tamirisa KP, Elkayam U, Briller JE, Mason PK, Pillarisetti J, Merchant FM, et al. 293. Pasqualucci D, Maiani S, Perra F, Cau M, Coiana A, Bianco P, et al. Danon disease in a
Arrhythmias in pregnancy. JACC Clin Electrophysiol 2022;8:120–35.  Sardinian family: different aspects of the same mutation-a case report. Eur Heart J Case
1016/j.jacep.2021.10.004 Rep 2023;7:ytad237. 
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4557
294. Autore C, Conte MR, Piccininno M, Bernabò P, Bonfiglio G, Bruzzi P, et al. Risk asso- 317. Atkinson HC, Begg EJ, Darlow BA. Drugs in human milk. Clinical pharmacokinetic con-
ciated with pregnancy in hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;40: siderations. Clin Pharmacokinet 1988;14:217–40. 
1864–9.  198814040-00003
295. Schinkel AF. Pregnancy in women with hypertrophic cardiomyopathy. Cardiol Rev 318. Long QT Drugs Database.  (29 January 2025, date last
2014;22:217–22.  accessed).
296. Goland S, van Hagen IM, Elbaz-Greener G, Elkayam U, Shotan A, Merz WM, et al. 319. Cuneo BF, Kaizer AM, Clur SA, Swan H, Herberg U, Winbo A, et al. Mothers with long
Pregnancy in women with hypertrophic cardiomyopathy: data from the European QT syndrome are at increased risk for fetal death: findings from a multicenter inter-
Society of Cardiology initiated Registry Of Pregnancy And Cardiac disease national study. Am J Obstet Gynecol 2020;222:263.e1–e11. 
(ROPAC). Eur Heart J 2017;38:2683–90.  ajog.2019.09.004
297. Moolla M, Mathew A, John K, Yogasundaram H, Alhumaid W, Campbell S, et al. 320. Crotti L, Tester DJ, White WM, Bartos DC, Insolia R, Besana A, et al. Long QT
Outcomes of pregnancy in women with hypertrophic cardiomyopathy: a systematic syndrome-associated mutations in intrauterine fetal death. JAMA 2013;309:
review. Int J Cardiol 2022;359:54–60.  1473–82. 
298. Fumagalli C, Zocchi C, Cappelli F, Celata A, Tassetti L, Sasso L, et al. Impact of preg- 321. Schwartz PJ, Garson A, Jr., Paul T, Stramba-Badiale M, Vetter VL, Wren C. Guidelines
nancy on the natural history of women with hypertrophic cardiomyopathy. Eur J Prev for the interpretation of the neonatal electrocardiogram. A task force of the European
Cardiol 2024;31:3–10.  Society of Cardiology. Eur Heart J 2002;23:1329–44. 
299. Musumeci MB, Spirito P, Conte MR, Lillo R, Devoto E, Francia P, et al. Clinical course of 2002.3274
pregnancy and long-term follow-up after delivery in hypertrophic cardiomyopathy. J 322. Schwartz PJ, Ackerman MJ, Antzelevitch C, Bezzina CR, Borggrefe M, Cuneo BF, et al.
Am Coll Cardiol 2021;77:1262–4.  Inherited cardiac arrhythmias. Nat Rev Dis Primers 2020;6:58. 
300. L’Écuyer É, Codsi E, Mongeon FP, Dore A, Morin F, Leduc L. Perinatal and cardiac out- s41572-020-0188-7
comes of women with hypertrophic cardiomyopathy. J Matern Fetal Neonatal Med 323. Rodríguez-Mañero M, Casado-Arroyo R, Sarkozy A, Leysen E, Sieira JA, Namdar M,
2022;35:8625–30.  et al. The clinical significance of pregnancy in Brugada syndrome. Rev Esp Cardiol
301. Gi WT, Amr A, Sedaghat-Hamedani F, Kayvanpour E, Mohr I, Meder M, et al. Two (Engl Ed) 2014;67:176–80. 
hearts at risk: emergency alcohol septal ablation in a pregnant woman with decompen- 324. Brugada Drugs Database. www.brugadadrugs.org (29 January 2025, date last accessed).
sated HOCM. JACC Case Rep 2020;2:139–44.  325. Talib S, van de Poll SW. Brugada syndrome diagnosed after Ramadan. Lancet 2013;
053 382:100. 
302. Shaikh A, Bajwa T, Bush M, Tajik AJ. Successful alcohol septal ablation in a pregnant 326. Cheung CC, Lieve KV, Roston TM, van der Ree MH, Deyell MW, Andrade JG, et al.
patient with symptomatic hypertrophic obstructive cardiomyopathy. J Cardiol Cases Pregnancy in catecholaminergic polymorphic ventricular tachycardia. JACC Clin
2018;17:151–4.  Electrophysiol 2019;5:387–94. 
303. Bello J, Pellegrini MV. Mavacamten. In: StatPearls. Treasure Island, FL: StatPearls 327. Kannankeril PJ, Moore JP, Cerrone M, Priori SG, Kertesz NJ, Ro PS, et al. Efficacy of
Publishing, 2023. Available from:  flecainide in the treatment of catecholaminergic polymorphic ventricular tachycardia:
(3 April 2025 date last accessed) a randomized clinical trial. JAMA Cardiol 2017;2:759–66. 
304. European Medicines Agency  jamacardio.2017.1320
information/camzyos-epar-product-information_en.pdf (3 April 2025, date last 328. De Ferrari GM, Dusi V, Spazzolini C, Bos JM, Abrams DJ, Berul CI, et al. Clinical man-
accessed). agement of catecholaminergic polymorphic ventricular tachycardia: the role of left car-
305. Maisch B, Mahrholdt H. The 2014 ESC Guidelines on the diagnosis and management of diac sympathetic denervation. Circulation 2015;131:2185–93. 
hypertrophic cardiomyopathy: what is new? Herz 2014;39:919–30.  CIRCULATIONAHA.115.015731
1007/s00059-014-4177-z 329. Crotti L, Odening KE, Sanguinetti MC. Heritable arrhythmias associated with abnormal
306. Tadmor OP, Keren A, Rosenak D, Gal M, Shaia M, Hornstein E, et al. The effect of dis- function of cardiac potassium channels. Cardiovasc Res 2020;116:1542–56. 
opyramide on uterine contractions during pregnancy. Am J Obstet Gynecol 1990;162: org/10.1093/cvr/cvaa068
482–6.  330. Bjerregaard P. Diagnosis and management of short QT syndrome. Heart Rhythm 2018;
307. Schwartz PJ, Stramba-Badiale M, Crotti L, Pedrazzini M, Besana A, Bosi G, et al. 15:1261–7. 
Prevalence of the congenital long-QT syndrome. Circulation 2009;120:1761–7. 331. Ahmed A, Phillips JR. Teenage pregnancy with catecholaminergic polymorphic ven-
 tricular tachycardia and documented ICD discharges. Clin Case Rep 2016;4:361–5.
308. Chockalingam P, Crotti L, Girardengo G, Johnson JN, Harris KM, van der Heijden JF, 
et al. Not all beta-blockers are equal in the management of long QT syndrome types 332. Romagano MP, Quiñones JN, Ahnert A, Martinez R, Smulian JC. Catecholaminergic
1 and 2: higher recurrence of events under metoprolol. J Am Coll Cardiol 2012;60: polymorphic ventricular tachycardia in pregnancy. Obstet Gynecol 2016;127:735–9.
2092–9.  
309. Dusi V, Pugliese L, De Ferrari GM, Odero A, Crotti L, Dagradi F, et al. Left cardiac sym- 333. Kloesel B, Ackerman MJ, Sprung J, Narr BJ, Weingarten TN. Anesthetic management of
pathetic denervation for long QT syndrome: 50 years’ experience provides guidance patients with Brugada syndrome: a case series and literature review. Can J Anaesth
for management. JACC Clin Electrophysiol 2022;8:281–94.  2011;58:824–36. 
jacep.2021.09.002 334. Roston TM, van der Werf C, Cheung CC, Grewal J, Davies B, Wilde AAM, et al. Caring
310. Bos JM, Crotti L, Rohatgi RK, Castelletti S, Dagradi F, Schwartz PJ, et al. Mexiletine for the pregnant woman with an inherited arrhythmia syndrome. Heart Rhythm 2020;
shortens the QT interval in patients with potassium channel-mediated type 2 long 17:341–8. 
QT syndrome. Circ Arrhythm Electrophysiol 2019;12:e007280.  335. Tanaka H, Katsuragi S, Tanaka K, Sawada M, Iwanaga N, Yoshimatsu J, et al. Maternal
1161/CIRCEP.118.007280 and neonatal outcomes in labor and at delivery when long QT syndrome is present. J
311. Crotti L, Neves R, Dagradi F, Musu G, Giannetti F, Bos JM, et al. Therapeutic efficacy of Matern Fetal Neonatal Med 2016;29:1117–9. 
mexiletine for long QT syndrome type 2: evidence from human induced pluripotent 1036023
stem cell-derived cardiomyocytes, transgenic rabbits, and patients. Circulation 2024; 336. Hammond BH, El Assaad I, Herber JM, Saarel EV, Cantillon D, Aziz PF. Contemporary
150:531–43.  maternal and fetal outcomes in the treatment of LQTS during pregnancy: is nadolol
312. Rashba EJ, Zareba W, Moss AJ, Hall WJ, Robinson J, Locati EH, et al. Influence of preg- bad for the fetus? Heart Rhythm 2022;19:1516–21. 
nancy on the risk for cardiac events in patients with hereditary long QT syndrome. 2022.05.001
LQTS Investigators. Circulation 1998;97:451–6.  337. Sharif-Kazemi MB, Emkanjoo Z, Tavoosi A, Kafi M, Kheirkhah J, Alizadeh A, et al.
313. Khositseth A, Tester DJ, Will ML, Bell CM, Ackerman MJ. Identification of a common Electrical storm in Brugada syndrome during pregnancy. Pacing Clin Electrophysiol
genetic substrate underlying postpartum cardiac events in congenital long QT syn- 2011;34:e18–21. 
drome. Heart Rhythm 2004;1:60–4.  338. Giustetto C, Cerrato N, Dusi V, Angelini F, De Ferrari G, Gaita F. The Brugada syn-
314. Heradien MJ, Goosen A, Crotti L, Durrheim G, Corfield V, Brink PA, et al. Does preg- drome: pharmacological therapy. Eur Heart J Suppl 2023;25:C32–7. 
nancy increase cardiac risk for LQT1 patients with the KCNQ1-A341V mutation? J Am 10.1093/eurheartjsupp/suad036
Coll Cardiol 2006;48:1410–5.  339. Bauersachs J, König T, van der Meer P, Petrie MC, Hilfiker-Kleiner D, Mbakwem A,
315. Seth R, Moss AJ, McNitt S, Zareba W, Andrews ML, Qi M, et al. Long QT syndrome et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a
and pregnancy. J Am Coll Cardiol 2007;49:1092–8.  position statement from the Heart Failure Association of the European Society of
09.054 Cardiology study group on peripartum cardiomyopathy. Eur J Heart Fail 2019;21:
316. Ishibashi K, Aiba T, Kamiya C, Miyazaki A, Sakaguchi H, Wada M, et al. Arrhythmia risk 827–43. 
and β-blocker therapy in pregnant women with long QT syndrome. Heart 2017;103: 340. Arany Z. Peripartum cardiomyopathy. N Engl J Med 2024;390:154–64. 
1374–9.  10.1056/NEJMra2306667
Downloaded
from

by
guest
on
22
January
2026

4558 E S C G u id e l in e s
341. Mielniczuk LM, Williams K, Davis DR, Tang AS, Lemery R, Green MS, et al. Frequency 363. Carlson S, Schultz J, Ramu B, Davis MB. Peripartum cardiomyopathy: risks diagnosis
of peripartum cardiomyopathy. Am J Cardiol 2006;97:1765–8.  and management. J Multidiscip Healthc 2023;16:1249–58. 
amjcard.2006.01.039 JMDH.S372747
342. Brar SS, Khan SS, Sandhu GK, Jorgensen MB, Parikh N, Hsu JW, et al. Incidence, mor- 364. Puri A, Sethi R, Singh B, Dwivedi S, Narain V, Saran R, et al. Peripartum cardiomyopathy
tality, and racial differences in peripartum cardiomyopathy. Am J Cardiol 2007;100: presenting with ventricular tachycardia: a rare presentation. Indian Pacing Electrophysiol
302–4.  J 2009;9:186–9. PMID: 19471599
343. Karaye KM, Ishaq NA, Sa’idu H, Balarabe SA, Talle MA, Isa MS, et al. Incidence, clinical 365. Saltzberg MT, Szymkiewicz S, Bianco NR. Characteristics and outcomes of
characteristics, and risk factors of peripartum cardiomyopathy in Nigeria: results from peripartum versus nonperipartum cardiomyopathy in women using a wearable
the PEACE registry. ESC Heart Fail 2020;7:235–43.  cardiac defibrillator. J Card Fail 2012;18:21–7. 
344. Sliwa K, Bauersachs J, Arany Z, Spracklen TF, Hilfiker-Kleiner D. Peripartum cardiomy- 09.004
opathy: from genetics to management. Eur Heart J 2021;42:3094–102.  366. McNamara DM, Elkayam U, Alharethi R, Damp J, Hsich E, Ewald G, et al. Clinical out-
10.1093/eurheartj/ehab458 comes for peripartum cardiomyopathy in North America: results of the IPAC study
345. Bauersachs J, Arrigo M, Hilfiker-Kleiner D, Veltmann C, Coats AJ, Crespo-Leiro MG, (investigations of pregnancy-associated cardiomyopathy). J Am Coll Cardiol 2015;66:
905–14. 
et al. Current management of patients with severe acute peripartum cardiomyopathy:
367. Davis MB, Arany Z, McNamara DM, Goland S, Elkayam U. Peripartum cardiomyop-
practical guidance from the Heart Failure Association of the European Society of
athy: JACC state-of-the-art review. J Am Coll Cardiol 2020;75:207–21. 
Cardiology study group on peripartum cardiomyopathy. Eur J Heart Fail 2016;18:
10.1016/j.jacc.2019.11.014
1096–105. 
368. Sliwa K, Jackson A, Viljoen C, Damasceno A, Mbanze I, Farhan HA, et al. Pregnancies in
346. Viljoen C, Hoevelmann J, Sliwa K. Peripartum cardiomyopathy in Europe: new insights
women after peri-partum cardiomyopathy: the global European Society of Cardiology
from the UK. Eur Heart J 2023;44:5142–5. 
EuroObservational research programme peri-partum cardiomyopathy registry. Eur
347. Ware JS, Li J, Mazaika E, Yasso CM, DeSouza T, Cappola TP, et al. Shared genetic pre-
Heart J 2025;46:1031–40. 
disposition in peripartum and dilated cardiomyopathies. N Engl J Med 2016;374:
369. Sliwa K, Petrie MC, Hilfiker-Kleiner D, Mebazaa A, Jackson A, Johnson MR,
233–41. 
et al. Long-term prognosis, subsequent pregnancy, contraception and overall
348. Goli R, Li J, Brandimarto J, Levine LD, Riis V, McAfee Q, et al. Genetic and phenotypic
management of peripartum cardiomyopathy: practical guidance paper from the
landscape of peripartum cardiomyopathy. Circulation 2021;143:1852–62. 
Heart Failure Association of the European Society of Cardiology study group on
org/10.1161/CIRCULATIONAHA.120.052395
peripartum cardiomyopathy. Eur J Heart Fail 2018;20:951–62. 
349. Sliwa K, Hilfiker-Kleiner D, Petrie MC, Mebazaa A, Pieske B, Buchmann E, et al. Current
1002/ejhf.1178
state of knowledge on aetiology, diagnosis, management, and therapy of peripartum 370. Sliwa K, Mebazaa A, Hilfiker-Kleiner D, Petrie MC, Maggioni AP, Laroche C,
cardiomyopathy: a position statement from the Heart Failure Association of the et al. Clinical characteristics of patients from the worldwide registry on
European Society of Cardiology working group on peripartum cardiomyopathy. Eur peripartum cardiomyopathy (PPCM): EURObservational research programme in con-
J Heart Fail 2010;12:767–78.  junction with the Heart Failure Association of the European Society of Cardiology
350. Hilfiker-Kleiner D, Haghikia A, Nonhoff J, Bauersachs J. Peripartum cardiomyopathy: study group on PPCM. Eur J Heart Fail 2017;19:1131–41. 
current management and future perspectives. Eur Heart J 2015;36:1090–7. https:// ejhf.780
doi.org/10.1093/eurheartj/ehv009 371. Fett JD, Fristoe KL, Welsh SN. Risk of heart failure relapse in subsequent pregnancy
351. Hilfiker-Kleiner D, Sliwa K. Pathophysiology and epidemiology of peripartum cardio- among peripartum cardiomyopathy mothers. Int J Gynaecol Obstet 2010;109:34–6.
myopathy. Nat Rev Cardiol 2014;11:364–70.  
352. Patten IS, Rana S, Shahul S, Rowe GC, Jang C, Liu L, et al. Cardiac angiogenic imbalance 372. Desplantie O, Tremblay-Gravel M, Avram R, Marquis-Gravel G, Ducharme A,
leads to peripartum cardiomyopathy. Nature 2012;485:333–8.  Jolicoeur EM. The medical treatment of new-onset peripartum cardiomyopathy: a sys-
1038/nature11040 tematic review of prospective studies. Can J Cardiol 2015;31:1421–6. 
353. Ricke-Hoch M, Pfeffer TJ, Hilfiker-Kleiner D. Peripartum cardiomyopathy: basic me- 1016/j.cjca.2015.04.029
chanisms and hope for new therapies. Cardiovasc Res 2020;116:520–31.  373. Haghikia A, Podewski E, Berliner D, Sonnenschein K, Fischer D, Angermann CE, et al.
org/10.1093/cvr/cvz252 Rationale and design of a randomized, controlled multicentre clinical trial to evaluate
354. Schelbert EB, Elkayam U, Cooper LT, Givertz MM, Alexis JD, Briller J, et al. Myocardial the effect of bromocriptine on left ventricular function in women with peripartum car-
damage detected by late gadolinium enhancement cardiac magnetic resonance is un- diomyopathy. Clin Res Cardiol 2015;104:911–7. 
common in peripartum cardiomyopathy. J Am Heart Assoc 2017;6:e005472. https:// 0869-5
doi.org/10.1161/JAHA.117.005472 374. van der Meer P, van Essen B, Viljoen C, Böhm M, Jackson A, Hilfiker-Kleiner D, et al.
355. Jackson AM, Macartney M, Brooksbank K, Brown C, Dawson D, Francis M, et al. A Bromocriptine treatment and outcomes in peripartum cardiomyopathy: the EORP
20-year population study of peripartum cardiomyopathy. Eur Heart J 2023;44: PPCM registry. Eur Heart J 2025;46:1017–27. 
5128–41.  ehae559
356. Gevaert S, Van Belleghem Y, Bouchez S, Herck I, De Somer F, De Block Y, et al. Acute 375. Haghikia A, Podewski E, Libhaber E, Labidi S, Fischer D, Roentgen P, et al. Phenotyping
and critically ill peripartum cardiomyopathy and ‘bridge to’ therapeutic options: a single and outcome on contemporary management in a German cohort of patients with
peripartum cardiomyopathy. Basic Res Cardiol 2013;108:366.  center experience with intra-aortic balloon pump, extra corporeal membrane oxygen-
1007/s00395-013-0366-9 ation and continuous-flow left ventricular assist devices. Crit Care 2011;15:R93. https://
376. Tremblay-Gravel M, Marquis-Gravel G, Avram R, Desplantie O, Ducharme A, Bibas L,
doi.org/10.1186/cc10098
et al. The effect of bromocriptine on left ventricular functional recovery in peripartum
357. Mebazaa A, Tolppanen H, Mueller C, Lassus J, DiSomma S, Baksyte G, et al. Acute heart
cardiomyopathy: insights from the BRO-HF retrospective cohort study. ESC Heart Fail
failure and cardiogenic shock: a multidisciplinary practical guidance. Intensive Care Med
2019;6:27–36. 
2016;42:147–63. 
377. Duncker D, Haghikia A, König T, Hohmann S, Gutleben KJ, Westenfeld R, et al. Risk for
358. Hilfiker-Kleiner D, Haghikia A, Berliner D, Vogel-Claussen J, Schwab J, Franke A, et al.
ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ven-
Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre rando-
tricular function—value of the wearable cardioverter/defibrillator. Eur J Heart Fail
mized study. Eur Heart J 2017;38:2671–9. 
2014;16:1331–6. 
359. Trongtorsak A, Kittipibul V, Mahabir S, Ibrahim M, Saint Croix GR, Hernandez GA,
378. Beyer SE, Dicks AB, Shainker SA, Feinberg L, Schermerhorn ML, Secemsky EA, et al.
et al. Effects of bromocriptine in peripartum cardiomyopathy: a systematic review
Pregnancy-associated arterial dissections: a nationwide cohort study. Eur Heart J
and meta-analysis. Heart Fail Rev 2022;27:533–43. 
2020;41:4234–42. 
021-10185-8 379. Tanaka H, Kamiya CA, Horiuchi C, Morisaki H, Tanaka K, Katsuragi S, et al. Aortic dis-
360. Sliwa K, Blauwet L, Tibazarwa K, Libhaber E, Smedema JP, Becker A, et al. Evaluation of section during pregnancy and puerperium: a Japanese nationwide survey. J Obstet
bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a Gynaecol Res 2021;47:1265–71. 
proof-of-concept pilot study. Circulation 2010;121:1465–73.  380. Braverman AC, Mittauer E, Harris KM, Evangelista A, Pyeritz RE, Brinster D, et al.
CIRCULATIONAHA.109.901496 Clinical features and outcomes of pregnancy-related acute aortic dissection. JAMA
361. Sieweke JT, Pfeffer TJ, Berliner D, König T, Hallbaum M, Napp LC, et al. Cardiogenic Cardiol 2021;6:58–66. 
shock complicating peripartum cardiomyopathy: importance of early left ventricular 381. Sayama S, Takeda N, Iriyama T, Inuzuka R, Maemura S, Fujita D, et al. Peripartum type B
unloading and bromocriptine therapy. Eur Heart J Acute Cardiovasc Care 2020;9: aortic dissection in patients with Marfan syndrome who underwent aortic root re-
173–82.  placement: a case series study. BJOG 2018;125:487–93. 
362. Radakrishnan A, Dokko J, Pastena P, Kalogeropoulos AP. Thromboembolism in peri- 1471-0528.14635
partum cardiomyopathy: a systematic review. J Thorac Dis 2024;16:645–60.  382. Peters P, van der Zande A, De Backer J, Jondeau G, Ahmad O, Richardson M, et al.
org/10.21037/jtd-23-945 Pregnancy outcomes in women with heritable thoracic aortic disease: data from the
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4559
EORP ESC Registry of Pregnancy and Cardiac disease (ROPAC) III. Eur Heart J Qual 403. Luehr M, Yildiz M, Ma WG, Heck R, Polycarpou A, Jassar A, et al. Acute type A aortic
Care Clin Outcomes 2025; DOI: 10.1093/ehjqcco/qcaf038 dissection in adolescents and young adults under 30 years of age: demographics, aeti-
383. Czerny M, Grabenwöger M, Berger T, Aboyans V, Della Corte A, Chen EP, et al. ology and postoperative outcomes of 139 cases. Eur J Cardiothorac Surg 2023;63:
EACTS/STS Guidelines for diagnosing and treating acute and chronic syndromes of ezad112. 
the aortic organ. Eur J Cardiothorac Surg 2024;65:ezad426.  404. Gravholt CH, Andersen NH, Conway GS, Dekkers OM, Geffner ME, Klein KO, et al.
ejcts/ezad426 Clinical practice guidelines for the care of girls and women with Turner syndrome:
384. Narula N, Devereux RB, Malonga GP, Hriljac I, Roman MJ. Pregnancy-related aortic proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J
complications in women with Marfan syndrome. J Am Coll Cardiol 2021;78:870–9. Endocrinol 2017;177:G1–G70. 
 405. Silberbach M, Roos-Hesselink JW, Andersen NH, Braverman AC, Brown N, Collins
385. Wallace SE, Regalado ES, Gong L, Janda AL, Guo DC, Russo CF, et al. MYLK pathogenic RT, et al. Cardiovascular health in Turner syndrome: a scientific statement from the
variants aortic disease presentation, pregnancy risk, and characterization of pathogenic American Heart Association. Circ Genomic Precis Med 2018;11:e000048. 
missense variants. Genet Med 2019;21:144–51.  org/10.1161/HCG.0000000000000048
0038-0 406. Duijnhouwer AL, Bons LR, Timmers H, van Kimmenade RRL, Snoeren M,
386. Regalado ES, Guo DC, Estrera AL, Buja LM, Milewicz DM. Acute aortic dissections Timmermans J, et al. Aortic dilatation and outcome in women with Turner syndrome.
with pregnancy in women with ACTA2 mutations. Am J Med Genet A 2014;164A: Heart 2019;105:693–700. 
106–12.  407. Meccanici F, Schotte MH, Snoeren M, Bons LR, van den Hoven AT, Kardys I, et al.
387. Jondeau G, Ropers J, Regalado E, Braverman A, Evangelista A, Teixedo G, et al. Aortic dilation and growth in women with Turner syndrome. Heart 2022;109:
International registry of patients carrying TGFBR1 or TGFBR2 mutations: results of 102–10. 
the MAC (Montalcino Aortic Consortium). Circ Cardiovasc Genet 2016;9:548–58. 408. Galian-Gay L, Rodriguez-Palomares JF. Turner syndrome and aortic complications:
 more benign than previously thought. Heart 2022;109:82–3. 
388. Mazzolai L, Teixido-Tura G, Lanzi S, Boc V, Bossone E, Brodmann M, et al. 2024 ESC heartjnl-2022-321330
Guidelines for the management of peripheral arterial and aortic diseases: developed by 409. Gravholt CH, Andersen NH, Christin-Maitre S, Davis SM, Duijnhouwer A, Gawlik A,
the task force on the management of peripheral arterial and aortic diseases of the et al. Clinical practice guidelines for the care of girls and women with Turner syn-
European Society of Cardiology (ESC) endorsed by the European Association for drome. Eur J Endocrinol 2024;190:G53–151. 
Cardio-Thoracic Surgery (EACTS), the European Reference Network on rare multi- 410. Carlson M, Airhart N, Lopez L, Silberbach M. Moderate aortic enlargement and bicus-
systemic vascular diseases (VASCERN), and the European Society of Vascular pid aortic valve are associated with aortic dissection in Turner syndrome: report of the
Medicine (ESVM). Eur Heart J 2024;45:3538–700.  international turner syndrome aortic dissection registry. Circulation 2012;126:2220–6.
ehae179 
389. Groth KA, Nielsen BB, Sheyanth IN, Gravholt CH, Andersen NH, Stochholm K. 411. Carlson M, Silberbach M. Dissection of the aorta in Turner syndrome: two cases and
Maternal health and pregnancy outcome in diagnosed and undiagnosed Marfan syn- review of 85 cases in the literature. J Med Genet 2007;44:745–9. 
drome: a registry-based study. Am J Med Genet A 2021;185:1414–20.  1136/jmg.2007.052019
10.1002/ajmg.a.62122 412. Matura LA, Ho VB, Rosing DR, Bondy CA. Aortic dilatation and dissection in Turner
390. Cauldwell M, Steer PJ, Curtis SL, Mohan A, Dockree S, Mackillop L, et al. Maternal and syndrome. Circulation 2007;116:1663–70. 
fetal outcomes in pregnancies complicated by Marfan syndrome. Heart 2019;105: CIRCULATIONAHA.106.685487
1725–31.  413. Grewal J, Valente AM, Egbe AC, Wu FM, Krieger EV, Sybert VP, et al. Cardiovascular
391. Claus J, Schoof L, Mir TS, Kammal AL, Schön G, Kutsche K, et al. Late diagnosis of outcomes of pregnancy in Turner syndrome. Heart 2021;107:61–6. 
Marfan syndrome is associated with unplanned aortic surgery and cardiovascular 1136/heartjnl-2020-316719
death. J Thorac Cardiovasc Surg 2025;169:1201–9.e33.  414. Cauldwell M, Steer PJ, Adamson D, Alexander C, Allen L, Bhagra C, et al. Pregnancies in
2024.09.016 women with Turner syndrome: a retrospective multicentre UK study. BJOG 2022;129:
392. Nucera M, Heinisch PP, Langhammer B, Jungi S, Mihalj M, Schober P, et al. The impact 796–803. 
of sex and gender on aortic events in patients with Marfan syndrome. Eur J Cardiothorac 415. Galian-Gay L, Pijuan-Domenech A, Cantalapiedra-Romero J, Serrano B, Goya M, Maiz
Surg 2022;62:ezac305.  N, et al. Pregnancy-related aortic complications in women with bicuspid aortic valve.
393. Meijboom LJ, Vos FE, Timmermans J, Boers GH, Zwinderman AH, Mulder BJ. Heart 2023;109:1153–8. 
Pregnancy and aortic root growth in the Marfan syndrome: a prospective study. Eur 416. Ganapathi AM, Ranney DN, Peterson MD, Lindsay ME, Patel HJ, Pyeritz RE, et al.
Heart J 2005;26:914–20.  Location of aortic enlargement and risk of type A dissection at smaller diameters.
394. Sayama S, Iriyama T, Takeda N, Yamauchi H, Toshimitsu M, Seyama T, et al. Proposed J Am Coll Cardiol 2022;79:1890–7. 
management policy for pregnant women with Loeys–Dietz syndrome following 417. Kalogerakos PD, Zafar MA, Li Y, Mukherjee SK, Ziganshin BA, Rizzo JA, et al. Root dila-
prophylactic aortic root replacement based on experience from a tertiary care center. tation is more malignant than ascending aortic dilation. J Am Heart Assoc 2021;10:
Int Heart J 2022;63:176–9.  e020645. 
395. Cauldwell M, Steer PJ, Curtis S, Mohan AR, Dockree S, Mackillop L, et al. Maternal and 418. Blood Pressure Lowering Treatment Trialists’ Collaboration. Age-stratified and
fetal outcomes in pregnancies complicated by the inherited aortopathy Loeys–Dietz blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for
syndrome. BJOG 2019;126:1025–31.  the prevention of cardiovascular disease and death: an individual participant-level
396. Bowen JM, Hernandez M, Johnson DS, Green C, Kammin T, Baker D, et al. Diagnosis data meta-analysis. Lancet 2021;398:1053–64. 
and management of vascular Ehlers–Danlos syndrome: experience of the UK national 6736(21)01921-8
diagnostic service, Sheffield. Eur J Hum Genet 2023;31:749–60.  419. Weinstein J, Shinfeld A, Simchen M, Cahan T, Frogel J, Arad M, et al. Anesthesia in parturi-
s41431-023-01343-7 ents presenting with Marfan syndrome. Isr Med Assoc J 2021;23:437–40. PMID: 34251127
397. Murray ML, Pepin M, Peterson S, Byers PH. Pregnancy-related deaths and complica- 420. Curtis SL, Swan L. Aortopathy in pregnancy. Heart 2022;108:1851–7. 
tions in women with vascular Ehlers–Danlos syndrome. Genet Med 2014;16: 10.1136/heartjnl-2021-319828
874–80.  421. van Steenbergen GJ, Tsang QHY, van der Heijden OWH, Vart P, Rodwell L,
398. Pepin MG, Schwarze U, Rice KM, Liu M, Leistritz D, Byers PH. Survival is affected by Roos-Hesselink JW, et al. Timing of cardiac surgery during pregnancy: a patient-level
mutation type and molecular mechanism in vascular Ehlers–Danlos syndrome (EDS meta-analysis. Eur Heart J 2022;43:2801–11. 
type IV). Genet Med 2014;16:881–8.  422. Liu H, Yang L, Chen CY, Qian SC, Ma LY, Diao YF, et al. Management strategies and
399. Frank M, Adham S, Seigle S, Legrand A, Mirault T, Henneton P, et al. Vascular Ehlers– outcomes in pregnancy-related acute aortic dissection: a multicentre cohort study in
Danlos syndrome: long-term observational study. J Am Coll Cardiol 2019;73:1948–57. China. Heart 2024;110:1298–306. 
 423. Curry RA, Gelson E, Swan L, Dob D, Babu-Narayan SV, Gatzoulis MA, et al. Marfan
400. Haem T, Benson B, Dernoncourt A, Gondry J, Schmidt J, Foulon A. Vascular Ehlers– syndrome and pregnancy: maternal and neonatal outcomes. BJOG 2014;121:610–7.
Danlos syndrome and pregnancy: a systematic review. BJOG 2024;131:1620–9. 
 424. Roman MJ, Pugh NL, Hendershot TP, Devereux RB, Dietz H, Holmes K, et al. Aortic
401. Renard M, Francis C, Ghosh R, Scott AF, Witmer PD, Adès LC, et al. Clinical validity of complications associated with pregnancy in Marfan syndrome: the NHLBI national
genes for heritable thoracic aortic aneurysm and dissection. J Am Coll Cardiol 2018;72: registry of genetically triggered thoracic aortic aneurysms and cardiovascular condi-
605–15.  tions (GenTAC). J Am Heart Assoc 2016;5:e004052. 
402. Arnaud P, Hanna N, Benarroch L, Aubart M, Bal L, Bouvagnet P, et al. Genetic diversity 116.004052
and pathogenic variants as possible predictors of severity in a French sample of non- 425. Pepin M, Schwarze U, Superti-Furga A, Byers PH. Clinical and genetic features of
syndromic heritable thoracic aortic aneurysms and dissections (nshTAAD). GIM 2019; Ehlers–Danlos syndrome type IV, the vascular type. N Engl J Med 2000;342:673–80.
21:2015–24.  
Downloaded
from

by
guest
on
22
January
2026

4560 E S C G u id e l in e s
426. Kuperstein R, Cahan T, Yoeli-Ullman R, Ben Zekry S, Shinfeld A, Simchen MJ. Risk of 447. Wang Z, Sun H, Zhang C, Lu L, Zhang L, Wang D. Outcomes of acute type A aortic
aortic dissection in pregnant patients with the Marfan syndrome. Am J Cardiol 2017; dissection repair during pregnancy. Int J Gynaecol Obstet 2023;161:927–33. 
119:132–7.  org/10.1002/ijgo.14586
427. Kang JW, Song HG, Yang DH, Baek S, Kim DH, Song JM, et al. Association between 448. van der Linde D, Konings EE, Slager MA, Witsenburg M, Helbing WA, Takkenberg JJ,
bicuspid aortic valve phenotype and patterns of valvular dysfunction and bicuspid aor- et al. Birth prevalence of congenital heart disease worldwide: a systematic review and
topathy: comprehensive evaluation using MDCT and echocardiography. JACC meta-analysis. J Am Coll Cardiol 2011;58:2241–7. 
Cardiovasc Imaging 2013;6:150–61.  025
428. Della Corte A, Bancone C, Buonocore M, Dialetto G, Covino FE, Manduca S, et al. 449. Liu Y, Chen S, Zühlke L, Black GC, Choy MK, Li N, et al. Global birth prevalence of
Pattern of ascending aortic dimensions predicts the growth rate of the aorta in pa- congenital heart defects 1970–2017: updated systematic review and meta-analysis
tients with bicuspid aortic valve. JACC Cardiovasc Imaging 2013;6:1301–10. https:// of 260 studies. Int J Epidemiol 2019;48:455–63. 
doi.org/10.1016/j.jcmg.2013.07.009 450. Erikssen G, Liestøl K, Seem E, Birkeland S, Saatvedt KJ, Hoel TN, et al. Achievements in
429. Donnelly RT, Pinto NM, Kocolas I, Yetman AT. The immediate and long-term impact congenital heart defect surgery: a prospective, 40-year study of 7038 patients. Circulation
of pregnancy on aortic growth rate and mortality in women with Marfan syndrome. 2015;131:337–46. discussion 346. 
J Am Coll Cardiol 2012;60:224–9.  012033
430. Leśniak-Sobelga A, Tracz W, KostKiewicz M, Podolec P, Pasowicz M. Clinical and 451. Balint OH, Siu SC, Mason J, Grewal J, Wald R, Oechslin EN, et al. Cardiac outcomes
echocardiographic assessment of pregnant women with valvular heart diseases—ma- after pregnancy in women with congenital heart disease. Heart 2010;96:1656–61.
ternal and fetal outcome. Int J Cardiol 2004;94:15–23.  
2003.03.017 452. De Backer J, Bondue A, Budts W, Evangelista A, Gallego P, Jondeau G, et al. Genetic
431. Whelton P, Carey R, Aronow W, Casey D, Collins K, Dennison Himmelfarb C, et al. counselling and testing in adults with congenital heart disease: a consensus document
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline of the ESC Working Group of grown-up congenital heart disease, the ESC Working
for the prevention, detection, evaluation, and management of high blood pressure Group on aorta and peripheral vascular disease and the European Society of
in adults: executive summary: a report of the American College of Cardiology/ Human Genetics. Eur J Prev Cardiol 2020;27:1423–35. 
American Heart Association task force on clinical practice guidelines. Circulation 2047487319854552
453. Vriend JW, Drenthen W, Pieper PG, Roos-Hesselink JW, Zwinderman AH, van
2018;138:e426–83. 
Veldhuisen DJ, et al. Outcome of pregnancy in patients after repair of aortic coarcta-
432. Seely EW, Ecker J. Chronic hypertension in pregnancy. Circulation 2014;129:1254–61.
tion. Eur Heart J 2005;26:2173–8. 

454. Jimenez-Juan L, Krieger EV, Valente AM, Geva T, Wintersperger BJ, Moshonov H, et al.
433. Roberts EA, Pistner A, Osobamiro O, Banning S, Shalhub S, Albright C, et al.
Cardiovascular magnetic resonance imaging predictors of pregnancy outcomes in wo-
Beta-blocker use during pregnancy correlates with less aortic root dilatation in pa-
men with coarctation of the aorta. Eur Heart J Cardiovasc Imaging 2014;15:299–306.
tients with Marfan’s syndrome. Aorta (Stamford) 2023;11:63–70. 

1055/a-2072-0469
455. Ciresi CM, Patel PR, Asdell SM, Hopkins KA, Hoyer MH, Kay WA. Management of se-
434. Ong KT, Perdu J, De Backer J, Bozec E, Collignon P, Emmerich J, et al. Effect of celipro-
vere coarctation of the aorta during pregnancy. JACC Case Rep 2020;2:116–9. https://
lol on prevention of cardiovascular events in vascular Ehlers–Danlos syndrome: a pro-
doi.org/10.1016/j.jaccas.2019.11.060
spective randomised, open, blinded-endpoints trial. Lancet 2010;376:1476–84. https://
456. Fuchs M, Zaidi AN, Rose J, Sisk T, Daniels CJ, Bradley EA. Location matters: left heart
doi.org/10.1016/S0140-6736(10)60960-9
obstruction in pregnancy. Eur J Obstet Gynecol Reprod Biol 2016;196:38–43. 
435. Zhu JM, Ma WG, Peterss S, Wang LF, Qiao ZY, Ziganshin BA, et al. Aortic dissection in
org/10.1016/j.ejogrb.2015.10.026
pregnancy: management strategy and outcomes. Ann Thorac Surg 2017;103:1199–206.
457. Bredy C, Mongeon FP, Leduc L, Dore A, Khairy P. Pregnancy in adults with repaired/

unrepaired atrial septal defect. J Thorac Dis 2018;10:S2945–52. 
436. Rommens KL, Sandhu HK, Miller CC, 3rd, Cecchi AC, Prakash SK, Saqib NU, et al.
21037/jtd.2017.10.130
In-hospital outcomes and long-term survival of women of childbearing age with aortic
458. Zuber M, Gautschi N, Oechslin E, Widmer V, Kiowski W, Jenni R. Outcome of preg-
dissection. J Vasc Surg 2021;74:1135–42.e1. 
nancy in women with congenital shunt lesions. Heart 1999;81:271–5. 
437. Gouda P, Kay R, Habib M, Aziz A, Aziza E, Welsh R. Clinical features and complications
10.1136/hrt.81.3.271
of Loeys–Dietz syndrome: a systematic review. Int J Cardiol 2022;362:158–67. https://
459. Drenthen W, Pieper PG, van der Tuuk K, Roos-Hesselink JW, Voors AA, Mostert B,
doi.org/10.1016/j.ijcard.2022.05.065
et al. Cardiac complications relating to pregnancy and recurrence of disease in the off-
438. Boileau C, Guo DC, Hanna N, Regalado ES, Detaint D, Gong L, et al. TGFB2 mutations
spring of women with atrioventricular septal defects. Eur Heart J 2005;26:2581–7.
cause familial thoracic aortic aneurysms and dissections associated with mild systemic

features of Marfan syndrome. Nat Genet 2012;44:916–21. 
460. Mendelson MA. Pregnancy in women with left-to-right cardiac shunts: any risk? Int J
2348
Cardiol Congenit Heart Dis 2021;5:100209. 
439. Marsili L, Overwater E, Hanna N, Baujat G, Baars MJH, Boileau C, et al. Phenotypic
100209
spectrum of TGFB3 disease-causing variants in a Dutch–French cohort and first report 461. Lindley KJ, Bairey Merz CN, Asgar AW, Bello NA, Chandra S, Davis MB, et al.
of a homozygous patient. Clin Genet 2020;97:723–30.  Management of women with congenital or inherited cardiovascular disease from pre-
13700 conception through pregnancy and postpartum: JACC focus seminar 2/5. J Am Coll
440. Shalhub S, Regalado ES, Guo DC, Milewicz DM. The natural history of type B aortic Cardiol 2021;77:1778–98. 
dissection in patients with PRKG1 mutation c.530G>A (p.Arg177Gln). J Vasc Surg 462. Greutmann M, Von Klemperer K, Brooks R, Peebles D, O’Brien P, Walker F.
2019;70:718–23.  Pregnancy outcome in women with congenital heart disease and residual haemo-
441. McKellar SH, MacDonald RJ, Michelena HI, Connolly HM, Sundt TM, 3rd. Frequency of dynamic lesions of the right ventricular outflow tract. Eur Heart J 2010;31:1764–70.
cardiovascular events in women with a congenitally bicuspid aortic valve in a single 
community and effect of pregnancy on events. Am J Cardiol 2011;107:96–9. https:// 463. Romeo JLR, Takkenberg JJM, Roos-Hesselink JW, Hanif M, Cornette JMJ, van Leeuwen
doi.org/10.1016/j.amjcard.2010.08.061 WJ, et al. Outcomes of pregnancy after right ventricular outflow tract reconstruction
442. Wojnarski CM, Svensson LG, Roselli EE, Idrees JJ, Lowry AM, Ehrlinger J, et al. Aortic with an allograft conduit. J Am Coll Cardiol 2018;71:2656–65. 
dissection in patients with bicuspid aortic valve-associated aneurysms. Ann Thorac Surg jacc.2018.03.522
2015;100:1666–73. discussion 1673–4.  464. Romeo JLR, Papageorgiou G, Takkenberg JJM, Roos-Hesselink JW, van Leeuwen WJ,
126 Cornette JMJ, et al. Influence of pregnancy on long-term durability of allografts in right
443. den Hartog AW, Franken R, Zwinderman AH, Timmermans J, Scholte AJ, van den Berg ventricular outflow tract. J Thorac Cardiovasc Surg 2020;159:1508–16.e1. 
MP, et al. The risk for type B aortic dissection in Marfan syndrome. J Am Coll Cardiol org/10.1016/j.jtcvs.2019.08.083
2015;65:246–54.  465. Duarte VE, Graf JA, Marshall AC, Economy KE, Valente AM. Transcatheter pulmonary
444. Minsart AF, Mongeon FP, Laberge AM, Morin F, Dore A, Leduc L. Obstetric and car- valve performance during pregnancy and the postpartum period. JACC Case Rep 2020;
diac outcomes in women with Marfan syndrome and an aortic root diameter ≤ 45 2:847–51. 
mm. Eur J Obstet Gynecol Reprod Biol 2018;230:68–72.  466. Kozicka U, Weroński K, Rużyłło W, Demkow M, Kowalski M, Śpiewak M, et al.
ejogrb.2018.09.012 Pregnancy after transcatheter pulmonary valve implantation. Can J Cardiol 2017;33:
445. Loeys BL, Schwarze U, Holm T, Callewaert BL, Thomas GH, Pannu H, et al. Aneurysm 1737.e5–.e7. 
syndromes caused by mutations in the TGF-beta receptor. N Engl J Med 2006;355: 467. Baris L, Ladouceur M, Johnson MR, Kozelj M, Festa P, Caruana M, et al. Pregnancy in
788–98.  tetralogy of fallot data from the ESC EORP ROPAC registry. IJC Congenital Heart
446. van Hagen IM, van der Linde D, van de Laar IM, Muiño Mosquera L, De Backer J, Disease 2021;2:100059. 
Roos-Hesselink JW. Pregnancy in women with SMAD3 mutation. J Am Coll Cardiol 468. Balci A, Drenthen W, Mulder BJ, Roos-Hesselink JW, Voors AA, Vliegen HW, et al.
2017;69:1356–8.  Pregnancy in women with corrected tetralogy of fallot: occurrence and predictors
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4561
of adverse events. Am Heart J 2011;161:307–13.  490. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022
027 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur
469. Lima FV, Koutrolou-Sotiropoulou P, Yen TY, Stergiopoulos K. Clinical characteristics Heart J 2022;43:3618–731. 
and outcomes in pregnant women with Ebstein anomaly at the time of delivery in the 491. McGoon MD, Benza RL, Escribano-Subias P, Jiang X, Miller DP, Peacock AJ, et al.
USA: 2003–2012. Arch Cardiovasc Dis 2016;109:390–8.  Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol 2013;
2016.01.010 62:D51–9. 
470. Horiuchi C, Kamiya CA, Ohuchi H, Miyoshi T, Tsuritani M, Iwanaga N, et al. Pregnancy 492. Sitbon O, Sattler C, Bertoletti L, Savale L, Cottin V, Jaïs X, et al. Initial dual oral com-
outcomes and mid-term prognosis in women after arterial switch operation for bination therapy in pulmonary arterial hypertension. Eur Respir J 2016;47:1727–36.
dextro-transposition of the great arteries—tertiary hospital experiences and review 
of literature. J Cardiol 2019;73:247–54.  493. Cheron C, McBride SA, Antigny F, Girerd B, Chouchana M, Chaumais M-C, et al. Sex
471. Canobbio MM, Morris CD, Graham TP, Landzberg MJ. Pregnancy outcomes after atrial and gender in pulmonary arterial hypertension. Eur Respir Rev 2021;30:200330. https://
repair for transposition of the great arteries. Am J Cardiol 2006;98:668–72.  doi.org/10.1183/16000617.0330-2020
494. Luo J, Shi H, Xu L, Su W, Li J. Pregnancy outcomes in patients with pulmonary arterial
org/10.1016/j.amjcard.2006.03.050
hypertension: a retrospective study. Medicine (Baltimore) 2020;99:e20285. 
472. Bowater SE, Selman TJ, Hudsmith LE, Clift PF, Thompson PJ, Thorne SA. Long-term
org/10.1097/MD.0000000000020285
outcome following pregnancy in women with a systemic right ventricle: is the deteri-
495. Bedard E, Dimopoulos K, Gatzoulis MA. Has there been any progress made on preg-
oration due to pregnancy or a consequence of time? Congenit Heart Dis 2013;8:302–7.
nancy outcomes among women with pulmonary arterial hypertension? Eur Heart J

2009;30:256–65. 
473. Harada G, Inai K, Shimada E, Ishido M, Shinohara T, Ogawa M. Management of preg-
496. Ma R, Gao H, Cui J, Shi H, Yang Z, Jin Z, et al. Pregnancy feasibility in women with mild
nancy and delivery in women with transposition of the great arteries after atrial switch
pulmonary arterial hypertension: a systematic review and meta-analysis. BMC
operation: a 16-year single-center experience. J Obstet Gynaecol Res 2022;48:351–9.
Pregnancy Childbirth 2023;23:427. 

497. Zhang Q, Zhu F, Shi G, Hu C, Zhang W, Huang P, et al. Maternal outcomes among preg-
474. Pizula J, Devera J, Ng TMH, Yeung SL, Thangathurai J, Herrick N, et al. Outcome of
nant women with congenital heart disease-associated pulmonary hypertension.
pregnancy in women with D-transposition of the great arteries: a systematic review.
Circulation 2023;147:549–61. 
J Am Heart Assoc 2022;11:e026862. 
498. Lai W, Ding Y, Wen L. Long-term outcomes of pregnant women with pulmonary
475. Trigas V, Nagdyman N, Pildner von Steinburg S, Oechslin E, Vogt M, Berger F, et al.
hypertension diagnosed by echocardiography: a retrospective cohort study in a single
Pregnancy-related obstetric and cardiologic problems in women after atrial switch op- center from China. Pulm Circ 2021;11:2045894020966876. 
eration for transposition of the great arteries. Circ J 2014;78:443–9.  2045894020966876
1253/circj.CJ-12-1051 499. Lv C, Huang Y, Liao G, Wu L, Chen D, Gao Y. Pregnancy outcomes in women with
476. Mahdi N-A, Guerma L, Desrosiers-Gagnon C, Dore A, Mongeon F-P, Mondésert B, pulmonary hypertension: a retrospective study in China. BMC Pregnancy Childbirth
et al. Sex-related differences and influence of pregnancy in transposition of great arter- 2023;23:16. 
ies with systemic right ventricle. JACC Adv 2024;3:101015.  500. Sharma B, Sikka P, Chopra S, Bansal R, Suri V, Aggarwal N, et al. Pregnancy in
jacadv.2024.101015 Eisenmenger syndrome: a case series from a tertiary care hospital of Northern
477. Stoll VM, Drury NE, Thorne S, Selman T, Clift P, Chong H, et al. Pregnancy outcomes India. Cardiol Young 2023;33:2185–2189. 
in women with transposition of the great arteries after an arterial switch operation. S1047951122004152
JAMA Cardiol 2018;3:1119–22.  501. Su JY, Chen HF, Wang SM. Pregnancy outcome analysis of 94 patients with pulmonary
478. Kirzner J, Pirmohamed A, Ginns J, Singh HS. Long-term management of the arterial arterial hypertension during pregnancy. Eur Rev Med Pharmacol Sci 2022;26:1970–7.
switch patient. Curr Cardiol Rep 2018;20:68.  
1012-9 502. Liu Y, Li Y, Zhang J, Zhang D, Li J, Zhao Y, et al. Maternal and fetal outcomes of preg-
479. Sobhani NC, Corbetta-Rastelli CM, Agarwal A, D’Alton ME, Friedman AM, Wen T. nant women with pulmonary arterial hypertension associated with congenital heart
Delivery trends and obstetric outcomes in patients with fontan circulation. Am J disease in Beijing, China: a retrospective study. Pulm Circ 2022;12:e12079. https://
Obstet Gynecol MFM 2023;5:100921.  doi.org/10.1002/pul2.12079
480. Bartczak-Rutkowska A, Tomkiewicz-Pająk L, Kawka-Paciorkowska K, Bajorek N, 503. Sliwa K, van Hagen IM, Budts W, Swan L, Sinagra G, Caruana M, et al. Pulmonary hyper-
Ciepłucha A, Ropacka-Lesiak M, et al. Pregnancy outcomes in women after the fontan tension and pregnancy outcomes: data from the Registry Of Pregnancy and Cardiac
procedure. J Clin Med 2023;12:783.  disease (ROPAC) of the European Society of Cardiology. Eur J Heart Fail 2016;18:
481. Cauldwell M, Steer PJ, Bonner S, Asghar O, Swan L, Hodson K, et al. Retrospective UK 1119–28. 
multicentre study of the pregnancy outcomes of women with a Fontan repair. Heart 504. Li Q, Dimopoulos K, Liu T, Xu Z, Liu Q, Li Y, et al. Peripartum outcomes in a large popu-
2018;104:401–6.  lation of women with pulmonary arterial hypertension associated with congenital heart
482. Garcia Ropero A, Baskar S, Roos Hesselink JW, Girnius A, Zentner D, Swan L, et al. disease. Eur J Prev Cardiol 2019;26:1067–76. 
Pregnancy in women with a fontan circulation: a systematic review of the literature. 505. Shu T, Feng P, Liu X, Wen L, Chen H, Chen Y, et al. Multidisciplinary team manage-
ments and clinical outcomes in patients with pulmonary arterial hypertension during
Circ Cardiovasc Qual Outcomes 2018;11:e004575. 
the perinatal period. Front Cardiovasc Med 2021;8:795765.  CIRCOUTCOMES.117.004575
fcvm.2021.795765 483. Girnius A, Zentner D, Valente AM, Pieper PG, Economy KE, Ladouceur M, et al.
506. Chen GC, Gao H, Zhang L, Tong T. Evaluation of therapeutic efficacy of anticoagulant
Bleeding and thrombotic risk in pregnant women with Fontan physiology. Heart
drugs for patients with venous thromboembolism during pregnancy: a systematic re-
2021;107:1390–7. 
view and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2019;238:7–11. 
484. Wolfe NK, Sabol BA, Kelly JC, Dombrowski M, Benhardt AC, Fleckenstein J, et al.
10.1016/j.ejogrb.2019.04.038
Management of Fontan circulation in pregnancy: a multidisciplinary approach to
507. Kamp JC, von Kaisenberg C, Greve S, Winter L, Park DH, Fuge J, et al. Pregnancy in
care. Am J Obstet Gynecol MFM 2021;3:100257. 
pulmonary arterial hypertension: midterm outcomes of mothers and offspring. J
100257
Heart Lung Transplant 2021;40:229–33. 
485. Khan A, Kim YY. Pregnancy in complex CHD: focus on patients with Fontan circulation
508. de Raaf MA, Beekhuijzen M, Guignabert C, Vonk Noordegraaf A, Bogaard HJ.
and patients with a systemic right ventricle. Cardiol Young 2015;25:1608–14. 
Endothelin-1 receptor antagonists in fetal development and pulmonary arterial hyper-
org/10.1017/S1047951115002279
tension. Reprod Toxicol 2015;56:45–51. 
486. Montanaro C, Boyle S, Wander G, Johnson MR, Roos-Hesselink JW, Patel R, et al.
509. Amann U, Nadine W, Kollhorst B, Haug U. Prescribing of endothelin receptor antago-
Pregnancy in patients with the Fontan operation. Eur J Prev Cardiol 2024;31: nists and riociguat in women of childbearing age in a large German claims database study.
1336–44.  Reprod Toxicol 2023;119:108415. 
487. Breviario S, Krishnathasan K, Dimopoulos K, Gribaudo E, Constantine A, Li W, et al. 510. Kourlaba G, Relakis J, Kontodimas S, Holm MV, Maniadakis N. A systematic review and
Pregnancy in women with a Fontan circulation: short and long-term outcomes. Int J meta-analysis of the epidemiology and burden of venous thromboembolism among
Cardiol 2024;415:132445.  pregnant women. Int J Gynaecol Obstet 2016;132:4–10. 
488. Ladouceur M, Benoit L, Basquin A, Radojevic J, Hauet Q, Hascoet S, et al. How preg- 2015.06.054
nancy impacts adult cyanotic congenital heart disease: a multicenter observational 511. Abbasi N, Balayla J, Laporta DP, Kezouh A, Abenhaim HA. Trends, risk factors and
study. Circulation 2017;135:2444–7.  mortality among women with venous thromboembolism during labour and delivery:
116.027152 a population-based study of 8 million births. Arch Gynecol Obstet 2014;289:275–84.
489. Presbitero P, Somerville J, Stone S, Aruta E, Spiegelhalter D, Rabajoli F. Pregnancy in 
cyanotic congenital heart disease. Outcome of mother and fetus. Circulation 1994; 512. Bourjeily G, Paidas M, Khalil H, Rosene-Montella K, Rodger M. Pulmonary embolism in
89:2673–6.  pregnancy. Lancet 2010;375:500–12. 
Downloaded
from

by
guest
on
22
January
2026

4562 E S C G u id e l in e s
513. Bukhari S, Fatima S, Barakat AF, Fogerty AE, Weinberg I, Elgendy IY. Venous thrombo- a systematic review. J Thromb Haemost 2017;15:1942–50. 
embolism during pregnancy and postpartum period. Eur J Intern Med 2022;97:8–17. 13802
 536. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. 2019
514. Rodger MA, Hague WM, Kingdom J, Kahn SR, Karovitch A, Sermer M, et al. ESC Guidelines for the diagnosis and management of acute pulmonary embolism de-
Antepartum dalteparin versus no antepartum dalteparin for the prevention of preg- veloped in collaboration with the European Respiratory Society (ERS). Eur Heart J
nancy complications in pregnant women with thrombophilia (TIPPS): a multinational 2020;41:543–603. 
open-label randomised trial. Lancet 2014;384:1673–83.  537. Kaur G, Oliveira-Gomes D, Rivera FB, Gulati M. Chest pain in women: considerations
S0140-6736(14)60793-5 from the 2021 AHA/ACC chest pain guideline. Curr Probl Cardiol 2023;48:101697.
515. Sennström M, Rova K, Hellgren M, Hjertberg R, Nord E, Thurn L, et al. 
Thromboembolism and in vitro fertilization—a systematic review. Acta Obstet 538. Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, et al. 2021
Gynecol Scand 2017;96:1045–52.  AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the evaluation and diagno-
516. Rova K, Passmark H, Lindqvist PG. Venous thromboembolism in relation to in vitro fer- sis of chest pain: a report of the American College of Cardiology/American Heart
tilization: an approach to determining the incidence and increase in risk in successful Association Joint Committee on clinical practice guidelines. Circulation 2021;144:
cycles. Fertil Steril 2012;97:95–100.  e368–454. 
517. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis 539. Hayes SN, Kim ESH, Saw J, Adlam D, Arslanian-Engoren C, Economy KE, et al.
and treatment of venous thromboembolism in pregnancy: a systematic review of Spontaneous coronary artery dissection: current state of the science: a scientific state-
safety and efficacy. Blood 2005;106:401–7.  ment from the American Heart Association. Circulation 2018;137:e523–57. 
0626 org/10.1161/CIR.0000000000000564
518. Romualdi E, Dentali F, Rancan E, Squizzato A, Steidl L, Middeldorp S, et al. 540. Siennicka A, Kłysz M, Chełstowski K, Tabaczniuk A, Marcinowska Z, Tarnowska P, et al.
Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic Reference values of D-dimers and fibrinogen in the course of physiological pregnancy:
review and a meta-analysis of the literature. J Thromb Haemost 2013;11:270–81. the potential impact of selected risk factors-a pilot study. Biomed Res Int 2020;2020:
 3192350. 
519. Bistervels IM, Buchmüller A, Wiegers HMG, Ní Áinle F, Tardy B, Donnelly J, et al. 541. Sadeghi S, Golshani M, Safaeian B. New cut-off point for D-dimer in the diagnosis of
Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and pulmonary embolism during pregnancy. Blood Res 2021;56:150–5. 
post-partum women with a history of venous thromboembolism (Highlow study): 5045/br.2021.2021069
an open-label, multicentre, randomised, controlled trial. Lancet 2022;400:1777–87. 542. Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H, et al. 2014
 ESC Guidelines on the diagnosis and treatment of aortic diseases: document covering
520. Chan WS, Spencer FA, Ginsberg JS. Anatomic distribution of deep vein thrombosis in acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The
pregnancy. Cmaj 2010;182:657–60.  task force for the diagnosis and treatment of aortic diseases of the European Society of
521. Chan WS, Lee A, Spencer FA, Crowther M, Rodger M, Ramsay T, et al. Predicting deep Cardiology (ESC). Eur Heart J 2014;35:2873–926. 
venous thrombosis in pregnancy: out in “LEFt” field? Ann Intern Med 2009;151:85–92. ehu281
 543. Cantwell R, Clutton-Brock T, Cooper G, Dawson A, Drife J, Garrod D, et al. Saving
522. Righini M, Jobic C, Boehlen F, Broussaud J, Becker F, Jaffrelot M, et al. Predicting deep mothers’ lives: reviewing maternal deaths to make motherhood safer: 2006–2008.
venous thrombosis in pregnancy: external validation of the LEFT clinical prediction The eighth report of the confidential enquiries into maternal deaths in the United
rule. Haematologica 2013;98:545–8.  Kingdom. BJOG 2011;118:1–203. 
523. Chan WS, Spencer FA, Lee AY, Chunilal S, Douketis JD, Rodger M, et al. Safety of with- 544. James AH, Jamison MG, Biswas MS, Brancazio LR, Swamy GK, Myers ER. Acute myo-
holding anticoagulation in pregnant women with suspected deep vein thrombosis fol- cardial infarction in pregnancy: a United States population-based study. Circulation
lowing negative serial compression ultrasound and iliac vein imaging. CMAJ 2013;185: 2006;113:1564–71. 
E194–200.  545. Smilowitz NR, Gupta N, Guo Y, Zhong J, Weinberg CR, Reynolds HR, et al. Acute
524. Kline JA, Williams GW, Hernandez-Nino J. D-dimer concentrations in normal preg- myocardial infarction during pregnancy and the puerperium in the United States.
nancy: new diagnostic thresholds are needed. Clin Chem 2005;51:825–9.  Mayo Clin Proc 2018;93:1404–14. 
org/10.1373/clinchem.2004.044883 546. Markson F, Shamaki RG, Antia A, Osabutey A, Ogunniyi MO. Trends in the incidence
525. Righini M, Robert-Ebadi H, Elias A, Sanchez O, Le Moigne E, Schmidt J, et al. Diagnosis and in-patient outcomes of acute myocardial infarction in pregnancy: insights from the
of pulmonary embolism during pregnancy: a multicenter prospective management national inpatient sample. Am Heart J Plus 2023;34:100318. 
outcome study. Ann Intern Med 2018;169:766–73.  ahjo.2023.100318
526. van der Pol LM, Tromeur C, Bistervels IM, Ni Ainle F, van Bemmel T, Bertoletti L, et al. 547. Dayan N, Filion KB, Okano M, Kilmartin C, Reinblatt S, Landry T, et al. Cardiovascular
Pregnancy-adapted YEARS algorithm for diagnosis of suspected pulmonary embolism. risk following fertility therapy: systematic review and meta-analysis. J Am Coll Cardiol
N Engl J Med 2019;380:1139–49.  2017;70:1203–13. 
527. Bellesini M, Robert-Ebadi H, Combescure C, Dedionigi C, Le Gal G, Righini M. D-dimer 548. Tweet MS, Lewey J, Smilowitz NR, Rose CH, Best PJM. (August 1, 2020)
to rule out venous thromboembolism during pregnancy: a systematic review and Pregnancy-associated myocardial infarction: prevalence, causes, and interventional
meta-analysis. J Thromb Haemost 2021;19:2454–67.  management. Circ Cardiovasc Interv. 2020;13:292–304:e008687. DOI: 10.1161/
528. Barrios D, Rosa-Salazar V, Morillo R, Nieto R, Fernández S, Zamorano JL, et al. CIRCINTERVENTIONS.120.008687
Prognostic significance of right heart thrombi in patients with acute symptomatic pul- 549. Roth A, Elkayam U. Acute myocardial infarction associated with pregnancy. J Am Coll
monary embolism: systematic review and meta-analysis. Chest 2017;151:409–16. Cardiol 2008;52:171–80. 
 550. Tweet MS, Hayes SN, Codsi E, Gulati R, Rose CH, Best PJM. Spontaneous coronary
529. Parunov LA, Soshitova NP, Ovanesov MV, Panteleev MA, Serebriyskiy II. Epidemiology artery dissection associated with pregnancy. J Am Coll Cardiol 2017;70:426–35.
of venous thromboembolism (VTE) associated with pregnancy. Birth Defects Res C 
Embryo Today 2015;105:167–84.  551. Havakuk O, Goland S, Mehra A, Elkayam U. Pregnancy and the risk of spontaneous
530. Harris SA, Velineni R, Davies AH. Inferior vena cava filters in pregnancy: a systematic coronary artery dissection: an analysis of 120 contemporary cases. Circ Cardiovasc
review. J Vasc Interv Radiol 2016;27:354–60.e8.  Interv 2017;10:e004941. 
024 552. Koul AK, Hollander G, Moskovits N, Frankel R, Herrera L, Shani J. Coronary artery
531. Bistervels IM, Buchmüller A, Tardy B. Inferior vena cava filters in pregnancy: safe or sor- dissection during pregnancy and the postpartum period: two case reports and review
ry? Front Cardiovasc Med 2022;9:1026002.  of literature. Catheter Cardiovasc Interv 2001;52:88–94. 
532. Gándara E, Carrier M, Rodger MA. Management of pregnancy associated venous- 726X(200101)52:1<88::AID-CCD1022>3.0.CO;2-P
thromboembolism: a survey of practices. Thromb J 2014;12:12.  553. Al-Hussaini A, Abdelaty A, Gulsin GS, Arnold JR, Garcia-Guimaraes M,
1186/1477-9560-12-12 Premawardhana D, et al. Chronic infarct size after spontaneous coronary artery dis-
533. Ho VT, Dua A, Lavingia K, Rothenberg K, Rao C, Desai SS. Thrombolysis for venous section: implications for pathophysiology and clinical management. Eur Heart J 2020;
thromboembolism during pregnancy: a literature review. Vasc Endovascular Surg 2018; 41:2197–205. 
52:527–34.  554. Jeejeebhoy FM, Zelop CM, Lipman S, Carvalho B, Joglar J, Mhyre JM, et al. Cardiac ar-
534. Rodriguez D, Jerjes-Sanchez C, Fonseca S, Garcia-Toto R, Martinez-Alvarado J, rest in pregnancy: a scientific statement from the American Heart Association.
Panneflek J, et al. Thrombolysis in massive and submassive pulmonary embolism during Circulation 2015;132:1747–73. 
pregnancy and the puerperium: a systematic review. J Thromb Thrombolysis 2020;50: 555. Wagner SM, Waldman IN, Karikari KA, Kunselman AR, Smith ER, Deimling TA. The
929–41.  impact of pregnancy on the evaluation of chest pain and shortness of breath in the
535. Martillotti G, Boehlen F, Robert-Ebadi H, Jastrow N, Righini M, Blondon M. Treatment emergency department. J Acute Med 2018;8:149–53. 
options for severe pulmonary embolism during pregnancy and the postpartum period: 201812_8(4).0002
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4563
556. Katja Prokselj MB. Cardiovascular imaging in pregnancy. Int J Cardiol Congenit Heart Dis systematic review and meta-analysis. Am J Obstet Gynecol MFM 2023;5:100878. https://
2021;5:100235.  doi.org/10.1016/j.ajogmf.2023.100878
557. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC 578. Turner JM, Robertson NT, Hartel G, Kumar S. Impact of low-dose aspirin on adverse
Guidelines for the management of acute coronary syndromes. Eur Heart J 2023;44: perinatal outcome: meta-analysis and meta-regression. Ultrasound Obstet Gynecol
3720–826.  2020;55:157–69. 
558. Moran C, Ni Bhuinneain M, Geary M, Cunningham S, McKenna P, Gardiner J. 579. Van Doorn R, Mukhtarova N, Flyke IP, Lasarev M, Kim K, Hennekens CH, et al. Dose of
Myocardial ischaemia in normal patients undergoing elective caesarean section: a peri- aspirin to prevent preterm preeclampsia in women with moderate or high-risk factors:
partum assessment. Anaesthesia 2001;56:1051–8.  a systematic review and meta-analysis. PLoS One 2021;16:e0247782. 
2044.2001.02271.x 1371/journal.pone.0247782
559. Tamis-Holland JE, Jneid H, Reynolds HR, Agewall S, Brilakis ES, Brown TM, et al. 580. Chang JC, Chen YJ, Chen IC, Lin WS, Chen YM, Lin CH. Perinatal outcomes after statin
Contemporary diagnosis and management of patients with myocardial infarction in exposure during pregnancy. JAMA Netw Open 2021;4:e2141321. 
the absence of obstructive coronary artery disease: a scientific statement from the 1001/jamanetworkopen.2021.41321
American Heart Association. Circulation 2019;139:e891–908.  581. Karadas B, Uysal N, Erol H, Acar S, Koc M, Kaya-Temiz T, et al. Pregnancy outcomes
1161/CIR.0000000000000670 following maternal exposure to statins: a systematic review and meta-analysis. Br J Clin
560. Faden MS, Bottega N, Benjamin A, Brown RN. A nationwide evaluation of spontan- Pharmacol 2022;88:3962–76. 
eous coronary artery dissection in pregnancy and the puerperium. Heart 2016;102: 582. Botha TC, Pilcher GJ, Wolmarans K, Blom DJ, Raal FJ. Statins and other lipid-lowering
1974–9.  therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: a
561. Chan N, Premawardhana D, Al-Hussaini A, Wood A, Bountziouka V, Kotecha D, et al. retrospective review of 39 pregnancies. Atherosclerosis 2018;277:502–7. 
Pregnancy and spontaneous coronary artery dissection: lessons from survivors and non- org/10.1016/j.atherosclerosis.2018.05.038
survivors. Circulation 2022;146:69–72.  583. Tita AT, Szychowski JM, Boggess K, Dugoff L, Sibai B, Lawrence K, et al. Treatment for
122.059635 mild chronic hypertension during pregnancy. N Engl J Med 2022;386:1781–92. https://
562. Alfonso F, de la Torre Hernández JM, Ibáñez B, Sabaté M, Pan M, Gulati R, et al. doi.org/10.1056/NEJMoa2201295
Rationale and design of the BA-SCAD (beta-blockers and antiplatelet agents in patients 584. Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH
with spontaneous coronary artery dissection) randomized clinical trial. Rev Esp Cardiol Guidelines for the management of arterial hypertension the task force for the manage-
(Engl Ed) 2022;75:515–22.  ment of arterial hypertension of the European Society of Hypertension: Endorsed by the
563. Adlam D, Alfonso F, Maas A, Vrints C. European Society of Cardiology, Acute International Society of Hypertension (ISH) and the European Renal Association (ERA). J
Cardiovascular Care Association, SCAD study group: a position paper on spontan- Hypertens 2023;41:1874–2071. 
eous coronary artery dissection. Eur Heart J 2018;39:3353–68.  585. McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024
1093/eurheartj/ehy080 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur
564. Saw J, Humphries K, Aymong E, Sedlak T, Prakash R, Starovoytov A, et al. Spontaneous Heart J 2024;45:3912–4018. 
coronary artery dissection: clinical outcomes and risk of recurrence. J Am Coll Cardiol 586. Olié V, Moutengou E, Grave C, Deneux-Tharaux C, Regnault N, Kretz S, et al.
2017;70:1148–58.  Prevalence of hypertensive disorders during pregnancy in France (2010–2018): the na-
565. Tweet MS, Olin JW. Insights into spontaneous coronary artery dissection: can recur- tionwide CONCEPTION study. J Clin Hypertens (Greenwich) 2021;23:1344–53. https://
rence be prevented? J Am Coll Cardiol 2017;70:1159–61.  doi.org/10.1111/jch.14254
2017.07.726 587. Ford ND, Cox S, Ko JY, Ouyang L, Romero L, Colarusso T, et al. Hypertensive disor-
566. Cerrato E, Giacobbe F, Quadri G, Macaya F, Bianco M, Mori R, et al. Antiplatelet ther- ders in pregnancy and mortality at delivery hospitalization—United States, 2017–
apy in patients with conservatively managed spontaneous coronary artery dissection 2019. MMWR Morb Mortal Wkly Rep 2022;71:585–91. 
from the multicentre DISCO registry. Eur Heart J 2021;42:3161–71.  mmwr.mm7117a1
10.1093/eurheartj/ehab372 588. Malhamé I, Nerenberg K, McLaughlin K, Grandi SM, Daskalopoulou SS, Metcalfe A.
567. Cauldwell M, Steer PJ, von Klemperer K, Kaler M, Grixti S, Hale J, et al. Maternal and Hypertensive disorders and cardiovascular severe maternal morbidity in the US, 2015–
neonatal outcomes in women with history of coronary artery disease. Heart 2020; 2019. JAMA Netw Open 2024;7:e2436478. 
106:380–6.  2024.36478
568. Hayes SN, Tweet MS, Adlam D, Kim ESH, Gulati R, Price JE, et al. Spontaneous cor- 589. Villar J, Carroli G, Wojdyla D, Abalos E, Giordano D, Ba’aqeel H, et al. Preeclampsia,
onary artery dissection: JACC state-of-the-art review. J Am Coll Cardiol 2020;76: gestational hypertension and intrauterine growth restriction, related or independent
961–84.  conditions? Am J Obstet Gynecol 2006;194:921–31. 
569. Janssen E, de Leeuw PW, Maas A. Spontaneous coronary artery dissections and asso- 2005.10.813
ciated predisposing factors: a narrative review. Neth Heart J 2019;27:246–51. https:// 590. National high blood pressure education program working group report on high blood
doi.org/10.1007/s12471-019-1235-4 pressure in pregnancy. Am J Obstet Gynecol 1990;163:1691–712. 
570. Lameijer H, Burchill LJ, Baris L, Ruys TP, Roos-Hesselink JW, Mulder BJM, et al. 1016/0002-9378(90)90653-O
Pregnancy in women with pre-existent ischaemic heart disease: a systematic review 591. Stergiou GS, O’Brien E, Myers M, Palatini P, Parati G. STRIDE BP: an international ini-
with individualised patient data. Heart 2019;105:873–80.  tiative for accurate blood pressure measurement. J Hypertens 2020;38:395–9. https://
heartjnl-2018-314364 doi.org/10.1097/HJH.0000000000002289
571. Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC 592. Penny JA, Halligan AW, Shennan AH, Lambert PC, Jones DR, de Swiet M, et al.
Guidelines for the management of chronic coronary syndromes. Eur Heart J 2024; Automated, ambulatory, or conventional blood pressure measurement in pregnancy:
45:3415–537.  which is the better predictor of severe hypertension? Am J Obstet Gynecol 1998;178:
572. Horlocker TT, Vandermeuelen E, Kopp SL, Gogarten W, Leffert LR, Benzon HT. 521–6. 
Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: 593. Ilic A, Ilic DJ, Tadic S, Stefanovic M, Stojsic-Milosavljevic A, Pavlovic K, et al. Influence of
American Society of Regional Anesthesia and Pain Medicine evidence-based guidelines non-dipping pattern of blood pressure in gestational hypertension on maternal cardiac
(fourth edition). Reg Anesth Pain Med 2018;43:263–309.  function, hemodynamics and intrauterine growth restriction. Pregnancy Hypertens
0000000000000763 2017;10:34–41. 
573. Bettiol A, Avagliano L, Lombardi N, Crescioli G, Emmi G, Urban ML, et al. 594. Ilić Đ, Ilić A, Stojšić S, Stojšić-Milosavljević A, Papović J, Grković D, et al. Effect of dipping
Pharmacological interventions for the prevention of fetal growth restriction: a system- pattern of gestational hypertension onmaternal symptoms and physical findings, birth
atic review and network meta-analysis. Clin Pharmacol Ther 2021;110:189–99. https:// weight and preterm delivery. Acta Clin Croat 2021;60:641–50. 
doi.org/10.1002/cpt.2164 20471/acc.2021.60.04.11
574. D’Antonio F, Khalil A, Rizzo G, Fichera A, Herrera M, Buca D, et al. Aspirin for preven- 595. Chappell LC, Tucker KL, Galal U, Yu LM, Campbell H, Rivero-Arias O, et al. Effect of
tion of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic self-monitoring of blood pressure on blood pressure control in pregnant individuals
review and meta-analysis. Am J Obstet Gynecol MFM 2023;5:100803.  with chronic or gestational hypertension: the BUMP 2 randomized clinical trial.
1016/j.ajogmf.2022.100803 JAMA 2022;327:1666–78. 
575. Datta P, Rewers-Felkins K, Kallem RR, Baker T, Hale TW. Transfer of low dose aspirin into 596. Tucker KL, Mort S, Yu LM, Campbell H, Rivero-Arias O, Wilson HM, et al. Effect of
human milk. J Hum Lact 2017;33:296–9.  self-monitoring of blood pressure on diagnosis of hypertension during higher-risk
576. Grab D, Paulus WE, Erdmann M, Terinde R, Oberhoffer R, Lang D, et al. Effects of low- pregnancy: the BUMP 1 randomized clinical trial. JAMA 2022;327:1656–65. https://
dose aspirin on uterine and fetal blood flow during pregnancy: results of a randomized, doi.org/10.1001/jama.2022.4712
placebo-controlled, double-blind trial. Ultrasound Obstet Gynecol 2000;15:19–27. 597. Cnossen JS, Morris RK, ter Riet G, Mol BW, van der Post JA, Coomarasamy A, et al.
 Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauter-
577. Jiang Y, Chen Z, Chen Y, Wei L, Gao P, Zhang J, et al. Low-dose aspirin use during preg- ine growth restriction: a systematic review and bivariable meta-analysis. Cmaj 2008;
nancy may be a potential risk for postpartum hemorrhage and increased blood loss: a 178:701–11. 
Downloaded
from

by
guest
on
22
January
2026

4564 E S C G u id e l in e s
598. Kifle MM, Dahal P, Vatish M, Cerdeira AS, Ohuma EO. The prognostic utility of soluble 622. Wang Y, Guo X, Obore N, Ding H, Wu C, Yu H. Aspirin for the prevention of pre-
fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PIGF) biomarkers for eclampsia: a systematic review and meta-analysis of randomized controlled studies.
predicting preeclampsia: a secondary analysis of data from the INSPIRE trial. BMC Front Cardiovasc Med 2022;9:936560. 
Pregnancy Childbirth 2022;22:520.  623. Garovic VD, Dechend R, Easterling T, Karumanchi SA, McMurtry Baird S, Magee LA,
599. NICE. Hypertension in Adults: Diagnosis and Management.  et al. Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacother-
guidance/ng136 (10 April 2024, date last accessed). apy: a scientific statement from the American Heart Association. Hypertension 2022;
600. Patel D, Yulia A. Placental growth factor testing for pre-eclampsia. Case Rep Womens 79:e21–41. 
Health 2022;33:e00387.  624. Hoeltzenbein M, Beck E, Fietz AK, Wernicke J, Zinke S, Kayser A, et al. Pregnancy out-
601. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ come after first trimester use of methyldopa: a prospective cohort study. Hypertension
ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;39: 2017;70:201–8. 
3021–104.  625. Lindheimer MD, Taler SJ, Cunningham FG. Hypertension in pregnancy. J Am Soc
602. Cífková R, Johnson MR, Kahan T, Brguljan J, Williams B, Coca A, et al. Peripartum man- Hypertens 2010;4:68–78. 
agement of hypertension: a position paper of the ESC Council on Hypertension and 626. Antza C, Dimou C, Doundoulakis I, Akrivos E, Stabouli S, Haidich AB, et al. The flipside
of hydralazine in pregnancy: a systematic review and meta-analysis. Pregnancy
the European Society of Hypertension. Eur Heart J Cardiovasc Pharmacother 2020;6:
Hypertens 2020;19:177–86. 
384–93. 
627. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P. Diagnosis, evaluation, and man-
603. Wu P, Green M, Myers JE. Hypertensive disorders of pregnancy. BMJ 2023;381:
agement of the hypertensive disorders of pregnancy. Pregnancy Hypertens 2014;4:
e071653. 
105–45. 
604. Magee LA, von Dadelszen P, Rey E, Ross S, Asztalos E, Murphy KE, et al. Less-tight ver-
628. Koopmans CM, Bijlenga D, Groen H, Vijgen SM, Aarnoudse JG, Bekedam DJ, et al.
sus tight control of hypertension in pregnancy. N Engl J Med 2015;372:407–17. https://
Induction of labour versus expectant monitoring for gestational hypertension or
doi.org/10.1056/NEJMoa1404595
mild pre-eclampsia after 36 weeks’ gestation (HYPITAT): a multicentre, open-label
605. Thangaratinam S, Rogozinska E, Jolly K, Glinkowski S, Roseboom T, Tomlinson JW,
randomised controlled trial. Lancet 2009;374:979–88. 
et al. Effects of interventions in pregnancy on maternal weight and obstetric outcomes:
S0140-6736(09)60736-4
meta-analysis of randomised evidence. BMJ 2012;344:e2088. 
629. Churchill D, Duley L, Thornton JG, Moussa M, Ali HS, Walker KF. Interventionist ver-
bmj.e2088
sus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation.
606. Santos S, Voerman E, Amiano P, Barros H, Beilin LJ, Bergström A, et al. Impact of ma-
Cochrane Database Syst Rev 2018;10:CD003106. 
ternal body mass index and gestational weight gain on pregnancy complications: an in- CD003106.pub3
dividual participant data meta-analysis of European, North American and Australian 630. Kuklina E, Callaghan W. Chronic heart disease and severe obstetric morbidity among
cohorts. BJOG 2019;126:984–95.  hospitalisations for pregnancy in the USA: 1995–2006. BJOG 2011;118:345–52. https://
607. Liu YH, Zhang YS, Chen JY, Wang ZJ, Liu YX, Li JQ, et al. Comparative effectiveness of doi.org/10.1111/j.1471-0528.2010.02743.x
prophylactic strategies for preeclampsia: a network meta-analysis of randomized con- 631. Cauldwell M, Adamson D, Bhatia K, Bhagra C, Bolger A, Everett T, et al. Direct current
trolled trials. Am J Obstet Gynecol 2023;228:535–46.  cardioversion in pregnancy: a multicentre study. BJOG 2023;130:1269–74. 
2022.10.014 org/10.1111/1471-0528.17457
608. Woo Kinshella ML, Sarr C, Sandhu A, Bone JN, Vidler M, Moore SE, et al. Calcium for 632. Barnes EJ, Eben F, Patterson D. Direct current cardioversion during pregnancy should
pre-eclampsia prevention: a systematic review and network meta-analysis to guide be performed with facilities available for fetal monitoring and emergency caesarean
personalised antenatal care. BJOG 2022;129:1833–43.  section. BJOG 2002;109:1406–7. 
0528.17222 633. Senarath S, Nanayakkara P, Beale AL, Watts M, Kaye DM, Nanayakkara S. Diagnosis
609. Abalos E, Duley L, Steyn DW, Gialdini C. Antihypertensive drug therapy for mild to and management of arrhythmias in pregnancy. Europace 2022;24:1041–51. https://
moderate hypertension during pregnancy. Cochrane Database Syst Rev 2018;10: doi.org/10.1093/europace/euab297
CD002252.  634. Li JM, Nguyen C, Joglar JA, Hamdan MH, Page RL. Frequency and outcome of arrhyth-
610. Rolnik DL, Wright D, Poon LC, O’Gorman N, Syngelaki A, de Paco Matallana C, et al. mias complicating admission during pregnancy: experience from a high-volume and
Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J ethnically-diverse obstetric service. Clin Cardiol 2008;31:538–41. 
Med 2017;377:613–22.  1002/clc.20326
611. Deng NJ, Xian-Yu CY, Han RZ, Huang CY, Ma YT, Li HJ, et al. Pharmaceutical admin- 635. Miyoshi T, Maeno Y, Hamasaki T, Inamura N, Yasukochi S, Kawataki M, et al. Antenatal
istration for severe hypertension during pregnancy: network meta-analysis. Front therapy for fetal supraventricular tachyarrhythmias: multicenter trial. J Am Coll Cardiol
Pharmacol 2022;13:1092501.  2019;74:874–85. 
612. Poole JH, Long J. Maternal mortality—a review of current trends. Crit Care Nurs Clin 636. Lindley KJ, Judge N. Arrhythmias in pregnancy. Clin Obstet Gynecol 2020;63:878–92.
North Am 2004;16:227–30.  
613. McDonnell NJ. Cardiopulmonary arrest in pregnancy: two case reports of successful 637. Chen YC, Voskoboinik A, Gerche A, Marwick TH, McMullen JR. Prevention of patho-
logical atrial remodeling and atrial fibrillation: JACC state-of-the-art review. J Am Coll
outcomes in association with perimortem cesarean delivery. Br J Anaesth 2009;103:
Cardiol 2021;77:2846–64. 
406–9. 
638. Lee MS, Chen W, Zhang Z, Duan L, Ng A, Spencer HT, et al. Atrial fibrillation and atrial 614. Vanden Hoek TL, Morrison LJ, Shuster M, Donnino M, Sinz E, Lavonas EJ, et al. Part 12:
flutter in pregnant women—a population-based study. J Am Heart Assoc 2016;5:
cardiac arrest in special situations: 2010 American Heart Association guidelines for
e003182. 
cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 2010;
639. Chokesuwattanaskul R, Thongprayoon C, Bathini T, O’Corragain OA, Sharma K,
122:S829–61. 
Prechawat S, et al. Incidence of atrial fibrillation in pregnancy and clinical significance:
615. Bone JN, Sandhu A, Abalos ED, Khalil A, Singer J, Prasad S, et al. Oral antihypertensives for
a meta-analysis. Adv Med Sci 2019;64:415–22. 
nonsevere pregnancy hypertension: systematic review, network meta- and trial sequential
07.003
analyses. Hypertension 2022;79:614–28. 
640. Chauveau S, Le Vavasseur O, Morel E, Dulac A, Chevalier P. Flecainide is a safe and
121.18415
effective treatment for pre-excited atrial fibrillation rapidly conducted to the ventricle
616. Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P. Hydralazine for treat-
in pregnant women: a case series. Eur Heart J Case Rep 2019;3:ytz066. 
ment of severe hypertension in pregnancy: meta-analysis. BMJ 2003;327:955–60.
10.1093/ehjcr/ytz066
 641. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020
617. Awaludin A, Rahayu C, Daud NAA, Zakiyah N. Antihypertensive medications for se- ESC Guidelines for the diagnosis and management of atrial fibrillation developed in col-
vere hypertension in pregnancy: a systematic review and meta-analysis. Healthcare laboration with the European Association for Cardio-Thoracic Surgery (EACTS): the
(Basel) 2022;10:325.  task force for the diagnosis and management of atrial fibrillation of the European
618. Dooley M, Goa KL. Urapidil. A reappraisal of its use in the management of hyperten- Society of Cardiology (ESC) developed with the special contribution of the
sion. Drugs 1998;56:929–55.  European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42:
619. Naulty J, Cefalo RC, Lewis PE. Fetal toxicity of nitroprusside in the pregnant ewe. Am J 373–498. 
Obstet Gynecol 1981;139:708–11.  642. Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns H, et al. 2024
620. Chappell LC, Brocklehurst P, Green ME, Hunter R, Hardy P, Juszczak E, et al. Planned ESC Guidelines for the management of atrial fibrillation developed in collaboration
early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J
a randomised controlled trial. Lancet 2019;394:1181–90.  2024;45:3314–414. 
S0140-6736(19)31963-4 643. Teppo K, Lip GYH, Airaksinen KEJ, Halminen O, Haukka J, Putaala J, et al. Comparing
621. Rolnik DL, Nicolaides KH, Poon LC. Prevention of preeclampsia with aspirin. Am J CHA(2)DS(2)-VA and CHA(2)DS(2)-VASc scores for stroke risk stratification in pa-
Obstet Gynecol 2022;226:S1108–19.  tients with atrial fibrillation: a temporal trends analysis from the retrospective Finnish
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4565
AntiCoagulation in Atrial Fibrillation (FinACAF) cohort. Lancet Reg Health Eur 2024; Cardiovasc Electrophysiol 2010;21:877–82. 
43:100967.  01727.x
644. Goland S, Elkayam U. Anticoagulation in pregnancy. Cardiol Clin 2012;30:395–405. 667. Miyoshi T, Kamiya CA, Katsuragi S, Ueda H, Kobayashi Y, Horiuchi C, et al. Safety and
 efficacy of implantable cardioverter-defibrillator during pregnancy and after delivery.
645. Brugada J, Katritsis DG, Arbelo E, Arribas F, Bax JJ, Blomström-Lundqvist C, et al. 2019 Circ J 2013;77:1166–70. 
ESC Guidelines for the management of patients with supraventricular tachycardiathe 668. Natale A, Davidson T, Geiger MJ, Newby K. Implantable cardioverter-defibrillators and
task force for the management of patients with supraventricular tachycardia of the pregnancy: a safe combination? Circulation 1997;96:2808–12. 
European Society of Cardiology (ESC). Eur Heart J 2020;41:655–720.  01.CIR.96.9.2808
10.1093/eurheartj/ehz467 669. Abello M, Peinado R, Merino JL, Gnoatto M, Mateos M, Silvestre J, et al. Cardioverter
646. Amsterdam EA, Kulcyski J, Ridgeway MG. Efficacy of cardioselective beta-adrenergic defibrillator implantation in a pregnant woman guided with transesophageal echocar-
blockade with intravenously administered metoprolol in the treatment of supraventri- diography. Pacing Clin Electrophysiol 2003;26:1913–4. 
cular tachyarrhythmias. J Clin Pharmacol 1991;31:714–8.  9592.2003.00293.x
1552-4604.1991.tb03765.x 670. Silversides CK, Harris L, Haberer K, Sermer M, Colman JM, Siu SC. Recurrence rates of
647. Ramlakhan KP, Kauling RM, Schenkelaars N, Segers D, Yap SC, Post MC, et al.
arrhythmias during pregnancy in women with previous tachyarrhythmia and impact on
Supraventricular arrhythmia in pregnancy. Heart 2022;108:1674–81. 
fetal and neonatal outcomes. Am J Cardiol 2006;97:1206–12. 
10.1136/heartjnl-2021-320451
amjcard.2005.11.041
648. Ghosh N, Luk A, Derzko C, Dorian P, Chow CM. The acute treatment of maternal
671. Boulé S, Ovart L, Marquié C, Botcherby E, Klug D, Kouakam C, et al. Pregnancy in wo-
supraventricular tachycardias during pregnancy: a review of the literature. J Obstet
men with an implantable cardioverter-defibrillator: is it safe? Europace 2014;16:
Gynaecol Can 2011;33:17–23. 
1587–94. 
649. Tanaka K, Tanaka H, Kamiya C, Katsuragi S, Sawada M, Tsuritani M, et al. Beta-blockers
672. Duncker D, König T, Hohmann S, Bauersachs J, Veltmann C. Avoiding untimely implan-
and fetal growth restriction in pregnant women with cardiovascular disease. Circ J
table cardioverter/defibrillator implantation by intensified heart failure therapy opti-
2016;80:2221–6. 
mization supported by the wearable cardioverter/defibrillator-the PROLONG
650. Jaeggi ET, Carvalho JS, De Groot E, Api O, Clur SA, Rammeloo L, et al. Comparison of
study. J Am Heart Assoc 2017;6:e004512. 
transplacental treatment of fetal supraventricular tachyarrhythmias with digoxin, fle-
673. Duncker D, Westenfeld R, Konrad T, Pfeffer T, Correia de Freitas CA, Pfister R, et al.
cainide, and sotalol: results of a nonrandomized multicenter study. Circulation 2011;
Risk for life-threatening arrhythmia in newly diagnosed peripartum cardiomyopathy
124:1747–54. 
651. Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, et al. Amiodarone versus with low ejection fraction: a German multi-centre analysis. Clin Res Cardiol 2017;
sotalol for atrial fibrillation. N Engl J Med 2005;352:1861–72.  106:582–9. 
NEJMoa041705 674. Olic JJ, Stöllberger C, Schukro C, Odening KE, Reuschel E, Fischer M, et al. Usage of the
652. Vaidya VR, Arora S, Patel N, Badheka AO, Patel N, Agnihotri K, et al. Burden of ar- wearable cardioverter-defibrillator during pregnancy. Int J Cardiol Heart Vasc 2022;41:
rhythmia in pregnancy. Circulation 2017;135:619–21.  101066. 
CIRCULATIONAHA.116.026681 675. Tuzcu V, Gul EE, Erdem A, Kamali H, Saritas T, Karadeniz C, et al. Cardiac interventions
653. Cleary-Goldman J, Salva CR, Infeld JI, Robinson JN. Verapamil-sensitive idiopathic left in pregnant patients without fluoroscopy. Pediatr Cardiol 2015;36:1304–7. 
ventricular tachycardia in pregnancy. J Matern Fetal Neonatal Med 2003;14:132–5. org/10.1007/s00246-015-1181-x
 676. Gorgels AP, van den Dool A, Hofs A, Mulleneers R, Smeets JL, Vos MA, et al.
654. Frohn-Mulder IM, Stewart PA, Witsenburg M, Den Hollander NS, Wladimiroff JW, Comparison of procainamide and lidocaine in terminating sustained monomorphic
Hess J. The efficacy of flecainide versus digoxin in the management of fetal supraven- ventricular tachycardia. Am J Cardiol 1996;78:43–6. 
tricular tachycardia. Prenat Diagn 1995;15:1297–302.  9149(96)00224-X
1970151309 677. Komura S, Chinushi M, Furushima H, Hosaka Y, Izumi D, Iijima K, et al. Efficacy of pro-
655. Alsaied T, Baskar S, Fares M, Alahdab F, Czosek RJ, Murad MH, et al. First-line antiar- cainamide and lidocaine in terminating sustained monomorphic ventricular tachycar-
rhythmic transplacental treatment for fetal tachyarrhythmia: a systematic review and dia. Circ J 2010;74:864–9. 
meta-analysis. J Am Heart Assoc 2017;6:e007164.  678. Ortiz M, Martín A, Arribas F, Coll-Vinent B, Del Arco C, Peinado R, et al. Randomized
007164 comparison of intravenous procainamide vs. intravenous amiodarone for the acute
656. van der Heijden LB, Oudijk MA, Manten GT, ter Heide H, Pistorius L, Freund MW. treatment of tolerated wide QRS tachycardia: the PROCAMIO study. Eur Heart J
Sotalol as first-line treatment for fetal tachycardia and neonatal follow-up. 2017;38:1329–35. 
Ultrasound Obstet Gynecol 2013;42:285–93.  679. Mhyre JM, Tsen LC, Einav S, Kuklina EV, Leffert LR, Bateman BT. Cardiac arrest during
657. Shah A, Moon-Grady A, Bhogal N, Collins KK, Tacy T, Brook M, et al. Effectiveness of hospitalization for delivery in the United States, 1998–2011. Anesthesiology 2014;120:
sotalol as first-line therapy for fetal supraventricular tachyarrhythmias. Am J Cardiol 810–8. 
2012;109:1614–8.  680. Schaap TP, Overtoom E, van den Akker T, Zwart JJ, van Roosmalen J, Bloemenkamp
658. Oudijk MA, Michon MM, Kleinman CS, Kapusta L, Stoutenbeek P, Visser GH, et al. KWM. Maternal cardiac arrest in The Netherlands: a nationwide surveillance study. Eur
Sotalol in the treatment of fetal dysrhythmias. Circulation 2000;101:2721–6. https://
J Obstet Gynecol Reprod Biol 2019;237:145–50. 
doi.org/10.1161/01.CIR.101.23.2721 04.028
659. Davis RL, Eastman D, McPhillips H, Raebel MA, Andrade SE, Smith D, et al. Risks of 681. Zelop CM, Einav S, Mhyre JM, Martin S. Cardiac arrest during pregnancy: ongoing clin-
congenital malformations and perinatal events among infants exposed to calcium chan-
ical conundrum. Am J Obstet Gynecol 2018;219:52–61. 
nel and beta-blockers during pregnancy. Pharmacoepidemiol Drug Saf 2011;20:138–45.
2017.12.232

682. McCartney CJ, Dark A. Caesarean delivery during cardiac arrest in late pregnancy.
660. Nanson J, Elcock D, Williams M, Deakin CD. Do physiological changes in pregnancy
Anaesthesia 1998;53:310–1. 
change defibrillation energy requirements? Br J Anaesth 2001;87:237–9. 
683. Zelop CM, Einav S, Mhyre JM, Lipman SS, Arafeh J, Shaw RE, et al. Characteristics and
org/10.1093/bja/87.2.237
outcomes of maternal cardiac arrest: a descriptive analysis of Get with the guidelines
661. Wang YC, Chen CH, Su HY, Yu MH. The impact of maternal cardioversion on fetal
data. Resuscitation 2018;132:17–20. 
haemodynamics. Eur J Obstet Gynecol Reprod Biol 2006;126:268–9. 
029
1016/j.ejogrb.2005.11.021
684. Mogos MF, Salemi JL, Spooner KK, McFarlin BL, Salihu HM. Differences in mortality
662. Brown O. Direct current cardioversion during pregnancy. BJOG 2003;110:713–4.
between pregnant and nonpregnant women after cardiopulmonary resuscitation.

663. Chen G, Sun G, Xu R, Chen X, Yang L, Bai Y, et al. Zero-fluoroscopy catheter ablation Obstet Gynecol 2016;128:880–8. 
of severe drug-resistant arrhythmia guided by Ensite NavX system during pregnancy: 685. Archer TL, Suresh P, Shapiro AE. Cardiac output measurement, by means of electrical
two case reports and literature review. Medicine (Baltimore) 2016;95:e4487. https:// velocimetry, may be able to determine optimum maternal position during gestation,
doi.org/10.1097/MD.0000000000004487 labour and caesarean delivery, by preventing vena caval compression and maximising
664. Driver K, Chisholm CA, Darby AE, Malhotra R, Dimarco JP, Ferguson JD. Catheter ab- cardiac output and placental perfusion pressure. Anaesth Intensive Care 2011;39:
lation of arrhythmia during pregnancy. J Cardiovasc Electrophysiol 2015;26:698–702. 308–11. 
 686. Pavek P, Ceckova M, Staud F. Variation of drug kinetics in pregnancy. Curr Drug Metab
665. Mladoniczky S, Nagy Z, Földesi C, Som Z, Bálint HO, Környei L, et al. Case series of 2009;10:520–9. 
catheter-based arrhythmia ablation in 13 pregnant women. Clin Cardiol 2023;46: 687. Berg RA, Hemphill R, Abella BS, Aufderheide TP, Cave DM, Hazinski MF, et al. Part 5:
942–9.  adult basic life support: 2010 American Heart Association guidelines for cardiopul-
666. Szumowski L, Szufladowicz E, Orczykowski M, Bodalski R, Derejko P, Przybylski A, monary resuscitation and emergency cardiovascular care. Circulation 2010;122:
et al. Ablation of severe drug-resistant tachyarrhythmia during pregnancy. J S685–705. 
Downloaded
from

by
guest
on
22
January
2026

4566 E S C G u id e l in e s
688. Dijkman A, Huisman CM, Smit M, Schutte JM, Zwart JJ, van Roosmalen JJ, et al. Cardiac Rhythm Society. Europace 2022;24:1981–2003. 
arrest in pregnancy: increasing use of perimortem caesarean section due to emergency euac125
skills training? BJOG 2010;117:282–7.  712. Sabbag A, Aabel EW, Castrini AI, Siontis KC, Laredo M, Nizard J, et al. Mitral valve pro-
689. Katz V, Balderston K, DeFreest M. Perimortem cesarean delivery: were our assump- lapse: arrhythmic risk during pregnancy and postpartum. Eur Heart J 2024;45:1831–9.
tions correct? Am J Obstet Gynecol 2005;192:1916–20. discussion 1920–1921. https:// 
doi.org/10.1016/j.ajog.2005.02.038 713. Aabel EW, Dejgaard LA, Chivulescu M, Helle-Valle TM, Edvardsen T, Hasselberg NE,
690. Kim DR, Wang E. Prevention of supine hypotensive syndrome in pregnant women et al. Flecainide in patients with arrhythmic mitral valve syndrome: a case series. Heart
treated with transcranial magnetic stimulation. Psychiatry Res 2014;218:247–8. Rhythm 2023;20:635–6. 
 714. Roos-Hesselink JW, van der Zande JA, Johnson MR. Pregnancy outcomes in women
691. Hidaka N, Chiba Y, Fukushima K, Wake N. Pregnant women with complete atrioven- with heart disease: how to improve? Eur Heart J 2023;44:1541–3. 
tricular block: perinatal risks and review of management. Pacing Clin Electrophysiol 2011; 1093/eurheartj/ehad035
34:1161–76.  715. Tornos P, Sambola A, Permanyer-Miralda G, Evangelista A, Gomez Z, Soler-Soler J.
692. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. 2021 Long-term outcome of surgically treated aortic regurgitation: influence of guideline ad-
ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J herence toward early surgery. J Am Coll Cardiol 2006;47:1012–7. 
2021;42:3427–520.  1016/j.jacc.2005.10.049
693. Güdal M, Kervancioğlu C, Oral D, Gürel T, Erol C, Sonel A. Permanent pacemaker im- 716. Kuchibhatla A, Soghrati N, Saleh Y, Rushing G, Halim MA, Pelletier M, et al.
plantation in a pregnant woman with the guidance of ECG and two-dimensional echo- Transcatheter or surgical aortic valve replacement in pregnant women? A comprehen-
cardiography. Pacing Clin Electrophysiol 1987;10:543–5.  sive review of the current literature. J Invasive Cardiol 2025;37. 
8159.1987.tb04518.x 25270/jic/24.00065
694. Chua KCM, Lim ETS, Chong DTT, Tan BY, Ho KL, Ching CK. Implantation of a dual- 717. Justin Paul G, Anne Princy S, Anju S, Anita S, Cecily Mary M, Gnanavelu G, et al.
chamber permanent pacemaker in a pregnant patient guided by intracardiac echocar- Pregnancy outcomes in women with heart disease: the Madras Medical College
diography and electroanatomic mapping. HeartRhythm Case Rep 2017;3:542–5. https:// Pregnancy And Cardiac (M-PAC) registry from India. Eur Heart J 2023;44:1530–40.
doi.org/10.1016/j.hrcr.2017.09.003 
695. Hartz J, Clark BC, Ito S, Sherwin ED, Berul CI. Transvenous nonfluoroscopic pace- 718. Carvajal HG, Lindley KJ, Shah T, Brar AK, Barger PM, Billadello JJ, et al. Impact of preg-
maker implantation during pregnancy guided by 3-dimensional electroanatomic map- nancy on autograft dilatation and aortic valve function following the Ross procedure.
ping. HeartRhythm Case Rep 2017;3:490–2.  Congenit Heart Dis 2018;13:217–21. 
696. Kumari A, Kumar K, Kumar Sinha A. The pattern of valvular heart diseases in India dur- 719. Wichert-Schmitt B, Grewal J, Malinowski AK, Pfaller B, Losenno KL, Kiess MC, et al.
ing pregnancy and its outcomes. Cureus 2021;13:e16394.  Outcomes of pregnancy in women with bioprosthetic heart valves with or without
cureus.16394 valve dysfunction. J Am Coll Cardiol 2022;80:2014–24. 
697. Baghel J, Keepanasseril A, Pillai AA, Mondal N, Jeganathan Y, Kundra P. Prediction of 2022.09.019
adverse cardiac events in pregnant women with valvular rheumatic heart disease. 720. Jacobson LT, Hade EM, Collins TC, Margolis KL, Waring ME, Van Horn LV, et al.
Heart 2020;106:1400–6.  Breastfeeding history and risk of stroke among parous postmenopausal women in
698. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/ the women’s health initiative. J Am Heart Assoc 2018;7:e008739. 
EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022;43: 1161/JAHA.118.008739
561–632.  721. Daughety MM, Zilberman-Rudenko J, Shatzel JJ, McCarty OJT, Raghunathan V,
699. Samiei N, Amirsardari M, Rezaei Y, Parsaee M, Kashfi F, Hantoosh Zadeh S, et al. DeLoughery TG. Management of anticoagulation in pregnant women with mechanical
Echocardiographic evaluation of hemodynamic changes in left-sided heart valves in heart valves. Obstet Gynecol Surv 2020;75:190–8. 
pregnant women with valvular heart disease. Am J Cardiol 2016;118:1046–52. 0000000000000751
 722. Özkan M, Çakal B, Karakoyun S, Gürsoy OM, Çevik C, Kalçık M, et al. Thrombolytic
700. Diao M, Kane A, Ndiaye MB, Mbaye A, Bodian M, Dia MM, et al. Pregnancy in women therapy for the treatment of prosthetic heart valve thrombosis in pregnancy with low-
with heart disease in sub-Saharan Africa. Arch Cardiovasc Dis 2011;104:370–4. https:// dose, slow infusion of tissue-type plasminogen activator. Circulation 2013;128:532–40.
doi.org/10.1016/j.acvd.2011.04.001 
701. Hameed A, Karaalp IS, Tummala PP, Wani OR, Canetti M, Akhter MW, et al. The effect 723. Countouris ME, Marino AL, Raymond M, Hauspurg A, Berlacher KL. Infective endocar-
of valvular heart disease on maternal and fetal outcome of pregnancy. J Am Coll Cardiol ditis in pregnancy: a contemporary cohort. Am J Perinatol 2024;41:e230–5. 
2001;37:893–9.  org/10.1055/a-1877-5763
702. Bortnick AE, Levine LD. Valvular heart disease in pregnancy. Clin Obstet Gynecol 2020; 724. Sinner GJ, Annabathula R, Viquez K, Alnabelsi TS, Leung SW. Infective endocarditis in
63:910–22.  pregnancy from 2009 to 2019: the consequences of injection drug use. Infect Dis (Lond)
703. Orwat S, Diller GP, van Hagen IM, Schmidt R, Tobler D, Greutmann M, et al. Risk of 2021;53:633–9. 
pregnancy in moderate and severe aortic stenosis: from the multinational ROPAC 725. Dagher MM, Eichenberger EM, Addae-Konadu KL, Dotters-Katz SK, Kohler CL,
registry. J Am Coll Cardiol 2016;68:1727–37.  Fowler VG, et al. Maternal and fetal outcomes associated with infective endocarditis
704. Elassy SM, Elmidany AA, Elbawab HY. Urgent cardiac surgery during pregnancy: a con- in pregnancy. Clin Infect Dis 2021;73:1571–9. 
tinuous challenge. Ann Thorac Surg 2014;97:1624–9.  726. Izewski JM, Bell BZ, Haas DM. Antibiotics in labor and delivery. Obstet Gynecol Clin
athoracsur.2013.10.067 North Am 2023;50:137–50. 
705. Myerson SG, Mitchell AR, Ormerod OJ, Banning AP. What is the role of balloon dila- 727. Halliday BP, Wassall R, Lota AS, Khalique Z, Gregson J, Newsome S, et al. Withdrawal
tation for severe aortic stenosis during pregnancy? J Heart Valve Dis 2005;14:147–50. of pharmacological treatment for heart failure in patients with recovered dilated car-
706. Yagel O, Alter R, Nissan B, Zwas DR, Rosenbloom JI, Eyal O, et al. A pregnant woman diomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet 2019;393:
with severe symptomatic aortic stenosis: how should we treat? JACC Case Rep 2024; 61–73. 
29:102205.  728. Rakisheva A, Sliwa K, Bauersachs J, Van Linthout S, Chopra VK, Bayes-Genis A, et al.
707. Herzig MS, McIlvaine S, Feinberg L, Spiel MH, Carroll BJ. Outcomes of bicuspid aortic Multidisciplinary care of peripartum heart failure: a scientific statement of the Heart
valve in pregnancy. Am J Cardiol 2024;221:74–6.  Failure Association of the ESC. Eur J Heart Fail 2024;26:742–53. 
2024.04.038 1002/ejhf.3246
708. Pomini F, Mercogliano D, Cavalletti C, Caruso A, Pomini P. Cardiopulmonary bypass 729. Sliwa K, Anthony J. Late maternal deaths: a neglected responsibility. Lancet 2016;387:
in pregnancy. Ann Thorac Surg 1996;61:259–68.  2072–3. 
4975(95)00818-7 730. Labbene I, Arrigo M, Tavares M, Hajjej Z, Brandão JL, Tolppanen H, et al. Decongestive
709. Minhas AS, Rahman F, Gavin N, Cedars A, Vaught AJ, Zakaria S, et al. Cardiovascular effects of levosimendan in cardiogenic shock induced by postpartum cardiomyopathy.
and obstetric delivery complications in pregnant women with valvular heart disease. Anaesth Crit Care Pain Med 2017;36:39–42. 
Am J Cardiol 2021;158:90–7.  009
710. Ducas RA, Javier DA, D’Souza R, Silversides CK, Tsang W. Pregnancy outcomes in wo- 731. Wong RW, Seasely AR, Gongora E, Hoopes CW, Bellot S, McElwee SK, et al.
men with significant valve disease: a systematic review and meta-analysis. Heart 2020; Strategies and outcomes of extracorporeal membrane oxygenation use in peripartum
106:512–9.  patients: a single institution experience. J Matern Fetal Neonatal Med 2024;37:2355293.
711. Sabbag A, Essayagh B, Barrera JDR, Basso C, Berni A, Cosyns B, et al. EHRA expert 
consensus statement on arrhythmic mitral valve prolapse and mitral annular disjunc- 732. Hilfiker-Kleiner D, Westhoff-Bleck M, Gunter HH, von Kaisenberg CS, Bohnhorst B,
tion complex in collaboration with the ESC Council on valvular heart disease and Hoeltje M, et al. A management algorithm for acute heart failure in pregnancy. The
the European Association of Cardiovascular Imaging endorsed by the Heart Rhythm Hannover experience. Eur Heart J 2015;36:769–70. 
Society, by the Asia Pacific Heart Rhythm Society, and by the Latin American Heart eurheartj/ehv039
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4567
733. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC 754. Cubillo A, Morales S, Goñi E, Matute F, Muñoz JL, Pérez-Díaz D, et al. Multidisciplinary
Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task consensus on cancer management during pregnancy. Clin Transl Oncol 2021;23:
force for the diagnosis and treatment of acute and chronic heart failure of the 1054–66. 
European Society of Cardiology (ESC) developed with the special contribution of 755. Narayanan M, Elkayam U, Naqvi TZ. Echocardiography in pregnancy: part 2. Curr
the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129–200. Cardiol Rep 2016;18:90. 
 756. Furenäs E, Eriksson P, Wennerholm UB, Dellborg M. Pregnancy in a healthy popula-
734. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 tion: dynamics of NTproBNP and hs-cTroponin T. Open Heart 2020;7:e001293.
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. 
Eur Heart J 2021;42:3599–726.  757. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al.
735. Libhaber E, Sliwa K, Bachelier K, Lamont K, Böhm M. Low systolic blood pressure and 2022 ESC Guidelines on cardio-oncology developed in collaboration with the
high resting heart rate as predictors of outcome in patients with peripartum cardiomy- European Hematology Association (EHA), the European Society for Therapeutic
opathy. Int J Cardiol 2015;190:376–82.  Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society
736. Haghikia A, Tongers J, Berliner D, König T, Schäfer A, Brehm M, et al. Early ivabradine (IC-OS). Eur Heart J 2022;43:4229–361. 
treatment in patients with acute peripartum cardiomyopathy: subanalysis of the 758. Chait-Rubinek L, Mariani JA, Goroncy N, Herschtal A, Wheeler GC, Dwyer MK, et al.
German PPCM registry. Int J Cardiol 2016;216:165–7.  A retrospective evaluation of risk of peripartum cardiac dysfunction in survivors of
2016.04.143 childhood, adolescent and young adult malignancies. Cancers (Basel) 2019;11:1046.
737. Egidy Assenza G, Dimopoulos K, Budts W, Donti A, Economy KE, Gargiulo GD, et al. 
Management of acute cardiovascular complications in pregnancy. Eur Heart J 2021;42: 759. Thompson KA, Hildebrandt MA, Ater JL. Cardiac outcomes with pregnancy after car-
4224–40.  diotoxic therapy for childhood cancer. J Am Coll Cardiol 2017;69:594–5. 
738. Sliwa K, Azibani F, Baard J, Osman A, Zühlke L, Lachmann A, et al. Reducing late ma- 10.1016/j.jacc.2016.11.040
ternal death due to cardiovascular disease—a pragmatic pilot study. Int J Cardiol 2018; 760. Lane-Cordova AD, Khan SS, Grobman WA, Greenland P, Shah SJ. Long-term cardio-
272:70–6.  vascular risks associated with adverse pregnancy outcomes: JACC review topic of the
739. Kaye AB, Bhakta A, Moseley AD, Rao AK, Arif S, Lichtenstein SJ, et al. Review of car- week. J Am Coll Cardiol 2019;73:2106–16. 
761. Parikh NI, Gonzalez JM, Anderson CAM, Judd SE, Rexrode KM, Hlatky MA, et al.
diovascular drugs in pregnancy. J Womens Health (Larchmt) 2019;28:686–97. https://
Adverse pregnancy outcomes and cardiovascular disease risk: unique opportunities
doi.org/10.1089/jwh.2018.7145
for cardiovascular disease prevention in women: a scientific statement from the
740. Mebazaa A, Yilmaz MB, Levy P, Ponikowski P, Peacock WF, Laribi S, et al.
American Heart Association. Circulation 2021;143:e902–16. 
Recommendations on pre-hospital & early hospital management of acute heart failure:
CIR.0000000000000961
a consensus paper from the Heart Failure Association of the European Society of
762. Ghossein-Doha C, Thilaganathan B, Vaught AJ, Briller JE, Roos-Hesselink JW.
Cardiology, the European Society of Emergency Medicine and the Society of
Hypertensive pregnancy disorder, an under-recognized women specific risk factor
Academic Emergency Medicine. Eur J Heart Fail 2015;17:544–58. 
for heart failure? Eur J Heart Fail 2025;27:459–72. 
1002/ejhf.289
763. Hauspurg A, Jeyabalan A. Postpartum preeclampsia or eclampsia: defining its place and
741. Punnoose LR, Coscia LA, Armenti DP, Constantinescu S, Moritz MJ. Pregnancy out-
management among the hypertensive disorders of pregnancy. Am J Obstet Gynecol
comes in heart transplant recipients. J Heart Lung Transplant 2020;39:473–80.
2022;226:S1211–21. 

764. Brown MC, Best KE, Pearce MS, Waugh J, Robson SC, Bell R. Cardiovascular disease
742. Acuna S, Zaffar N, Dong S, Ross H, D’Souza R. Pregnancy outcomes in women with
risk in women with pre-eclampsia: systematic review and meta-analysis. Eur J Epidemiol
cardiothoracic transplants: a systematic review and meta-analysis. J Heart Lung
2013;28:1–19. 
Transplant 2020;39:93–102. 
765. Lopes Perdigao J, Lewey J, Hirshberg A, Koelper N, Srinivas SK, Elovitz MA, et al.
743. Dagher O, Alami Laroussi N, Carrier M, Cecere R, Charbonneau E, de Denus S, et al.
Furosemide for accelerated recovery of blood pressure postpartum in women with
Pregnancy after heart transplantation: a well-thought-out decision? The Quebec pro-
a hypertensive disorder of pregnancy: a randomized controlled trial. Hypertension
vincial experience—a multi-centre cohort study. Transpl Int 2018;31:977–87. https://
2021;77:1517–24. 
doi.org/10.1111/tri.13144
766. Jannet D, Carbonne B, Sebban E, Milliez J. Nicardipine versus metoprolol in the treat-
744. D’Souza R, Soete E, Silversides CK, Zaffar N, Van Mieghem T, Van Cleemput J, et al.
ment of hypertension during pregnancy: a randomized comparative trial. Obstet
Pregnancy outcomes following cardiac transplantation. J Obstet Gynaecol Can 2018;
Gynecol 1994;84:354–9.
40:566–71. 
767. ACOG committee opinion no. 767: emergent therapy for acute-onset, severe hyper-
745. Macera F, Occhi L, Masciocco G, Varrenti M, Frigerio M. A new life: motherhood after
tension during pregnancy and the postpartum period. Obstet Gynecol 2019;133:
heart transplantation. A single-center experience and review of literature.
e174–80. 
Transplantation 2018;102:1538–44.  768. Buchanan TA, Xiang AH, Page KA. Gestational diabetes mellitus: risks and manage-
746. O’Boyle PJ, Smith JD, Danskine AJ, Lyster HS, Burke MM, Banner NR. De novo HLA
ment during and after pregnancy. Nat Rev Endocrinol 2012;8:639–49. 
sensitization and antibody mediated rejection following pregnancy in a heart transplant
10.1038/nrendo.2012.96
recipient. Am J Transplant 2010;10:180–3.  769. Claesson R, Ignell C, Shaat N, Berntorp K. Hba1c as a predictor of diabetes after ges-
02875.x tational diabetes mellitus. Prim Care Diabetes 2017;11:46–51. 
747. Ginwalla M, Pando MJ, Khush KK. Pregnancy-related human leukocyte antigen sensi- pcd.2016.09.002
tization leading to cardiac allograft vasculopathy and graft failure in a heart transplant 770. Burlina S, Dalfrà MG, Chilelli NC, Lapolla A. Gestational diabetes mellitus and future
recipient: a case report. Transplant Proc 2013;45:800–2.  cardiovascular risk: an update. Int J Endocrinol 2016;2016:2070926. 
transproceed.2012.10.038 10.1155/2016/2070926
748. Kuczaj A, Pawlak S, Śliwka J, Przybyłowski P. Pregnancies after orthotopic heart trans- 771. Grandi SM, Filion KB, Yoon S, Ayele HT, Doyle CM, Hutcheon JA, et al. Cardiovascular
plantation: a single-center experience. Transplant Proc 2022;54:1065–9.  disease-related morbidity and mortality in women with a history of pregnancy compli-
10.1016/j.transproceed.2022.01.026 cations. Circulation 2019;139:1069–79. 
749. Irani RA, Coscia LA, Chang E, Lappen JR. Society for Maternal–Fetal Medicine consult 118.036748
series #66: prepregnancy evaluation and pregnancy management of patients with solid 772. Crump C, Sundquist J, McLaughlin MA, Dolan SM, Govindarajulu U, Sieh W, et al.
organ transplants. Am J Obstet Gynecol 2023;229:B10–32.  Adverse pregnancy outcomes and long term risk of ischemic heart disease in mothers:
ajog.2023.04.022 national cohort and co-sibling study. BMJ 2023;380:e072112. 
750. Bry C, Hubert D, Reynaud-Gaubert M, Dromer C, Mal H, Roux A, et al. Pregnancy bmj-2022-072112
after lung and heart–lung transplantation: a French multicentre retrospective study 773. Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC
of 39 pregnancies. ERJ Open Res 2019;5:00254-2018.  Guidelines for the management of cardiovascular disease in patients with diabetes. Eur
23120541.00254-2018 Heart J 2023;44:4043–140. 
751. Durst JK, Rampersad RM. Pregnancy in women with solid-organ transplants: a review. 774. Adam S, McIntyre HD, Tsoi KY, Kapur A, Ma RC, Dias S, et al. Pregnancy as an oppor-
Obstet Gynecol Surv 2015;70:408–18.  tunity to prevent type 2 diabetes mellitus: FIGO best practice advice. Int J Gynaecol
752. Peccatori FA, Azim HA Jr, Orecchia R, Hoekstra HJ, Pavlidis N, Kesic V, et al. Cancer, Obstet 2023;160:56–67. 
pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and 775. Fu J, Retnakaran R. The life course perspective of gestational diabetes: an opportunity
follow-up. Ann Oncol 2013;24:vi160–70.  for the prevention of diabetes and heart disease in women. EClinicalMedicine 2022;45:
753. Silverstein J, Post AL, Chien AJ, Olin R, Tsai KK, Ngo Z, et al. Multidisciplinary manage- 101294. 
ment of cancer during pregnancy. JCO Oncol Pract 2020;16:545–57.  776. Catov JM, Snyder GG, Fraser A, Lewis CE, Liu K, Althouse AD, et al. Blood pressure
1200/OP.20.00077 patterns and subsequent coronary artery calcification in women who delivered
Downloaded
from

by
guest
on
22
January
2026

4568 E S C G u id e l in e s
preterm births. Hypertension 2018;72:159–66.  789. Magnus MC, Wallace MK, Demirci JR, Catov JM, Schmella MJ, Fraser A. Breastfeeding
HYPERTENSIONAHA.117.10693 and later-life cardiometabolic health in women with and without hypertensive disor-
777. Catov JM, Snyder GG, Bullen BL, Barinas-Mitchell EJM, Holzman C. Women with pre- ders of pregnancy. J Am Heart Assoc 2023;12:e026696. 
term birth have evidence of subclinical atherosclerosis a decade after delivery. J 122.026696
Womens Health (Larchmt) 2019;28:621–7.  790. Peters SAE, Yang L, Guo Y, Chen Y, Bian Z, Du J, et al. Breastfeeding and the risk of
778. Hall PS, Nah G, Vittinghoff E, Parker DR, Manson JE, Howard BV, et al. Relation of maternal cardiovascular disease: a prospective study of 300 000 Chinese women. J
pregnancy loss to risk of cardiovascular disease in parous postmenopausal women Am Heart Assoc 2017;6:e006081. 
(from the Women’s Health Initiative). Am J Cardiol 2019;123:1620–5.  791. Gunderson EP, Hurston SR, Ning X, Lo JC, Crites Y, Walton D, et al. Lactation and
10.1016/j.amjcard.2019.02.012 progression to type 2 diabetes mellitus after gestational diabetes mellitus: a prospect-
779. Kyriacou H, Al-Mohammad A, Muehlschlegel C, Foster-Davies L, Bruco MEF, Legard ive cohort study. Ann Intern Med 2015;163:889–98. 
C, et al. The risk of cardiovascular diseases after miscarriage, stillbirth, and induced 792. Countouris ME, Holzman C, Althouse AD, Snyder GG, Barinas-Mitchell E, Reis SE,
abortion: a systematic review and meta-analysis. Eur Heart J Open 2022;2:oeac065. et al. Lactation and maternal subclinical atherosclerosis among women with and with-
 out a history of hypertensive disorders of pregnancy. J Womens Health (Larchmt) 2020;
780. Tørris C, Bjørnnes AK. Duration of lactation and maternal risk of metabolic syndrome: 29:789–98. 
a systematic review and meta-analysis. Nutrients 2020;12:2718.  793. Matsunaga T, Kadomatsu Y, Tsukamoto M, Kubo Y, Okada R, Nagayoshi M, et al.
3390/nu12092718 Associations of breastfeeding history with metabolic syndrome and cardiovascular
781. Tschiderer L, Seekircher L, Kunutsor SK, Peters SAE, O’Keeffe LM, Willeit P. risk factors in community-dwelling parous women: the Japan multi-institutional collab-
Breastfeeding is associated with a reduced maternal cardiovascular risk: systematic re- orative cohort study. PLoS One 2022;17:e0262252. 
view and meta-analysis involving data from 8 studies and 1 192 700 parous women. J pone.0262252
Am Heart Assoc 2022;11:e022746.  794. Nguyen B, Gale J, Nassar N, Bauman A, Joshy G, Ding D. Breastfeeding and cardiovas-
782. Wang YX, Arvizu M, Rich-Edwards JW, Manson JE, Wang L, Missmer SA, et al. cular disease hospitalization and mortality in parous women: evidence from a large
Breastfeeding duration and subsequent risk of mortality among US women: a pro- Australian cohort study. J Am Heart Assoc 2019;8:e011056. 
spective cohort study. EClinicalMedicine 2022;54:101693.  JAHA.118.011056
eclinm.2022.101693 795. McKinney J, Keyser L, Clinton S, Pagliano C. ACOG committee opinion no. 736: op-
783. Kirkegaard H, Bliddal M, Støvring H, Rasmussen KM, Gunderson EP, Køber L, et al. timizing postpartum care. Obstet Gynecol 2018;132:784–5. 
Breastfeeding and later maternal risk of hypertension and cardiovascular disease— AOG.0000000000002849
the role of overall and abdominal obesity. Prev Med 2018;114:140–8.  796. Gamble DT, Brikinns B, Myint PK, Bhattacharya S. Hypertensive disorders of preg-
10.1016/j.ypmed.2018.06.014 nancy and subsequent cardiovascular disease: current national and international guide-
784. Qu G, Wang L, Tang X, Wu W, Sun Y. Association between duration of breastfeeding lines and the need for future research. Front Cardiovasc Med 2019;6:55. 
and maternal hypertension: a systematic review and meta-analysis. Breastfeed Med 10.3389/fcvm.2019.00055
2018;13:318–26.  797. Hedeager Momsen AM, Høtoft D, Ørtenblad L, Friis Lauszus F, Krogh RHA, Lynggaard
785. Schwarz EB, Ray RM, Stuebe AM, Allison MA, Ness RB, Freiberg MS, et al. Duration of V, et al. Diabetes prevention interventions for women after gestational diabetes mel-
lactation and risk factors for maternal cardiovascular disease. Obstet Gynecol 2009;113: litus: an overview of reviews. Endocrinol Diabetes Metab 2021;4:e00230. 
974–82.  10.1002/edm2.230
786. Peters SA, van der Schouw YT, Wood AM, Sweeting MJ, Moons KG, Weiderpass E, et al. 798. Kitt J, Fox R, Frost A, Shanyinde M, Tucker K, Bateman PA, et al. Long-term blood pres-
Parity, breastfeeding and risk of coronary heart disease: a pan-European case-cohort sure control after hypertensive pregnancy following physician-optimized self-
study. Eur J Prev Cardiol 2016;23:1755–65.  management: the POP-HT randomized clinical trial. JAMA 2023;330:1991–9. https://
787. Stuebe AM, Michels KB, Willett WC, Manson JE, Rexrode K, Rich-Edwards JW. doi.org/10.1001/jama.2023.21523
Duration of lactation and incidence of myocardial infarction in middle to late adult- 799. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC
hood. Am J Obstet Gynecol 2009;200:138.e1–e8.  Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021;
10.001 42:3227–337. 
788. Chetwynd EM, Stuebe AM, Rosenberg L, Troester M, Rowley D, Palmer JR. 800. Balaji B, Ranjit Mohan A, Rajendra P, Mohan D, Ram U, Viswanathan M. Gestational
Cumulative lactation and onset of hypertension in African-American women. Am J diabetes mellitus postpartum follow-up testing: challenges and solutions. Can J
Epidemiol 2017;186:927–34.  Diabetes 2019;43:641–6. 
Downloaded
from

by
guest
on
22
January
2026
